# **Hit List**

Clear Generate Collection Print Fwd Refs Bkwd Refs Generate OACS

Search Results - Record(s) 1 through 67 of 67 returned.

1. Document ID: US 20040097401 A1

Using default format because multiple data bases are involved.

L8: Entry 1 of 67

File: PGPB

May 20, 2004

PGPUB-DOCUMENT-NUMBER: 20040097401

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040097401 A1

TITLE: Lysine in therapeutic angiogenesis, particularly in treating ischaemic

conditions

PUBLICATION-DATE: May 20, 2004

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Datta, Debatosh

Kolkata

TN

US-CL-CURRENT: <u>514/2</u>; <u>514/564</u>, <u>514/565</u>

Full Title Citation Fro	nt Review Classification [	Date Reference Sequences	Attachments   Claims   KMC   Draw Desc

2. Document ID: US 20040087486 A1

L8: Entry 2 of 67

File: PGPB

May 6, 2004

PGPUB-DOCUMENT-NUMBER: 20040087486

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040087486 A1

TITLE: Methods and compositions for treating platelet-related disorders

PUBLICATION-DATE: May 6, 2004

INVENTOR-INFORMATION:

NAME

CITY

STATE

RULE-47

Hanson, Stephen R.

Stone Mountain

GΑ

US

COUNTRY

US-CL-CURRENT: 514/2

ABSTRACT:

The invention relates to the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

## 3. Document ID: US 20040082659 A1

L8: Entry 3 of 67

File: PGPB

Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040082659

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040082659 A1

TITLE: Enhancement of vascular function by modulation of endogenous nitric oxide

production or activity

PUBLICATION-DATE: April 29, 2004

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cooke, John P.	Palo Alto	CA	US	
Dzau, Victor J.	Newton	MA	US	
Gibbons, Gary H.	Atlanta	GA	US	

US-CL-CURRENT: <u>514/565</u>; <u>514/2</u>, <u>514/564</u>

#### ABSTRACT:

Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes

Full Title Citation Front Review	Classification   Date   Reference	Claims KMC Draw Desc
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	 

## 4. Document ID: US 20040033971 A1

L8: Entry 4 of 67

File: PGPB

Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040033971

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040033971 A1

TITLE: Polypeptides and nucleic acids encoding same

PUBLICATION-DATE: February 19, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gangolli, Esha A.	Madison	CT	US	
Patturajan, Meera	Branford	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	

Kekuda, Ramesh	Norwalk	CT	US
Stone, David J.	Guilford	CT	US
Anderson, David	Branford	CT	US
Shimkets, Richard A.	Guilford	CT	US
Burgess, Catherine E.	Wethersfield	CT	US
Zerhusen, Bryan D.	Branford	CT	US
Liu, Xiaohong	Branford	CT	US
Spytek, Kimberly A.	New Haven	CT	US
Casman, Stacie J.	North Haven	CT	US
Boldog, Ference L.	North Haven	CT	US
Smithson, Glennda	Guilford	CT	US
Li, Li	Branford	CT	US
Ji, Weizhen	Branford	CT	US
MacDougall, John R.	Hamden	CT	US
•			

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/7.1, 514/2, 530/387.1, 536/23.1

## ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention farther discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Full Title Citation Front Review Classification Date Reference Sequences	Attachments   Claims   KMC   Draw Desi

5. Document ID: US 20040018960 A1

L8: Entry 5 of 67 File: PGPB Jan 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040018960

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040018960 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: January 29, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

US-CL-CURRENT: 514/2; 424/649, 514/185

## ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by

conjugating the paclitaxel or docetaxel to a water soluble polymer such as polyglutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Drawl Desc

6. Document ID: US 20040002440 A1

L8: Entry 6 of 67

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002440

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002440 A1

TITLE: Novel diagnostic agents of chronic or persistent chlamydial diseases and uses

thereof

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Timms, Peter Queensland AU Mathews, Sarah Anne Queensland AU

US-CL-CURRENT: 514/2; 435/6, 435/7.32, 514/44

## ABSTRACT:

The present invention discloses compositions and methods for detecting organisms of the Chlamydiaceae family, including species of Chlamydia and Chlamyclophila, in the persistent phase of their developmental cycle and for the diagnosis of chronic or persistent infections caused by such organisms. The present invention also discloses methods for screening agents that are useful inter alia for modulating a gene whose expression is altered in the persistent phase of the chiamydial developmental cycle or for modulating the level and/or functional activity of an expression product of that gene. Also disclosed are methods and compositions for the treatment and/or prophylaxis of infections, including chronic infections, caused by chamydial organisms using the aforesaid modulatory agents and optionally agents that are effective in modulating the expression of a gene associated with the lytic phase of said developmental cycle or in modulating the level and/or functional activity of an expression product of that gene. The invention also discloses methods and compositions for the treatment and/or prophylaxis of such infections using a first immunopotentiating agent that elicits the production of elements that are immunointeractive with an antigen associated with the persistent phase of the chlamydial developmental cycle and a second immunopotentiating agent that elicits the production of elements that are immuno-interactive with an antigen associated with the lytic phase of said developmental cycle.

Full Title Citation Front Review		
		The state of the s

7. Document ID: US 20030229003 A1

L8: Entry 7 of 67

File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229003

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229003 A1

TITLE: Use of transcription factors for treating inflammation and other diseases

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47 Oettgen, Peter Brookline MΑ US Libermann, Towia US Newton MΆ Goldring, Mary Auburndale MA US

US-CL-CURRENT: 514/1; 435/4, 435/6, 514/2, 514/44, 514/54

#### ABSTRACT:

The present invention provides a method of treating inflammation in a mammal comprising altering the activity of a transcription factor involved in the inflammatory response. The invention also relates to the use of transcription factors to screen compounds that are capable of reducing inflammation. The invention also relates to the use of transcription factors in methods of diagnosing the presence of an inflammatory disease in a tissue of a mammal and methods of monitoring the treatment of an inflammatory disease in a tissue of a mammal.

Full   Title   Citation   Front   Review   Classific:	ation Date Reference Sequences	Attachments   Claims   KMC   Draw Desc

## 8. Document ID: US 20030215840 A1

L8: Entry 8 of 67

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215840

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030215840 A1

TITLE: Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules

PUBLICATION-DATE: November 20, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas J.	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	
Galvin, Katherine M.	Jamaica Plain	MA	US	
Healy, Aileen	Medford	MA	US	
Acton, Susan L.	Lexington	MA	US	
Donoghue, Mary A.	West Roxbury	MA	US	
Stagliano, Nancy	North Reading	MA	US	

h eb b g e e e f b e

Perodin, Jacqueline Rodrigue-Way, Amelie Arlington Malden MA MA US US

US-CL-CURRENT: 435/6; 424/146.1, 435/7.2, 514/1, 514/2, 514/44

#### ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 and 6585 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

Full Title Citation Front Review	Classes D. Date	Composes	OHrobareta Chi-	14.030
stone intra-increment attouts i wearen	Classification   Date	Retate tide   Seductices	Mudriments ciam	S KONC DIAMO DES

## 9. Document ID: US 20030215452 A1

L8: Entry 9 of 67

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215452

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030215452 A1

TITLE: Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules

PUBLICATION-DATE: November 20, 2003

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Carroll, Joseph M.	Cambridge	AM	US	
Healy, Aileen	Medford	MA	US	
Weich, Nadine S.	Brookline	MA	US	
Kelly, Louise M.	Brookline	MA	US	

US-CL-CURRENT: 424/146.1; 435/6, 435/7.2, 514/1, 514/2, 514/44

## ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the

h eb bgeeef e

hc ef be

differential expression of 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 and 13249 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

Full Title Citation Fron	rt Review Classificatio	n Date Reference	Sequences	Attachments Claims	KMC Draw Desc

## 10. Document ID: US 20030211472 A1

L8: Entry 10 of 67

File: PGPB

Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211472

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030211472 A1

TITLE: 125 human secreted proteins

PUBLICATION-DATE: November 13, 2003

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Feng, Ping	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US .	
Ni, Jian	Rockville	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	
Soppet, Daniel R.	Centreville	VA	US	
Moore, Paul A.	Germantown	MD	US	
Kyaw, Hla	Frederick	MD	US	
LaFleur, David W.	Washington	DC	US	
Shi, Yanggu	Gaithersburg	MD	US	
Janat, Fouad	Westerly	RI	US	
Endress, Gregory A.	Potomac	MD	US	
Carter, Kenneth C.	North Potomac	MD	US	

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

## ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

b

# Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Desc

## 11. Document ID: US 20030211095 A1

L8: Entry 11 of 67

File: PGPB

Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211095

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030211095 A1

TITLE: Peptide for regulation of urokinase plasminogen activator and method of

optimizing therapeutic efficacy

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME

CITY

STATE

RULE-47

Higazi, Abd. Al-Roof

D.N. Shimshon

ΤL

COUNTRY

US-CL-CURRENT: 424/94.64; 514/2

#### ABSTRACT:

The present invention relates to compositions of the polypeptide EEIIMI, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents comprising scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents.

				<del></del>
Full Title Citation Front Review Classification	Date	Reference Seguences	Attachments Claims	MONO Deploy Doc
	L'at-	Halefallee   Dogadiloos	Attornio Ciattis	Radio Plant Pest

## 12. Document ID: US 20030199425 A1

L8: Entry 12 of 67

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199425

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199425 A1

TITLE: Compositions and methods for treatment of hyperplasia

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Desai, Neil P. Los Angeles CA US Soon-Shiong, Patrick Los Angeles CA US

US-CL-CURRENT: <u>514/2</u>; <u>424/45</u>, <u>514/291</u>, <u>514/365</u>, <u>514/449</u>

### ABSTRACT:

In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.

Full Title Citation	Front Review	Classification D	ate Reference Sequence	es   Attachments   (	Claims  KMC   Draw Desc
***************************************		······································		······································	

13. Document ID: US 20030176320 A1

L8: Entry 13 of 67

File: PGPB

Sep 18, 2003

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030176320

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030176320 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: September 18, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

US-CL-CURRENT: <u>514/2</u>; <u>514/8</u>

#### ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as polyglutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

FUI	Title	Citation   Front   Review   Classification   Date   Reference   Sequences   Attachments   Claims   KMC   Draw Desc
······································		
	14.	Document ID: US 20030166507 A1

File: PGPB

PGPUB-DOCUMENT-NUMBER: 20030166507

PGPUB-FILING-TYPE: new

L8: Entry 14 of 67

DOCUMENT-IDENTIFIER: US 20030166507 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: September 4, 2003

### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	បន	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David	Sugar Land	TX	US	

US-CL-CURRENT: 514/2; 514/8, 600/1

#### ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as polyglutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

· <del></del>									
	27:14 Sec. 1		of Parameters		Other and Street Land	. Ph	Dodge and	Campagage !	District the second of the sec
20121120	nte :	UNZRODI	1000	Review	Classification	1) 210			Attachments Claims KWC Draw Desc
		Other Land							THE PARTY OF THE P
									·

15. Document ID: US 20030154504 A1

L8: Entry 15 of 67

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030154504

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030154504 A1

TITLE: Methods and compositions for modulating carbohydrate metabolism

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Farese, Robert V. JR. San Francisco CA US Chen, Hubert C. San Francisco CA US

US-CL-CURRENT: 800/18; 514/2, 514/3

## ABSTRACT:

Methods and compositions for modulating carbohydrate metabolism in a host are provided. In the subject methods, diacylglycerol acyltransferase (DGAT) activity (specifically DGAT1 activity) is modulated, e.g., reduced or enhanced, to achieve a desired insulin and/or leptin sensitivity, thereby modulating carbohydrate metabolism, e.g., increasing or decreasing blood glucose levels, glucose uptake into cells and assimilation into glycogen. Also provided are pharmaceutical compositions for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the treatment of hosts suffering conditions associated with abnormal carbohydrate metabolism, such as obesity or diabetes.

Full Title Citation Front Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC	Draw, Desc
•								
	*							

ef

## 16. Document ID: US 20030152574 A1

L8: Entry 16 of 67

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152574

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030152574 A1

TITLE: Methods and compositions to treat cardiovascular disease using 1419, 58765 and

2210

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Logan, Thomas Joseph

Springfield

PΑ

US

Chun, Miyoung

Belmont

MΆ

US

US-CL-CURRENT:  $\underline{424}/\underline{146.1}$ ;  $\underline{435}/\underline{7.2}$ ,  $\underline{514}/\underline{1}$ ,  $\underline{514}/\underline{2}$ ,  $\underline{514}/\underline{44}$ 

#### ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1419, 58765 or 2210 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

Full Title Citation Front Review	Classification Date	Reference Sequences	Attachments Claims	KWMC   Drawn Desc

17. Document ID: US 20030130170 A1

L8: Entry 17 of 67

File: PGPB

Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030130170

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030130170 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: July 10, 2003

### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

Page 12 of 45

US-CL-CURRENT: 514/2; 514/8, 514/9

#### ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as polyglutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full Title Citation Front	Review Classification Date	Reference Sequences	Attachments Claims KWiC Draw Desc

## 18. Document ID: US 20030109420 A1

L8: Entry 18 of 67

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030109420

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030109420 A1

TITLE: Diagnostic markers of acute coronary syndrome and methods of use thereof

PUBLICATION-DATE: June 12, 2003

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars	Escondido	CA	US	
Dahlen, Jeffrey	San Diego	CA	US	
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	
Kirchick, Howard J.	San Diego	CA	US	

US-CL-CURRENT: 514/2; 435/7.1

## ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of acute coronary syndromes. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for myocardial injury and one or more non-specific markers for myocardial injury. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. In various aspects, the invention provides methods for the early detection and differentiation of stable angina, unstable angina, and myocardial infarction. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

Full Title Citation Front Review	Classification   Date	Reference Sequences	Attachments Claims	KWIC Draw, Desc

19. Document ID: US 20030104977 A1

L8: Entry 19 of 67

File: PGPB

Jun 5, 2003

b g ee e f h e b

e hc ef

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030104977

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104977 A1

TITLE: METHODS FOR INDUCING ANGIOGENESIS USING MORPHOGENIC PROTEINS AND STIMULATORY

**FACTORS** 

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

RIPAMONTI, UGO SANDTON 7.A RAMOSHEBI, LENTSHA NATHANIEL **JOHANNESBURG** 7.A

US-CL-CURRENT: 514/2

#### ABSTRACT:

The present invention provides a method for inducing angiogenesis at a target locus in a mammal using morphogenic proteins. In addition, this invention also features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method, the morphogenic protein is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and morphogenic protein stimulatory factor can be administered simultaneously to the target locus. Alternatively, the two components are administered separately, in any order.

Full Title Citation Front Review Classification	Date Reference Sequences	Attachments   Claims   KMC   Draw Desi

20. Document ID: US 20030092658 A1

L8: Entry 20 of 67 File: PGPB

PGPUB-DOCUMENT-NUMBER: 20030092658

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030092658 A1

TITLE: Novel human enzyme family members and uses thereof

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Meyers, Rachel E. Newton MA US Glucksmann, Maria Alexandra Lexington MA US Rudolph-Owen, Laura A. Jamaica Plain MΑ US

US-CL-CURRENT: <u>514/44</u>; <u>424/130.1</u>, <u>435/6</u>, <u>514/2</u>

## ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human

h e b b g ee e f h c ef b Record List Display Page 14 of 45

leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Full Title Citation Front	Review Classification D.	ate Reference Sequences	Attachments   Claims	KoviC - Draw, Desc

## 21. Document ID: US 20030083231 A1

L8: Entry 21 of 67

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083231

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030083231 A1

TITLE: Blood cell deficiency treatment method

PUBLICATION-DATE: May 1, 2003

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ahlem, Clarence N.	San Diego	CA	US	
Reading, Christopher	San Diego	CA	US	
Frincke, James	San Diego	CA	US	
Stickney, Dwight	Granite Bay	CA	US ·	
Lardy, Henry A.	Madison	WI	US	
Marwah, Padma	Middleton	WI	US	
Marwah, Ashok	Middleton	WI	US	
Prendergast, Patrick T.	Straffan		IE	

US-CL-CURRENT: <u>514/2</u>; <u>514/169</u>, <u>514/173</u>, <u>514/26</u>, <u>514/44</u>, <u>514/63</u>

## ABSTRACT:

The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D--glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17--one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost--4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandros- tane that can be used in the treatment method.

Full   Title   Citation   Front	Review   Classification   Date	Reference Sequences Affac	hments   Claims   KMC   Draw Desc

22. Document ID: US 20030073617 A1

L8: Entry 22 of 67

File: PGPB

Apr 17, 2003

h eb bgeeef

hc ef b e

PGPUB-DOCUMENT-NUMBER: 20030073617

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030073617 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: April 17, 2003

### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

US-CL-CURRENT: <u>514/2</u>; <u>514/171</u>, <u>514/27</u>, <u>514/283</u>, <u>514/34</u>, <u>514/449</u>, <u>514/8</u>

#### ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as polyglutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full Title Citation Front	Review Classification Dat	e Reference Sequences	Attachments Claims 6000	Draw. Des:

23. Document ID: US 20030073615 A1

L8: Entry 23 of 67 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073615

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030073615 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: April 17, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Bellaire	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

US-CL-CURRENT: 514/2; 514/8

### ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-

Record List Display Page 16 of 45

glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWC | Draw. Des.

24. Document ID: US 20030073118 A1

L8: Entry 24 of 67

File: PGPB

Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073118

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030073118 A1

TITLE: MID 9002, a human sulfatase family member and uses therefor

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Williamson, Mark W. Saugus MA US

US-CL-CURRENT: 435/6; 424/130.1, 514/1, 514/2, 514/44

#### ABSTRACT:

The invention provides isolated nucleic acids molecules, designated MID 9002 nucleic acid molecules, which encode novel sulfatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MID 9002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MID 9002 gene has been introduced or disrupted. The invention still further provides isolated MID 9002 proteins, fusion proteins, antigenic peptides and anti-MID 9002 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Full Title Citation Front Review Classification Date Reference Sequences	Attachments Claims Kill Draw Design

25. Document ID: US 20020151046 A1

L8: Entry 25 of 67

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151046

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020151046 A1

TITLE: 52871, a novel human G protein coupled receptor and uses thereof

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Glucksmann, Maria Alexandra Lexington MA US

Silos-Santiago, Inmaculada

Cambridge

MA

US

US-CL-CURRENT: 435/320.1; 435/325, 435/6, 435/69.1, 435/7.1, 514/2, 530/324, 530/387.7, 536/23.5

## ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 52871 nucleic acid molecules, which encode novel G-Protein Coupled Receptor molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52871 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52871 gene has been introduced or disrupted. The invention still further provides isolated 52871 proteins, fusion proteins, antigenic peptides and anti-52871 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Full Title Citation Front	Review Classification	Date Reference	Sequences Attachme	rts Claims RMC	Drawn Desc

26. Document ID: US 20020131959 A1

L8: Entry 26 of 67

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020131959

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020131959 A1

TITLE: Means and methods for the modulation of arteriogenesis

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47
Buschmann, Ivo Freiburg DE
Van Royen, Niels Gundelfingen DE
Hofer, Imo March DE

US-CL-CURRENT: 424/93.21; 424/85.1, 424/85.2, 514/2, 514/44

## ABSTRACT:

The present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar connections. In particular, the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an organ, tissue or cells with transforming growth factor beta 1 (TGF.beta.1) or a nucleic acid molecule encoding TGF.beta.1. The present invention also relates to the use of TGF.beta.1 or a nucleic acid molecule encoding TGF.beta.1 for the preparation of pharmaceutical compositions for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Furthermore, the present invention relates to a method for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF.beta.1. The present invention further involves the use of an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the

biological activity of TGF.beta.1 for the preparation of pharmaceutical compositions for the treatment of tumors.

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Des

27. Document ID: US 20020119913 A1

L8: Entry 27 of 67

File: PGPB

Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119913

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020119913 A1

TITLE: 61833, a novel human pyridoxyl-dependent decarboxylase family member and uses

thereof

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Glucksmann, Maria Alexandra Lexington MA US

US-CL-CURRENT: 514/2; 435/320.1, 435/325, 435/6, 435/69.1, 435/7.2, 530/324,

530/387.9, 536/23.5

#### ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 61833 nucleic acid molecules, which encode novel pyridoxyl-dependent decarboxylase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 61833 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 61833 gene has been introduced or disrupted. The invention still further provides isolated 61833 proteins, fusion proteins, antigenic peptides and anti-61833 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Full Title Citation Front Review	Classification   Date   Reference   Sequences   Attachments   Claims   KWC   Draw Desi

28. Document ID: US 20020061521 A1

L8: Entry 28 of 67

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061521

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061521 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Rosen, Craig A. Laytonsville MD US Ruben, Steven M. Olney MD US

Barash, Steven C.

Rockville

MD

US

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

#### ABSTRACT:

The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

· THEFT	******	7111111111111111111			***************************************				
- 1	ull	Title	Citation Front	Review	Classification Date	Reference Sequences	Attachments	Claims KWC	Draw Desc

29. Document ID: US 20020061294 A1

L8: Entry 29 of 67

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061294

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061294 A1

TITLE: MONONUCLEAR PHAGOCYTES IN THERAPEUTIC DRUG DELIVERY

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

LEWIS, CLAIRE E. SHEFFIELD GB
HARRIS, ADRIAN L. OXFORD GB
MARSHALL, JULIAN M OXFORD GB

US-CL-CURRENT: 424/93.21; 424/450, 435/320.1, 435/325, 435/69.1, 514/2, 514/44

#### ABSTRACT:

The invention relates to the exploitation of the migratory behaviour of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the munonuclear phagocyte to a target area.

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Desc

30. Document ID: US 20020058612 A1

L8: Entry 30 of 67

File: PGPB

May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor

and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Franco, Wayne P.

Rocky Hill

CT

US

US-CL-CURRENT: 514/2; 424/43

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Full Title Citation Front	Review Classification	Date Reference Sequences Atta	chments   Claims   KWWC   Draw Desc
	,		

## 31. Document ID: US 20020037832 A1

L8: Entry 31 of 67

File: PGPB

Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037832

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020037832 A1

TITLE: Use of alpha-MSH and EPO for preventing or treating ischemic conditions

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

STATE COUNTRY RULE-47 CITY NAME

DK Abyhoj Nielsen, Soren DK Abyhoj Frokiaer, Jorgen DK Frederiksberg Jonassen, Thomas Engelbrecht Norkild DK Bjerke, Thorbjorn Fredensborg

US-CL-CURRENT: 514/2; 514/169

b g ee e f e hc h e b

### ABSTRACT:

Alpha--melanocyte stimulating hormone (.alpha.-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions.

Full Title Citation Front Review	Classification Date Reference Sequences Attachments Claims KMC Draw Desc

## 32. Document ID: US 20020013275 A1

L8: Entry 32 of 67

File: PGPB

Jan 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020013275

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020013275 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: January 31, 2002

### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kunz, Lawrence L.	Redmond	WA	US	
Klein, Richard A.	Lynnwood	AW	US	
Reno, John M.	Brier	WA	US	
Grainger, David J.	Cambridge	AL	GB	
Metcalfe, James C.	Cambridge		GB	
Weissberg, Peter L.	Cambridge		GB	
Anderson, Peter G.	Birmingham		US	

US-CL-CURRENT: 514/12; 514/2, 514/411

## ABSTRACT:

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

Full Title C	itation   Front   Review	Classification	Date Reference	Sequences: Attacl	hments Claims	KMMC   Drawn Desc
***************************************	=					

33. Document ID: US 20020006895 A1

L8: Entry 33 of 67

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006895

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006895 A1

TITLE: Method of treatment of cardiovascular injuries

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Moulton, Karen S. Weston MA US Folkman, Judah Brookline MA US

US-CL-CURRENT: 514/2; 424/85.6, 424/85.7, 514/326, 514/475

## ABSTRACT:

The present invention provides a method for treating cardiovascular ailments. The method involves first screening an individual to determine their risk of having the potential for unstable plaques. Such individuals can be selected by looking at one of the following criteria: (i) increased plaque neovascularization, (ii) area ratio of intima to wall area of a plaque, (iii) evidence of plaque hemorrhage, or (iv) inflammatory cells associated with plaque vessels. Looking at these criteria permits one to select individuals having the potential for unstable plaques. The method then involves treating the selected individual with an effective amount of an angiogenesis inhibitor.

Full Title Citation Front Review Classification Date Reference Sequences (Attachments )	Claims   KWAC   Draw Desc

## 34. Document ID: US 20010053357 A1

L8: Entry 34 of 67 File: PGPB Dec 20, 2001

PGPUB-DOCUMENT-NUMBER: 20010053357

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010053357 A1

TITLE: LIGAND BINDING SITE OF RAGE AND USES THEREOF

PUBLICATION-DATE: December 20, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
STERN, DAVID	GREAT NECK	NY	US	
YAN, SHI DU	NEW YORK	NY	US	
SCHMIDT, ANN MARIE	FRANKLIN LAKE	NJ	US	
LAMSTER, IRA	WYCKOFF	NJ	US	

US-CL-CURRENT: 424/130.1; 514/12, 514/2, 530/350

## ABSTRACT:

P-Q-R-L-E-W-K (Seq. I.D. No. 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE. The present invention also provides for a method for inhibiting interaction of an amyloid-.beta. peptide with a receptor for advanced glycation end product which is on the surface of a cell, which comprises contacting the cell with the peptide or a functionally equivalent agent, wherein the peptide or agent is capable of inhibiting interaction of the amyloid-.beta. peptide with the receptor for advanced glycation end product, and the peptide or agent is present in an amount effective to inhibit interaction of the amyloid-.beta. peptide with the receptor for advanced glycation endproduct.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drawu Desc
					•							

35. Document ID: US 20010029251 A1

L8: Entry 35 of 67

File: PGPB

Oct 11, 2001

PGPUB-DOCUMENT-NUMBER: 20010029251

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010029251 A1

TITLE: Methods and compositions for preventing or retarding the development of a

atherosclerotic lesions

PUBLICATION-DATE: October 11, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Gonczol, Eva

Rosemont

PΑ

US

Berencsi, Klara

Rosemont

PA

US

US-CL-CURRENT: 514/44; 514/2

### ABSTRACT:

A method for preventing or retarding the development atherosclerotic lesions or restenosis involves administering to a subject, preferably a human, an effective amount of an anti-viral composition directed against CMV, and optionally an antimicrobial composition directed against C. pneumoniae. These compositions may be conventional chemical anti-microbial pharmaceutics. Alternatively, the compositions may contain a cytomegalovirus (CMV) protein or fragment thereof (or nucleic acid containing compositions expressing such protein or fragment). Such compositions may contain an immunogenic C. pneumoniae protein or fragment thereof (or nucleic acid containing compositions expressing such protein or fragment). The protein/nucleic acid compositions are administered in an amount capable of inducing cell mediated immunity and/or antibody response in the subject.

Review Classification Date Reference Sequence	

36. Document ID: US 6759386 B2

L8: Entry 36 of 67

File: USPT

Jul 6, 2004

US-PAT-NO: 6759386

h e b b g ee e f h c Record List Display Page 24 of 45

DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME

CITY

Full Title Citation Front Review Classification Date Reference

STATE

ZIP CODE

COUNTRY

Franco; Wayne P.

Rocky Hill

CT

060**67** 

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

### ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

************	**********		
	37.	Document ID:	US 6737404 B2

L8: Entry 37 of 67

File: USPT

May 18, 2004

Claims KWC Drawa Desc

US-PAT-NO: 6737404

DOCUMENT-IDENTIFIER: US 6737404 B2

TITLE: Methods of using analogs of human basic fibroblast growth factor mutated at

one or more of the positions glutamate 89, aspartate 101 or leucine 137

DATE-ISSUED: May 18, 2004

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Springer; Barry A. Wilmington DE Pantoliano; Michael W. Boxford PA Sharp; Celia M. Doylestown PA

US-CL-CURRENT: <u>514/12</u>; <u>514/2</u>, <u>530/399</u>

## ABSTRACT:

The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating

ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.

30 Claims, 2 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 2

38. Document ID: US 6696063 B1

L8: Entry 38 of 67

File: USPT

Feb 24, 2004

US-PAT-NO: 6696063

DOCUMENT-IDENTIFIER: US 6696063 B1

TITLE: Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or

without lipodystrophy

DATE-ISSUED: February 24, 2004

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Torres; Ramon A.

New York

Mili

US-CL-CURRENT: 424/198.1; 514/2, 530/399

## ABSTRACT:

Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.

27 Claims, 0 Drawing figures Exemplary Claim Number: 1

39. Document ID: US 6605592 B2

L8: Entry 39 of 67

File: USPT

Aug 12, 2003

US-PAT-NO: 6605592

DOCUMENT-IDENTIFIER: US 6605592 B2

TITLE: Protein HOFNF53

DATE-ISSUED: August 12, 2003

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Ni; Jian	Germantown	MD			
Baker; Kevin P.	Darnestown	MD			
Birse; Charles E.	North Potomac	MD			
Ebner; Reinhard	<b>Gaithe</b> rsburg	MD			
Fiscella; Michele	Bethesda	MD			
Komatsoulis; George A.	Silver Spring	MD			
LaFleur; David W.	Washington	DC			
Moore; Paul A.	Germantown	MD			
Olsen; Henrik S.	<b>Gaithe</b> rsbu <b>r</b> g	MD			
Rosen; Craig A.	Laytonsville	MD			
Ruben; Steven M.	Olney	MD			
Soppet; Daniel R.	Centreville	AV			
Young; Paul E.	Gaithersburg	MD			
Wei; Ping	Brookeville	MD			
Florence; Kimberly A.	Rockville	MD			

US-CL-CURRENT: 514/2; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1, 435/71.1, 435/71.2, 514/12, 514/8, 530/350

### ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. In particular, the present application relates to a novel human protein, Protein HOFNF53. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

19 Claims, 22 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 22

		·
Full Title Citation Front Review	Classifications Ohis Chiefence Claim	s KNMC Drawn Desc
	2007 200 2010 75.00000000000000000000000000000000000	

40. Document ID: US 6592862 B1

L8: Entry 40 of 67

File: USPT

Jul 15, 2003

US-PAT-NO: 6592862

DOCUMENT-IDENTIFIER: US 6592862 B1

TITLE: Methods for the modulation of the browth of collateral arteries and/or other

arteries from preexisting arteriolar corrections

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE

COUNTRY

Schaper; Wolfgang

Bad Nauheim/F

DE

hebbgeeef ebcefbe

Ito; Wulf D.

Luneburg

DE

US-CL-CURRENT: 424/85.1; 514/12, 514/2, 514/3

#### ABSTRACT:

Described is the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting tisque or malls with a monocyte chemotactic protein (MCP) or a nudeic acid molecule encoding said MCP. Furthermore, the use of a MCP or a nucleic acid molecule encoding said MCP for the preparation of pharmaceutical compositions for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described, Also provided are methods for the treatment of tumors comprising contacting tissue or cells with an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the attraction of monocytes. Described is further the use of an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar definections through attraction of monocytes for the preparation of pharmaceutical compositions for the treatment of tumors.

14 Claims, 14 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

Full Title Citation Front Review	Classification Date	laims KWMC Drawn Desc

41. Document ID: US 6558952 B1

L8: Entry 41 of 67

File: USPT

May 6, 2003

US-PAT-NO: 6558952

DOCUMENT-IDENTIFIER: US 6558952 B1

TITLE: Treatment for diabetes

DATE-ISSUED: May 6, 2003

INVENTOR-INFORMATION:

NAME CITY

TY STATE ZIP CODE COUNTRY

Parikh; Indu Chapel Hill NC

Lane; Anne Westmoun: CA

Nardi; Ronald V. Mahwah NJ

Brand; Stephen J. Lincoln MA

US-CL-CURRENT: <u>435/384</u>; <u>424/93.1</u>, <u>435/320.1</u>, <u>435/325</u>, <u>435/366</u>, <u>435/383</u>, <u>514/2</u>, <u>514/309</u>, <u>514/399</u>, <u>514/44</u>, <u>514/866</u>, <u>530/309</u>, <u>530/399</u>

## ABSTRACT:

Methods and compositions for treating dial mellitus in a patient in need thereof are provided. The methods include administrating to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF-.alpha., in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells

transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF-.alpha. gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin/CCK receptor ligand and EGF receptor ligand.

3 Claims, 16 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Full Title Citation Front	Review Classification Date Reference Clair	ns KWWC Draww Des

42. Document ID: US 6541224 B2

L8: Entry 42 of 67

File: USPT

Apr 1, 2003

US-PAT-NO: 6541224

DOCUMENT-IDENTIFIER: US 6541224 B2

TITLE: Tumor necrosis factor delta polypephides

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Yu; Guo-Liang Berkeley CA
Ni; Jian Germantown MD
Gentz; Reiner L. Rockville MD

Dillon; Patrick J. Carlsbad

US-CL-CURRENT: 435/69.5; 435/69.1, 435/69.7, 435/7.71, 435/70.1, 514/12, 514/2,

CA

530/350, 530/351

#### ABSTRACT:

The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

50 Claims, 7 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 11

Full Title Citation	Front	Review Classific	ition   Date	eference	Claims	KMMC Drawt Desc

43. Document ID: US 6541008 B1

L8: Entry 43 of 67 File: USPT Apr 1, 2003

US-PAT-NO: 6541008

DOCUMENT-IDENTIFIER: US 6541008 B1

Feb 18, 2003

## Record List Display

TITLE: Vascular endothelial growth factor of protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

ZIP CODE COUNTRY NAME CITY STATE Dunedin NZWise; Lyn M. NZDunedin Mercer; Andrew A. Dunedin ΝZ Savory; Loreen J. Fleming; Stephen B. NZDunedin ΑU Stacker; Steven A. Parkville

US-CL-CURRENT: 424/198.1; 514/2, 530/350

### ABSTRACT:

The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate useful cellular responses and/or antagonize undesired biological activities. Disclosed are methods which stimulate or inhibit these biological activities, methods for therapeutic applications and antagonists of ORFV2-VEGF and/or NZ10.

17 Claims, 15 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 10

ं Full ं	Title	Citation Front Review Classification Dail Reference Claims KMC Draw Desc
•••••	******	
	44.	Document ID: US 6521211 B1

File: USPT

US-PAT-NO: 6521211

L8: Entry 44 of 67

DOCUMENT-IDENTIFIER: US 6521211 B1

TITLE: Methods of imaging and treatment with targeted compositions

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Unger; Evan C. Tucson AZ

Wu; Yunqiu T. cson AZ

US-CL-CURRENT:  $\underline{424/9.52}$ ;  $\underline{424/450}$ ,  $\underline{424/9.5}$ ,  $\underline{424/9.51}$ ,  $\underline{514/18}$ ,  $\underline{514/2}$ ,  $\underline{600/431}$ ,  $\underline{600/437}$ 

#### ABSTRACT:

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of

ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

58 Claims, 17 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 12

Claims KWMC Draw Desc

45. Document ID: US 6518238 B1

L8: Entry 45 of 67

File: USPT

Feb 11, 2003

US-PAT-NO: 6518238

DOCUMENT-IDENTIFIER: US 6518238 B1

TITLE: Method of treating psychological and metabolic disorders using IGF or

Full Title Citation Front Reviews Classification Date Reference

IGF/IGFBP-3

DATE-ISSUED: February 11, 2003

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Mascarenhas; Desmond

Lo: s Hills

CA

US-CL-CURRENT: 514/2; 514/12, 530/399

## ABSTRACT:

Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with TOF that HOF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of TGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.

4 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Review Classification Date Reference Claims KMC Draw Desc

**1** 46. **Document ID**: **US** 6518236 B1

L8: Entry 46 of 67

File: USPT

Feb 11, 2003

US-PAT-NO: 6518236

DOCUMENT-IDENTIFIER: US 6518076 BD

e b b g ee e f h

e ho

TITLE: FGF homologs

DATE-ISSUED: February 11, 2003

INVENTOR-INFORMATION:

NAME STATE ZIP CODE COUNTRY

Deisher; Theresa A. Seattle WA
Conklin; Darrell C. Seattle WA
Raymond; Fenella WA
Bukowski; Thomas R. Wattle WA
Holderman; Susan D. Seattle WA

Hansen; Birgit Seattle WA

Sheppard; Paul O. Redmond WA

US-CL-CURRENT: 514/2; 435/69.7, 514/12, 530/350, 530/399

### ABSTRACT:

The present invention relates to colynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family the polypeptides, and polynucleotides encoding them, are proliferative for muscle of the in particular cardiac cells and may be used for remodeling cardiac tissue and approving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.

5 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

Full Title Citation Front Reviews (Station Date: Reference) Claims KMC Draw	a Desc

47. Document ID: US 6514937 B1

L8: Entry 47 of 67 File: USPT Feb 4, 2003

US-PAT-NO: 6514937

DOCUMENT-IDENTIFIER: US 651403

TITLE: Method of treating psychological and metabolic disorders using IGF or

IGF/IGFBP-3

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME CTTT STATE ZIP CODE COUNTRY

Mascarenhas; Desmond tos Hills CA

US-CL-CURRENT: 514/12; 424/139 324/520, 124/537, 424/546, 514/2, 514/3, 514/4,

530/303, 530/324, 530/333

### ABSTRACT:

Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated in high sense sense, aging, or premature aging by treating such subjects with the or mutant 1GF either alone or complexed with IGFBP-3.

Page 32 of 45

Record List Display

Methods for increasing the 1900 and the DHEA or DHEAS and treating or alleviating the symptoms of subjects with diagrams characterized by low levels of DHEA or DHEAS by administering effective amounts. IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided. Also a wided are methods for the treatment of polycystic ovarian syndrome (PCOS) by langer administration of IGF/IGFBP-3 complex.

1 Claims, 0 Drawing figures Exemplary Claim Number: 1

Full Title Citation Front Reviews Classification Date Reference Claims MMC Draw Desc

48. Document ID: US 55 120 15 B1

L8: Entry 48 of 67

File: USPT

Feb 4, 2003

US-PAT-NO: 6514935

DOCUMENT-IDENTIFIER: US 651 135

TITLE: Methods of treating hyper - sion

DATE-ISSUED: February 4, 2000

INVENTOR-INFORMATION:

NAME

STATE

ZIP CODE

COUNTRY

Lee; Mu-En

MA

Newn

Yet; Shaw-Fang

US-CL-CURRENT: 514/2

ABSTRACT:

The invention features a method of inhibiting hypertension in a mammal by administering to the mammal and regard that reduces expression or activity of SmLIM.

3 Claims, 24 Drawing figure Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full Title Citation Front Review Classification Dalij Scherence

Claims KMC Draw Des

49. Document ID: 1997 B1

L8: Entry 49 of 67

File: USPT

Dec 31, 2002

US-PAT-NO: 6500798

DOCUMENT-IDENTIFIER: US 65: 198 B1

\*\* See image for Certific - of Co recting

TITLE: Use of colostrinin, constituent pentides thereof, and analogs thereof, as

oxidative stress regulators

DATE-ISSUED: December 31, 2002

INVENTOR-INFORMATION:

NAME

C : TY

ZIP CODE

COUNTRY

Stanton; G. John

as Cill

STATE TX

Hughes, Jr.; Thomas K.

Calvesta

Boldogh; Istvan

Elveston

TXTX

US-CL-CURRENT: 514/2; 424/535, 514/12, 514/13, 514/14, 514/15, 514/16, 514/17, 514/18, 530/300, 530/324, 530/326, 530/327, 530/<u>328, 530/329, 530/334, 530/350</u>

## ABSTRACT:

The present invention provides met. its than utilize compositions containing colostrinin, an constituent peptid thereof, an active analog thereof, and combinations thereof, as an oxida estress regulator.

23 Claims, 11 Drawing figure a Exemplary Claim Number: 1 Number of Drawing Sheets: 8

	Full Title Citation Front Review Classification D	, Terence Claims	KWWC Drawt Desc
--	---	------------------	-----------------

50. Document ID: US 649814 B1

L8: Entry 50 of 67

File: USPT

Dec 24, 2002

US-PAT-NO: 6498144

DOCUMENT-IDENTIFIER: US 6498144 B1

TITLE: Use of scatter factor to en since and ingenesis

DATE-ISSUED: December 24, 2002

INVENTOR-INFORMATION:

NAME

CITY

ZIP CODE STATE

COUNTRY

Goldberg; Itzhak D.

Englewhod

NJ

Rosen; Eliot M.

Port mingtor NY

US-CL-CURRENT: 514/12; 514/2, 530 14, 530/350, 530/399

## ABSTRACT:

This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation utilizing scatter factor, either alone or in combination with a growth factor.

5 Claims, 39 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 12

		·	
Full Title 0	Citation Front Review Classification Dates	Reference Claims KNNC Dram, De	Š
		,	

e

51. Document ID: US 649192. 31

L8: Entry 51 of 67 File: USPT Dec 10, 2002

US-PAT-NO: 6491922

DOCUMENT-IDENTIFIER: US 6491922 Bl

TITLE: Methods and compounds for treating autoimmune and vascular disease

DATE-ISSUED: December 10, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Ho; John L. New York NY

US-CL-CURRENT: 424/193.1; 424/265. 424/265.1, 514/2

#### ABSTRACT:

The present invention relates to methods of treating inflammatory diseases, inhibiting production of adhesion is lecules on endothelial cells, inhibiting production of nitric oxide synthas by macrophages, inhibiting production of tissue factor by endothelial cells, rever any the inhibitory effects of lipophosphoglycan on endothelial cells or macrophages, and targeting a material to endothelial cells, fibroblasts, or monocytes, by adminimized the lipophosphoglycan or lipophosphoglycan or lipophosphoglycan analog. Also disclosed is an isolated and antagonized transcription of the gene.

14 Claims, 42 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 38

# Full | Title | Citation | Froftis Review | Classification | Dates Science | Claims | Claims | KMC | Draw Desc

52. Document 1D: US 647579 B1

L8: Entry 52 of 67 File: USPT Nov 5, 2002

US-PAT-NO: 6475796

DOCUMENT-IDENTIFIER: US 6475796 B1

TITLE: Vascular endothalial growth factor variants

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME CIR STATE ZIP CODE COUNTRY

Pollitt; N. Stephen Lo Pltos CA Abraham; Judith A. Se Se CA

US-CL-CURRENT: 435/455; 424/198.1, 44/2, 530/350

ABSTRACT:

The invention is directed to a met ad of enhancing the biological activity of

h eb bgécef e hc ef be

the invention concerns thods of containing such VEGF variants.

vascular endothelial growth factor (VEGF). The invention further concerns certain VEGF variants having enhanced biol dical activity, methods and means for preparing these variants, and phachaceutical compositions comprising them. In a further aspect, standat using, and articles of manufacture

17 Claims, 17 Drawing figures Exemplary Claim Number: 🔝 Number of Drawing Sheet : 17

Full Title Citation Front **Re**view Class**river** Date Reference

53. Document ID: US 644093 31

L8: Entry 53 of 67

File: USPT

Aug 27, 2002

US-PAT-NO: 6440934

DOCUMENT-IDENTIFIER: US 440934 B

TITLE: Angiogenically e ective u.

.esc of FGF-2 and method of use

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME

CIT

STATE ZIP CODE COUNTRY

Whitehouse; Martha Jo

Sa: Trancisco

CA

US-CL-CURRENT: 514/12; 24/423, 4 514/410, 514/411, 514/5, 514/56, 536/17.2, 536/21, 604/1-1.03

. 424/94.4, 435/69.4, 514/2, 514/358, /350 . 530/380, 530/381, 530/383, 530/399,

## ABSTRACT:

invention is directed to a unit do 48 .mu.g/kg of an FGF-2 of SEQ II mutein thereof in a pha maceutica present invention is di acted to artery disease, compris ng admini. peripheral vein of a husan patient safe and angiogenically effective active fragment or mutein thereof. before re-treatment is required. 3 to a method of administration which fluids, heparin and/or ate of ir present invention is di amted to therapeutically effective amount therapeutically effecti = carrier unexpected; in addition penefit w

The present invention has multiple aspects. In particular, in one aspect, the present composition comprising 0.2 .mu.g/kg to an angiogenically active fragment or contable carrier. In another aspect, the ethos for treating a human patient for coronary ring thato one or more coronary vessels or a n need of treatment for coronary artery disease a se of a recombinant FGF-2, or an angiogenically The single unit dose composition of the present invention provides an angiogenic e fect in a human CAD patient that lasts six months another aspect, the present invention is directed optimizes patient's safety. In this embodiment, play a role. In another aspect, the Mrs eutical composition comprising a FGF-2, alone or in combination with heparin, in a

he ma mitude and duration of benefit were the route was unexpected.

e

58 Claims, 5 Drawing figures Exemplary Claim Number: Number of Drawing Sheet: 5

54. Document ID: US 640713

L8: Entry 54 of 67

File: USPT

Jun 18, 2002

US-PAT-NO: 6407135

DOCUMENT-IDENTIFIER: UP 6407135 B1

TITLE: Conjugates of d thiocarbama' as with pharmacologically active agents and uses

therefor

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Lai; Ching-San

Encinitas

 $-\epsilon \Lambda$ 

Wang; Tingmin

San Marc

 $F_{a}$ 

US-CL-CURRENT: 514/423; 514/2, 514 4, 533/402, 548/565, 548/573

### ABSTRACT:

side-effects due to the protective fects imparted by modifying the cleaved.

In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarb es, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention continuates about a new class of pharmacologically active agents (e.g., anti-inflamma > 27 age to) which cause a much lower incidence of pharmacologically active agents as "scribed herein. In addition, invention conjugates are more effective than amodified pharmacologically active agents because cells and tissues contacted by the harmacologically active agent(s) are protected from the potentially damaging effe of mitric oxide overproduction induced thereby as a result of the co-production o oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologica active agent, when invention conjugate is

21 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

Full Title Citation Front, Review Classification, Date Agreence Claims MAC Draw Desc

55. Document ID: US 640355

L8: Entry 55 of 67

File: USPT

Jun 11, 2002

US-PAT-NO: 6403552

DOCUMENT-IDENTIFIER: US 6403552 B1

TITLE: Ob receptor and methods for the diagrams is and treatment of body weight

disorders

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME CI : STATE ZIP CODE COUNTRY

eb b geeef the **ef** b h

Tartaglia; Louis A. MA Tepper; Robert I. TA? MΑ B: MA Culpepper; Janice A. line H: White; David W. ook MA

US-CL-CURRENT: 514/2; 424/143.1, 428 49.7

#### ABSTRACT:

The present invention relates to t of nucleotides that encode Ob recei mammalian body weight regulation. cell expression systems, ObR prot∈ activity that can be used for diag and/or the treatment of body weigh cachexia and anorexia.

so very, identification and characterization (ONR), a receptor protein that participates in invention encompasses obR nucleotides, host firmion proteins, polypeptides and peptides, antibodies to the receptor, transg an anals that express an obR transgene, or recombinant knock-out animals that we not express the ObR, antagonists and agonists of the receptor, and other compound that modulate obR gene expression or ObR is, any screening, clinical trial monitoring, asorders, including but not limited to obesity,

41 Claims, 40 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 34

Full Title Citation Front, Review Classification Date Careference

Claims

56. Document ID: US 62357

L8: Entry 56 of 67

File: USPT

May 22, 2001

US-PAT-NO: 6235713

DOCUMENT-IDENTIFIER: US 6235713 BT

DATE-ISSUED: May 22, 2001

### INVENTOR-INFORMATION:

COUNTRY STATE ZIP CODE NAME CITY AU Achen; Marc G. Fitzroy ΑU i dha Wilks; Andrew F. AU Stacker; Steven A. North arby FI Alitalo; Kari Espoc

US-CL-CURRENT: 514/12; 514/2, 530/ 530/412, <u>530/413</u>

### ABSTRACT:

permeability, as well as nucleotid antibodies and other antagonists expressing it, pharmaceutical com and diagnostic applications.

VEGF-D, a new member of the PDGF for in of growth factors, which among other things stimulates endothelial cell prolis and angiogenesis and increases vascular regrences encoding it, methods for producing it, transfected or transformed host cells for as containing it, and uses thereof in medical

16 Claims, 22 Drawing figures

c + h cef e b geeef h e b

Exemplary Claim Number: 1 Number of Drawing Sheets: 21

ker coleme Claims KNMC Draw Desc Full Title Citation Front Review Class

57. Document ID: US 61567.

L8: Entry 57 of 67

File: USPT

Dec 5, 2000

US-PAT-NO: 6156731

DOCUMENT-IDENTIFIER: US 6156

TITLE: Polypeptide composition for

admin**istration** 

DATE-ISSUED: December 5, 2000

INVENTOR-INFORMATION:

NAME

CI. · view STATE ZIP CODE

COUNTRY

Grass; George M.

Sweetana; Stephanie A.

CA

IN

US-CL-CURRENT: <u>514/15</u>; <u>424/185.1</u>, 530/300, 530/311, 530/313, 530/32 6, 530/327, 530/328

514/12, 514/13, 514/14, 514/16, 514/2,

ABSTRACT:

There is disclosed a composition selected from LHRH, an LHRH and therapeutically effective amount protease enzyme inhibitor envelop possesses enhanced bioavailability about a protesse sensition and a somatostatin analog, in a permeability enhancing agent, and a protesse enzyme inhibitor envelop possesses enhanced bioavailability and administration.

16 Claims, 4 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

**58.** Document ID: US 603408

L8: Entry 58 of 67

File: USPT

Mar 7, 2000

US-PAT-NO: 6034053

DOCUMENT-IDENTIFIER: US 60340

TITLE: EGF-isoflavone conjugates prevention of restenosis

DATE-ISSUED: March 7, 2000

**INVENTOR-INFORMATION:** 

NAME CITY

ZIP CODE STATE

COUNTRY

Uckun; Fatih M.

Trieu; Vuong N. lose :

White 🐣

MN MN

h e b b g ee e f c ef

Page 39 of 45

## Record List Display

530/391.7

ABSTRACT:

Genistein, for inhibiting or prev

A protein conjugate containing EG d to a tyrosine kinase inhibitor such as estenosis following vascular injury.

19 Claims, 35 Drawing figure: Exemplary Claim Number: i Number of Drawing Sheets: 7

Full Title Citation Front Review Classific	Dis Référence Claims KMC Draw Desc

59. Document ID: US 60.

L8: Entry 59 of 67

File: USPT

Feb 22, 2000

US-PAT-NO: 6027921

DOCUMENT-IDENTIFIER: US 6027921

TITLE: Chimeric proteins for use DNA encoding chimeric proteins

insport of a selected substance into cells and

DATE-ISSUED: February 22, 2000

INVENTOR-INFORMATION:

STATE ZIP CODE COUNTRY NAME

Heartlein; Michael W. MA ah Lemontt; Jeffrey F. tton MA MA Concino; Michael F.

325, 435/366, 514/2, 530/350, 530/399, **US-CL-CURRENT:** 435/69.7; 135/32

536/23.4

### ABSTRACT:

h.

Chimeric proteins, which comprise carrier domain which binds a cell useful in transporting a selected blood or lymph, into cells; quant chimeric proteins; DNA emoding encoding the chimeric proceins; chimeric proteins, which express method of producing the chimeric proteins; a method of using the and a method of reducing vtrace administration of the chameric r substance into cells.

49 Claims, 18 Drawing figures Exemplary Claim Number: Number of Drawing Sheets: 17

ad-binding domain of a first receptor and a a meceptor other than the first receptor, ance present in extracellular fluids, such as me assays for the selected substance using meric proteins; plasmids which contain DNA cells, modified to contain DNA encoding the tionally, secrete the chimeric proteins; a a method of isolating the chimeric proteins to assay the selected substance; evels of the selected substance through mich results in transport of the selected

Full Title Citation Fig. 18 19 Class Space Reference

60. Document ID: US 60253

L8: Entry 60 of 67

File: USPT

Feb 15, 2000

US-PAT-NO: 6025368

DOCUMENT-IDENTIFIER: US -025368

TITLE: Method for trea s chronic stress-related disorders using IGF he .

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

STATE ZIP CODE COUNTRY NAME CIT

Mascarenhas; Desmond ills CALos Sanders; Martin Hi] CA

US-CL-CURRENT: 514/310: ....../69.1 514/2, 530/303, 530/324, 530/333

#### ABSTRACT:

reatir Methods are provided psychological disorder / metabol disorders, conditions as ociated treating such subjects with IGF increasing the levels - FA c subjects with disorder .∴act+ effective amounts of THE clone of for increasing the level of T4 at with disorders characterized by 1 amounts of IGF alone complexe

eviating the symptoms of subjects with Fors, chronic stress-related disorders, sleep mal senescence, aging, or premature aging by one or complexed with IGFBP-3. Methods for treating or alleviating the symptoms of W levels of DHEA or DHEAS by administering ad with IGFBP-3 are also provided. Methods ing or alleviating the symptoms of subjects els of T3 or T4 by administering effective GFBP-3 are additionally provided.

6 Claims: 0 Drawing in Exemplary Claim Number: ...

Title Citation Fixed Reviews CLA

61. **Document** 10 IS 6015

L8: Entry 61 of 67

File: USPT

Jan 18, 2000

US-PAT-NO: 6015786

DOCUMENT-IDENTIFIE

5786

levels using IGF or IGF/IGFBP-3 TITLE: Method for incrementing sex

DATE-ISSUED: January 1:

INVENTOR-INFORMATION:

ZIP CODE COUNTRY STATE NAME CIT

Mascarenhas; Desmc. CA

CASanders; Martin

 $\frac{514}{2}$ ,  $\frac{514}{21}$ ,  $\frac{514}{3}$ ,  $\frac{514}{4}$ US-CL-CURRENT: 514/12; 124/520,

ABSTRACT:

h c eb b g coef

Methods are provided for treating psychological dison in the tabe. disorders, conditions and winater treating such subje s TG:
Methods for increas q Methods for increas g symptoms of subject war disadministering effec mounts are also provided. I to ds for it the symptoms of sub c with diadministering effect lv amounts are additionally probin

riating the symptoms of subjects with rs, chronic stress-related disorders, sleep senescence, aging, or premature aging by MF either alone or complexed with IGFBP-3. DHEAS and treating or alleviating the lized by low levels of DHEA or DHEAS by muhant IGF alone or complexed with IGFBP-3 and the level of T4 and treating or alleviating characterized by low levels of T3 or T4 by mutant IGF alone or complexed with IGFBP-3

6 Claims, 0 Drawing i Exemplary Claim Num E

## Full Title & Citation Front Review Class

## Confidence

**Elaims KW**IC Draw Desc

☐ 62. Document 19: US 5935:

L8: Entry 62 of

File: USPT

Aug 10, 1999

US-PAT-NO: 5935924

DOCUMENT-IDENTIFIED 9355 1

TITLE: Treatment of a lestive "

DATE-ISSUED: August 0 909

INVENTOR-INFORMATIC

TATE ZIP CODE COUNTRY NAME

Bunting; Stuart Harri CA

Clark; Ross

CA Gillett; Nancy ំនេះ ន CAJin; Hongkui San F CA Yang; Renhui

: :

US-CL-CURRENT: 514/

### ABSTRACT:

A mammal with conge e . . . reated by administering to the mammal an heart . rament results in increased left ventricular effective amount of the other at maximum, increased cardiac output, and also results in reduced left ventricular cystolic pressure, and asseries increased stroke volume in the st la vascular resistance. These measurements end-diastolic pressure ad medu st in vascular resistance. These measurements otion by increased ventricular contractility and indicate improveme: ar liam anc: decreased periphera

12 Claims, 5 Drawin in thes Exemplary Claim Nu:

Number of Drawing 8

***************************************	5 555 FF 1	***************************************		
53. Document	US 5°F	Ž		
<b>L8:</b> Entry 63 of 67			Te: USPT	Aug 3, 1999
US-PAT-NO: 5932540				
DOCUMENT-IDENTIFIER:	3251			
** See image for <u>Ce</u> :	<b>ċe</b>	<u>Frr</u>		·
TITLE: Vascular endot	1 g.	fact		
DATE-ISSUED: August	:9			
INVENTOR-INFORMATION				COLUMBAN
NAME	CITY		STATE ZIP CODE	COUNTRY
Hu; Jing-Shan	lun	£.	**	
Rosen; Craig A.	∍ayt	il. ∋	CM	
Cao; Liang	loi	à		НК
US-CL-CURRENT: $514/2$	<u> 326</u>	<u>9</u> ,	402	
ABSTRACT:				
Disclosed are human	pol ···	3	pingically active, diagn	osticallv or
therapeutically usef	:m·		b derivatives thereof,	
encoding such VEGF2 }	pti:	Al. o	ded are procedures for	
polypeptides by recor	la (	ques	ntibodies and antagoni	
polypeptides. Such po	5i	be 1	therapeutically for st	
healing and for vasc antibodies and antage	is: s <b>t</b> o	r.	provided are methods anglogenesis and thus	
inflammation, diabet	tinopat		id arthritis, and psor	
,	1		, ,	
186 Claims, 22 Drawi	nures			
Exemplary Claim Numbe				
Number of Drawing Sh	., 9			
			•	
Full Title Citation From	S. Marian State Co.	7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Retele Cal	Claims KWC Draw Desc
The state of the s	14 44 14 14 14 14 14 14 14 14 14 14 14 1		***************************************	
F (4 D		•	•	
Document	US 5021			•
<b>L8:</b> Entry 64 of 67			Tile: USPT	Jul 13, 1999
				*
US-PAT-NO: 5922322				
DOCUMENT-IDENTIFIER:	20			
mimin. Edbada (acar)	:= <del>+</del> 4		is by fibrinolytic mat	riv .
TITLE: Fibrin(ogen) metalloproteinase	iati.	· ·	is by libilinolytic mat	LIX
ne carropro cernase				
DATE-ISSUED: July 13		š.		
INVENTOR-INFORMATION				
NAME			STATE ZIP CODE	COUNTRY
Bini; Alessandra			ИĀ	
US-CL-CURRENT: 424/97	424	20 1	<u>63, 435/212, 435/226, 5</u>	1 <u>4</u> / <u>2</u>
$\mathbf{h} = \mathbf{e} \cdot \mathbf{b}$ , $\mathbf{b} \cdot \mathbf{g}$ .	<i>§</i> *		c ef b e	

### ABSTRACT:

The invention provides fibrinogen, and relate preferably an endogenc can be performed in vi (ogen) and fibrinolytic method of thrombolytic administered to a sub metalloproteinase can preferably with agents fibrinolytic therapy. fibrinolytic metallopr procedures. Also provi performing fibrinolytic

tether reusing degradation of fibrin(ogen) (i.e., fibrin, by eans of a fibrinolytic metalloproteinase, of in a such as MMP-3. The method of the invention dr.a.s di enstic information characterizing fibrin The mathod can also be performed in vivo as a a a fibrinolytic metalloproteinase is thrombus in situ. The endogenous fibrinolytic in conjunction with other active agents, admin. lytic activity to improve thrombolytic and urther provides compositions containing a -ving ': i inver - performance of fibrinolytic or thrombolytic esclude a fibrinolytic metalloproteinase for

30 Claims, 11 Drawing Exemplary Claim Numbe: Number of Drawing Shew

Full Title Citation Faori

Electrical designation of the control of the contro

ly ic andedures.

Claims KVOC Draw D

.... 65. Document 1

L8: Entry 65 of 67

File: USPT

Oct 20, 1998

US-PAT-NO: 5824644

DOCUMENT-IDENTIFIER: U #2484

TITLE: Method of atten

- . . . sis

Souis

DATE-ISSUED: October 2

INVENTOR-INFORMATION:

NAME

STATE

MO

ZIP CODE

COUNTRY

Abendschein; Dana R.

ı.F.

US-CL-CURRENT: 514/12:

11/01, 530/324, 530/350, 530/380

ABSTRACT:

A method is disclosed comprises administer: the blood vessel subjetactor pathway inhibit substantially reduce from about 0.5 mg/kg twelve (12) hours to see the comprise of the second s

a i to . (TPPL) stenosis after balloon angioplasty. The method enterally or locally to the luminal surface of iloon angioplasty an effective amount of tissue prolonged period of time sufficient to include. An exemplary amount of the TFPI is the sea prolonged administration of about

14 Claims, 13 Drawing Exemplary Claim Number Number of Drawing She

Full Tille (Challan)

66. Document

L8: Entry 66 of €

File: USPT Aug 26, 1997

3.567 10.1

US-PAT-NO: 5661122

DOCUMENT-IDENTIFIER: 6111.

TITLE: Treatment of ire

DATE-ISSUED: August 2

INVENTOR-INFORMATIO

COUNTRY NAME STATE ZIP CODE

CAClark; Ross G. Jin; Hongkui rit.  $\cap \Lambda$ Paoni; Nicholas F.  $\cdot A$ 

CA Yang; Renhui

US-CL-CURRENT: 514/0:

ABSTRACT:

Methods of enhancing and and a second mality and cardiac performance in a mammal ed. I a first method a mammal with with congestive hea ministering to the mammal an effective congestive heart far (GH) and insulin-like growth factor (IGFamount of a combinat tering to the mammal an effective amount of a I). A second method co plesence of an ACE inhibitor. This method results combination of GH and dislity and cardiac performance above the level in enhancement of management eferably the mammal is a human. achieved with ACE i

8 Claims, 13 Drawin Exemplary Claim Nur Number of Drawing

Full Title Enation From

Reference Claims KWIC Draw. Desc

**Document** 5

Mar 11, 1997 L8: Entry 67 of File: USPT

US-PAT-NO: 5610134 DOCUMENT-IDENTIFIED:

t failure TITLE: Treatment of

DATE-ISSUED: March

INVENTOR-INFORMATI

NAME STATE ZIP CODE COUNTRY

Clark; Ross G. CA $^{\circ}$ A Jin; Hongkui

rest to CAPaoni; Nicholas F.

" + inc Yang; Renhui CA

US-CL-CURRENT: 514/

### ABSTRACT:

Methods of enhancing with congestive heart of a combination of GH and in enhancement of method achieved with ACE

10 Claims, 13 Drawi Exemplary Claim Num Number of Drawing ity and cardiac performance in a mammal d. In a first method a mammal with inistering to the mammal an effective (GH) and insulin-like growth factor (IGF-ring to the mammal an effective amount of a presence of an ACE inhibitor. This method results dity and cardiac performance above the level referably the mammal is a human.

Full Title Citation	ं व्यक्तिकृति । संदर्भ के विकास	Sign Marketon	Clai	ms KWC Draw Desc
Clear Gener				enerate OACS
Terms			Documents	
L7 AND co				67

Change Forms!

ext Page

Go to Doc#

# **Hit List**

Clear Generate Collection Print Fwd Refs Bkwd Refs Generate OACS

Search Results - Record(s) 1 through 33 of 33 returned.

1. Document ID: US 6139819 A

Using default format because multiple data bases are involved.

L27: Entry 1 of 33

File: USPT

Oct 31, 2000

US-PAT-NO: 6139819

DOCUMENT-IDENTIFIER: US 6139819 A

\*\* See image for Certificate of Correction \*\*

TITLE: Targeted contrast agents for diagnostic and therapeutic use

DATE-ISSUED: October 31, 2000

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE

COUNTRY

Unger; Evan C.

Tucson

ΑZ

Fritz; Thomas A.
Gertz; Edward W.

Tucson
Paradise Valley

AZ AZ

US-CL-CURRENT: 424/9.52; 424/450, 424/9.51

Full Title Citation Front Review Classification Date Reference Claims KMC Draw Des

2. Document ID: US 6133274 A

L27: Entry 2 of 33

File: USPT

Oct 17, 2000

US-PAT-NO: 6133274

DOCUMENT-IDENTIFIER: US 6133274 A

TITLE: Hydroxyl-containing bicyclic compounds

DATE-ISSUED: October 17, 2000

INVENTOR-INFORMATION:

CITY

STATE ZIP CODE

COUNTRY

Underiner; Gail E.

Brier

AW AW

Porubek; David Klein; J. Peter Seattle Vashon Island

WA

Woodson; Paul

Edmonds

WA

US-CL-CURRENT: 514/263.36; 544/267

ABSTRACT:

NAME

Disclosed are therapeutic compounds having the formula:

h eb bgeeef e

h c ef

b e

(R) j-(core moiety),

including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 -- (CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 -- (CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 -- CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.

13 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 10

Full Title Citation Front Review	KWMC   Drawn Des
	*

## 3. Document ID: US 6124433 A

L27: Entry 3 of 33

File: USPT

Sep 26, 2000

US-PAT-NO: 6124433

DOCUMENT-IDENTIFIER: US 6124433 A

TITLE: Compositions and methods for treatment and diagnosis of cardiovascular disease

DATE-ISSUED: September 26, 2000

INVENTOR-INFORMATION:

NAME ZIP CODE CITY STATE COUNTRY

Falb; Dean A. Wellesley MA Gimbrone, Jr.; Michael A. Jamaica Plain

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/324, 530/326, 536/23.1,

<u>536/23.5</u>

### ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds

in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

5 Claims, 53 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 53

Full	Title   Citation   Front   Review	Classification   Date   Reference	Claims   KMC   Draw Desc
		•	
······			
	4. Document ID: US 610	3730 A	
L27:	Entry 4 of 33	File: USPT	Aug 15, 2000

US-PAT-NO: 6103730

DOCUMENT-IDENTIFIER: US 6103730 A

TITLE: Amine substituted compounds

DATE-ISSUED: August 15, 2000

### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		
Ridgers; Lance H.	Bothell	WA		

US-CL-CURRENT: 514/263.2; 514/151, 514/210.21, 514/263.21, 514/263.22, 514/263.23, 514/263.24, 514/263.35, 544/268, 544/269, 544/270, 544/271, 544/272

### ABSTRACT:

Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula:

CORE MOIETY--(R).sub.j

In these compounds, j is an integer from one to three; the core moiety is a cyclic core, the cyclic core being non-cyclic or at least one five- to seven-member non-heterocyclic ring or heterocycle; and R is selected from the group consisting of amine, hydrogen, halogen, hydroxyl, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic group or formula I. At least one R having formula I: ##STR1## In formula I, n is an integer from four to twenty; and each R.sub.1 or R.sub.2 is independently hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or cyclic or heterocyclic group. The compounds are useful in treating or preventing, for example, sepsis syndrome, hematopoietic or organ toxicity, cancer, viral activity, AIDS and AIDS-related indications, allopecia caused by cytotoxic therapies, and progression of an inflammatory or autoimmune disease.

7 Claims, 23 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 23

	Review Classification Date Reference	Claims KMC Drawt Desc
run inne channi right	Meliletti Classification Date Meleterice	C121113 1 10910   01200 0 630
		•

## 5. Document ID: US 6100271 A

L27: Entry 5 of 33

File: USPT

Aug 8, 2000

US-PAT-NO: 6100271

DOCUMENT-IDENTIFIER: US 6100271 A

TITLE: Therapeutic compounds containing xanthinyl

DATE-ISSUED: August 8, 2000

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	AW		
Leigh; Alistair J.	Brier	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	AW		

US-CL-CURRENT: 514/263.2; 514/210.21, 514/234.2, 514/263.22, 514/263.23, 514/263.24, 514/263.35, 544/268, 544/269, 544/271

### ABSTRACT:

Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:

CORE MOIETY -- (R).sub.j

wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; 0; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub. (1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyallyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

14 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

Full Title Citation Front Review Classification Date Reference	Drawt Desc

e

6. Document ID: US 6093743 A

L27: Entry 6 of 33

File: USPT

Jul 25, 2000

US-PAT-NO: 6093743

DOCUMENT-IDENTIFIER: US 6093743 A

TITLE: Therapeutic methods employing disulfide derivatives of dithiocarbamates and

compositions useful therefor

DATE-ISSUED: July 25, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Lai; Ching-San Encinitas CA

Vassilev; Vassil San Diego CA

US-CL-CURRENT: 514/599; 514/706, 514/707, 514/851, 514/861, 514/863, 514/866,

<u>514/909, 514/912</u>

#### ABSTRACT:

The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

51 Claims, 11 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

Full   Title   Citation   Front   Review   Classification   Date   Reference
--

## 7. Document ID: US 6043250 A

L27: Entry 7 of 33

File: USPT

Mar 28, 2000

US-PAT-NO: 6043250

DOCUMENT-IDENTIFIER: US 6043250 A

TITLE: Methods for using therapeutic compounds containing xanthinyl

DATE-ISSUED: March 28, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

h eb bgeeef e hc ef be

Klein; J. Peter Vashon WA
Leigh; Alistair J. Brier WA
Underiner; Gail E. Brier WA
Kumar; Anil M. Seattle WA
Rice; Glenn C. Seattle WA

US-CL-CURRENT: 514/234.2; 514/210.21, 514/263.2, 514/263.22, 514/263.23, 514/263.35

#### ABSTRACT:

Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:

CORE MOIETY -- (R).sub.j

wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C(.sub.1-10) alkyl, C(.sub.2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C(.sub.1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub. (1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or 0, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

6 Claims, 0 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

	<b>88</b> 0 1 - 2
Full Title Citation Front Review Classification Date Reference	Claims KMC Draw, Desc
	···-

## 8. Document ID: US 6040157 A

L27: Entry 8 of 33

File: USPT

Mar 21, 2000

US-PAT-NO: 6040157

DOCUMENT-IDENTIFIER: US 6040157 A

\*\* See image for <u>Certificate of Correction</u> \*\*

TITLE: Vascular endothelial growth factor 2

DATE-ISSUED: March 21, 2000

INVENTOR-INFORMATION:

h eb bgeeef e hc ef be

Page 7 of 30

## Record List Display

NAME

CITY

STATE

COUNTRY

Hu; Jing-Shan

Sunnyvale

ZIP CODE

CA

Rosen; Craig A.

Laytonsville

MD

Cao; Liang

South Horizons

ΗK

US-CL-CURRENT: 435/69.4; 435/243, 435/320.1, 435/325, 435/7.1, 530/399, 536/23.51

#### ABSTRACT:

Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeuticall sefl fragments, analogs, or derivatives thereof, and DNA (RNA) enco such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

75 Claims, 48 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC   Drawn Desc

## 9. Document ID: US 6020463 A

L27: Entry 9 of 33

File: USPT

Feb 1, 2000

US-PAT-NO: 6020463

DOCUMENT-IDENTIFIER: US 6020463 A

\*\* See image for Certificate of Correction \*\*

TITLE: Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target

DATE-ISSUED: February 1, 2000

## INVENTOR-INFORMATION:

NAME

CITY

ZIP CODE STATE

COUNTRY

Falb; Dean A.

Wellesley

MA

Gimbrone, Jr.; Michael A.

Jamaica Plain

ef

b

e

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.1

## ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as

treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

3 Claims, 41 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 53

Full	Title Citation Front Review Classification	Date Reference	
	10. Document ID: US 6020337 A Entry 10 of 33	File: USPT	Feb 1, 2000

US-PAT-NO: 6020337

DOCUMENT-IDENTIFIER: US 6020337 A

TITLE: Electronegative-substituted long chain xanthine compounds

DATE-ISSUED: February 1, 2000

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Leigh; Alistair J.	Brier	WA		
Michnick; John	Seattle	WA		
Kumar; Anil M.	Seattle	AW		
Klein; J. Peter	Vashon	WA		
Underiner; Gail	Malvern	PA		

US-CL-CURRENT: 514/263.34; 514/210.21, 514/263.36, 544/267, 544/272, 544/277

#### ABSTRACT:

Therapeutic compounds, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, having a formula: ##STR1## wherein R.sub.0 is selected from the group consisting of hydrogen, halo, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, wherein the substituents of substituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl are other than halo; n is an integer from one to sixteen; R.sub.1, R.sub.2, and R.sub.3 are independently selected from the group consisting of a halo; haloacetoxy; hydrogen; hydroxy; oxo; --N.dbd.C.dbd.S; --N.dbd.C.dbd.O; --0--C.tbd.N; --C.tbd.N; --N.dbd.N.dbd.N; and --C--(R.sub.5).sub.3, R.sub.5 being independently a halo or hydrogen, at least one R.sub.5 being halo, at least one of R.sub.1, R.sub.2, and R.sub.3 being halo, cyano, isocyano, isothiocyano, azide or haloacetoxy group; R.sub.4 is hydrogen, C.sub.(1-6) alkyl, C.sub.(1-6) alkenyl, cyclo C.sub.(4-6) alkyl, or phenyl; one or more hydrogen atoms of (CH.sub.2).sub.n -- CH.sub.a -- CH.sub.b --CH.sub.c may be replaced with: i) at least one of halogen atom, hydroxyl, oxo, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyalkyl, or C.sub. (2-10) alkenyl; or ii) one or more unsaturated bonds; and any two adjacent carbon atoms of (CH.sub.2).sub.n --CH.sub.a --CH.sub.b --CH.sub.c may be instead separated by at least one oxygen atom. These compounds are useful in treating or preventing diseases by inhibiting selective second messenger pathways.

17 Claims, 16 Drawing figures

h eb bgeeef e hc ef b

Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full Title Citation Front Review Classification Date Reference

11. Document ID: US 6018025 A

L27: Entry 11 of 33

File: USPT

Jan 25, 2000

US-PAT-NO: 6018025

DOCUMENT-IDENTIFIER: US 6018025 A

\*\* See image for Certificate of Correction \*\*

TITLE: Compositions and methods for the treatment and diagnosis of cardiovascular

disease using rchd528 as a target

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Falb; Dean A. Wellesley MA

Gimbrone, Jr.; Michael A. Jamaica Plain MA

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/324, 530/326, 536/23.1,

536/23.5

### ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

5 Claims, 41 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 53

Full Title Citation Front	Review Classification Date	Reference Claims	KMMC Draint Desc
· · · · · · · · · · · · · · · · · · ·			

12. Document ID: US 5889011 A

L27: Entry 12 of 33 File: USPT Mar 30, 1999

h eb b g ee ef e h c ef b

US-PAT-NO: 5889011

DOCUMENT-IDENTIFIER: US 5889011 A

\*\* See image for Certificate of Correction \*\*

TITLE: Substituted amino alkyl compounds

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Klein; J. Peter Vashon Island WA
Underiner; Gail E. Brier WA
Leigh; Alistair J. Brier WA

US-CL-CURRENT: 514/263.35; 544/264, 544/265, 544/267

### ABSTRACT:

Compounds and pharmaceutical compositions thereof comprise the formula:

(R)j- (core moiety),

including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten, R'.sub.1 and R'.sub.2 are independently hydrogen or methyl and R'.sub.3 and R'.sub.4 are hydrogen. The compounds are useful in treating or preventing, for example, sepsis syndrome, hematopoietic or organ toxicity, baldness, hair loss or allopecia caused by cytotoxic therapies, and progression of an inflammatory or autoimmune disease.

9 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

Full Title Citation Front	Review Classification	Date Reference	Claims KMC Draw Desc

## 13. Document ID: US 5882925 A

L27: Entry 13 of 33 File: USPT Mar 16, 1999

US-PAT-NO: 5882925

DOCUMENT-IDENTIFIER: US 5882925 A

## \*\* See image for <u>Certificate of Correction</u> \*\*

TITLE: Compositions and method for the treatment and diagnosis of cardiovascular disease using rchd502 as a target

DATE-ISSUED: March 16, 1999

h eb bgeeef e hc ef b e

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Falb; Dean A. Wellesley MA

US-CL-CURRENT: <u>435</u>/<u>325</u>; <u>435</u>/<u>320.1</u>, <u>435</u>/<u>455</u>, <u>435</u>/<u>6</u>, <u>435</u>/<u>69.1</u>, <u>536/23.1</u>, <u>536</u>/<u>24.1</u>,

<u>536/24.3</u>

### ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

22 Claims, 53 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 53

Full Title Citation Front	Review Classification Date	Reference	Claims   KMC   Draw, Des

14. Document ID: US 5849578 A

L27: Entry 14 of 33 File: USPT Dec 15, 1998

US-PAT-NO: 5849578

DOCUMENT-IDENTIFIER: US 5849578 A

\*\* See image for Certificate of Correction \*\*

TITLE: Compositions and methods for the treatment and diagnosis of cardiovascular

using RCHD528 as a target

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Falb; Dean A. Massachusetts MA

US-CL-CURRENT: 435/325; 435/320.1, 435/455, 435/6, 435/69.1, 536/23.1, 536/24.1,

<u>536/24.3</u>

### ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation.

h eb bgeeef e hc ef be

Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

21 Claims, 53 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 53

Full   Title   Citation   Front	Review   Classification	Date Reference	Claims	KMC   Draw, Desc
······································	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		······	***************************************

## 15. Document ID: US 5837703 A

L27: Entry 15 of 33

File: USPT

Nov 17, 1998

US-PAT-NO: 5837703

DOCUMENT-IDENTIFIER: US 5837703 A

TITLE: Amino-alcohol substituted cyclic compounds

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Kumar; Anil M. Seattle WA Michnick; John Seattle WA Underiner; Gail E. Brier WΑ Klein; J. Peter Vashon Island WA Rice; Glenn C. Seattle WA

#### ABSTRACT:

Therapeutic compounds have the formula:

(X) j-(core moiety),

j being an integer from one to three, the core moiety comprising a core moiety, the core moiety being a heterocycle having one ring or two-fused rings, each ring having five or six ring atoms, A being a carbon atom of the core moiety and attached to a terminal carbon atom of (CH.sub.2).sub.m, and X has a structure and X being a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## \*C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or

more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkyl or alkenyl of up to twelve carbon atoms in length, or -- (CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxyl. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkyl or alkenyl of up to eight carbon atoms in length, -- (CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxyl, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxyl group.

9 Claims, 39 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 38

		·	
and the transfer of the contract of	Section 1 Section 19 Section 1		
ull Title Citation Front	Review Classification Date	Reference C	lairns KWiC Draw Desi
	The state of the s		TO THIS POST DIEST

16. Document ID: US 5824677 A

L27: Entry 16 of 33

File: USPT

ZIP CODE

Oct 20, 1998

COUNTRY

US-PAT-NO: 5824677

DOCUMENT-IDENTIFIER: US 5824677 A

TITLE: Substituted amino alcohol compounds

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME CITY STATE
Klein; J. Peter Vashon WA
Underiner; Gail E. Brier WA

Kumar; Anil M. Seattle WA

US-CL-CURRENT: 514/222.5; 514/223.5, 514/224.5, 514/226.8, 514/227.5, 514/228.8, 514/229.2, 514/230.5, 514/230.8, 514/237.8, 514/248, 514/249, 514/255.02, 514/260.1, 514/274, 514/301, 514/303, 514/311, 514/351, 514/360, 514/361, 514/362, 514/363, 514/379, 514/365, 514/367, 514/395, 514/415, 514/418, 514/424, 514/425, 514/432, 514/432, 514/433, 514/438, 514/438, 514/452, 544/127, 544/128, 544/162, 544/2, 544/215, 544/219, 544/229, 544/235, 544/237, 544/255, 544/278, 544/3, 544/311, 544/353, 544/313, 544/36, 544/53, 544/63, 544/65, 544/66, 544/67, 544/8, 544/90, 544/91, 546/113, 546/114, 546/164, 546/300, 548/123, 548/125, 548/131, 548/134, 548/143, 548/146, 548/153, 548/174, 548/207, 548/214, 548/215, 548/217, 548/221, 548/228, 548/229, 548/237, 548/240, 548/241, 548/243, 548/247, 548/267.2, 548/303.7, 548/307.1, 548/453, 548/486, 548/543, 548/546, 549/14, 549/367, 549/368, 549/50, 549/75

## ABSTRACT:

Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure

of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocyle. R.sub.3 may be either hydrogen or C.sub.13. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a hetorocycle comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

18 Claims, 120 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 89

Full Title Citation	Front   Review	Classification	Reference	Claims	Kenc	Draw, Desc

## 17. Document ID: US 5817662 A

L27: Entry 17 of 33

File: USPT

Oct 6, 1998

US-PAT-NO: 5817662

DOCUMENT-IDENTIFIER: US 5817662 A

TITLE: Substituted amino alkyl compounds

DATE-ISSUED: October 6, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Klein; J. Peter Vashon Island WA
Underiner; Gail E. Brier WA
Leigh; Alistair J. Brier WA

US-CL-CURRENT: <u>514/263.35</u>; <u>424/824</u>, <u>424/825</u>

### ABSTRACT:

Compounds and pharmaceutical compositions thereof comprise the formula:

(R) j-(core moiety),

including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten,

R'.sub.1 and R'.sub.2 are independently hydrogen or methyl and R'.sub.3 and R'.sub.4 are hydrogen. The compounds are useful in treating or preventing, for example, sepsis syndrome, hematopoietic or organ toxicity, baldness, hair loss or allopecia caused by cytotoxic therapies, and progression of an inflammatory or autoimmune disease.

7 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims k	CONC	Diam Desc

18. Document ID: US 5807862 A

L27: Entry 18 of 33

File: USPT

Sep 15, 1998

US-PAT-NO: 5807862

DOCUMENT-IDENTIFIER: US 5807862 A

\*\* See image for Certificate of Correction \*\*

TITLE: Therapeutic compounds containing pyrimidinyl moieties

DATE-ISSUED: September 15, 1998

#### INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Klein; J. Peter Vashon WA Leigh; Alistair J. Brier WA Underiner; Gail E. WA Brier Kumar; Anil M. Seattle WA

US-CL-CURRENT: 514/269; 544/309, 544/310, 544/311, 544/312

## ABSTRACT:

Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:

CORE MOIETY--(R).sub.j

wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub. (1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --

ef

CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

6 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

Full Title I	Citation Front	Review Classifica	tion Date Refere	ince	Claims KOOC	Drawt Desc
		· · · · · · · · · · · · · · · · · · ·				

19. Document ID: US 5807861 A

L27: Entry 19 of 33

File: USPT

Sep 15, 1998

US-PAT-NO: 5807861

DOCUMENT-IDENTIFIER: US 5807861 A

\*\* See image for Certificate of Correction \*\*

TITLE: Amine substituted xanthinyl compounds

DATE-ISSUED: September 15, 1998

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	AW		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		
Ridgers; Lance H.	Bothell	AW		
Rice; Glenn C.	Seattle	WA		
Leung; David W.	Mercer Island	WA		

US-CL-CURRENT: 514/263.35; 514/151, 514/210.21, 514/263.2, 514/263.22, 514/263.23, 514/81

## ABSTRACT:

A method for treating a disease caused by an undesirable cell response mediated by a proliferative intracellular signaling pathway is provided wherein an effective amount of a compound is administered. The compound, resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof, has the formula

CORE MOIETY--(R).sub.j

wherein j is an integer from one to three; the core moiety is xanthinyl; and R is independently selected from the group consisting of amine, hydrogen, halogen, hydroxyl, C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, 2-bromopropyl, 4-chloropentyl, cyclohexyl, cyclopentyl, 3-dimethylaminobutyl, 2-hydroxyethyl, 5-hydroxyhexyl, 3-hydroxypropyl, 2-methoxyethyl, 4-methoxy-n-butyl, phenyl, and formula I, at least one R comprising formula I ##STR1## wherein (CH.sub.2).sub.n is optionally substituted; n is an integer from five to twenty; each R.sub.1 or R.sub.2 is independently hydrogen or an optionally substituted group that is herein defined; and

wherein, when the (CH.sub.2).sub.n, R.sub.1 or R.sub.2 is substituted, a substituent is selected from the group consisting of carbamoyl, primary, secondary and tertiary amino, C.sub.(2-8) alkenyl, C.sub.(1-8) alkyl, C.sub.(1-8) alkoxyl, C.sub.(1-8)

h eb bgeeef e hc ef b e

Sep 8, 1998

## Record List Display

hydroxyalkyl, azido, carbonato, carbonyl, carboxyl, cyano, C.sub.(1-8) haloalkyl, isocyano, isomercaptocyano, phospho, phosphonato, sulfonato, alkylsulfonyl, alkylsulfoxidyl, mercaptocarbonyl, mercaptocarbonato, thioureido and ureido.

21 Claims, 23 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 23

Full	Title	Citation Front Review Classification Date Reference Claims KMC Draw. Desc
	20.	Document ID: US 5804584 A

File: USPT

US-PAT-NO: 5804584

L27: Entry 20 of 33

DOCUMENT-IDENTIFIER: US 5804584 A

\*\* See image for Certificate of Correction \*\*

TITLE: Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms

DATE-ISSUED: September 8, 1998

#### INVENTOR-INFORMATION:

COUNTRY NAME CITY STATE ZIP CODE Underiner; Gail E. Brier WA Porubek; David Seattle WA Vashon Island WA Klein; J. Peter Woodson; Paul Edmonds WΆ

US-CL-CURRENT: 514/269; 514/256, 544/242, 544/298, 544/301, 544/302

#### ABSTRACT:

Disclosed are therapeutic compounds having the formula:

## (R)j-(core moiety),

including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.

9 Claims, 15 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 10

Sep 1, 1998

Full	Title	Citation   Front   Review   Classification   Date   Reference   Section   Section   Claims   KN/IC   Draw Desc	

File: USPT

US-PAT-NO: 5801182

L27: Entry 21 of 33

DOCUMENT-IDENTIFIER: US 5801182 A

TITLE: Amine substituted compounds

DATE-ISSUED: September 1, 1998

### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	AW		
Ridgers; Lance H.	Bothell	WA		

US-CL-CURRENT: 514/269; 514/274, 544/310, 544/311, 544/312

### ABSTRACT:

Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula:

CORE MOIETY -- (R).sub.j

In these compounds, j is an integer from one to three; the core moiety is a cyclic core, the cyclic core being non-cyclic or at least one five- to seven-member non-heterocyclic ring or heterocycle; and R is selected from the group consisting of amine, hydrogen, halogen, hydroxyl, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic group or formula I. At least one R having formula I: ##STR1## In formula I, n is an integer from four to twenty; and each R.sub.1 or R.sub.2 is independently hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or cyclic or heterocyclic group. The compounds are useful in treating or preventing, for example, sepsis syndrome, hematopoietic or organ toxicity, cancer, viral activity, AIDS and AIDS-related indications, allopecia caused by cytotoxic therapies, and progression of an inflammatory or autoimmune disease.

16 Claims, 23 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 23

Full   Title   Citation   Front   Review   Classification   Date   Reference	MMC   Drawn Desc

## 22. Document ID: US 5801181 A

L27: Entry 22 of 33

File: USPT

Sep 1, 1998

US-PAT-NO: 5801181

DOCUMENT-IDENTIFIER: US 5801181 A

h eb bgeeef e hc ef be

Page 19 of 30

COUNTRY

Record List Display

TITLE: Amino alcohol substituted cyclic compounds

DATE-ISSUED: September 1, 1998

INVENTOR-INFORMATION:

NAME CITY

CITY STATE ZIP CODE Seattle WA

Michnick; John Seattle WA Underiner; Gail E. Brier WA

Klein; J. Peter Vashon Island W

Rice; Glenn C. Seattle WA

US-CL-CURRENT: 514/263.35; 514/183, 514/249, 514/266.3, 514/274, 514/309, 514/315,

 $\underline{514}/\underline{418}, \ \underline{514}/\underline{425}, \ \underline{514}/\underline{617}, \ \underline{514}/\underline{619}, \ \underline{514}/\underline{626}, \ \underline{514}/\underline{668}, \ \underline{514}/\underline{669}$ 

### ABSTRACT:

Therapeutic compounds have the formula:

(X)j--(core moiety),

J being an integer from one to three, the core moiety having at least one, five- to seven-membered ring and X being a racemic mixture, R or S enantiomer, slovate, hydrate, or salt of: ##STR1## \*C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH. sub.2). sub.t may be substituted by a keto or hydroxy group.

45 Claims, 41 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 38

Full Title Citation Front	Review Classification [	Date Reference	Claims Wild Draw Desc

23. Document ID: US 5785965 A

L27: Entry 23 of 33 File: USPT Jul 28, 1998

US-PAT-NO: 5785965

DOCUMENT-IDENTIFIER: US 5785965 A

TITLE: <u>VEGF</u> gene transfer into endothelial cells for vascular prosthesis

h eb bgeeef e hc ef b e

DATE-ISSUED: July 28, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Pratt; Richard E.

Palo Alto

CA

Dzau; Victor J.

Los Altos Hills

CA

US-CL-CURRENT:  $\underline{424}/\underline{93.21}$ ;  $\underline{424}/\underline{93.1}$ ,  $\underline{424}/\underline{93.2}$ ,  $\underline{435}/\underline{325}$ ,  $\underline{435}/\underline{455}$ ,  $\underline{435}/\underline{456}$ 

#### ABSTRACT:

Endothelial cells derived from subcutaneous adipose tissue are genetically modified to express the endothelial cell-specific angiogenic factor  $\underline{\text{VEGF}}$ . The modified cells are sodded onto a vascular prosthesis for transplantation into an autologous or allogeneic recipient. The method accelerates endothelialization on the luminal surface of the vessel, and promotes collateral circulation in distal ischemic organs.

11 Claims, 4 Drawing figures Exemplary Claim Number: 1,6 Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KWIC	Drawt Desc

24. Document ID: US 5780476 A

L27: Entry 24 of 33

File: USPT

Jul 14, 1998

US-PAT-NO: 5780476

DOCUMENT-IDENTIFIER: US 5780476 A

TITLE: Hydroxyl-containing xanthine compounds

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Underiner; Gail E.

Brier

WA

Porubek; David

Seattle

WA

Klein; J. Peter

Vashon Island

WA

Woodson; Paul

Edmonds

WA

US-CL-CURRENT: 514/263.36

#### ABSTRACT:

Disclosed are therapeutic compounds having the formula:

### (R)j - (core moiety),

including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3

h eb bgeeef e hc ef b e

--CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.3 -- CH.sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.

11 Claims, 15 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 10

F	ับ[[	Title	Citation	Front	Review	Classification	Reference				Claims	OMC	Drawi Desi
			•	•			 ,			***************************************	1		·
	,												
******	*******		***************************************	***********	***************************************	***************************************	 ***************************************	***************************************	***************************************		***************************************	**********	***************************************
												•••••	

## 25. Document ID: US 5777117 A

L27: Entry 25 of 33

File: USPT

Jul 7, 1998

US-PAT-NO: 5777117

DOCUMENT-IDENTIFIER: US 5777117 A

TITLE: Method for preparing substituted amino alcohol compounds

DATE-ISSUED: July 7, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Klein; J. Peter Vashon WA Underiner; Gail E. Brier WA Kumar; Anil M. Seattle WA

US-CL-CURRENT: <u>544/267</u>; <u>544/257</u>, <u>544/285</u>, <u>544/286</u>, <u>544/287</u>, <u>544/311</u>, <u>546/141</u>, <u>546/243</u>, <u>546/246</u>, <u>548/477</u>, <u>548/546</u>

### ABSTRACT:

Disclosed is a process for preparing compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or -- (CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is -- (CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocyle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

22 Claims, 118 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 92

## 26. Document ID: US 5777115 A

L27: Entry 26 of 33

File: USPT

Jul 7, 1998

US-PAT-NO: 5777115

DOCUMENT-IDENTIFIER: US 5777115 A

TITLE: Acetal-and ketal-substituted pyrimidine compounds

DATE-ISSUED: July 7, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Leigh; Alistair Underiner; Gail

Brier

WΑ

Brier

WA

US-CL-CURRENT: <u>544/242</u>; <u>544/267</u>

### ABSTRACT:

Acetal-and ketal-substituted compounds and pharmaceutical compositions thereof have the following formula:

CORE MOIETY--(R).sub.j,

including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is non-cyclic or cyclic a monocyclic moiety having at least one nitrogen atom within the ring and R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted alkyl C.sub.(1-6), alkenyl C.sub.(2-6), cyclic or heterocyclic groups, and groups having a structure prescribed by formula I. At least one R has the formula

-- (CH.sub.2).sub.n -- C-- (R.sub.1).sub.3 I

wherein n is an integer from three to twenty; R.sub.1 is selected from among hydrogen; halogen; hydroxide; substituted or unsubstituted C.sub. (1-6) alkyl, C.sub. (1-6) alkoxy, C.sub.2-6) alkenyl, cyclic or heterocyclic group; --OR.sub.2, R.sub.2 being hydrogen or a substituted or unsubstituted C.sub.(1-6) alkyl, C.sub.(2-6) alkenyl, cyclic or heterocyclic group; -- (CH.sub.2).sub.p -- C(R.sub.3).sub.3 (wherein p is zero or an integer from one to ten, R.sub.3 is hydrogen, halogen, hydroxide, substituted or unsubstituted C.sub.(1-6) alkyl, C.sub.(1-6) alkoxy, C.sub.(2-6) alkenyl, cyclic or heterocyclic group, or --OR.sub.2, R.sub.2 being defined above). The inventive compounds are useful in a large variety of therapeutic indications for treating or preventing disease mediated by intracellular signaling through specific intracellular signaling pathways.

13 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

Full	Title	Citation	Front	Pawisto	Classification	Date	Raferance	Claims	KWWC Draw Desi
1 411	11116	; Chanon ;	FIDIRE	L/ 25 0 1500	Classification	L'ale	Materatica	2000 CH 1012	Mode   Didok Desi

e

27. Document ID: US 5770595 A

h e b b g ee e f e h c ef

Page 23 of 30

L27: Entry 27 of 33

File: USPT

Jun 23, 1998

US-PAT-NO: 5770595

DOCUMENT-IDENTIFIER: US 5770595 A

TITLE: Oxime substituted therapeutic compounds

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Klein; J. Peter

Vashon

WA

Leigh; Alistair

Brier

AW

US-CL-CURRENT: <u>514/263.35</u>; <u>514/151</u>, <u>544/271</u>, <u>544/273</u>

#### ABSTRACT:

Oxime-substituted compounds are preferably cyclic or heterocyclic compounds. The oxime-substituted compounds and pharmaceutical compositions thereof have the formula:

CORE MOIETY--(R).sub.j

including resolved enantiomers (both syn and anti forms) and/or diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is non-cyclic or cyclic and R may be selected from among: hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10), alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, and formula I. At least one R has the formula I:

--(CH.sub.2).sub.n --C--(R.sub.1).sub.p, I

wherein n is an integer from three to twenty; p is two or three; R.sub.1 is selected from among hydrogen; halogen; hydroxide; substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; =N--OR.sub.2, R.sub.2 being hydrogen or a substitute or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; and --(CH.sub.2).sub.s --C (R.sub.3).sub.t (wherein s is zero or an integer from one to ten, t is two or three, R.sub.3 is hydrogen, halogen, hydroxide, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C(.sub.2-10) alkenyl, cyclic or heterocyclic group, or .dbd.N--OR.sub.2, R.sub.2 being defined above). At least one R.sub.1 or one R.sub.3 is .dbd.N--OR.sub.2, p or t corresponding to the at least one R.sub.1 or one R.sub.3 is two, and a second R.sub.1 or second R.sub.3, bonded to the same --C as the at least one R.sub.1 or one R.sub.3, is other than .dbd.N--OR.sub.2. These disclosed compounds are useful in a large variety of therapeutic indications for treating or preventing disease mediated by intracellular signaling through specific intracellular signaling pathways.

22 Claims, 19 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 19

Full Title Citation	Front Review	Classification D	ate Reference	Claims	KWMC Drawn Desc

28. Document ID: US 5750575 A

L27: Entry 28 of 33

File: USPT

May 12, 1998

US-PAT-NO: 5750575

DOCUMENT-IDENTIFIER: US 5750575 A

\*\* See image for Certificate of Correction \*\*

TITLE: Substituted amino alcohol compounds

DATE-ISSUED: May 12, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Klein; J. Peter Vashon WA Underiner; Gail E. Brier WA Kumar; Anil M. Seattle WA

US-CL-CURRENT: <u>514/617</u>; <u>514/653</u>, <u>564/182</u>, <u>564/355</u>, <u>564/361</u>

#### ABSTRACT:

Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocyle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a carbocycle comprising a substituted or unsubstituted ring system, the ring system having a single ring or two fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

18 Claims, 115 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 90

Füll	Title	Citation		Classification	Date	Reference		Claims	KWWC Draw	

29. Document ID: US 5670506 A

L27: Entry 29 of 33 File: USPT Sep 23, 1997

US-PAT-NO: 5670506

DOCUMENT-IDENTIFIER: US 5670506 A

TITLE: Halogen, isothiocyanate or azide substituted xanthines

DATE-ISSUED: September 23, 1997

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Leigh; Alistair Brier WA Michnick; John Seattle WA

h eb bgeeef e hc ef b e

Kumar; Anil

Seattle

WA

Underiner; Gail

Brier

WA

US-CL-CURRENT: 514/141; 544/267, 544/272, 544/277

#### ABSTRACT:

There is disclosed a compound having the formula: ##STR1## wherein n is an integer from 5 to 9, wherein the core moiety is a heterocylic moiety wherein C.sub.a, C.sub.b, and C.sub.c are an R or S enantiomer or racemic mixture and the C.sub.a, C.sub.b, and C.sub.c carbon atoms are bonded together by a single bond, double bond, ether or ester linkages, wherein R.sub.1, R.sub.2 and R.sub.3 are independently halo, hydroxy, hydrogen, keto, isothiocyano, azide or haloacetoxy with the proviso that at least one of R.sub.1, R.sub.2 or R.sub.3 must be a halo, isothiocyano, azide or haloacetoxy group, wherein R.sub.4 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkenyl, cyclo C.sub.4-6 alkyl, or phenyl, and wherein halo refers to fluoro, chloro, bromo and iodo and salts thereof and pharmaceutical compositions thereof.

17 Claims, 14 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 14

|--|

Claims KMMC Draw Des-

30. Document ID: US 5641783 A

L27: Entry 30 of 33

File: USPT

Jun 24, 1997

US-PAT-NO: 5641783

DOCUMENT-IDENTIFIER: US 5641783 A

TITLE: Substituted amino alcohol compounds

DATE-ISSUED: June 24, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Klein; J. Peter

Vashon

WA

Underiner; Gail E.

Brier

WΆ

Kumar; Anil M.

Seattle

WA

US-CL-CURRENT: 514/263.35; 514/183, 514/222.5, 514/223.5, 514/224.2, 514/226.8,  $\underline{514}/\underline{227.5}, \ \underline{514}/\underline{228.8}, \ \underline{514}/\underline{229.2}, \ \underline{514}/\underline{230.5}, \ \underline{514}/\underline{230.8}, \ \underline{514}/\underline{237.8}, \ \underline{514}/\underline{241}, \ \underline{514}/\underline{242},$ <u>514/243, 514/246, 514/247, 514/248, 514/249, 514/252.16, 514/256, 514/259.5, </u> <u>514/264.1, 514/266.3, 514/270, 514/274, 514/297, 514/300, 514/301, 514/302, 514/303, </u> <u>514/306, 514/307, 514/311, 514/312, 514/315, 514/345, 514/351, 514/357, 514/359, </u> <u>514</u>/3<u>60</u>, <u>514</u>/361, 514/362, 514/363, 514/364, 514/365, 514/367, 514/369, 514/372, <u>514/373, 514/374, 514/375, 514/376, 514/378, 514/379, 514/380, 514/381, 514/383, </u> <u>514/389, 514/394, 514/395, 514/398, 514/399, 514/401, 514/404, 514/406, 514/413, </u> <u>514/415, 514/416, 514/418, 514/423, 514/424, 514/425, 514/427, 514/428, 544/1, </u> <u>544/2, 544/215, 544/216, 544/219, 544/220, 544/224, 544/235, 544/239,</u> <u>544/254, 544/255, 544/257, 544/262, 544/272, 544/277, 544/278, 544/280, 544/283, </u> 544/286, 544/3, 544/301, 544/311, 544/335, 544/336, 544/350, 544/353, 544/385, <u>544/401</u>, <u>544/53</u>, <u>544/63</u>, <u>544/65</u>, <u>544/66</u>, <u>544/67</u>, <u>544/8</u>, <u>544/90</u>, <u>544/91</u>, <u>546/102</u>, 546/113, 546/114, 546/115, 546/117, 546/118, 546/119, 546/122, 546/138, 546/139, <u>546/150</u>, <u>546/153</u>, <u>546/157</u>, <u>546/164</u>, <u>546/176</u>, <u>546/178</u>, <u>546/242</u>, <u>546/243</u>, <u>546/246</u>, 546/264, 546/300, 546/334, 548/100, 548/123, 548/125, 548/127, 548/128, 548/131,

h eb bgeeef

e hc ef b

 $\frac{548/134}{548/221}, \frac{548/146}{548/225}, \frac{548/153}{548/228}, \frac{548/229}{548/229}, \frac{548/235}{548/235}, \frac{548/237}{548/237}, \frac{548/240}{548/240}, \frac{548/241}{548/241}, \frac{548/243}{548/243}, \frac{548/247}{548/241}, \frac{548/243}{548/241}, \frac{548/243}{548/241}, \frac{548/243}{548/241}, \frac{548/243}{548/241}, \frac{548/243}{548/241}, \frac{548/243}{548/319.1}, \frac{548/323.5}{548/340.1}, \frac{548/348.1}{548/349.1}, \frac{548/356.1}{548/356.1}, \frac{548/370.1}{548/370.1}, \frac{548/379.4}{548/503}, \frac{548/452}{548/452}, \frac{548/453}{548/450}, \frac{548/482}{548/550}, \frac{548/482}{548/565}, \frac{548/485}{548/566}$ 

### ABSTRACT:

Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocycle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

22 Claims, 115 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 88

Full	itation	Front	Review	Classification	Date	Reference		Cla	sims l	OMC	Draw Desc

## 31. Document ID: US 5521315 A

L27: Entry 31 of 33

File: USPT

ZIP CODE

May 28, 1996

COUNTRY

US-PAT-NO: 5521315

DOCUMENT-IDENTIFIER: US 5521315 A

TITLE: Olefin substituted long chain compounds

DATE-ISSUED: May 28, 1996

### INVENTOR-INFORMATION:

NAME CITY STATE Underiner; Gail Brier WΑ Porubek; David Seattle WA Klein; J. Peter · WA Vashon Eiseman; Elisa Seattle WA Leigh; Alistair Brier WA Kumar: Anil Seattle WΔ Michnick; John Seattle WA

US-CL-CURRENT: <u>546/243</u>; <u>544/285</u>, <u>546/242</u>

## ABSTRACT:

h eb b g ee ef e h c ef b e

There is disclosed an olefin-substituted compound having the formula:

R-- (core moiety),

wherein R is a straignt chain hydrocarbon having at least one double bond and a carbon chain length of from about 6 to about 18 carbon atoms, wherein multiple double bonds are separated from each other by at least three carbon atoms, wherein the closest double bond to the core moiety is at least five carbon atoms from the core moiety, and wherein the hydrocarbon chain may be substituted by a hydroxyl, halo, keto or dimethylanimo group and/or interrupted by an oxygen atom and salts thereof and pharmaceutical compositions thereof.

7 Claims, 22 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 22

itation Front Review	Classification	Date Reference	Claims	KOMC   Draw, Desc
,	·····		 	

### 32. Document ID: US 5470878 A

L27: Entry 32 of 33

File: USPT

Nov 28, 1995

US-PAT-NO: 5470878

DOCUMENT-IDENTIFIER: US 5470878 A

TITLE: Cell signaling inhibitors

DATE-ISSUED: November 28, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Michnick; John Seattle WA
Underiner; Gail E. Brier WA
Klein; J. Peter Vashon Island WA
Rice; Glenn C. Seattle WA

### ABSTRACT:

Therapeutic compounds have the formula:

(X) j-(non-cyclic core moiety),

j being an integer from one to three, the core moiety is non-cyclic and X is a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## \*C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds

may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms. r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxy group.

10 Claims, 43 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 42

# 33. Document ID: AU 758178 B, WO 200013710 A2, AU 9959095 A, EP 1107791 A2, US 6331309 B1, JP 2002524425 W

L27: Entry 33 of 33

File: DWPI

Mar 20, 2003

DERWENT-ACC-NO: 2000-256866

DERWENT-WEEK: 200329

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Hydrogel compositions useful for controlled delivery of growth factors e.g. in treatment of ischemia and in wound healing

INVENTOR: JENNINGS, R N; PROTTER, A A; WANG, Y J; YANG, B

PRIORITY-DATA: 1998US-099168P (September 4, 1998), 1999US-0390164 (September 3, 1999)

#### PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 758178 B	March 20, 2003		000	A61K047/10
WO 200013710 A2	March 16, 2000	E	027	A61K047/10
AU 9959095 A	March 27, 2000		000	
EP 1107791 A2	June 20, 2001	E	000	A61K047/10
US 6331309 B1	December 18, 2001		000	A61F013/00
JP 2002524425 W	August 6, 2002		033	A61K038/22

INT-CL (IPC): A61 F  $\frac{13}{00}$ ; A61 K  $\frac{9}{10}$ ; A61 K  $\frac{9}{70}$ ; A61 K  $\frac{38}{18}$ ; A61 K  $\frac{38}{22}$ ; A61 K  $\frac{47}{10}$ ; A61 K  $\frac{47}{26}$ ; A61 K  $\frac{47}{32}$ ; A61 K  $\frac{47}{34}$ ; A61 K  $\frac{47}{36}$ ; A61 P  $\frac{9}{10}$ ; A61 P  $\frac{17}{02}$ 

ABSTRACTED-PUB-NO: US 6331309B BASIC-ABSTRACT:

NOVELTY - Hydrogel composition comprises polypeptide growth factor, water-miscible anionic polymer, water-miscible non-ionic polymeric viscosity controlling agent and

DETAILED DESCRIPTION - A hydrogel composition for the controlled release delivery of a polypeptide growth factor comprises: (a) a polypeptide growth factor containing at least one region of positive charge; (b) a water-miscible anionic polymer; (c) a water-miscible non-ionic polymeric viscosity controlling agent; and (d) water.

INDEPENDENT CLAIMS are included for:

h eb bgeeef e hc ef be

(A) a hydrogel composition for the controlled release administration of basic fibroblast growth factor comprising: (a) a basic fibroblast growth factor; (b) 0.001-0.1 wt.% water-miscible anionic polymer; (c) 0.5-25 wt.% non-ionic, water-miscible polymeric viscosity controlling agent; and (d) water;

- (B) a method for producing a controlled release growth factor composition comprising dispersing in water: (a) a water miscible, non-ionic polymeric viscosity controlling agent; (b) a water miscible, anionic polymer to impart controlled release of the growth factor from the composition; and (c) a polypeptide growth factor having at least one region of positive charge;
- (C) a method of treating ischemia comprising administration to a region of ischemic tissue a controlled release hydrogel composition comprising: (a) an angiogenic polypeptide growth factor having at least one region of positive charge; (b) a water-miscible anionic polymer; (c) a water-miscible non-ionic polymer viscosity controlling agent; and (d) water.

ACTIVITY - Vasotropic, Vulnerary.

Male and female Sprague-Dawley rats were briefly anesthetized by <u>inhalation</u> of isoflurane. Gel formulations containing varying dosages of <u>bFGF</u> (e.g. 4.0 mg/ml <u>bFGF</u>, 10% polyoxyethylene-polyoxypropylene and 0.80% sodium carboxy methyl cellulose), as well as control gel formulations containing no <u>bFGF</u>, were injected subcutaneously. Five days after injection, animals were euthanized. The tissue immediately surrounding the injection site showed substantial angiogenesis in the treated group. In the control group there was no angiogenesis.

MECHANISM OF ACTION - Angiogenesis-Stimulator; FGF-Agonist.

USE - The formulations are useful for the controlled delivery of growth factors. They can be used for the controlled delivery of angiogenic growth factors for the treatment of ischemic tissue and/or for wound healing. The compositions can be used to treat conditions characterized by ischemia in order to restore blood flow to the affected area. Such conditions include <u>coronary artery disease</u> and peripheral vascular disease.

ADVANTAGE - The formulations can be prepared as homogeneous compositions by simple mixing techniques. The water-miscible anionic polymer can be used to impart an efficacious release rate when used at low concentrations.

ABSTRACTED-PUB-NO:

WO 200013710A EQUIVALENT-ABSTRACTS:

NOVELTY - Hydrogel composition comprises polypeptide growth factor, water-miscible anionic polymer, water-miscible non-ionic polymeric viscosity controlling agent and water.

DETAILED DESCRIPTION - A hydrogel composition for the controlled release delivery of a polypeptide growth factor comprises: (a) a polypeptide growth factor containing at least one region of positive charge; (b) a water-miscible anionic polymer; (c) a water-miscible non-ionic polymeric viscosity controlling agent; and (d) water.

INDEPENDENT CLAIMS are included for:

- (A) a hydrogel composition for the controlled release administration of basic fibroblast growth factor comprising: (a) a basic fibroblast growth factor; (b) 0.001-0.1 wt.% water-miscible anionic polymer; (c) 0.5-25 wt.% non-ionic, water-miscible polymeric viscosity controlling agent; and (d) water;
- (B) a method for producing a controlled release growth factor composition comprising dispersing in water: (a) a water miscible, non-ionic polymeric viscosity controlling agent; (b) a water miscible, anionic polymer to impart controlled release of the growth factor from the composition; and (c) a polypeptide growth factor having at

least one region of positive charge;

(C) a method of treating ischemia comprising administration to a region of ischemic tissue a controlled release hydrogel composition comprising: (a) an angiogenic polypeptide growth factor having at least one region of positive charge; (b) a water-miscible anionic polymer; (c) a water-miscible non-ionic polymer viscosity controlling agent; and (d) water.

ACTIVITY - Vasotropic, Vulnerary.

Male and female Sprague-Dawley rats were briefly anesthetized by <u>inhalation</u> of isoflurane. Gel formulations containing varying dosages of <u>bFGF</u> (e.g. 4.0 mg/ml <u>bFGF</u>, 10% polyoxyethylene-polyoxypropylene and 0.80% sodium carboxy methyl cellulose), as well as control gel formulations containing no <u>bFGF</u>, were injected subcutaneously. Five days after injection, animals were euthanized. The tissue immediately surrounding the injection site showed substantial angiogenesis in the treated group. In the control group there was no angiogenesis.

MECHANISM OF ACTION - Angiogenesis-Stimulator; FGF-Agonist.

USE - The formulations are useful for the controlled delivery of growth factors. They can be used for the controlled delivery of angiogenic growth factors for the treatment of ischemic tissue and/or for wound healing. The compositions can be used to treat conditions characterized by ischemia in order to restore blood flow to the affected area. Such conditions include <u>coronary artery disease</u> and peripheral vascular disease.

ADVANTAGE - The formulations can be prepared as homogeneous compositions by simple mixing techniques. The water-miscible anionic polymer can be used to impart an efficacious release rate when used at low concentrations.

Full Title Citation Front Re	view   Classification   Dat	e Reference		Claims	KWIC	Drawt Des
			***************************************	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	**********	**************
Clear Generate Collec	tion Print	Fwd Refs	Bkwd Refs	Genen	ate OA	cs
					==1	
Terms			Documents			
(L26) AND @PY <=	= 2000				33	

Previous Page Next Page Go to Doc#

## **Hit List**

Clear Generate Collection Print Fwd Refs Bkwd Refs Generate OACS

## **Search Results -** Record(s) 1 through 29 of 29 returned.

## 1. Document ID: US 20040097401 A1

## Using default format because multiple data bases are involved.

L28: Entry 1 of 29

File: PGPB

May 20, 2004

PGPUB-DOCUMENT-NUMBER: 20040097401

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040097401 A1

TITLE: Lysine in therapeutic angiogenesis, particularly in treating ischaemic

conditions

PUBLICATION-DATE: May 20, 2004

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Datta, Debatosh

Kolkata

IN

US-CL-CURRENT: 514/2; 514/564, 514/565

 Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, Desc

## 2. Document ID: US 20040033971 A1

L28: Entry 2 of 29

File: PGPB

Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040033971

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040033971 A1

TITLE: Polypeptides and nucleic acids encoding same

PUBLICATION-DATE: February 19, 2004

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gangolli, Esha A.	Madison	CT	US	
Patturajan, Meera	Branford	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Kekuda, Ramesh	Norwalk	CT	US	
Stone, David J.	Guilford	CT	US	
Anderson, David	Branford	CT	US	
Shimkets, Richard A.	Guilford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	

h eb bgeeef e hc ef be

Record	List	Dist	olav
1400014			

Branford	CT	US
Branford	CT	US
New Haven	CT	US
North Haven	CT	US
North Haven	CT	US
Guilford	CT	US
Branford	CT	US
Branford	CT	US
Hamden	CT	US
	Branford New Haven North Haven Guilford Branford Branford	Branford CT New Haven CT North Haven CT Guilford CT Branford CT Branford CT

 $\text{US-CL-CURRENT: } \underline{514/44}; \ \underline{435/320.1}, \ \underline{435/325}, \ \underline{435/6}, \ \underline{435/7.1}, \ \underline{514/2}, \ \underline{530/387.1}, \ \underline{536/23.1}$ 

#### ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention farther discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Title Citati	on Front Review Classificatio	on Date Reference Sequence	s Attachments Claims	KNMC   Drawn Desi
T 3. Docu	ment ID: US 200302290	03 A1		
L28: Entry 3	of 29	File: PGPB	Dec	: 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229003

PGPUB-FILING-TYPE: new

L28: Entry 3 of 29

DOCUMENT-IDENTIFIER: US 20030229003 A1

TITLE: Use of transcription factors for treating inflammation and other diseases

PUBLICATION-DATE: December 11, 2003

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Oettgen, Peter	Brookline	MA	US	
Libermann, Towia	Newton	MA	US	
Goldring, Mary	Auburndale	MA	US	

US-CL-CURRENT: 514/1; 435/4, 435/6, 514/2, 514/44, 514/54

## ABSTRACT:

The present invention provides a method of treating inflammation in a mammal comprising altering the activity of a transcription factor involved in the inflammatory response. The invention also relates to the use of transcription factors to screen compounds that are capable of reducing inflammation. The invention also relates to the use of transcription factors in methods of diagnosing the presence of an inflammatory disease in a tissue of a mammal and methods of monitoring the treatment of an inflammatory disease in a tissue of a mammal.

_													
- 1		Title	Citation	Front	© covience	Class Rigation	Frats	Reference	Sequences	Attachments	Claims	KNMC	Draw Desc
- L	_	114000 (	Chanon	1 10 111	une o tenn	Classication	Date	Meterientos	escapioniscos.	Profession fried in S	in the turns t	1,000	Condition Condition

## 4. Document ID: US 20030215840 A1

L28: Entry 4 of 29

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215840

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030215840 A1

TITLE: Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules

PUBLICATION-DATE: November 20, 2003

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas J.	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US .	
Galvin, Katherine M.	Jamaica Plain	MA	US	
Healy, Aileen	Medford	MA	US	
Acton, Susan L.	Lexington	MA	US	
Donoghue, Mary A.	West Roxbury	MA	US	
Stagliano, Nancy	North Reading	MA	US	
Perodin, Jacqueline	Arlington	MA	US	
Rodrigue-Way, Amelie	Malden	MA	US	

US-CL-CURRENT:  $\underline{435/6}$ ;  $\underline{424/146.1}$ ,  $\underline{435/7.2}$ ,  $\underline{514/1}$ ,  $\underline{514/2}$ ,  $\underline{514/44}$ 

#### ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 and 6585 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

 						***************************************	
 Title Citation	Front Rev	iew Classification	Date Refer	ence Sequences	Attachments	Claims 10000	Drawn Desc

5. Document ID: US 20030199425 A1

L28: Entry 5 of 29

File: PGPB

oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199425

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199425 A1

TITLE: Compositions and methods for treatment of hyperplasia

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Desai, Neil P. Los Angeles CA US

Soon-Shiong, Patrick Los Angeles CA US

US-CL-CURRENT: 514/2; 424/45, 514/291, 514/365, 514/449

#### ABSTRACT:

In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.

******	Title Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC D	ravu Desc

## 6. Document ID: US 20030152574 A1

L28: Entry 6 of 29 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152574

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030152574 A1

TITLE: Methods and compositions to treat cardiovascular disease using 1419, 58765 and

2210

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Logan, Thomas Joseph Springfield PA US Chun, Miyoung Belmont MA US

US-CL-CURRENT: 424/146.1; 435/7.2, 514/1, 514/2, 514/44

### ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial

h eb bgeeef e hc ef be

Page 5 of 20

## Record List Display

cell disorders. Specifically, the present invention identifies the differential expression of 1419, 58765 or 2210 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw Description 7. Document ID: US 20030104977 A1

L28: Entry 7 of 29 File: PGPB Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104977

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104977 A1

TITLE: METHODS FOR INDUCING ANGIOGENESIS USING MORPHOGENIC PROTEINS AND STIMULATORY

FACTORS

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

RIPAMONTI, UGO SANDTON ZA RAMOSHEBI, LENTSHA NATHANIEL JOHANNESBURG ZA

US-CL-CURRENT: 514/2

### ABSTRACT:

The present invention provides a method for inducing angiogenesis at a target locus in a mammal using morphogenic proteins. In addition, this invention also features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method, the morphogenic protein is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and morphogenic protein stimulatory factor can be administered simultaneously to the target locus. Alternatively, the two components are administered separately, in any order.

							;;					
******	Title C	itation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMC	Drawn Desc
L				·								
					*******************					**********	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

8. Document ID: US 20030083231 A1

L28: Entry 8 of 29 File: PGPB May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083231

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030083231 A1

Sep 19, 2002

## Record List Display

TITLE: Blood cell deficiency treatment method

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

RULE-47 CITY STATE COUNTRY NAME San Diego CA US Ahlem, Clarence N. US San Diego CA Reading, Christopher San Diego US Frincke, James CA Stickney, Dwight Granite Bay CA US Lardy, Henry A. Madison WI US Middleton WI US Marwah, Padma US Marwah, Ashok Middleton WI Straffan ΙE Prendergast, Patrick T.

US-CL-CURRENT: 514/2; 514/169, 514/173, 514/26, 514/44, 514/63

#### ABSTRACT:

The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2, 3, 4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D--glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17--one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost--4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandros- tane that can be used in the treatment method.

<u>.</u>	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Desc
······	~~~~~				~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		***************************************	***************************************	······································		······	
	9.	Documen	nt ID:	US 20	020131959	A1						

File: PGPB

PGPUB-DOCUMENT-NUMBER: 20020131959

PGPUB-FILING-TYPE: new

L28: Entry 9 of 29

DOCUMENT-IDENTIFIER: US 20020131959 A1

TITLE: Means and methods for the modulation of arteriogenesis

PUBLICATION-DATE: September 19, 2002

#### INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47
Buschmann, Ivo Freiburg DE
Van Royen, Niels Gundelfingen DE
Hofer, Imo March DE

US-CL-CURRENT: 424/93.21; 424/85.1, 424/85.2, 514/2, 514/44

#### ABSTRACT:

The present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar

h eb bgeeef e hc ef be

connections. In particular, the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an organ, tissue or cells with transforming growth factor beta 1 (TGF.beta.1) or a nucleic acid molecule encoding TGF.beta.1. The present invention also relates to the use of TGF.beta.1 or a nucleic acid molecule encoding TGF.beta.1 for the preparation of pharmaceutical compositions for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Furthermore, the present invention relates to a method for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF.beta.1. The present invention further involves the use of an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF.beta.1 for the preparation of pharmaceutical compositions for the treatment of tumors.

	Title	Citation Fr	ont Review	Classification	Date	Reference	Sequences	Attachments	Claims -	KWAC	Drawi Desc
			······································	······································	······		······	·>>	***************************************		***************************************
	10.	Documen	t ID: US 2	002006152	l A1						
L28:	Entr	y 10 of 2	29			File:	PGPB		May	23,	2002

PGPUB-DOCUMENT-NUMBER: 20020061521

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061521 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: May 23, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

#### ABSTRACT:

The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods

and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Dram Desc

11. Document ID: US 20020061294 A1

L28: Entry 11 of 29

File: PGPB

May 23, 2002

May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020061294

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061294 A1

TITLE: MONONUCLEAR PHAGOCYTES IN THERAPEUTIC DRUG DELIVERY

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

LEWIS, CLAIRE E. SHEFFIELD GB
.HARRIS, ADRIAN L. OXFORD GB

MARSHALL, JULIAN M OXFORD GB

 $\text{US-CL-CURRENT: } \underline{424/93.21; } \underline{424/450}, \underline{435/320.1}, \underline{435/325}, \underline{435/69.1}, \underline{514/2}, \underline{514/44} \\ \underline{514/450}, \underline{51$ 

#### ABSTRACT:

The invention relates to the exploitation of the migratory behaviour of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the munonuclear phagocyte to a target area.

- [ -		Title	Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Desc
*******	********	**********	
		12.	Document ID: US 20020058612 A1

File: PGPB

PGPUB-DOCUMENT-NUMBER: 20020058612

PGPUB-FILING-TYPE: new

L28: Entry 12 of 29

DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Franco, Wayne P. Rocky Hill CT US

US-CL-CURRENT: 514/2; 424/43

h eb bgeeef e hc ef b e

#### ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

30004	Title Citation Front Review Classification Date	Reference Sequence	s Attachments Claims KWC	Draw. Desc
			•	
	13. Document ID: US 20020037832 A1			
L28:	Entry 13 of 29	File: PGPB	Mar 28,	2002

PGPUB-DOCUMENT-NUMBER: 20020037832

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020037832 A1

TITLE: Use of alpha-MSH and EPO for preventing or treating ischemic conditions

PUBLICATION-DATE: March 28, 2002

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nielsen, Soren	Abyhoj		DK	
Frokiaer, Jorgen	Abyhoj		DK	
Jonassen, Thomas Engelbrecht Norkild	Frederiksberg		DK	
Bjerke, Thorbjorn	Fredensborg		DK	

US-CL-CURRENT: 514/2; 514/169

### ABSTRACT:

Alpha--melanocyte stimulating hormone (.alpha.-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions.

			•		
	Title Citation Front Re	eview Classification Date	Reference Sequences	Attachments Claims	KOMC   Drawn Desc
·····	······	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
<b>,</b>	14 December 110. 1	TIC 2002000 (205 A 1			
Lui	14. Document ID: 1	US 20020000893 A1			
L28:	Entry 14 of 29		File: PGPB	Jan	17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006895

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006895 A1

TITLE: Method of treatment of cardiovascular injuries

PUBLICATION-DATE: January 17, 2002

h eb bgeeef e hc ef be

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Moulton, Karen S.

Weston

MΑ

US

Folkman, Judah

Brookline

MA

US

US-CL-CURRENT: 514/2; 424/85.6, 424/85.7, 514/326, 514/475

#### ABSTRACT:

The present invention provides a method for treating cardiovascular ailments. The method involves first screening an individual to determine their risk of having the potential for unstable plaques. Such individuals can be selected by looking at one of the following criteria: (i) increased plaque neovascularization, (ii) area ratio of intima to wall area of a plaque, (iii) evidence of plaque hemorrhage, or (iv) inflammatory cells associated with plaque vessels. Looking at these criteria permits one to select individuals having the potential for unstable plaques. The method then involves treating the selected individual with an effective amount of an angiogenesis inhibitor.

Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw Desc

## 15. Document ID: US 6759386 B2

L28: Entry 15 of 29

File: USPT

Jul 6, 2004

US-PAT-NO: 6759386

DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor

and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Franco; Wayne P.

Rocky Hill

CT

06067

US-CL-CURRENT: <u>514/2</u>; <u>514/12</u>, <u>514/14</u>, <u>514/8</u>, <u>530/300</u>

## ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 4

Title Citation Front Review Classification Date Reference Claims KMC Draw Desc

## 16. Document ID: US 6737404 B2

L28: Entry 16 of 29

File: USPT

May 18, 2004

US-PAT-NO: 6737404

DOCUMENT-IDENTIFIER: US 6737404 B2

TITLE: Methods of using analogs of human basic fibroblast growth factor mutated at

one or more of the positions glutamate 89, aspartate 101 or leucine 137

DATE-ISSUED: May 18, 2004

INVENTOR-INFORMATION:

NAME

CITY Wilmington STATE ZIP CODE

COUNTRY

Springer; Barry A.

Boxford

DE

Pantoliano; Michael W.

D - -- 1 - -- t- - - --

PA

Sharp; Celia M.

Doylestown

PA

US-CL-CURRENT: 514/12; 514/2, 530/399

#### ABSTRACT:

The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.

30 Claims, 2 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 2

Title Citation	Front Review	Classification	Date Reference	Claims   KMC   Draw Desc

## 17. Document ID: US 6605592 B2

L28: Entry 17 of 29

File: USPT

Aug 12, 2003

US-PAT-NO: 6605592

DOCUMENT-IDENTIFIER: US 6605592 B2

TITLE: Protein HOFNF53

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY
Ni; Jian Germantown MD
Baker; Kevin P. Darnestown MD

Birse; Charles E. North Potomac MD
Ebner; Reinhard Gaithersburg MD
Fiscella; Michele Bethesda MD

h eb bgeeef e hc ef b e

Komatsoulis; George A.	Silver Spring	MD
LaFleur; David W.	Washington	DC
Moore; Paul A.	Germantown	MD
Olsen; Henrik S.	Gaithersburg	MD
Rosen; Craig A.	Laytonsville	MD
Ruben; Steven M.	Olney	MD
Soppet; Daniel R.	Centreville	VA
Young; Paul E.	Gaithersburg	MD
Wei; Ping	Brookeville	MD
Florence; Kimberly A.	Rockville	MD

US-CL-CURRENT: 514/2; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1, 435/71.1, 435/71.2, 514/12, 514/8, 530/350

#### ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. In particular, the present application relates to a novel human protein, Protein HOFNF53. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

19 Claims, 22 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 22

 Title Citation	Front	Review	Classification	Date	Reference		Claims	KMAC	Draint Desi
:						 			

## 18. Document ID: US 6592862 B1

L28: Entry 18 of 29

File: USPT

Jul 15, 2003

US-PAT-NO: 6592862

DOCUMENT-IDENTIFIER: US 6592862 B1

TITLE: Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections

------ ---- productions according to

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE

Schaper; Wolfgang

Ito; Wulf D.

Bad Nauheim/Rodgen Luneburg DE DE

COUNTRY

US-CL-CURRENT: <u>424/85.1</u>; <u>514/12</u>, <u>514/2</u>, <u>514/8</u>

## ABSTRACT:

Described is the modulation of the growth of collateral arteries and/or other arteries from preexisting arterlolar connections. Methods are provided for enhancing the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting tissue or cells with a monocyte chemotactic protein

(MCP) or a nudeic acid molecule encoding said MCP. Furthermore, the use of a MCP or a nucleic acid molecule encoding said MCP for the preparation of pharmaceutical compositions for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described, Also provided are methods for the treatment of tumors comprising contacting tissue or cells with an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the attraction of monocytes. Described is further the use of an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through attraction of monocytes for the preparation of pharmaceutical compositions for the treatment of tumors.

14 Claims, 14 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KWIC D	raw, Desi
*****					***************************************	••••••	•••••	 **********	 **************		

## 19. Document ID: US 6541224 B2

L28: Entry 19 of 29

File: USPT

Apr 1, 2003

US-PAT-NO: 6541224

DOCUMENT-IDENTIFIER: US 6541224 B2

TITLE: Tumor necrosis factor delta polypeptides

DATE-ISSUED: April 1, 2003

## INVENTOR-INFORMATION:

CITY STATE ZIP CODE COUNTRY NAME Yu; Guo-Liang Berkeley CA Ni; Jian Germantown MD Gentz; Reiner L. Rockville MD Dillon; Patrick J. Carlsbad CA

US-CL-CURRENT: 435/69.5; 435/69.1, 435/69.7, 435/7.71, 435/70.1, 514/12, 514/2, 530/350, 530/351

#### ABSTRACT:

The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

50 Claims, 7 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 11

,,,,,,	Citation		Classification	Date	Reference	Claims	KWWC Draw, Des	Ĭ
								_

## 20. Document ID: US 6541008 B1

L28: Entry 20 of 29 File: USPT Apr 1, 2003

US-PAT-NO: 6541008

DOCUMENT-IDENTIFIER: US 6541008 B1

TITLE: Vascular endothelial growth factor-like protein from orf viruses binds and

activates mammalian <u>VEGF</u> receptor-2, and uses thereof

DATE-ISSUED: April 1, 2003

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wise; Lyn M.	Dunedin			NZ
Mercer; Andrew A.	Dunedin			NZ
Savory; Loreen J.	Dunedin			NZ
Fleming; Stephen B.	Dunedin			NZ
Stacker; Steven A.	Parkville			AU

US-CL-CURRENT: 424/198.1; 514/2, 530/350

#### ABSTRACT:

The invention is based on the discovery that a viral  $\underline{\text{VEGF}}$ -like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the  $\underline{\text{VEGF}}$  receptor-2 to form bioactive complexes which mediate useful cellular responses and/or antagonize undesired biological activities. Disclosed are methods which stimulate or inhibit these biological activities, methods for therapeutic applications and antagonists of ORFV2-VEGF and/or NZ10.

17 Claims, 15 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 10

,,,,,		Citation		Review	Classification		Reference				Claims	KMC	Drawt Desc
	******		*************		***************************************	*********		*************	*************	***********		·····	

## ☐ 21. Document ID: US 6521211 B1

L28: Entry 21 of 29 File: USPT Feb 18, 2003

US-PAT-NO: 6521211

DOCUMENT-IDENTIFIER: US 6521211 B1

TITLE: Methods of imaging and treatment with targeted compositions

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Unger; Evan C. Tucson AZ Wu; Yunqiu Tucson AZ

US-CL-CURRENT: 424/9.52; 424/450, 424/9.5, 424/9.51, 514/18, 514/2, 600/431, 600/437

h eb bgeeef e hc ef b e

#### ABSTRACT:

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

58 Claims, 17 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 12

, <u>,</u>	Title   Citation   Front   Rev	iew Classification D.	ste   Reference		Claims KMC Draw. Desc
	22. Document ID: U	S 6518236 B1	***************************************		
L28:	Entry 22 of 29		File:	USPT	Feb 11, 2003

US-PAT-NO: 6518236

DOCUMENT-IDENTIFIER: US 6518236 B1

TITLE: FGF homologs

DATE-ISSUED: February 11, 2003

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deisher; Theresa A.	Seattle	WA .		
Conklin; Darrell C.	Seattle	AW		
Raymond; Fenella	Seattle	AW		
Bukowski; Thomas R.	Seattle	AW		
Holderman; Susan D.	Seattle	WA		
Hansen; Birgit	Seattle	AW		
Sheppard; Paul O.	Redmond	WA		

US-CL-CURRENT: <u>514/2</u>; <u>435/69.7</u>, <u>514/12</u>, <u>530/350</u>, <u>530/399</u>

### ABSTRACT:

The present invention relates to polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.

5 Claims, 3 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 3

,	Title Citation Front	Review Classificatio	on Date Reference Claims KWC	Draw Des
7				

23. Document ID: US 6514935 B1

L28: Entry 23 of 29

File: USPT

Feb 4, 2003

US-PAT-NO: 6514935

DOCUMENT-IDENTIFIER: US 6514935 B1

TITLE: Methods of treating hypertension

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME

CITY

Andover

STATE ZIP CODE

COUNTRY

Lee; Mu-En

Yet; Shaw-Fang

Newton

MA MA

US-CL-CURRENT: 514/2

ABSTRACT:

The invention features a method of inhibiting hypertension in a mammal by administering to the mammal a compound that reduces expression or activity of SmLIM.

3 Claims, 24 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 11

,	Title	Citation Front	Review   Cl.	assification	Date   Refere	nee		Claims	KWC	Draint Dest
***************************************	***********			******************	***************************************		, ,		*************	***************************************
<b>,</b> 1	24	D	. 110 (40)	0144 D1						

1... 24. Document ID: US 6498144 B1

L28: Entry 24 of 29

File: USPT

Dec 24, 2002

US-PAT-NO: 6498144

DOCUMENT-IDENTIFIER: US 6498144 B1

TITLE: Use of scatter factor to enhance angiogenesis

DATE-ISSUED: December 24, 2002

INVENTOR-INFORMATION:

NAME CITY

STATE ZIP CODE

COUNTRY

Goldberg; Itzhak D.

Englewood

NЈ

Rosen; Eliot M.

Port Washington

NY

US-CL-CURRENT: 514/12; 514/2, 530/324, 530/350, 530/399

ABSTRACT:

This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation utilizing scatter factor, either alone or in combination with a growth factor.

h eb b g ee ef e h c ef b

5 Claims, 39 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 12

25. Document ID: US 6475796 B1

L28: Entry 25 of 29

File: USPT

Nov 5, 2002

US-PAT-NO: 6475796

DOCUMENT-IDENTIFIER: US 6475796 B1

TITLE: Vascular endothelial growth factor variants

Title Citation Front Review Classification Date Reference

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Pollitt; N. Stephen

Los Altos

CA

Abraham; Judith A.

San Jose

CA

US-CL-CURRENT: 435/455; 424/198.1, 514/2, 530/350

#### ABSTRACT:

The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors ( $\underline{\text{VEGF}}$ ). The invention further concerns certain  $\underline{\text{VEGF}}$  variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.

17 Claims, 17 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 17

Title Citation Front Review Classification Date Reference

Claims KWC Draw, Des

26. Document ID: US 6440934 B1

L28: Entry 26 of 29

File: USPT

Aug 27, 2002

US-PAT-NO: 6440934

DOCUMENT-IDENTIFIER: US 6440934 B1

TITLE: Angiogenically effective unit dose of FGF-2 and method of use

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Whitehouse; Martha Jo

San Francisco

CA

h eb b g ee ef e h c ef b

US-CL-CURRENT: 514/12; 424/423, 424/85.2, 424/94.4, 435/69.4, 514/2, 514/358, 514/410, 514/411, 514/54, 514/56, 530/350, 530/380, 530/381, 530/383, 530/399, 536/17.2, 536/21, 604/101.03

#### ABSTRACT:

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 .mu.g/kg to 48 .mu.g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts six months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.

58 Claims, 5 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 5

	•	Title	Citation Front	Review	Classification	Date Re	eference			C	laims	KOMC	Draw Desi	į
·······			······	***************************************				······································	···········	······································		********		,
l		27.	Document II	D: US	5235713 B1		•							

File: USPT

May 22, 2001

US-PAT-NO: 6235713

DOCUMENT-IDENTIFIER: US 6235713 B1

TITLE: Vascular endothelial growth factor-D (VEGF-D) polypeptides

DATE-ISSUED: May 22, 2001

L28: Entry 27 of 29

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Achen; Marc G.	Fitzroy			AU
Wilks; Andrew F.	South Yarra			AU
Stacker; Steven A.	North Fitzroy			AU
Alitalo; Kari	Espoo			FI

US-CL-CURRENT: 514/12; 514/2, 530/399, 530/412, 530/413

#### ABSTRACT:

<u>VEGF</u>-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical

h eb bgeeef e hc ef b e

and diagnostic applications.

16 Claims, 22 Drawing figures Exemplary Claim Number: 1

Number of Drawing Sheets: 21

28. Document ID: US 5932540 A

L28: Entry 28 of 29

File: USPT

Aug 3, 1999

US-PAT-NO: 5932540

DOCUMENT-IDENTIFIER: US 5932540 A

\*\* See image for Certificate of Correction \*\*

TITLE: Vascular endothelial growth factor 2

DATE-ISSUED: August 3, 1999

INVENTOR-INFORMATION:

NAME

CITY

Title Citation Front Review Classification Date Reference

STATE

ZIP CODE

COUNTRY

Hu; Jing-Shan

Sunnyvale

Rosen; Craig A.

Laytonsville

MD

Cao; Liang

Hong Kong

ΗK

US-CL-CURRENT: <u>514/2</u>; <u>530/326</u>, <u>530/399</u>, <u>530/402</u>

### ABSTRACT:

Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

186 Claims, 22 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 19

		Title	Citation	Front		Classification		Reference			Claims	KWIC	Draw, Desc
****	******	*********	**********	******	************	*******************	*********	*******	**************	 **********		***************************************	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

29. Document ID: US 5824644 A

L28: Entry 29 of 29

File: USPT

Oct 20, 1998

US-PAT-NO: 5824644

DOCUMENT-IDENTIFIER: US 5824644 A

TITLE: Method of attenuating arterial stenosis

h e b b g eeef h c ef DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Abendschein: Dana R.

St. Louis

MO

US-CL-CURRENT: 514/12; 424/422, 514/2, 514/21, 530/324, 530/350, 530/380

## ABSTRACT:

A method is disclosed for attenuating stenosis after balloon angioplasty. The method comprises administering to a host parenterally or locally to the luminal surface of the blood vessel subjected to said balloon angioplasty an effective amount of tissue factor pathway inhibitor (TFPI) for a prolonged period of time sufficient to substantially reduce the extent of restenosis. An exemplary amount of the TFPI is from about 0.5 mg/kg to about 6 mg/kg during a prolonged administration of about twelve (12) hours to 36 hours.

14 Claims, 13 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 11

, <u>,</u>	Title	Citation	Frent	Review	Classification	Date	Reference			C	laims	KOMC	Draw, De	Ĭ
Clea		Genei	rate Co	llection	Pont		Fwd Refs	Bkwc	i Reis	1	Gene	rate C	)ACS	~
						*****		 ***************************************						
	Ter	ms		7				Doc	uments					
	L2.	3 AND (	514/2	).CCLS								29		

Display Format: - Change Format

Previous Page

Next Page

Go to Doc#







Protein Published Nucleotide Genome Structure MIMO PMC Journals Boo! Search PubMed Gο Clear for coronary artery disease AND growth factor Limits Preview/Index History Clipboard Details About Entrez Display Show: 500 Sort Summary Send to Text Text Version Items 1-500 of 548 Page of 2 Next 1: Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E. Related Articles, Links Entrez PubMed Overview Help | FAQ Comparative effects of AT1-antagonism and angiotensin-converting enzyme Tutorial inhibition on markers of inflammation and platelet aggregation in patients New/Noteworthy with coronary artery disease. E-Utilities J Am Coll Cardiol. 2004 Jul 21;44(2):362-8. PMID: 15261932 [PubMed - indexed for MEDLINE] **PubMed Services** Journals Database 7 2. Grunenfelder J, Umbehr M, Plass A, Bestmann L, Maly FE, Zund G, Related Articles, Links MeSH Database Turina M. Single Citation Matcher **Batch Citation Matcher** Genetic polymorphisms of apolipoprotein E4 and tumor necrosis factor beta **Clinical Queries** as predisposing factors for increased inflammatory cytokines after LinkOut cardiopulmonary bypass. Cubby J Thorac Cardiovasc Surg. 2004 Jul; 128(1):92-7. PMID: 15224026 [PubMed - indexed for MEDLINE] Related Resources Order Documents 3: Nakajima K, Tabata S, Yamashita T, Kusuhara M, Arakawa K, Related Articles, Links **NLM Gateway** Ohmori R. Yonemura A, Higashi K, Ayaori M, Nakamura H, TOXMET Ohsuzu F. Consumer Health Clinical Alerts Plasma vascular endothelial growth factor level is elevated in patients with ClinicalTrials.gov multivessel coronary artery disease. PubMed Central Clin Cardiol. 2004 May;27(5):281-6. PMID: 15188944 [PubMed - in process] 4. Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Related Articles, Links Bucknall CA, Redwood SR, Pearson JD, Marber MS. Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation. 2004 Jun 22;109(24):2986-92. Epub 2004 Jun 07. PMID: 15184289 [PubMed - in process] 5: Lemstrom KB, Nykanen AI, Tikkanen JM, Krebs R, Sihvola RK, Related Articles, Links Kallio EA, Olivier R, Koskinen PK Role of angiogenic growth factors in transplant coronary artery disease. Ann Med. 2004;36(3):184-93. PMID: 15181974 [PubMed - in process] 6: Penny WF, Hammond HK. Related Articles, Links Clinical use of intracoronary gene transfer of fibroblast growth factor for coronary artery disease. Curr Gene Ther. 2004 Jun;4(2):225-30. PMID: 15180588 [PubMed - in process] 7. Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli Related Articles, Links G, Antelli A, Canistro D, Francolini G, Macri G, Mastrorilli F, Paolini M, Ferrari R. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and

progression to heart failure after acute myocardial infarction.

e ch

fcg

cb

h g

	J Am Coll Cardiol. 2004 Jun 2;43(11):2000-8. PMID: 15172404 [PubMed - indexed for MEDLINE]	-
8:	Choy E.	Related Articles, Links
	Clinical experience with inhibition of interleukin-6. Rheum Dis Clin North Am. 2004 May;30(2):405-15, viii. Review. PMID: 15172049 [PubMed - indexed for MEDLINE]	
□9:	Rosinberg A, Khan TA, Sellke FW, Laham RJ.	Related Articles, Links
	Therapeutic angiogenesis for myocardial ischemia. Expert Rev Cardiovasc Ther. 2004 Mar;2(2):271-83. Review. PMID: 15151475 [PubMed - indexed for MEDLINE]	
□10	: Christiansen JF, Hartwig D, Bechtel JF, Kluter H, Sievers H, Schonbeck U, Bartels C.	Related Articles, Links
	Diseased vein grafts express elevated inflammatory cytocompared with atherosclerotic coronary arteries.  Ann Thorac Surg. 2004 May;77(5):1575-9.  PMID: 15111145 [PubMed - indexed for MEDLINE]	okine levels
□11	• Tentolouris C, Tousoulis D, Antoniades C, Bosinakou E. Kotsopoulou M, Trikas A, Toutouzas P, Stefanadis C.	Related Articles, Links
	Endothelial function and proinflammatory cytokines in pischemic heart disease and dilated cardiomyopathy. Int J Cardiol. 2004 Apr;94(2-3):301-5. PMID: 15093997 [PubMed - indexed for MEDLINE]	patients with
□ 12	: Wykretowicz A, Furmaniuk J, Smielecki J, Deskur-Smielecka E, Szczepanik A, Banaszak A, Wysocki H.	Related Articles, Links
	The oxygen stress index and levels of circulating interle interleukin-6 in patients with chronic heart failure. Int J Cardiol. 2004 Apr, 94(2-3):283-7. PMID: 15093994 [PubMed - indexed for MEDLINE]	ukin-10 and
□ 13	Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL.	Related Articles, Links
	Reduced pericardial levels of endostatin correlate with c development in patients with ischemic heart disease.  J Am Coll Cardiol. 2004 Apr 21;43(8):1383-7.  PMID: 15093871 [PubMed - indexed for MEDLINE]	ollateral
□14	· Poreba R, Skoczynska A, Derkacz A.	Related Articles, Links
	[Effect of tobacco smoking on endothelial function in pactoronary arteriosclerosis] Pol Arch Med Wewn. 2004 Jan;111(1):27-36. Polish. PMID: 15088418 [PubMed - indexed for MEDLINE]	atients with
□15	: Dimkovie N.	Related Articles, Links
	[Erythropoietin administration in the predialysis period] Med Pregl. 2003 Nov-Dec;56(11-12):529-35. Review. Serbian. PMID: 15080045 [PubMed - indexed for MEDLINE]	
□ 16	: Gouni-Berthold I, Sachinidis A.	Related Articles, Links
	Molecular mechanisms explaining the preventive effects the development of proliferative diseases.  Curr Pharm Des. 2004;10(11):1261-71. Review.  PMID: 15078140 [PubMed - indexed for MEDLINE]	of catechins on
□ 17	Brydon L, Edwards S, Mohamed-Ali V, Steptoe A	Related Articles, Links

	Socioeconomic status and stress-induced increases in in Brain Behav Immun. 2004 May;18(3):281-90. PMID: 15050655 [PubMed - indexed for MEDLINE]	terleukin-6.
□ 18	Kovalev IA, Martsinkevich GI, Suslova TE, Sokolov AA.	Related Articles, Links
	[Endothelial dysfunction and risk factors of its development with family history of atherosclerosis]  Kardiologiia. 2004;44(1):39-42. Russian.  PMID: 15029147 [PubMed - indexed for MEDLINE]	ment in subjects
T 19	Llorente-Cortes V, Otero-Vinas M, Berrozpe M, Badimon L.	Related Articles, Links
	Intracellular lipid accumulation, low-density lipoprotein protein expression, and cell survival in vascular smooth derived from normal and atherosclerotic human coronar Eur J Clin Invest. 2004 Mar;34(3):182-90. PMID: 15025676 [PubMed - indexed for MEDLINE]	muscle cells
□ 20:	van Royen N, Voskuil M, Hoefer I, Jost M, de Graaf S, Hedwig F, Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST	Related Articles, Links
	CD44 regulates arteriogenesis in mice and is differential patients with poor and good collateralization. Circulation. 2004 Apr 6;109(13):1647-52. Epub 2004 Mar 15. PMID: 15023889 [PubMed - indexed for MEDLINE]	lly expressed in
□ 21:	Ikonomidis I, Andreotti F, Nihoyannopoulos P.	Related Articles, Links
	Reduction of daily life ischaemia by aspirin in patients vunderlying link between thromboxane A2 and macropha stimulating factor.  Heart. 2004 Apr;90(4):389-93.  PMID: 15020512 [PubMed - indexed for MEDLINE]	vith angina: age colony
□ 22:	Williams MJ, Sutherland WH, Whelan AP, McCormick MP, de Jong SA	Related Articles, Links
	Acute effect of drinking red and white wines on circulatinflammation-sensitive molecules in men with coronary Metabolism. 2004 Mar;53(3):318-23. PMID: 15015143 [PubMed - indexed for MEDLINE]	ing levels of artery disease.
□ 23:	Yohannes P, Rao M, Burjonrappa S, Sudan R.	Related Articles, Links
	Laparoscopic nephron-sparing surgery in a Jehovah's Wi J Endourol. 2004 Feb;18(1):59-62. PMID: 15006056 [PubMed - indexed for MEDLINE]	itness patient.
□ 24:	Perrin L.A., June JE, Rosebury W, Robertson A, Kovesdi I, Bruder JT, Kessler PD, Keiser JA, Gordon D.	Related Articles, Links
	Increased revascularization efficacy after administration encoding VEGF(121). Gene Ther. 2004 Mar;11(6):512-21. PMID: 14999223 [PubMed - indexed for MEDLINE]	of an adenovirus
□ 25:	Avanzas P. Arroyo-Espliguero R. Cosin-Sales J. Quiles J. Zouridakis E. Kaski JC.	Related Articles, Links
	Prognostic value of neopterin levels in treated patients w and chest pain but without obstructive coronary artery di Am J Cardiol. 2004 Mar 1;93(5):627-9. PMID: 14996595 [PubMed - indexed for MEDLINE]	
□ 26:	Syed IS, Sanborn TA, Rosengart TK.	Related Articles, Links

cb

hg e e

e fcg


e ch

ch

h g

e fcg


e ch



cb

h g


е



e ch

cb

h g



e ch

e fcg


cb

h g

fcg

e ch

		rage / 01 30
	PMID: 14617549 [PubMed - indexed for MEDLINE]	
□ 54	: Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Kaibuchi K, Takeshita A.	Related Articles, Links
	Long-term treatment with a specific Rho-kinase inhibito cardiac allograft vasculopathy in mice. Circ Res. 2004 Jan 9;94(1):46-52. Epub 2003 Nov 13. PMID: 14615290 [PubMed - indexed for MEDLINE]	or suppresses
□ 55	: Grines C, Rubanyi GM, Kleiman NS, Marrott P, Watkins MW.	Related Articles, Links
	Angiogenic gene therapy with adenovirus 5 fibroblast gr (Ad5FGF-4): a new option for the treatment of coronary Am J Cardiol. 2003 Nov 7;92(9B):24N-31N. Review. PMID: 14615023 [PubMed - indexed for MEDLINE]	
□ 56	: Moien-Afshari F. McManus BM, Laher I.	Related Articles, Links
	Immunosuppression and transplant vascular disease: ber effects.	nefits and adverse
,	Pharmacol Ther. 2003 Nov;100(2):141-56. Review. PMID: 14609717 [PubMed - indexed for MEDLINE]	
□ <b>5</b> 7	: Boehm M, Nabel EG.	Related Articles, Links
	The cell cycle and cardiovascular diseases. Prog Cell Cycle Res. 2003;5:19-30. Review. PMID: 14593697 [PubMed - indexed for MEDLINE]	
□ 58	Panutsopulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA.	Related Articles, Links
	Peripheral monocytes from diabetic patients with corona display increased bFGF and VEGF mRNA expression. J Transl Med. 2003 Oct 06;1(1):6. PMID: 14585103 [PubMed - as supplied by publisher]	artery disease
□ 59	Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y.	Related Articles, Links
	Human epicardial adipose tissue is a source of inflamma Circulation. 2003 Nov 18;108(20):2460-6. Epub 2003 Oct 27. PMID: 14581396 [PubMed - indexed for MEDLINE]	tory mediators.
<b>5</b> 60	: Walter RB, Fuchs D, Weiss G, Walter TR, Reinhart WH	Related Articles, Links
	HMG-CoA reductase inhibitors are associated with decr neopterin levels in stable coronary artery disease. Clin Chem Lab Med. 2003 Oct;41(10):1314-9. PMID: 14580158 [PubMed - indexed for MEDLINE]	eased serum
<b>61</b>	: Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M, Bertazzoni G, Gazzaniga PP, Alessandri C.	Related Articles, Links
	Serum metalloproteinase 9 levels in patients with corona novel marker of inflammation.  J Investig Med. 2003 Sep;51(5):295-300.  PMID: 14577520 [PubMed - indexed for MEDLINE]	arry artery disease: a
□ 62	: Koch W, Tiroch K, von Beckerath N, Schomig A, Kastrati A.	Related Articles, Links
	Tumor necrosis factor-alpha, lymphotoxin-alpha, and interpolymorphisms and restenosis after coronary artery stems Cytokine. 2003 Nov 21;24(4):161-71. PMID: 14572794 [PubMed - indexed for MEDLINE]	<b>-</b>
□ 63	: Juan-Babot JO, Martinéz-Gonzalez J, Berrozpe M, Badimon L.	Related Articles, Links



cb hg e e fcg


h

e ch

Del Valle H, Dulbecco E, Werba P, Cuniberti L, Martinez V, De

72: Crottogini A, Meckert PC, Vera Janavel G, Lascano E, Negroni J, Related Articles, Links

h e



cb

h g

e fcg

e

e ch

□ 81	Wei M, Kuukasjarvi P, Laurikka J, Kaukinen S, Honkonen EL, Metsanoja R, Tarkka M.	Related Articles, Links	
	Relation of cytokines to vasodilation after coronary arte World J Surg. 2003 Oct;27(10):1093-8. Epub 2003 Aug 21. PMID: 12925902 [PubMed - indexed for MEDLINE]	ry bypass grafting.	
□ 82	: Glowinska B, Urban M.	Related Articles, Links	
	[Selected cytokines (II-6, II-8, II-10, MCP-1, TNF-alpha adolescents with atherosclerosis risk factors: obesity, hy diabetes] Wiad Lek. 2003;56(3-4):109-16. Polish. PMID: 12923954 [PubMed - indexed for MEDLINE]		
□ 83	Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.	Related Articles, Links	
	Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.  Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 07.  PMID: 12907464 [PubMed - indexed for MEDLINE]		
□ 84	: Watkins MW, Rubanyi GM.	Related Articles, Links	
	Gene therapy for coronary artery disease: preclinical and initial clinical results with intracoronary administration of Ad5FGF-4.  Ernst Schering Res Found Workshop. 2003;(43):61-78. Review. No abstract available. PMID: 12894451 [PubMed - indexed for MEDLINE]		
□ 85	: Geraldes P. Sirois MG, Tanguay JF.	Related Articles, Links	
	Specific contribution of estrogen receptors on mitogen-kinase pathways and vascular cell activation. Circ Res. 2003 Sep 5;93(5):399-405. Epub 2003 Jul 31. PMID: 12893737 [PubMed - indexed for MEDLINE]	activated protein	
□ 86	Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE.	Related Articles, Links	
	Migration inhibitory factor mediates angiogenesis via m protein kinase and phosphatidylinositol kinase. Circ Res. 2003 Aug 22;93(4):321-9. Epub 2003 Jul 24. PMID: 12881477 [PubMed - indexed for MEDLINE]	itogen-activated	
□ 87	: Xia H., Redman CM.	Related Articles, Links	
	Oxysterols suppress constitutive fibrinogen expression. Thromb Haemost. 2003 Jul;90(1):43-51. PMID: 12876624 [PubMed - indexed for MEDLINE]		
₩ 88	Murata S, Miniati DN, Kown MH, Koransky ML, Balsam LB, Lijkwan MA, Martens JM, Robbins RC	Related Articles, Links	
	Elevated cyclic adenosine monophosphate ameliorates i reperfusion injury in rat cardiac allografts.  J Heart Lung Transplant. 2003 Jul;22(7):802-9.  PMID: 12873549 [PubMed - indexed for MEDLINE]	schemia-	
□ 89	Holm T, Damas JK, Holven K, Nordoy I, Brosstad FR, Ueland T, Wahre T, Kjekshus J, Froland SS, Eiken HG, Solum NO, Gullestad L, Nenseter M, Aukrust P.	Related Articles, Links L	
	CXC-chemokines in coronary artery disease: possible p interactions between oxidized low-density lipoprotein, p peripheral blood mononuclear cells.  J Thromb Haemost. 2003 Feb;1(2):257-62.  PMID: 12871498 [PubMed - indexed for MEDLINE]	_	

h cb hg e e e fcg e ch

h g

e fcg

e ch

b e

cb


h

790: Aldhahi W, Hamdy O.	Related Articles, Links
Adipokines, inflammation, and the endothelium in dis Curr Diab Rep. 2003 Aug;3(4):293-8. Review. PMID: 12866991 [PubMed - indexed for MEDLINE]	abetes.
791: Chien S.	Related Articles, Links
Molecular and mechanical bases of focal lipid accumwall. Prog Biophys Mol Biol. 2003 Oct;83(2):131-51.	ulation in arterial
PMID: 12865076 [PubMed - in process]  92: Azar RR, Klayme S, Germanos M, Kassab R, Tawm S, Aboujaoude S, Naman R.	Related Articles, Links
Effects of aspirin (325 mg/day) on serum high-sensiti protein, cytokines, and adhesion molecules in healthy Am J Cardiol. 2003 Jul 15;92(2):236-9. No abstract available. PMID: 12860235 [PubMed - indexed for MEDLINE]	
93: Berg HF, Maraha B, Scheffer GJ, Peeters MF, Kluytmans JA.	Related Articles, Links
Effect of clarithromycin on inflammatory markers in atherosclerosis. Clin Diagn Lab Immunol. 2003 Jul;10(4):525-8. PMID: 12853380 [PubMed - indexed for MEDLINE]	patients with
94: Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M.	Related Articles, Links
Toward surgical angiogenesis using slow-released batactor. Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112 PMID: 12853053 [PubMed - indexed for MEDLINE]	•
95: Smith DA, Zouridakis EG, Mariani M, Fredericks S, Cole D, K	aski Related Articles, Links
Neopterin levels in patients with coronary artery dise Chlamydia pneumoniae seropositivity.  Am Heart J. 2003 Jul;146(1):69-74.  PMID: 12851610 [PubMed - indexed for MEDLINE]	ase are independent of
96: Hedman M, Yla-Herttuala S.	Related Articles, Links
Gene therapy for the treatment of peripheral vascular artery disease. Drugs Today (Barc). 2000 Sep;36(9):609-17. PMID: 12847566 [PubMed]	disease and coronary
97: Heeneman S. Cleutjens JP, Faber BC, Creemers EE, van Suyler RJ, Lutgens E, Cleutjens KB, Daemen MJ	Related Articles, Links
The dynamic extracellular matrix: intervention strate failure and atherosclerosis.  J Pathol. 2003 Jul;200(4):516-25. Review. PMID: 12845619 [PubMed - indexed for MEDLINE]	gies during heart
98: Giomarelli P, Scolletta S, Borrelli E, Biagioli B.	Related Articles, Links
Myocardial and lung injury after cardiopulmonary by interleukin (IL)-10.  Ann Thorac Surg. 2003 Jul;76(1):117-23.  PMID: 12842524 [PubMed - indexed for MEDLINE]	pass: role of
99: Buschmann IR, Busch HJ, Mies G, Hossmann KA.	Related Articles, Links

cb

h g

fcg



coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost. 2003 Jun;89(6):1058-63. PMID: 12783119 [PubMed - indexed for MEDLINE] 109: <u>Kastrup J.</u> Related Articles, Links Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy? Curr Gene Ther. 2003 Jun;3(3):197-206. Review. PMID: 12762479 [PubMed - indexed for MEDLINE] 110: Koerselman J, van der Graaf Y, de Jaegere PP, Grobbee DE. Related Articles, Links Coronary collaterals: an important and underexposed aspect of coronary artery disease. Circulation. 2003 May 20;107(19):2507-11. Review. No abstract available. PMID: 12756191 [PubMed - indexed for MEDLINE] 111: Damas JK, Waehre T, Yndestad A, Otterdal K, Hognestad A, Related Articles, Links Solum NO, Gullestad L, Froland SS, Aukrust P. Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation. 2003 Jun 3;107(21):2670-6. Epub 2003 May 12. PMID: 12742982 [PubMed - indexed for MEDLINE] 112: Yoshioka S, Tsukamoto T, Chihara K. Related Articles, Links [Vascular smooth muscle cells in coronary heart disease] Nippon Rinsho. 2003 Apr;61 Suppl 4:80-5. Review. Japanese. No abstract available. PMID: 12734957 [PubMed - indexed for MEDLINE] 113: Amann FW. Related Articles, Links [Coronary stents] Ther Umsch. 2003 Apr;60(4):179-82. German. PMID: 12731426 [PubMed - indexed for MEDLINE] 114: Mazzone A, Gianetti J, Picano E, Bevilacqua S, Zucchelli G, Related Articles, Links Biagini A, Glauber M. Correlation between inflammatory response and markers of neuronal damage in coronary revascularization with and without cardiopulmonary bypass. Perfusion. 2003 Mar; 18(1):3-8. PMID: 12705643 [PubMed - indexed for MEDLINE] 115: Rasmussen HS, Rasmussen CS, Macko J. Related Articles, Links VEGF gene therapy for coronary artery disease and peripheral vascular Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):114-7. Review. PMID: 12699842 [PubMed - indexed for MEDLINE] 116: Kao J, Kobashigawa J, Fishbein MC, MacLellan WR, Burdick Related Articles, Links MD, Belperio JA, Strieter RM. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation. 2003 Apr 22;107(15):1958-61. Epub 2003 Apr 14. PMID: 12695288 [PubMed - indexed for MEDLINE] 117: Despres JP, Lemieux I, Pascot A, Almeras N, Dumont M, Nadeau Related Articles, Links A, Bergeron J, Prud'homme D. Gemfibrozil reduces plasma C-reactive protein levels in abdominally

h

obese men with the atherogenic dyslipidemia of the metabolic syndrome.

cb

hg e e

e fcg

e ch

b e

	Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):702-3. No abstr PMID: 12692010 [PubMed - indexed for MEDLINE]	act available.
118:	Ananyeva N. Tjurmin A. Saenko E. Haudenschild C.	Related Articles, Links
	Low density lipoproteins interact with acidic fibroblast modify its function.  Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 20 PMID: 12692004 [PubMed - indexed for MEDLINE]	
□ 119:	Khurana R, Simons M.	Related Articles, Links
	Insights from angiogenesis trials using fibroblast growt advanced arteriosclerotic disease.  Trends Cardiovasc Med. 2003 Apr;13(3):116-22. Review.  PMID: 12691676 [PubMed - indexed for MEDLINE]	h factor for
□ 120:	Abo-Auda W. Benza RL.	Related Articles, Links
	Therapeutic angiogenesis: review of current concepts a directions.  J Heart Lung Transplant. 2003 Apr;22(4):370-82. Review. No abs PMID: 12681415 [PubMed - indexed for MEDLINE]	
□ 121:	Hughes GC, Post MJ, Simons M, Annex BH.	Related Articles, Links
	Translational physiology: porcine models of human condisease: implications for preclinical trials of therapeutic J Appl Physiol. 2003 May;94(5):1689-701. Review. PMID: 12679343 [PubMed - indexed for MEDLINE]	2 2
□ 122:	Kwak HJ, Pae HO, Oh GS, Choi BM, Jang SI, Jung S, Chung HT.	Related Articles, Links
	Molsidomine ameliorates experimental allergic enceph Lewis rats. Immunopharmacol Immunotoxicol. 2003 Feb;25(1):41-52. PMID: 12675198 [PubMed - indexed for MEDLINE]	alomyelitis in
123	Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM; CAPTURE Study Investigators.	Related Articles, Links
	Serum level of the antiinflammatory cytokine interleuk important prognostic determinant in patients with acute syndromes.  Circulation. 2003 Apr 29;107(16):2109-14. Epub 2003 Mar 31.  PMID: 12668510 [PubMed - indexed for MEDLINE]	
124:	Felmeden DC, Blann AD, Lip GY.	Related Articles, Links
	Angiogenesis: basic pathophysiology and implications Eur Heart J. 2003 Apr;24(7):586-603. Review. No abstract availab PMID: 12657217 [PubMed - indexed for MEDLINE]	
□ 125:	Blake GJ, Ridker PM.	Related Articles, Links
222	C-reactive protein and other inflammatory risk markers syndromes.  J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):37S-42S. Review. PMID: 12644339 [PubMed - indexed for MEDLINE]	in acute coronary
<b>126</b> :	Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla- Herttuala S, Koskinen PK, Lemstrom KB.	Related Articles, Links
	Angiopoietin-1 protects against the development of car arteriosclerosis.  Circulation. 2003 Mar 11;107(9):1308-14.  PMID: 12628953 [PubMed - indexed for MEDLINE]	diac allograft

□ 127:	Libby P. Zhao DX.	Related Articles, Links
123.00 123.00 123.00 123.00 123.00	Allograft arteriosclerosis and immune-driven angiogene Circulation. 2003 Mar 11;107(9):1237-9. No abstract available. PMID: 12628940 [PubMed - indexed for MEDLINE]	esis.
<b>128</b> :	Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T, Janowska J, Szule A, Jastrzekbska-Maj E, Gasior Z.	Related Articles, Links
	Hyperlipidaemias and serum cytokines in patients with disease.  Acta Cardiol. 2003 Feb;58(1):9-15.  PMID: 12625489 [PubMed - indexed for MEDLINE]	coronary artery
□ 129:	Cotton JM, Hong Y, Hawe E, Mathur A, Humphries SE, Brown AS, Martin JF, Erusalimsky JD.	Related Articles, Links
	Rise of circulating thrombopoietin following cardiothor potentiated in patients with coronary atherosclerosis: copreceding increase in levels of interleukin-6. Thromb Haemost. 2003 Mar;89(3):538-43. PMID: 12624639 [PubMed - indexed for MEDLINE]	<b>-</b> -
T 130:	Braun-Dullaeus RC, Ziegler A, Bohle RM, Bauer E, Hein S, Tillmanns H, Haberbosch W.	Related Articles, Links
	Quantification of the cell-cycle inhibitors p27(Kip1) an human atherectomy specimens: primary stenosis versus J Lab Clin Med. 2003 Mar;141(3):179-89. PMID: 12624599 [PubMed - indexed for MEDLINE]	- ` - /
□ 131:	Kusumanto YH, Hospers GA, Mulder NH, Tio RA.	Related Articles, Links
	Therapeutic angiogenesis with vascular endothelial groperipheral and coronary artery disease: a review. Int J Cardiovasc Intervent. 2003;5(1):27-34. Review. PMID: 12623562 [PubMed - indexed for MEDLINE]	wth factor in
<b>132</b> :	Clejan S, Japa S, Clemetson C, Hasabnis SS, David O, Talano JV.	Related Articles, Links
	Blood histamine is associated with coronary artery dise and severity of inflammation and atherosclerosis. J Cell Mol Med. 2002 Oct-Dec;6(4):583-92. PMID: 12611642 [PubMed - indexed for MEDLINE]	ase, cardiac events
□ 133	Sellke FW, Ruel M.	Related Articles, Links
	Vascular growth factors and angiogenesis in cardiac sur Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review. PMID: 12607713 [PubMed - indexed for MEDLINE]	rgery.、
<b>134</b>	Sihvola RK, Tikkanen JM, Krebs R, Aaltola EM, Buchdunger E, Laitinen O, Koskinen PK, Lemstrom KB.	Related Articles, Links
	Platelet-derived growth factor receptor inhibition reduction arteriosclerosis of heart and aorta in cholesterol-fed rab Transplantation. 2003 Feb 15;75(3):334-9. PMID: 12589154 [PubMed - indexed for MEDLINE]	_
135	Lindmark E, Siegbahn A.	Related Articles, Links
	Tissue factor regulation and cytokine expression in morcell co-cultures: effects of a statin, an ACE-inhibitor an weight heparin. Thromb Res. 2002 Oct 1;108(1):77-84. PMID: 12586136 [PubMed - indexed for MEDLINE]	

h cb hg e e e fcg e ch b

□ 136	: Teramoto S, Yamamoto H, Ouchi Y.	Related Articles, Links
	Increased C-reactive protein and increased plasma inte synergistically affect the progression of coronary ather obstructive sleep apnea syndrome.  Circulation. 2003 Feb 11;107(5):E40-0. No abstract available.  PMID: 12578892 [PubMed - indexed for MEDLINE]	
□ 137	Nahrendorf M, Frantz S, Hu K, von zur Muhlen C, Tomaszewski M, Scheuermann H, Kaiser R, Jazbutyte V, Beer S, Bauer W, Neubauer S, Erti G, Allolio B, Callies F.	Related Articles, Links
	Effect of testosterone on post-myocardial infarction rei	modeling and
<b>41</b>	function. Cardiovasc Res. 2003 Feb;57(2):370-8. PMID: 12566109 [PubMed - indexed for MEDLINE]	
□ 138	: Suzuki M, Inaba S, Nagai T, Tatsuno H, Kazatani Y.	Related Articles, Links
	Relation of C-reactive protein and interleukin-6 to culp plaque size in patients with acute myocardial infarction Am J Cardiol. 2003 Feb 1,91(3):331-3. No abstract available. PMID: 12565091 [PubMed - indexed for MEDLINE]	
□ 139	: Khan TA, Sellke FW, Laham RJ.	Related Articles, Links
	Therapeutic angiogenesis: protein-based therapy for codisease.	ronary artery
	Expert Opin Pharmacother. 2003 Feb;4(2):219-26. Review. PMID: 12562312 [PubMed - indexed for MEDLINE]	•
□ 140	Yohnout B, Di Castelnuovo A, Trotta R, D'Orazi A, Panniteri G, Montali A, Donati MB, Area M, Iacoviello L.	Related Articles, Links
	Interleukin-1 gene cluster polymorphisms and risk of c disease.	oronary artery
	Haematologica. 2003 Jan;88(1):54-60. PMID: 12551827 [PubMed - indexed for MEDLINE]	
<b>141</b>	: Sim EK, Zhang L, Shim WS, Lim YL, Ge R.	Related Articles, Links
	Therapeutic angiogenesis for coronary artery disease. J Card Surg. 2002 Jul-Aug;17(4):350-4. Review. PMID: 12546086 [PubMed - indexed for MEDLINE]	
□ 142	: Kutryk MJ, Stewart DJ.	Related Articles, Links
	Angiogenesis of the heart. Microsc Res Tech. 2003 Feb 1;60(2):138-58. Review. PMID: 12539168 [PubMed - indexed for MEDLINE]	
□ 143	: SoRelle R.	Related Articles, Links
	Erythropoietinnot at the Olympics but maybe for ane patients. Circulation. 2003 Jan 21;107(2):e9004. No abstract available. PMID: 12538444 [PubMed - indexed for MEDLINE]	mic heart failure
□ 144	: Wang XQ, Jian ZJ, Xie JC.	Related Articles, Links
	[Changes in plasma concentration of interleukin-6 in el coronary artery disease complicated with heart failure] Hunan Yi Ke Da Xue Xue Bao. 2001 Jun 28;26(3):231-2. Chinese PMID: 12536690 [PubMed - indexed for MEDLINE]	7 1
□ 145		

		Insulin resistance and adiposity correlate with acute-ph soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003 Feb;166(2):387-94. PMID: 12535753 [PubMed - indexed for MEDLINE]	ase reaction and
	□ 146:	Martinez-Gonzalez J, Rius J, Castello A, Cases-Langhoff C, Badimon L.	Related Articles, Links
		Neuron-derived orphan receptor-1 (NOR-1) modulates muscle cell proliferation. Circ Res. 2003 Jan 10;92(1):96-103. PMID: 12522126 [PubMed - indexed for MEDLINE]	vascular smooth
	□ 147:	Lenihan DJ, Osman A, Sriram V, Aitsebaomo J, Patterson C.	Related Articles, Links
		Evidence for association of coronary sinus levels of her factor and collateralization in human coronary disease. Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1507-12. Ep PMID: 12521946 [PubMed - indexed for MEDLINE]	
	148:	Stompor T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Tracz W, Zdzienicka A, Klimeczek P, Janusz-Grzybowska E.	Related Articles, Links
		An association between coronary artery calcification so and selected markers of chronic inflammation in ESRD with peritoneal dialysis.  Am J Kidney Dis. 2003 Jan;41(1):203-11.  PMID: 12500238 [PubMed - indexed for MEDLINE]	
	T 149:	van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C; DALI-Study Group.	Related Articles, Links
		Strong decrease of high sensitivity C-reactive protein watervastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2003 Jan;166(1):129-35. PMID: 12482559 [PubMed - indexed for MEDLINE]	ith high-dose
	□ 150:	Mehrabi MR, Huber K, Serbecic N, Wild T, Wojta J, Tamaddon F, Morgan A, Ullrich R, Dietmar Glogar H	Related Articles, Links
		Elevated homocysteine serum level is associated with le homocysteine in coronary arteries of patients with coronary Res. 2002 Sep 1;107(5):189-96. PMID: 12479877 [PubMed - indexed for MEDLINE]	
	<b>[</b> 151:	Tamirisa KP, Mukherjee D.	Related Articles, Links
		Gene therapy in cardiovascular diseases. Curr Gene Ther. 2002 Dec;2(4):427-35. Review. PMID: 12477254 [PubMed - indexed for MEDLINE]	
	□ 152:	Lee CH, Smits PC.	Related Articles, Links
		Vascular growth factors for coronary angiogenesis.  J Interv Cardiol. 2002 Dec;15(6):511-8. Review.  PMID: 12476656 [PubMed - indexed for MEDLINE]	·
	□ 153:	Conraads VM, Beckers P, Bosmans J, De Clerck LS, Stevens WJ. Vrints CJ, Brutsaert DL.	Related Articles, Links
		Combined endurance/resistance training reduces plasma receptor levels in patients with chronic heart failure and disease.	
		Eur Heart J. 2002 Dec;23(23):1854-60. PMID: 12445534 [PubMed - indexed for MEDLINE]	
-	□ 154:	Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G.	Related Articles, Links

cb

hg e e e fcg

e ch

cb

h g

e fcg

e ch

	Angiogenic gene therapy strategies for the treatment of disease.	cardiovascular
	Curr Opin Mol Ther. 2002 Oct;4(5):476-81. Review. PMID: 12435049 [PubMed - indexed for MEDLINE]	
<b>155</b> :	Sun D, Xu C, Li J, Jiao X, Chen Y.	Related Articles, Links
	[Changes of inflammatory factors in patients with coroduring perioperation] Zhonghua Wai Ke Za Zhi. 2002 Aug;40(8):571-3. Chinese. PMID: 12417066 [PubMed - indexed for MEDLINE]	nary artery disease
□ 156:	Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A	Related Articles, Links
	Antiinflammatory and antiarteriosclerotic effects of pic Hypertension. 2002 Nov;40(5):687-93. PMID: 12411463 [PubMed - indexed for MEDLINE]	oglitazone.
□ 157:	Bouwman JJ, Visseren FL, Bosch MC, Bouter KP, Diepersloot RJ.	Related Articles, Links
	Procoagulant and inflammatory response of virus-infec Eur J Clin Invest. 2002 Oct;32(10):759-66. PMID: 12406025 [PubMed - indexed for MEDLINE]	ted monocytes.
□ 158:	Rosenkranz S, Knirel D, Dietrich H, Flesch M, Erdmann E, Bohm M.	Related Articles, Links
	Inhibition of the PDGF receptor by red wine flavonoids molecular explanation for the "French paradox". FASEB J. 2002 Dec;16(14):1958-60. Epub 2002 Oct 18. PMID: 12397093 [PubMed - indexed for MEDLINE]	s provides a
□ 159:	Grube E, Gerckens U, Buellesfeld L.	Related Articles, Links
	Drug-eluting stents: clinical experiences and perspective Minerva Cardioangiol. 2002 Oct;50(5):469-73. Review. PMID: 12384629 [PubMed - indexed for MEDLINE]	res.
□ 160:	Sheiban I. Carrieri L, Catuzzo B, Destefanis P, Oliaro E, Moretti C, Trevi GP.	Related Articles, Links
	Drug-eluting stent: the emerging technique for the prev restenosis.  Minerva Cardioangiol. 2002 Oct;50(5):443-53. Review.  PMID: 12384626 [PubMed - indexed for MEDLINE]	ention of
□ 161:	Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y, Tedgui A.	Related Articles, Links
	Increased plasma concentrations of interleukin-18 in ac syndromes.  Heart. 2002 Nov;88(5):467-9.  PMID: 12381634 [PubMed - indexed for MEDLINE]	ute coronary
□ 162:	Gouni-Berthold I, Sachinidis A.	Related Articles, Links
	Does the coronary risk factor low density lipoprotein al signaling in vascular smooth muscle cells? FASEB J. 2002 Oct;16(12):1477-87. Review. PMID: 12374770 [PubMed - indexed for MEDLINE]	ter growth and
□ 163:	Os I, Os A, Sandset PM, Bolling S, Seljeflot I, Djurovic S, Westheim A.	Related Articles, Links
	Hormone replacement therapy does not affect plasma he postmenopausal women with coronary artery disease. F pathway inhibitor antigen, a circulating anticoagulant, i	ree tissue factor

		1 age 15 01 50
	homocysteine. Cardiology. 2002;98(1-2):6-12. PMID: 12373040 [PubMed - indexed for MEDLINE]	
□ 164	: Kubik L, Gajewski M, Stankiewicz W, Plocharski A, Skolimowska B, Karpinski M, Dabrowski M, Szmigielski S, Kosior J, Pecak R.	Related Articles, Links
	[Selected inflammatory markers in patients with acute syndrome] Pol Merkuriusz Lek. 2002 Jul;13(73):32-5. Polish. PMID: 12362502 [PubMed - indexed for MEDLINE]	coronary
□ 165	Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG	Related Articles, Links
	Systemic interleukin-6 responses following administration gene transfer vectors to humans by different routes.  Mol Ther. 2002 Aug;6(2):287-97.  PMID: 12349828 [PubMed - indexed for MEDLINE]	tion of adenovirus
□ 166	: Vallely MP, Bannon PG, Hughes CF, Kritharides L.	Related Articles, Links
	Endothelial expression of intercellular adhesion molecule cell adhesion molecule 1 is suppressed by postbypass princreased soluble intercellular adhesion molecule 1 and adhesion molecule 1.  J Thorac Cardiovasc Surg. 2002 Oct;124(4):758-67.  PMID: 12324734 [PubMed - indexed for MEDLINE]	olasma containing
<b>167</b>	Zeleny M, Swertfeger DK, Weisgraber KH, Hui DY.	Related Articles, Links
	Distinct apolipoprotein E isoform preference for inhibit muscle cell migration and proliferation. Biochemistry. 2002 Oct 1;41(39):11820-3. PMID: 12269825 [PubMed - indexed for MEDLINE]	tion of smooth
□ 168	Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, Heine H.	Related Articles, Links
	TLR4-mediated inflammatory activation of human core endothelial cells by LPS. Cardiovasc Res. 2002 Oct;56(1):126-34. PMID: 12237173 [PubMed - indexed for MEDLINE]	onary artery
□ 169	Zhang C, Yang J, Feng J, Jennings LK.	Related Articles, Links
	Short-term administration of basic fibroblast growth fa coronary collateral development without exacerbating a balloon injury-induced vasoproliferation in atherosclere acute myocardial infarction.  J Lab Clin Med. 2002 Aug;140(2):119-25.  PMID: 12228768 [PubMed - indexed for MEDLINE]	atherosclerosis and
□ 170	Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, Isner JM	Related Articles, Links
	Plasma vascular endothelial growth factor (VEGF) level intramuscular and intramyocardial gene transfer of VEODNA.  Hum Gene Ther. 2002 Sep 1;13(13):1595-603.  PMID: 12228014 [PubMed - indexed for MEDLINE]	
□ 171	Galderisi M, Caso P, Cicala S, De Simone L, Barbieri M, Vitale G, de Divitiis O, Paolisso G.	Related Articles, Links
	Positive association between circulating free insulin-lik levels and coronary flow reserve in arterial systemic hy	

e ch b e

hg e e

e fcg

cb

	Am J Hypertens. 2002 Sep;15(9):766-72. PMID: 12219870 [PubMed - indexed for MEDLINE]	
□ 172:	Theoharides TC, Boucher W. Spear K.	Related Articles, Links
	Serum interleukin-6 reflects disease severity and osteon mastocytosis patients. Int Arch Allergy Immunol. 2002 Aug;128(4):344-50. PMID: 12218373 [PubMed - indexed for MEDLINE]	porosis in
□ 173:	Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD. Lip GY	Related Articles, Links
	Is the hypercoagulable state in atrial fibrillation mediate endothelial growth factor? Stroke. 2002 Sep;33(9):2187-91. PMID: 12215585 [PubMed - indexed for MEDLINE]	ed by vascular
□ 174:	Nauck M, Winkelmann BR, Hoffmann MM, Bohm BO, Wieland H, Marz W.	Related Articles, Links
	The interleukin-6 G(-174)C promoter polymorphism in cohort: no association with plasma interleukin-6, coron and myocardial infarction.  J Mol Med. 2002 Aug;80(8):507-13. Epub 2002 Jun 21.  PMID: 12185451 [PubMed - indexed for MEDLINE]	
□ 175:	Billia F. Carter K. Rao V. Gorezynski R. Feindel C. Ross HJ.	Related Articles, Links
	Transforming growth factor-beta expression is significated hearts preserved with blood/insulin versus crystalloid c J Heart Lung Transplant. 2002 Aug;21(8):918-22. PMID: 12163095 [PubMed - indexed for MEDLINE]	antly lower in ardioplegia.
<b>176:</b>	Eppler SM. Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF	Related Articles, Links
	A target-mediated model to describe the pharmacokiner hemodynamic effects of recombinant human vascular effector in humans.  Clin Pharmacol Ther. 2002 Jul;72(1):20-32.  PMID: 12152001 [PubMed - indexed for MEDLINE]	
□ 177:	Tashiro H, Shimokawa H, Sadamatu K, Yamamoto K.	Related Articles, Links
	Prognostic significance of plasma concentrations of transfactor-beta in patients with coronary artery disease.  Coron Artery Dis. 2002 May;13(3):139-43.  PMID: 12131016 [PubMed - indexed for MEDLINE]	nsforming growth
□ 178:	Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P.	Related Articles, Links
	Basic fibroblast growth factor changes in response to coangioplasty in patients with stable angina. Int J Cardiol. 2002 Aug;84(2-3):195-9. PMID: 12127372 [PubMed - indexed for MEDLINE]	pronary
□ 179:	Aronson D. Rayfield EJ.	Related Articles, Links
	How hyperglycemia promotes atherosclerosis: molecula Cardiovasc Diabetol. 2002 Apr 08;1(1):1. PMID: 12119059 [PubMed - as supplied by publisher]	ar mechanisms.
□ 180:	Damas JK, Waehre T, Yndestad A, Ueland T, Muller F, Eiken HG, Holm AM, Halvorsen B, Froland SS, Gullestad L, Aukrust P	Related Articles, Links


		_
	Stromal cell-derived factor-1alpha in unstable angina: antiinflammatory and matrix-stabilizing effects. Circulation. 2002 Jul 2;106(1):36-42. PMID: 12093767 [PubMed - indexed for MEDLINE]	potential
□ 181	Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ; AtheroGene Investigators.	Related Articles, Links
	Interleukin-18 is a strong predictor of cardiovascular d unstable angina. Circulation. 2002 Jul 2;106(1):24-30. PMID: 12093765 [PubMed - indexed for MEDLINE]	eath in stable and
□ 182	lto T, Ikeda U, Shimpo M, Ohki R, Takahashi M, Yamamoto K, Shimada K.	Related Articles, Links
	HMG-CoA reductase inhibitors reduce interleukin-6 sy vascular smooth muscle cells. Cardiovasc Drugs Ther. 2002 Mar; 16(2):121-6. PMID: 12090904 [PubMed - indexed for MEDLINE]	nthesis in human
□ 183	Alber HF, Dulak J, Frick M, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F.	Related Articles, Links
	Atorvastatin decreases vascular endothelial growth fac coronary artery disease. J Am Coll Cardiol. 2002 Jun 19;39(12):1951-5. PMID: 12084593 [PubMed - indexed for MEDLINE]	tor in patients with
□ 184	Cotton JM, Mathur A, Hong Y, Brown AS, Martin JF, Erusalimsky JD	Related Articles, Links
	Acute rise of circulating vascular endothelial growth fawith coronary artery disease following cardiothoracic seur Heart J. 2002 Jun;23(12):953-9. PMID: 12069450 [PubMed - indexed for MEDLINE]	actor-A in patients surgery.
<b>185</b>	Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M.	Related Articles, Links
	The effect of intracoronary fibroblast growth factor-2 or primary angioplasty or stent placement in a pig model of Clin Cardiol. 2002 Jun;25(6):271-8. PMID: 12058790 [PubMed - indexed for MEDLINE]	
T 186	Vale PR, Isner JM, Rosenfield K.	Related Articles, Links
	Therapeutic angiogenesis in critical limb and myocardi J Interv Cardiol. 2001 Oct;14(5):511-28. Review. PMID: 12053643 [PubMed - indexed for MEDLINE]	al ischemia
□ 187	Pradhan AD, Ridker PM	Related Articles, Links
	Do atherosclerosis and type 2 diabetes share a common basis? Eur Heart J. 2002 Jun;23(11):831-4. Review. No abstract available PMID: 12042000 [PubMed - indexed for MEDLINE]	•
□ 188:	Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, Siemionow M, Deitcher SR, DiCorleto PE.	Related Articles, Links
	Adenovirus encoding vascular endothelial growth factorspecific vascular patterns in vivo. Blood. 2002 Jun 15;99(12):4434-42. PMID: 12036873 [PubMed - indexed for MEDLINE]	or-D induces tissue-
□ 189:	Rauchhaus M. Gross M. Schulz S. Francis DP, Greiser P. Norwig A. Weidhase L. Coats AJ, Dietz R. Anker SD, Glaser C.	Related Articles, Links

cb

h g

e fcg

e ch



PMID: 11972524 [PubMed - indexed for MEDLINE]

	Times in the life would intolled for MEDDERAD	
□ 199	Rosen L.S.	Related Articles, Links
	Clinical experience with angiogenesis signaling inhibit vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44. Review. PMID: 11965229 [PubMed - indexed for MEDLINE]	tors: focus on
□ 200	Filippatos GS, Kardaras F.	Related Articles, Links
	Chemokines and other novel inflammatory markers in can their plasma levels tell us? Int J Cardiol. 2002 Apr;83(1):21-3. No abstract available. PMID: 11959379 [PubMed - indexed for MEDLINE]	hypertension: what
□ 201:	Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P.	Related Articles, Links
	Serum basic fibroblast growth factor levels in exercise myocardial ischemia more likely a marker of endothelia marker of ischemia? Eur J Med Res. 2002 Mar 28;7(3):93-7. PMID: 11953278 [PubMed - indexed for MEDLINE]	
202	Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM	Related Articles, Links
	Mechanisms of increased vascular superoxide producti diabetes mellitus: role of NAD(P)H oxidase and endotl synthase. Circulation. 2002 Apr 9;105(14):1656-62. PMID: 11940543 [PubMed - indexed for MEDLINE]	on in human nelial nitric oxide
□ 203:	Chaldakov GN, Fiore M, Stankulov IS, Hristova M, Antonelli A, Manni L, Ghenev PI, Angelucci F, Aloe L.	Related Articles, Links
	NGF, BDNF, leptin, and mast cells in human coronary metabolic syndrome. Arch Physiol Biochem. 2001 Oct;109(4):357-60. PMID: 11935372 [PubMed - indexed for MEDLINE]	atherosclerosis and
□ 204:	Zimmerman MA, Selzman CH, Raeburn CD, Calkins CM, Barsness K, Harken AH.	Related Articles, Links
	Clinical applications of cardiovascular angiogenesis. J Card Surg. 2001 Nov-Dec;16(6):490-7. Review. PMID: 11925031 [PubMed - indexed for MEDLINE]	
□ 205:	Matsumoto S, Kishida K, Shimomura I, Maeda N, Nagaretani H, Matsuda M, Nishizawa H, Kihara S, Funahashi T, Matsuzawa Y, Yamada A, Yamashita S, Tamura S, Kawata S.	Related Articles, Links
	Increased plasma HB-EGF associated with obesity and disease. Biochem Biophys Res Commun. 2002 Apr 5;292(3):781-6. Erratu Biophys Res Commun 2002 Jul 12;295(2):571. PMID: 11922634 [PubMed - indexed for MEDLINE]	
<b>206</b> :	Wang XL, Wang J, Rainwater DL.	Related Articles, Links
	Acute effects of insulin-like growth factor-1 and recomhormone on liporotein(a) levels in baboons.  Metabolism. 2002 Apr;51(4):508-13.  PMID: 11912562 [PubMed - indexed for MEDLINE]	binant growth
<b>207</b> :	Link A, Bohm M, Nickenig G.	Related Articles, Links

b e

h cb hg e e e fcg e ch


cb

h g

e fcg

e ch

b e



Page 25 of 56 PMID: 11849873 [PubMed - indexed for MEDLINE] 216: Lyness JM, Moynihan JA, Williford DJ, Cox C, Caine ED. Related Articles, Links Depression, medical illness, and interleukin-1beta in older cardiac Int J Psychiatry Med. 2001;31(3):305-10. PMID: 11841127 [PubMed - indexed for MEDLINE] 217: Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Oureshi N. Related Articles, Links Sellevold OF, Espevik T, Sundan A. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation. 2002 Feb 12;105(6):685-90. PMID: 11839622 [PubMed - indexed for MEDLINE] 218: von Schacky C, Baumann K, Angerer P. Related Articles, Links The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids. 2001;36 Suppl:S99-102. PMID: 11838000 [PubMed - indexed for MEDLINE] 219: Tateishi J, Waku S, Masutani M, Ohyanagi M, Iwasaki T. Related Articles, Links Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery disease. Am Heart J. 2002 Feb; 143(2): 272-6. PMID: 11835030 [PubMed - indexed for MEDLINE] 220: Blann AD. Belgore FM. McCollum CN, Silverman S, Lip PL. Related Articles, Links Lip GY Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond). 2002 Feb;102(2):187-94. PMID: 11834138 [PubMed - indexed for MEDLINE] 221: Spieker LE, Luscher TF, Noll G. Related Articles, Links Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis. J Cardiovasc Pharmacol. 2001 Nov;38 Suppl 2:S35-41. Review. PMID: 11811375 [PubMed - indexed for MEDLINE] 222: Khan TA, Sellke FW, Laham RJ. Related Articles, Links Therapeutic Angiogenesis for Coronary Artery Disease. Curr Treat Options Cardiovasc Med. 2002 Feb;4(1):65-74. PMID: 11792229 [PubMed - as supplied by publisher] 1 223: Sarkar N, Blomberg P, Wardell E, Eskandarpour M, Sylven C, Related Articles, Links Drvota V, Islam KB. Nonsurgical direct delivery of plasmid DNA into rat heart: time course, dose response, and the influence of different promoters on gene expression. J Cardiovasc Pharmacol. 2002 Feb;39(2):215-24. PMID: 11791007 [PubMed - indexed for MEDLINE] 224: Seshiah PN, Kerciakes DJ, Vasudevan SS, Lopes N, Su BY, Related Articles, Links Flavahan NA, Goldschmidt-Clermont PJ.

Activated monocytes induce smooth muscle cell death: role of

macrophage colony-stimulating factor and cell contact.

Circulation. 2002 Jan 15;105(2):174-80.

PMID: 11790697 [PubMed - indexed for MEDLINE]

h cb h g e fcg e ch e e

		1 484 2 9 91 9 9
□ 225:	Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K, Komesaroff PA	Related Articles, Links
	Dehydroepiandrosterone inhibits human vascular smoot proliferation independent of ARs and ERs. J Clin Endocrinol Metab. 2002 Jan;87(1):176-81. PMID: 11788644 [PubMed - indexed for MEDLINE]	oth muscle cell
□ 226:	Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri MG, Coli L, De Pascalis A, Iannelli S.	Related Articles, Links
	Low TGF-beta1 serum levels are a risk factor for ather in ESRD patients. Kidney Int. 2002 Jan;61(1):324-35. PMID: 11786115 [PubMed - indexed for MEDLINE]	osclerosis disease
<b>227</b> :	Saadeddin SM, Habbab MA, Ferns GA.	Related Articles, Links
	Markers of inflammation and coronary artery disease. Med Sci Monit. 2002 Jan;8(1):RA5-12. Review. PMID: 11782689 [PubMed - indexed for MEDLINE]	
□ 228:	Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C.	Related Articles, Links
	Analysis of risk factors for local delivery of low- and in adenovirus gene transfer vectors to individuals with a scomorbid conditions.  Hum Gene Ther. 2002 Jan 1;13(1):65-100.  PMID: 11779413 [PubMed - indexed for MEDLINE]	
□ 229:	Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.	Related Articles, Links
	Safety of local delivery of low- and intermediate-dose a transfer vectors to individuals with a spectrum of morb Hum Gene Ther. 2002 Jan 1;13(1):15-63. PMID: 11779412 [PubMed - indexed for MEDLINE]	_
□ 230:	Freedman SB, Isner JM.	Related Articles, Links
	Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002 Jan 1;136(1):54-71. Review. PMID: 11777364 [PubMed - indexed for MEDLINE]	
□ 231:	Harig F, Hohenstein B, von der Emde J, Weyand M.	Related Articles, Links
	Modulating IL-6 and IL-10 levels by pharmacologic stringer of different extracorporeal circulation paramete surgery.  Shock. 2001;16 Suppl 1:33-8.  PMID: 11770031 [PubMed - indexed for MEDLINE]	
□ 232:	Saiura A. Sata M, Hirata Y, Nagai R, Makuuchi M.	Related Articles, Links
	Tranilast inhibits transplant-associated coronary arterio murine model of cardiac transplantation. Eur J Pharmacol. 2001 Dec 21;433(2-3):163-8. PMID: 11755148 [PubMed - indexed for MEDLINE]	sclerosis in a
□ 233:	Weiss CR, Arai AE, Bui MN, Agyeman KO, Waclawiw MA, Balaban RS, Cannon RO 3rd	Related Articles, Links
	Arterial wall MRI characteristics are associated with el markers of inflammation in humans.	evated serum

 $h\,g\quad e\quad e\quad e\quad fcg\qquad \qquad e\quad ch\qquad \qquad b\quad e$ 

cb

		٤
	J Magn Reson Imaging. 2001 Dec;14(6):698-704. PMID: 11747026 [PubMed - indexed for MEDLINE]	
□ 234	Dulak J. Jozkowicz A, Frick M, Alber HF, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F.	Related Articles, Links
**************************************	Vascular endothelial growth factor: angiogenesis, ather J Am Coll Cardiol. 2001 Dec;38(7):2137-8. No abstract available. PMID: 11738334 [PubMed - indexed for MEDLINE]	
□ 235	Mazzone A, Cusa C, Mazzucchelli I, Vezzoli M, Ottini E, Pacifici R, Zuccaro P, Falcone C.	Related Articles, Links
	Increased production of inflammatory cytokines in pati myocardial ischemia. J Am Coll Cardiol. 2001 Dec;38(7):1895-901. PMID: 11738291 [PubMed - indexed for MEDLINE]	ents with silent
<b>236</b>	Mueller XM, Tevaearai HT, Genton CY, Chaubert P, von Segesser LK	Related Articles, Links
	Is an endocardial connection necessary for growth factor angiogenesis in transmyocardial laser revascularization ASAIO J. 2001 Nov-Dec;47(6):662-6. PMID: 11730207 [PubMed - indexed for MEDLINE]	
237	Hebert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore F.	Related Articles, Links
	Soluble Fas is a marker of coronary artery disease in pastage renal disease.  Am J Kidney Dis. 2001 Dec;38(6):1271-6.  PMID: 11728960 [PubMed - indexed for MEDLINE]	atients with end-
<b>238</b>	Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ.	Related Articles, Links
	The interleukin-6 -174 G/C promoter polymorphism is risk of coronary heart disease and systolic blood pressu Eur Heart J. 2001 Dec;22(24):2243-52. PMID: 11728144 [PubMed - indexed for MEDLINE]	
<b>239</b> :	Lamblin N, Bauters C, Helbecque N.	Related Articles, Links
	Gene polymorphisms of pro- (or anti-) inflammatory cyvascular disease. Eur Heart J. 2001 Dec;22(24):2219-20. No abstract available. PMID: 11728138 [PubMed - indexed for MEDLINE]	tokines and
<b>240</b> :	Huwer H, Welter C, Ozbek C, Seifert M, Straub U, Greilach P, Kalweit G, Isringhaus H.	Related Articles, Links
	Simultaneous surgical revascularization and angiogenic diffuse coronary artery disease. Eur J Cardiothorac Surg. 2001 Dec;20(6):1128-34. PMID: 11717016 [PubMed - indexed for MEDLINE]	gene therapy in
□ 241:	Vorchheimer DA, Fuster V	Related Articles, Links
	Inflammatory markers in coronary artery disease: let pr flames. JAMA. 2001 Nov 7;286(17):2154-6. No abstract available. PMID: 11694158 [PubMed - indexed for MEDLINE]	evention douse the
□ 242:	Lindmark E. Diderholm E, Wallentin L, Siegbahn A.	Related Articles, Links
	Relationship between interleukin 6 and mortality in pat coronary artery disease: effects of an early invasive or r strategy.	

h g

e fcg e ch

cb

JAMA. 2001 Nov 7;286(17):2107-13. PMID: 11694151 [PubMed - indexed for MEDLINE] 243: Ikeda U, Ito T, Shimada K. Related Articles, Links Interleukin-6 and acute coronary syndrome. Clin Cardiol. 2001 Nov;24(11):701-4. PMID: 11714126 [PubMed - indexed for MEDLINE] 244: Hong HJ, Hsiao G, Cheng TH, Yen MH. Related Articles, Links Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension. 2001 Nov;38(5):1044-8. PMID: 11711495 [PubMed - indexed for MEDLINE] 245: Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N. Related Articles, Links Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol. 2001 Nov 15;88(10):1125-8. PMID: 11703956 [PubMed - indexed for MEDLINE] Related Articles, Links **246:** Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol. 2001 Oct 18;88(8A):10K-15K. Review. PMID: 11694213 [PubMed - indexed for MEDLINE] 247: Davda J. Labhasetwar V. Related Articles, Links An update on angiogenesis therapy. Crit Rev Eukaryot Gene Expr. 2001;11(1-3):1-21. Review. PMID: 11693956 [PubMed - indexed for MEDLINE] 1 248: Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N. Related Articles, Links Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis. 2001 Nov;159(1):137-44. PMID: 11689215 [PubMed - indexed for MEDLINE] 249: Chaldakov GN, Stankulov IS, Fiore M, Ghenev PI, Aloe L. Related Articles, Links Nerve growth factor levels and mast cell distribution in human coronary atherosclerosis. Atherosclerosis. 2001 Nov;159(1):57-66. PMID: 11689207 [PubMed - indexed for MEDLINE] 1 250: Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Related Articles, Links Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J. 2001 Nov;142(5):872-80. PMID: 11685177 [PubMed - indexed for MEDLINE] 251: Berdowska A, Zwirska-Korczala K. Related Articles, Links

e e e fcg e ch b e

Seiler C, Pohl T, Wustmann K, Hutter D, Nicolet PA, Windecker Related Articles, Links

Neopterin measurement in clinical diagnosis.

J Clin Pharm Ther. 2001 Oct;26(5):319-29. Review. PMID: 11679022 [PubMed - indexed for MEDLINE]

h g

cb

hg e e

□ 252:	S, Eberli FR, Meier B.	
	Promotion of collateral growth by granulocyte-macropl stimulating factor in patients with coronary artery disea double-blind, placebo-controlled study.  Circulation. 2001 Oct 23;104(17):2012-7.  PMID: 11673338 [PubMed - indexed for MEDLINE]	
□ 253:	Watanabe K, Fukuda H, Sueda S, Funada J, Kitakaze M, Sekiya M.	Related Articles, Links
	Metabolism of hepatocyte growth factor in the heart in coronary artery disease: implication for coronary arteric Cardiovasc Drugs Ther. 2001 Mar;15(2):147-53. PMID: 11669408 [PubMed - indexed for MEDLINE]	•
□ 254:	Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS	Related Articles, Links
	Pregnancy-associated plasma protein A as a marker of syndromes. N Engl J Med. 2001 Oct 4;345(14):1022-9. PMID: 11586954 [PubMed - indexed for MEDLINE]	acute coronary
□ 255:	Kastrup J, Jorgensen E.	Related Articles, Links
	[Gene therapy of ischemic heart disease. Growth factor angiogenesis/arteriogenesis] Ugeskr Laeger. 2001 Jan 1;163(1):13-5. Danish. No abstract avail PMID: 11586665 [PubMed - indexed for MEDLINE]	
□ 256:	Choukroun G.	Related Articles, Links
	[Prevention and treatment of type 1 diabetes] Presse Med. 2001 Sep 1;30(24 Pt 2):21-3. French. PMID: 11577580 [PubMed - indexed for MEDLINE]	
<b>257:</b>	Basara N.	Related Articles, Links
	AdGVVEGF121.10 (GenVec). Curr Opin Investig Drugs. 2001 Jun;2(6):792-5. Review. PMID: 11572658 [PubMed - indexed for MEDLINE]	
□ 258:	Sadamatsu K., Shimokawa H., Tashiro H., Yamamoto K.	Related Articles, Links
	Long term treatment with enalapril reduces plasma con macrophage colony stimulating factor in patients with disease.  Heart. 2001 Oct;86(4):457-8. No abstract available.  PMID: 11559692 [PubMed - indexed for MEDLINE]	
□ 259:	Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE	Related Articles, Links
	Interleukin-6 gene -174g>c and -572g>c promoter poly strong predictors of plasma interleukin-6 levels after cobypass surgery.  Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1458-63.  PMID: 11557672 [PubMed - indexed for MEDLINE]	-
260:	Holm T, Berge RK, Andreassen AK, Ueland T, Kjekshus J, Simonsen S, Froland S, Gullestad L, Aukrust P.	Related Articles, Links
	Omega-3 fatty acids enhance tumor necrosis factor-alphtransplant recipients.  Transplantation. 2001 Aug 27;72(4):706-11.  PMID: 11544435 [PubMed - indexed for MEDLINE]	ha levels in heart

e fcg e ch b e

cb

h g

e e

e fcg

e ch

b e

261: Pieniazek P, Karczewska E, Stepien E, Tracz W, Konturek SJ. Related Articles, Links Incidence of Chlamydia pneumoniae infection in patients with coronary artery disease subjected to angioplasty or bypass surgery. Med Sci Monit. 2001 Sep-Oct;7(5):995-1001. PMID: 11535948 [PubMed - indexed for MEDLINE] 262: Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F. Related Articles, Links Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection. J Am Coll Cardiol. 2001 Sep;38(3):712-7. PMID: 11527622 [PubMed - indexed for MEDLINE] 263: Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Related Articles, Links Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 2001 Aug 14;104(7):746-9. PMID: 11502695 [PubMed - indexed for MEDLINE] 264: Setoguchi S, Mohri M, Shimokawa H, Takeshita A. Related Articles, Links Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol. 2001 Aug;38(2):493-8. PMID: 11499743 [PubMed - indexed for MEDLINE] 265: Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K. Related Articles, Links Tiemann M, Rutten H, Fichtlscherer S, Martin H. Zeiher AM HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001 Aug;108(3):391-7. PMID: 11489932 [PubMed - indexed for MEDLINE] 266: Wilke NM, Zenovich AG, Jerosch-Herold M, Henry TD. Related Articles, Links Cardiac Magnetic Resonance Imaging for the Assessment of Myocardial Angiogenesis. Curr Interv Cardiol Rep. 2001 Aug;3(3):205-212. PMID: 11485690 [PubMed - as supplied by publisher] **267:** Simons M, Post MJ. Related Articles, Links Coronary Artery Disease: Vascular Endothelial Growth Factor and Fibroblast Growth Factor. Curr Interv Cardiol Rep. 2001 Aug;3(3):185-191. PMID: 11485687 [PubMed - as supplied by publisher] 1 268: Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Related Articles, Links Kredan MB, Lewis MJ, Goodfellow J. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1196-202. PMID: 11451751 [PubMed - indexed for MEDLINE] 269: Izawa A, Suzuki Ji, Takahashi W, Amano J, Isobe M. Related Articles, Links Tranilast inhibits cardiac allograft vasculopathy in association with p21 (Waf1/Cip1) expression on neointimal cells in murine cardiac transplantation model. Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1172-8. PMID: 11451747 [PubMed - indexed for MEDLINE] 770: Vasa M. Fichtlscherer S. Aicher A. Adler K. Urbich C. Martin H. Related Articles, Links Zeiher AM, Dimmeler S.



Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.

Circ Res. 2001 Jul 6;89(1):E1-7.

PMID: 11440984 [PubMed - indexed for MEDLINE]

271: Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG. Related Articles, Links

Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization.

Am Heart J. 2001 Jul; 142(1):72-4.

PMID: 11431659 [PubMed - indexed for MEDLINE]

272: Aziz T, Saad RA, Burgess M, Yonan N, Hasleton P, Hutchinson Related Articles, Links

Transforming growth factor beta and myocardial dysfunction following heart transplantation.

Eur J Cardiothorac Surg. 2001 Jul;20(1):177-86. PMID: 11423293 [PubMed - indexed for MEDLINE]

273: Graff J, Andries D, Elsner M, Westrup D, Bassus S, Franz N.

Related Articles, Links Klinkhardt U, Harder S.

Platelet CD62 expression and PDGFAB secretion in patients undergoing ⊫ PTCA and treatment with abciximab.

Br J Clin Pharmacol. 2001 Jun;51(6):577-82.

PMID: 11422017 [PubMed - indexed for MEDLINE]

274: Blankenberg S, Rupprecht HJ, Bickel C, Espinola-Klein C, Related Articles, Links Rippin G, Hafner G, Ossendorf M, Steinhagen K, Meyer J.

Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation. 2001 Jun 19;103(24):2915-21.

PMID: 11413080 [PubMed - indexed for MEDLINE]

275: Wei M, Kuukasjarvi P, Laurikka J, Pehkonen E, Kaukinen S, Related Articles, Links Laine S, Tarkka M.

Cytokine responses in patients undergoing coronary artery bypass surgery after ischemic preconditioning.

Scand Cardiovasc J. 2001 Mar;35(2):142-6.

PMID: 11405491 [PubMed - indexed for MEDLINE]

276: Oesterle SN, Reifart N, Hauptmann E, Hayase M, Yeung AC. Related Articles, Links

Percutaneous in situ coronary venous arterialization: report of the first

human catheter-based coronary artery bypass.

Circulation. 2001 May 29;103(21):2539-43.

PMID: 11382720 [PubMed - indexed for MEDLINE]

277: Benjafield AV, Wang XL, Morris BJ.

e fcg

Related Articles, Links

Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease.

J Mol Med. 2001 Apr;79(2-3):109-15.

PMID: 11357933 [PubMed - indexed for MEDLINE]

1. 278: Hillebrands JL, Raue HP, Klatter FA, Hylkema MN, Platteel I, Related Articles, Links Hardonk-Wubbena A, Nieuwenhuis P, Rozing J.

Intrathymic immune modulation prevents acute rejection but not the development of graft arteriosclerosis (chronic rejection).

Transplantation. 2001 Apr 15;71(7):914-24.

PMID: 11349727 [PubMed - indexed for MEDLINE]

Walter R, Blau N, Kierat L, Schoedon G, Reinhart WH.

e ch

Related Articles, Links

cb

h g

e fcg


e ch

□ 279:		
10000 10000 10000 10000	Systemic tetrahydrobiopterin (BH4) levels and coronar Cardiology. 2000;94(4):265-6. No abstract available. PMID: 11326151 [PubMed - indexed for MEDLINE]	y artery disease.
<b>□ 280</b> :	Xue M, Ren S, Welch S, Shen GX.	Related Articles, Links
	Hirulog-like peptide reduces balloon catheter injury incommendation in rat carotid artery without increase in bleed J Vasc Res. 2001 Mar-Apr;38(2):144-52. PMID: 11316950 [PubMed - indexed for MEDLINE]	
<b>281</b> :	Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL. Pike M, Laham RJ, Simons M, Chronos NA.	. Related Articles, Links
	Pharmacokinetics and pharmacodynamics of recombin phase I trial in coronary artery disease. J Clin Pharmacol. 2001 Apr;41(4):378-85. PMID: 11304894 [PubMed - indexed for MEDLINE]	ant FGF-2 in a
□ 282:	Clark KJ, Cary NR, Grace AA, Metcalfe JC.	Related Articles, Links
	Microsatellite mutation of type II transforming growth receptor is rare in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):555-9. PMID: 11304472 [PubMed - indexed for MEDLINE]	factor-beta
<b>283</b> :	Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N	Related Articles, Links
	Role of circulating vascular endothelial growth factor a growth factor in patients with coronary artery disease. Heart Vessels. 2000;15(3):105-11. PMID: 11289497 [PubMed - indexed for MEDLINE]	nd hepatocyte
□ 284:	Ray S. Panja M.	Related Articles, Links
	Current understanding of pathogenesis of coronary artefuture implications.  J Indian Med Assoc. 2000 Nov;98(11):710-1, 714, 718.  PMID: 11265801 [PubMed - indexed for MEDLINE]	ery disease and its
<b>285</b> :	Brizzi MF, Formato L, Bonamini R.	Related Articles, Links
	The molecular mechanisms of angiogenesis: a new app cardiovascular diseases. Ital Heart J. 2001 Feb;2(2):81-92. Review. PMID: 11256548 [PubMed - indexed for MEDLINE]	roach to
□ 286:	Morse MA.	Related Articles, Links
	Technology evaluation: VEGF165 gene therapy, Valen Curr Opin Mol Ther. 2001 Feb;3(1):97-101. Review. PMID: 11249737 [PubMed - indexed for MEDLINE]	tis Inc.
<b>287</b> :	Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, Rose HS, Sayegh MH, Madsen JC	Related Articles, Links
	Indirect recognition of allopeptides promotes the development of allograft vasculopathy.  Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3276-81.  PMID: 11248069 [PubMed - indexed for MEDLINE]	opment of cardiac
□ 288:	Margaglione M, Bossone A, Cappucci G, Colaizzo D, Grandone E, Di Minno G	Related Articles, Links

Related Articles, Links

Haematologica. 2001 Feb;86(2):199-204. PMID: 11224491 [PubMed - indexed for MEDLINE] 289: Rosengart TK, Hillebrand K. Related Articles, Links Gene therapy for coronary artery disease. Adv Card Surg. 2001;13:107-20. Review. No abstract available. PMID: 11209652 [PubMed - indexed for MEDLINE] 1 290: Mueller XM, Tevaearai HT, Genton CY, Chaubert P, von Related Articles, Links Segesser LK. Myocardial angiogenesis induction with bone protein derived growth factors (animal experiment). Swiss Med Wkly. 2001 Jan 12;131(1-2):23-5. PMID: 11205183 [PubMed - indexed for MEDLINE] 1 291: Haroon ZA, Wannenburg T, Gupta M. Greenberg CS, Wallin R. Related Articles, Links Sane DC. Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression. Lab Invest. 2001 Jan;81(1):83-93. PMID: 11204277 [PubMed - indexed for MEDLINE] 1 292: Elghannam H. Tavackoli S, Ferlic L. Gotto AM Jr, Ballantyne Related Articles, Links CM, Marian AJ. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med. 2000;78(10):562-8. PMID: 11199329 [PubMed - indexed for MEDLINE] 293: Freedman SB, Isner JM. Related Articles, Links Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol. 2001 Mar;33(3):379-93. Review. PMID: 11181008 [PubMed - indexed for MEDLINE] 294: Durairaj A, Mehra A, Singh RP, Faxon DP. Related Articles, Links Therapeutic angiogenesis. Cardiol Rev. 2000 Sep-Oct;8(5):279-87. Review. PMID: 11174906 [PubMed - indexed for MEDLINE] 295: Shaw JA, Chin-Dusting JP, Kingwell BA, Dart AM. Related Articles, Links Diurnal variation in endothelium-dependent vasodilatation is not apparent in coronary artery disease. Circulation. 2001 Feb 13;103(6):806-12. PMID: 11171787 [PubMed - indexed for MEDLINE] **296:** Zhang S, Day I, Ye S. Related Articles, Links Nicotine induced changes in gene expression by human coronary artery endothelial cells. Atherosclerosis. 2001 Feb 1;154(2):277-83. PMID: 11166759 [PubMed - indexed for MEDLINE] 297: Lambiase P, Edwards R, Bucknall CA, Marber MS. Related Articles, Links Physiologically assessed collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation. 2001 Jan 30;103(4):E22. No abstract available. PMID: 11157734 [PubMed - indexed for MEDLINE]

298: Rutanen J, Rissanen TT, Kivela A, Vajanto I, Yla-Herttuala S.



 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} fcg \hspace{1cm} e \hspace{1cm} ch \hspace{1cm} b \hspace{1cm} e$ 


cb

h g

e fcg

e ch

b е



PMID: 11020087 [PubMed - indexed for MEDLINE] 1317: Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais Related Articles, Links M, Galt JR, Pike M, Yoshizawa C, Simons M. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation. 2000 Oct 3;102(14):1605-10. PMID: 11015335 [PubMed - indexed for MEDLINE] 1 318: Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan Related Articles, Links Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol. 2000 Oct; 192(2): 234-42. PMID: 11004701 [PubMed - indexed for MEDLINE] 319: Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG, Kumar Related Articles, Links The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis. 2000 Sep;152(1):249-56. PMID: 10996361 [PubMed - indexed for MEDLINE] 1320: Ishikawa M, Akishita M, Kozaki K, Toba K, Namiki A, Related Articles, Links Yamaguchi T, Orimo H, Ouchi Y. Expression of parathyroid hormone-related protein in human and experimental atherosclerotic lesions: functional role in arterial intimal thickening. Atherosclerosis. 2000 Sep;152(1):97-105. PMID: 10996344 [PubMed - indexed for MEDLINE] 321: Rosen CJ, Glowacki J, Craig W. Related Articles, Links Sex steroids, the insulin-like growth factor regulatory system, and aging: implications for the management of older postmenopausal women. J Nutr Health Aging. 1998;2(1):39-44. Review. PMID: 10995078 [PubMed - indexed for MEDLINE] 322: Woods A, Brull DJ, Humphries SE, Montgomery HE. Related Articles, Links Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000 Oct;21(19):1574-83. Review. No abstract available. PMID: 10988009 [PubMed - indexed for MEDLINE] **323:** August P, Leventhal B, Suthanthiran M. Related Articles, Links Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence. Curr Hypertens Rep. 2000 Apr;2(2):184-91. Review. PMID: 10981147 [PubMed - indexed for MEDLINE] 324: Kanda T, Inoue M, Kotajima N, Fujimaki S, Hoshino Y, Related Articles, Links Kurabayashi M. Kobayashi I. Tamura J. Circulating interleukin-6 and interleukin-6 receptors in patients with acute and recent myocardial infarction. Cardiology. 2000;93(3):191-6. PMID: 10965091 [PubMed - indexed for MEDLINE] 1325: Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD. Related Articles, Links Symes JF, Isner JM.

Left ventricular electromechanical mapping to assess efficacy of phVEGF

b e

cb h g e fcg e ch

h



(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.

Circulation. 2000 Aug 29;102(9):965-74.

PMID: 10961959 [PubMed - indexed for MEDLINE]

1 326: Bray PF.

Related Articles, Links

Platelet glycoprotein polymorphisms as risk factors for thrombosis.

Curr Opin Hematol. 2000 Sep;7(5):284-9. Review. PMID: 10961578 [PubMed - indexed for MEDLINE]

327: Gabriel AS, Ahnve S, Wretlind B, Martinsson A.

Related Articles, Links

IL-6 and IL-1 receptor antagonist in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction.

J Intern Med. 2000 Jul;248(1):61-6.

PMID: 10947882 [PubMed - indexed for MEDLINE]

328: Mukherjee D, Ellis SG.

Related Articles, Links

New options for untreatable coronary artery disease: angiogenesis and laser revascularization.

Cleve Clin J Med. 2000 Aug;67(8):577-83.

PMID: 10946453 [PubMed - indexed for MEDLINE]

1329: Hamano K, Bashuda H, Ito H, Shirasawa B, Okumura K, Esato K

Related Articles, Links

Graft vasculopathy and tolerance: does the balance of Th cells contribute to graft vasculopathy?

J Surg Res. 2000 Sep;93(1):28-34.

PMID: 10945940 [PubMed - indexed for MEDLINE]

☐ 330: O'Brien T, Simari RD.

Related Articles, Links

Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution.

Mayo Clin Proc. 2000 Aug;75(8):831-4. Review.

PMID: 10943238 [PubMed - indexed for MEDLINE]

331: Reinecke H, Erren M, Schurek JO, Kropf J, Kerber S, Breithardt Related Articles, Links

G. Assmann G. Cullen P.

Transforming growth factor beta and coronary artery disease.

Nutr Metab Cardiovasc Dis. 2000 Apr;10(2):101-2. No abstract available. PMID: 10919175 [PubMed - indexed for MEDLINE]

332: Bokemeyer D, Schmitz U, Kramer HJ.

Related Articles, Links

Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor.

Kidney Int. 2000 Aug;58(2):549-58.

PMID: 10916078 [PubMed - indexed for MEDLINE]

T 333: Xia H, Redman C.

Related Articles, Links

Enhanced secretion of ApoB by transfected HepG2 cells overexpressing fibrinogen.

Biochem Biophys Res Commun. 2000 Jun 24;273(1):377-84. PMID: 10873614 [PubMed - indexed for MEDLINE]

1. 334: Testa M, De Ruvo E, Russo A, Citterio F, Serino F, Mangoni A. Related Articles, Links Capogrossi MC, Sperti G.

Induction of interleukin-1beta and interleukin-6 gene expression in hypoperfused skeletal muscle of patients with peripheral arterial disease. Ital Heart J. 2000 Jan;1(1):64-7.

PMID: 10868926 [PubMed - indexed for MEDLINE]

h

cb

hg e e e fcg

e ch

b e

cb

□ 335:	lsobe M, Suzuki J, Morishita R, Kaneda Y, Amano J.	Related Articles, Links
	Gene therapy for heart transplantation-associated coror arteriosclerosis.  Ann N Y Acad Sci. 2000 May;902:77-83.  PMID: 10865827 [PubMed - indexed for MEDLINE]	nary
□ 336	Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA.	Related Articles, Links
	Effects of a single intracoronary injection of basic fibro in stable angina pectoris. Am J Cardiol. 2000 Jun 15;85(12):1414-9. PMID: 10856385 [PubMed - indexed for MEDLINE]	oblast growth factor
□ 337	Anderson JL. Muhlestein JB	Related Articles, Links
	The ACADEMIC study in perspective (Azithromycin idisease: elimination of myocardial infection with Chlar J Infect Dis. 2000 Jun;181 Suppl 3:S569-71. PMID: 10839761 [PubMed - indexed for MEDLINE]	
□ 338	Griffioen AW, Molema G.	Related Articles, Links
	Angiogenesis: potentials for pharmacologic interventic of cancer, cardiovascular diseases, and chronic inflama Pharmacol Rev. 2000 Jun;52(2):237-68. Review. PMID: 10835101 [PubMed - indexed for MEDLINE]	
□ 339	Suzuki H, Murakami M, Kondo T, Shibata M, Ezumi H, Okabayashi H, Yorozuya M, Makishima N, Hamazaki Y, Nakatani M, Namiki A, Katagiri T.	Related Articles, Links
	[Changes of serum hepatocyte growth factor in corona J Cardiol. 2000 May;35(5):319-24. Japanese. PMID: 10834175 [PubMed - indexed for MEDLINE]	ry artery disease]
□ 340	Lucassen AM, de Waal RM, Verheugt FW.	Related Articles, Links
	[Therapeutic angiogenesis as a new experimental treat disease] Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5. Review. Dut PMID: 10774292 [PubMed - indexed for MEDLINE]	
□ 341	Osterziel KJ, Blum WF, Strohm O, Dietz R.	Related Articles, Links
	The severity of chronic heart failure due to coronary as predicts the endocrine effects of short-term growth hor administration.  J Clin Endocrinol Metab. 2000 Apr;85(4):1533-9.  PMID: 10770193 [PubMed - indexed for MEDLINE]	-
□ 342	Ridker PM, Rifai N, Stampfer MJ, Hennekens CH.	Related Articles, Links
	Plasma concentration of interleukin-6 and the risk of frinfarction among apparently healthy men. Circulation. 2000 Apr 18;101(15):1767-72. PMID: 10769275 [PubMed - indexed for MEDLINE]	uture myocardial
□ 343	Yutani C, Ishibashi-Ueda H, Suzuki T, Kojima A.	Related Articles, Links
	Histologic evidence of foreign body granulation tissue lesions in patients with coronary stent restenosis. Cardiology. 1999;92(3):171-7. PMID: 10754347 [PubMed - indexed for MEDLINE]	and de novo
□ 344	Simonini A, Moscucci M, Muller DW, Bates ER, Pagani FD,	Related Articles, Links

e fcg e ch b e

Burdick MD, Strieter RM



IL-8 is an angiogenic factor in human coronary atherectomy tissue.

Circulation. 2000 Apr 4;101(13):1519-26.

PMID: 10747344 [PubMed - indexed for MEDLINE]

345: Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen Related Articles, Links PT, Kaartinen M, Nussberger J, Harringer W, Drexler H.



Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability.

Circulation. 2000 Mar 28;101(12):1372-8.

PMID: 10736279 [PubMed - indexed for MEDLINE]

346: Garcia-Moll X, Coccolo F, Cole D, Kaski JC.

Related Articles, Links



Serum neopterin and complex stenosis morphology in patients with unstable angina.

J Am Coll Cardiol. 2000 Mar 15;35(4):956-62.

PMID: 10732894 [PubMed - indexed for MEDLINE]

1347: Mehrabi MR, Sinzinger H, Ekmekcioglu C, Tamaddon F, Plesch Related Articles, Links K, Glogar HD, Maurer G, Stefenelli T, Lang IM



Accumulation of oxidized LDL in human semilunar valves correlates with coronary atherosclerosis.

Cardiovasc Res. 2000 Mar; 45(4):874-82.

PMID: 10728413 [PubMed - indexed for MEDLINE]

T348: Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L. Fishbein MC, Meehan WP, Hsueh WA.

Related Articles, Links



Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

Circulation. 2000 Mar 21;101(11):1311-8.

PMID: 10725292 [PubMed - indexed for MEDLINE]

1349: Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA. Related Articles, Links Schunkert H.



Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study.

J Clin Endocrinol Metab. 2000 Mar;85(3):1340-4. PMID: 10720088 [PubMed - indexed for MEDLINE]

350: Saitoh T. Kishida H. Tsukada Y, Fukuma Y, Sano J, Yasutake M, Related Articles, Links Fukuma N, Kusama Y, Hayakawa H.



Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris.

J Am Coll Cardiol. 2000 Mar 1;35(3):655-65.

PMID: 10716468 [PubMed - indexed for MEDLINE]

1351: Ruotolo G, Bavenholm P, Brismar K, Efendic S, Ericsson CG, de Related Articles, Links Faire U, Nilsson J, Hamsten A.



Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.

J Am Coll Cardiol. 2000 Mar 1;35(3):647-54.

PMID: 10716467 [PubMed - indexed for MEDLINE]

352: Tabib A, Leroux C, Mornex JF, Loire R.

Related Articles, Links



Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients.

Coron Artery Dis. 2000 Feb;11(1):41-6. PMID: 10715805 [PubMed - indexed for MEDLINE] 353: Garcia-Moll X, Cole D, Zouridakis E, Kaski JC. Related Articles, Links Increased serum neopterin: a marker of coronary artery disease activity in women. Heart. 2000 Mar;83(3):346-50. PMID: 10677418 [PubMed - indexed for MEDLINE] 1354: Pieniazek P, Karczewska E, Duda A, Tracz W, Pasowicz M, Related Articles, Links Konturek SJ. Association of Helicobacter pylori infection with coronary heart disease. J Physiol Pharmacol. 1999 Dec;50(5):743-51. PMID: 10695556 [PubMed - indexed for MEDLINE] 1355: Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Related Articles, Links Goncalves L. Unger EF. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res. 1999 Nov;44(2):294-302. PMID: 10690306 [PubMed - indexed for MEDLINE] Related Articles, Links 356: Chawla PS, Keelan MH, Kipshidze N. Angiogenesis for the treatment of vascular diseases. Int Angiol. 1999 Sep;18(3):185-92. Review. PMID: 10688416 [PubMed - indexed for MEDLINE] 1357: Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM, Related Articles, Links Meier B, Luscher TF. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol. 2000 Feb;35(2):173-8. PMID: 10672847 [PubMed - indexed for MEDLINE] 358: Harig F, Cesnjevar R, Mahmoud FO, von der Emde J. Related Articles, Links Perioperative factors influencing interleukin-10 release under cardiopulmonary bypass. Thorac Cardiovasc Surg. 1999 Dec;47(6):361-8. PMID: 10670793 [PubMed - indexed for MEDLINE] 1 359: Cutler CW, Shinedling EA, Nunn M, Jotwani R, Kim BO, Nares Related Articles, Links S. Iacopino AM. Association between periodontitis and hyperlipidemia: cause or effect? J Periodontol. 1999 Dec;70(12):1429-34. PMID: 10632517 [PubMed - indexed for MEDLINE] 360: Taher A, Ammash Z, Dabajah B, Nasrallah A, Mourad FH. Related Articles, Links Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case =report and literature review. Am J Hematol. 2000 Feb;63(2):90-3. Review. PMID: 10629575 [PubMed - indexed for MEDLINE] . 1361: Furukawa Y, Matsumori A, Hwang MW, Hirozane T, Ono K. Related Articles, Links Shioi T. Sasayama S. Cytokine gene expression during the development of graft coronary artery disease in mice. Jpn Circ J. 1999 Oct;63(10):775-82. PMID: 10553920 [PubMed - indexed for MEDLINE] Related Articles, Links Furukawa Y, Becker G, Stinn JL, Shimizu K, Libby P, Mitchell

h cb hg e e e fcg

e ch

b e

RN.



Interleukin-10 (IL-10) augments allograft arterial disease: paradoxical effects of IL-10 in vivo.

Am J Pathol. 1999 Dec; 155(6): 1929-39.

PMID: 10595923 [PubMed - indexed for MEDLINE]

**363:** Yamada N.

Related Articles, Links

[Physiopathology and therapy of acute coronary syndrome--molecular mechanism of formation and disruption of coronary atheroma]

Nippon Naika Gakkai Zasshi. 1999 Sep 10;88(9):1731-5. Review. Japanese. No abstract available.

PMID: 10581755 [PubMed - indexed for MEDLINE]

1 364: Hachida M, Lu H, Zhang X, Saito S, Furutani Y, Matsuoka R. Related Articles, Links Hoshi H, Koyanagi H.

Inhibitory effect of triptolide on platelet derived growth factor-A and coronary arteriosclerosis after heart transplantation.

Transplant Proc. 1999 Nov;31(7):2719-23. No abstract available. PMID: 10578264 [PubMed - indexed for MEDLINE]

365: Moussa I, Moses JW.

Related Articles, Links

Angiogenesis for treatment of ischemic heart disease: should we worry about progression of atherosclerosis?

Circulation. 1999 Nov 30;100(22):e109. No abstract available.

PMID: 10578010 [PubMed - indexed for MEDLINE]

Gullestad L, Simonsen S, Ueland T, Holm T, Aass H, Andreassen Related Articles, Links AK, Madsen S, Geiran O, Froland SS, Aukrust P.

Possible role of proinflammatory cytokines in heart allograft coronary artery disease.

Am J Cardiol. 1999 Nov 1;84(9):999-1003.

PMID: 10569653 [PubMed - indexed for MEDLINE]

367: Rus H. Niculescu F.

Related Articles, Links

Inflammatory response in unstable angina.

Circulation. 1999 Nov 9;100(19):e98. No abstract available. PMID: 10556236 [PubMed - indexed for MEDLINE]

1368: Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C. Related Articles, Links



Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.

Circulation. 1999 Nov 9;100(19):1945-50.

PMID: 10556219 [PubMed - indexed for MEDLINE]

1369: Meeking DR, Cummings MH, Thome S, Donald A, Clarkson P, Crook JR, Watts GF, Shaw KM.

Related Articles, Links

Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria.

Diabet Med. 1999 Oct;16(10):841-7.

PMID: 10547211 [PubMed - indexed for MEDLINE]

70: Hosenpud JD.

Related Articles, Links

Coronary artery disease after heart transplantation and its relation to cytomegalovirus.

Am Heart J. 1999 Nov;138(5 Pt 2):S469-72. Review. PMID: 10539850 [PubMed - indexed for MEDLINE]

h

cb

hg e e e fcg

e ch

b e

371: Kersten JR, Pagel PS, Chilian WM, Warltier DC. Related Articles, Links Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia. Cardiovasc Res. 1999 Jul; 43(1): 44-57. Review. PMID: 10536689 [PubMed - indexed for MEDLINE] 372: Safi J Jr. DiPaula AF Jr. Riccioni T, Kajstura J, Ambrosio G, Related Articles, Links Becker LC, Anversa P, Capogrossi MC. Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart. Microvasc Res. 1999 Nov;58(3):238-49. PMID: 10527767 [PubMed - indexed for MEDLINE] 373: Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM. Related Articles, Links Hackett NR, Isom OW, Crystal RG Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2. PMID: 10522716 [PubMed - indexed for MEDLINE] 374: Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek Related Articles, Links JO, Kropf J, Kerber S, Breithardt G, Assmann G, Cullen P Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2355-63. PMID: 10521364 [PubMed - indexed for MEDLINE] 1. 375: Ignatescu MC, Gharehbaghi-Schnell E, Hassan A, Rezaie-Majd Related Articles, Links S, Korschineck I, Schleef RR, Glogar HD, Lang IM. Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: In vivo correlation of lesional microvessel density and constrictive vascular remodeling. Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2340-7. PMID: 10521362 [PubMed - indexed for MEDLINE] 376: Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Related Articles, Links Mayskiy M, Isner JM. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg. 1999 Sep;68(3):830-6; discussion 836-7. PMID: 10509970 [PubMed - indexed for MEDLINE] 377: Kato K, Matsubara T, Iida K, Suzuki O, Sato Y. Related Articles, Links Elevated levels of pro-inflammatory cytokines in coronary artery thrombi. Int J Cardiol. 1999 Aug 31;70(3):267-73. PMID: 10501341 [PubMed - indexed for MEDLINE] 778: Sellke FW, Simons M. Related Articles, Links Angiogenesis in cardiovascular disease: current status and therapeutic potential. Drugs. 1999 Sep;58(3):391-6. Review. PMID: 10493268 [PubMed - indexed for MEDLINE] 17379: Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M. Related Articles, Links Iwasaki A, Hara M, Sasayama S FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine

model of cardiac transplantation.

e ch

b e

e fcg

h

cb

h g

Circulation. 1999 Sep 21;100(12):1322-9.

PMID: 10491378 [PubMed - indexed for MEDLINE]

T 380: Sato T, Yoshinouchi T, Sugimoto T, Sakamoto T, Fujieda H. Related Articles, Links Murao S, Sato H, Ohe T



Prognostic value of serum hepatocyte growth factor in patients with acute coronary syndromes.

Jpn Circ J. 1999 Aug;63(8):583-8.

PMID: 10478806 [PubMed - indexed for MEDLINE]

381: Hachida M, Zhang X, Lu H, Hoshi H, Koyanagi H.

Related Articles, Links



Effects of immunosuppressants on platelet-derived growth factor-A chain mRNA expression and coronary arteriosclerosis in rat cardiac allografts. Jpn Circ J. 1999 Apr;63(4):303-8.

PMID: 10475779 [PubMed - indexed for MEDLINE]

1382: Ishibashi T. Kijima M. Yokoyama K. Shindo J. Nagata K. Hirosaka A. Techigawara M. Abe Y. Sato E. Yamaguchi N. Watanabe N. Saito T. Machara K. Ohmoto Y. Maruyama Y.

Related Articles, Links



Expression of cytokine and adhesion molecule mRNA in atherectomy specimens from patients with coronary artery disease.

Jpn Circ J. 1999 Apr;63(4):249-54.

PMID: 10475771 [PubMed - indexed for MEDLINE]

1383: Spallarossa P. Rossettin P. Minuto F. Caruso D. Cordera R. Related Articles, Links

Battistini M. Barreca A. Masperone MA. Brunelli C.



Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.

Am J Cardiol. 1999 Aug 15;84(4):430-3.

PMID: 10468082 [PubMed - indexed for MEDLINE]

384: Hussain MM, Strickland DK, Bakillah A

Related Articles, Links



The mammalian low-density lipoprotein receptor family.

Annu Rev Nutr. 1999;19:141-72. Review.

PMID: 10448520 [PubMed - indexed for MEDLINE]

17 385: Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP.

Related Articles, Links



Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation.

Circulation. 1999 Aug 3;100(5):547-52.

PMID: 10430770 [PubMed - indexed for MEDLINE]

Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG.

Related Articles, Links



Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999 Aug 3;100(5):468-74.

PMID: 10430759 [PubMed - indexed for MEDLINE]

387: Losordo DW, Vale PR, Isner JM.

Related Articles, Links



Gene therapy for myocardial angiogenesis.

Am Heart J. 1999 Aug; 138(2 Pt 2): S132-41. Review. PMID: 10426872 [PubMed - indexed for MEDLINE]

388: Casterella PJ, Teirstein PS.

Related Articles, Links

		1450 1101 30
	Prevention of coronary restenosis. Cardiol Rev. 1999 Jul-Aug;7(4):219-31. Review. PMID: 10423674 [PubMed - indexed for MEDLINE]	
□ 389:	Nogueira JB.	Related Articles, Links
	[Hypertensive cardiopathy. From arterial hypertension	to congestive heart
<u> </u>	failure] Rev Port Cardiol. 1999 Jun;18(6):635-46. Review. Portuguese. PMID: 10422461 [PubMed - indexed for MEDLINE]	
□ 390:	Wan S, Izzat MB, Lee TW, Wan IY, Tang NL, Yun AP.	Related Articles, Links
	Avoiding cardiopulmonary bypass in multivessel CAB response and myocardial injury.  Ann Thorac Surg. 1999 Jul;68(1):52-6; discussion 56-7.  PMID: 10421114 [PubMed - indexed for MEDLINE]	G reduces cytokine
□ 391:	Herity NA. Ward MR, Lo S. Yeung AC.	Related Articles, Links
	Review: Clinical aspects of vascular remodeling. J Cardiovasc Electrophysiol. 1999 Jul;10(7):1016-24. Review. PMID: 10413382 [PubMed - indexed for MEDLINE]	
□ 392:	Ikemoto M. Hasegawa K. Kihara Y. Iwakura A. Komeda M. Yarnazato A. Fujita M.	Related Articles, Links
	Development of enzyme-linked immunosorbent assay growth factor and its clinical application. Clin Chim Acta. 1999 May;283(1-2):171-82. PMID: 10404741 [PubMed - indexed for MEDLINE]	for acidic fibroblast
□ 393:	Yamashita N, Hoshida S, Otsu K, Asahi M, Kuzuya T, Hori M.	Related Articles, Links
	Exercise provides direct biphasic cardioprotection via a superoxide dismutase activation.  J Exp Med. 1999 Jun 7;189(11):1699-706.  PMID: 10359573 [PubMed - indexed for MEDLINE]	manganese
□ 394:	Hattersley AT, Tooke JE.	Related Articles, Links
	The fetal insulin hypothesis: an alternative explanation of low birthweight with diabetes and vascular disease. Lancet. 1999 May 22;353(9166):1789-92. Review. PMID: 10348008 [PubMed - indexed for MEDLINE]	of the association
□ 395:	Patterson C. Runge MS.	Related Articles, Links
	Therapeutic angiogenesis: the new electrophysiology? Circulation. 1999 May 25;99(20):2614-6. Review. No abstract ava PMID: 10338451 [PubMed - indexed for MEDLINE]	ailable.
□ 396:	Zhang X, Hachida M, Lu H, Hoshi H, Koyanagi H.	Related Articles, Links
	Effect of 15-deoxyspergualine on coronary arteriosclered derived growth factor-A mRNA expression in the trans Transplant Proc. 1999 May;31(3):1706-9. No abstract available. PMID: 10331045 [PubMed - indexed for MEDLINE]	osis and platelet- planted heart.
□ 397:	Kahn NN.	Related Articles, Links
<b>4</b>	Platelet-stimulated thrombin and PDGF are normalized Ca2+ channel blockers. Am J Physiol. 1999 May;276(5 Pt 1):E856-62. PMID: 10329979 [PubMed - indexed for MEDLINE]	by insulin and
□ 398:	Hachida M. Zhang X. Lu H. Hoshi H. Koyanagi H.	Related Articles, Links

h cb hg e e e fcg e ch b e

cb

h g


e fcg

e

e ch


bе

Multiglycosidorum tripterygii, a new immunosuppressant, supresses coronary arteriosclerosis after heart transplantation. J Heart Lung Transplant. 1999 Mar; 18(3):248-54. PMID: 10328151 [PubMed - indexed for MEDLINE] 399: McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. Related Articles, Links Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation. 1999 May 4;99(17):2317-22. PMID: 10226099 [PubMed - indexed for MEDLINE] 400: Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S. Related Articles, Links Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation. 1999 Mar 30;99(12):1540-7. PMID: 10096928 [PubMed - indexed for MEDLINE] 1 401: Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M. Related Articles, Links Sasayama S. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7. PMID: 10082659 [PubMed - indexed for MEDLINE] 402: Fukumoto H, Naito Z, Asano G, Aramaki T. Related Articles, Links Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. J Atheroscler Thromb. 1998;5(1):29-35. PMID: 10077455 [PubMed - indexed for MEDLINE] 403: Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Related Articles, Links Mauiner B. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 1999 Feb 15;83(4):515-8. PMID: 10073853 [PubMed - indexed for MEDLINE] 404: Song IS, Yang WS, Kim SB, Lee JH, Kwon TW, Park JS. Related Articles, Links Association of plasma fibringen concentration with vascular access failure in hemodialysis patients. Nephrol Dial Transplant. 1999 Jan;14(1):137-41. PMID: 10052493 [PubMed - indexed for MEDLINE] 1. 405: Dickson TJ, Gurudutt V, Nguyen AQ, Kumfer K, Maxted W. Related Articles, Links Brown J, Mahomed Y, Sharp T, Aufiero TX, Fineberg N, March KL. Establishment of a clinically correlated human pericardial fluid bank: evaluation of intrapericardial diagnostic potential. Clin Cardiol. 1999 Jan;22(1 Suppl 1):I40-2. PMID: 9929767 [PubMed - indexed for MEDLINE] Related Articles, Links Hachida M, Zhang X, Lu H, Hoshi H, Furutani Y, Matsuoka R,



cb hg e e e fcg e ch b e

h



undergoing percutaneous interventions.

Am Heart J. 1998 Aug; 136(2):357-61. PMID: 9704702 [PubMed - indexed for MEDLINE]

423: Kagan SA, Myers SI.

Related Articles, Links

Mediators of restenosis. Surg Clin North Am: 1998 Jun;78(3):481-500. Review. PMID: 9673658 [PubMed - indexed for MEDLINE]

424: Remme WJ

Related Articles, Links

The sympathetic nervous system and ischaemic heart disease.

cb

h

h g e fcg e ch

b e

cb

hg e e

e fcg

e ch

b e

Eur Heart J. 1998 Jun;19 Suppl F:F62-71. Review. PMID: 9651738 [PubMed - indexed for MEDLINE]

□ 425:	Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M.	Related Articles, Links
	Therapeutic angiogenesis with basic fibroblast growth fand early results. Ann Thorac Surg. 1998 Jun;65(6):1540-4. PMID: 9647055 [PubMed - indexed for MEDLINE]	factor: technique
□ <b>42</b> 6:	Hachida M, Zhang XL, Lu H, Hoshi H, Koyanagi H.	Related Articles, Links
	Inhibitory effect of Multiglycosidorum tripterygii on coarteriosclerosis after heart transplantation.  Transplantation. 1998 Jun 15;65(11):1446-50.  PMID: 9645800 [PubMed - indexed for MEDLINE]	oronary
<b>427:</b>	Vonhof S, Brost B, Stille-Siegener M, Grumbach IM, Kreuzer H, Figulla HR.	Related Articles, Links
	Monocyte activation in congestive heart failure due to disease and idiopathic dilated cardiomyopathy. Int J Cardiol. 1998 Feb 28;63(3):237-44. PMID: 9578350 [PubMed - indexed for MEDLINE]	coronary artery
□ 428:	Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, Gullestad L.	Related Articles, Links
	Elevated circulating levels of C-C chemokines in patier heart failure. Circulation. 1998 Mar 31;97(12):1136-43. PMID: 9537339 [PubMed - indexed for MEDLINE]	nts with congestive
<b>1</b> 429:	Molestina RE, Dean D, Miller RD, Ramirez JA, Summersgill JT.	Related Articles, Links
	Characterization of a strain of Chlamydia pneumoniae is coronary atheroma by analysis of the omp1 gene and bis human endothelial cells. Infect Immun. 1998 Apr;66(4):1370-6. PMID: 9529055 [PubMed - indexed for MEDLINE]	
☐ <b>430</b> :	Selzman CH, Whitehill TA, Shames BD, Pulido EJ, Cain BS, Harken AH, Cain BC	Related Articles, Links
	The biology of estrogen-mediated repair of cardiovascu Ann Thorac Surg. 1998 Mar;65(3):868-74. Review. Erratum in: A Jul;66(1):310. Cain BC[corrected to Cain BS]. PMID: 9527242 [PubMed - indexed for MEDLINE]	
□ 431:	Foegh ML, Ramwell PW	Related Articles, Links
	Pharmacologic control of smooth muscle cells in allogr Transpl Immunol. 1997 Dec;5(4):267-75. Review. No abstract ava PMID: 9504146 [PubMed - indexed for MEDLINE]	
□ 432:	Schwartz SM.	Related Articles, Links
	Smooth muscle migration in vascular development and Transpl Immunol. 1997 Dec;5(4):255-60. Review. No abstract ava PMID: 9504144 [PubMed - indexed for MEDLINE]	
□ 433:	Pober JS, Ma W, Biedermann B, Libby P.	Related Articles, Links
	Vascular cells have limited capacities to activate and di implications for transplant vascular sclerosis.  Transpl Immunol. 1997 Dec;5(4):251-4. Review. No abstract avail PMID: 9504143 [PubMed - indexed for MEDLINE]	

cb

h g

e fcg

e ch

b e

Related Articles, Links 434: Eickelberg O, Roth M, Block LH. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. Int J Cardiol. 1997 Dec 31;62 Suppl 2:S31-7. Review. PMID: 9488193 [PubMed - indexed for MEDLINE] 435: Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Related Articles, Links Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol. 1998 Feb; 18(2):277-82. Erratum in: Arterioscler Thromb Vasc Biol 1998 Jul;18(7):1197. PMID: 9484994 [PubMed - indexed for MEDLINE] 436: Brilla CG, Rybinski L, Gehrke D, Rupp H. Related Articles, Links Transmyocardial laser revascularization—an innovative pathophysiologic concept Herz. 1997 Aug;22(4):183-9. Review. German. PMID: 9378452 [PubMed - indexed for MEDLINE] 1 437: Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjala H. Related Articles, Links Airaksinen J. Leinonen M, Saikku P, Juvonen T. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2843-7. PMID: 9409264 [PubMed - indexed for MEDLINE] 438: Plenz G, Koenig C, Severs NJ, Robenek H. Related Articles, Links Smooth muscle cells express granulocyte-macrophage colony-stimulating factor in the undiseased and atherosclerotic human coronary artery. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2489-99. PMID: 9409219 [PubMed - indexed for MEDLINE] 439: Shanahan CM, Cary NR, Osbourn JK, Weissberg PL. Related Articles, Links Identification of osteoglycin as a component of the vascular matrix. Differential expression by vascular smooth muscle cells during neointima formation and in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2437-47. PMID: 9409213 [PubMed - indexed for MEDLINE] 1 440: Fukumoto Y, Shimokawa H, Kozai T, Kadokami T, Kuwata K, Related Articles, Links Yonemitsu Y, Kuga T, Egashira K, Sueishi K, Takeshita A. Vasculoprotective role of inducible nitric oxide synthase at inflammatory coronary lesions induced by chronic treatment with interleukin-1beta in pigs in vivo. Circulation. 1997 Nov 4;96(9):3104-11. PMID: 9386181 [PubMed - indexed for MEDLINE] 1 441: Bombardini T. Picano E. Related Articles, Links The coronary angiogenetic effect of heparin: experimental basis and clinical evidence. Angiology. 1997 Nov;48(11):969-76. Review. PMID: 9373049 [PubMed - indexed for MEDLINE] 442: Suzuki J, Isobe M, Yamazaki S, Horie S, Okubo Y, Sekiguchi M. Related Articles, Links Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-

cb

hg e e

e fcg e ch


	associated antigen-1 in a heterotopic murine model of heart		
	transplantation. J Heart Lung Transplant. 1997 Nov;16(11):1141-8. PMID: 9402514 [PubMed - indexed for MEDLINE]		
□ 443:	Nishimura M, Ushiyama M, Yoshimura M.	Related Articles, Links	
	[Serum hepatocyte growth factor as a possible indicator lesions] Rinsho Byori. 1997 Sep;45(9):831-6. Japanese. PMID: 9311255 [PubMed - indexed for MEDLINE]	r of vascular	
□ 444:	Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N, Eber B, Wilders-Truschnig M, Esterbauer H, Klein W.	Related Articles, Links	
	Increased neopterin in patients with chronic and acute of syndromes.  J Am Coll Cardiol. 1997 Sep;30(3):703-7.  PMID: 9283529 [PubMed - indexed for MEDLINE]	coronary	
□ 445:	Wakasaki H. Koya D. Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL.	Related Articles, Links	
	Targeted overexpression of protein kinase C beta2 isofo causes cardiomyopathy.  Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9320-5.  PMID: 9256480 [PubMed - indexed for MEDLINE]	orm in myocardium	
□ 446:	Nagao K, Tsuchihashi K, Ura N, Nakata T, Shimamoto K.	Related Articles, Links	
	Appropriate hematocrit levels of erythropoietin suppler end-stage renal failure complicated by coronary artery Can J Cardiol. 1997 Aug;13(8):747-53. Review. PMID: 9284841 [PubMed - indexed for MEDLINE]		
□ 447:	Wang XL, Liu SX, Wilcken DE.	Related Articles, Links	
	Circulating transforming growth factor beta 1 and corol Cardiovasc Res. 1997 May;34(2):404-10. PMID: 9205555 [PubMed - indexed for MEDLINE]	nary artery disease.	
□ 448:	Nishigaki K, Minatoguchi S, Seishima M, Asano K, Noda T, Yasuda N, Sano H, Kumada H, Takemura M, Noma A, Tanaka T, Watanabe S, Fujiwara H	Related Articles, Links	
	Plasma Fas ligand, an inducer of apoptosis, and plasma inhibitor of apoptosis, in patients with chronic congesti J Am Coll Cardiol. 1997 May;29(6):1214-20. PMID: 9137215 [PubMed - indexed for MEDLINE]		
□ 449:	Hasdai D, Barak V, Leibovitz E, Herz I, Sclarovsky S, Eldar M, Scheinowitz M.	Related Articles, Links	
	Serum basic fibroblast growth factor levels in patients of disease.  Int J Cardiol. 1997 Apr 18;59(2):133-8.  PMID: 9158164 [PubMed - indexed for MEDLINE]	with ischemic heart	
☐ <b>450</b> :	Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE.	Related Articles, Links	
	Growth hormone increases and insulin-like growth fact circulating lipoprotein(a) Eur J Endocrinol. 1997 Apr;136(4):377-81. PMID: 9150696 [PubMed - indexed for MEDLINE]	or-I decreases	
□ 451:	Botker HE, Skjaerbaek C, Eriksen UH, Schmitz O, Orskov H.	Related Articles, Links	


ch

h g

fcg

e ch





ch

h g

e fcg

e ch


cb

h g

e fcg

e ch

bе



	human coronary angiogenesis-like responses in vitro. Atherosclerosis. 1995 Aug;116(2):261-8. PMID: 7575781 [PubMed - indexed for MEDLINE]	
□ 477	Fuster V. Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ.	Related Articles, Links
	The three processes leading to post PTCA restenosis: d lesion substrate. Thromb Haemost. 1995 Jul;74(1):552-9. Review. No abstract ava. PMID: 8578523 [PubMed - indexed for MEDLINE]	-
<b> 478</b>	Clausell N, de Lima VC, Molossi S, Liu P, Turley E, Gotlieb AI, Adelman AG, Rabinovitch M	Related Articles, Links
	Expression of tumour necrosis factor alpha and accumulation fibronectin in coronary artery restenotic lesions retrieve Br Heart J. 1995 Jun;73(6):534-9. PMID: 7626352 [PubMed - indexed for MEDLINE]	
□ 479	Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA	Related Articles, Links
	Regulation of vascular endothelial growth factor in care Circ Res. 1995 May;76(5):758-66. PMID: 7728992 [PubMed - indexed for MEDLINE]	diac myocytes.
□ 480	Vijayakumar M, Fall CH, Osmond C, Barker DJ	Related Articles, Links
,	Birth weight, weight at one year, and left ventricular m Br Heart J. 1995 Apr;73(4):363-7. PMID: 7756071 [PubMed - indexed for MEDLINE]	ass in adult life.
T 481	Eritsland J, Seljeflot I, Arnesen H, Westvik AB, Kierulf P.	Related Articles, Links
	Effect of long-term, moderate-dose supplementation was acids on monocyte procoagulant activity and release of patients with coronary artery disease.  Thromb Res. 1995 Feb 15;77(4):337-46.  PMID: 7740525 [PubMed - indexed for MEDLINE]	
<b>482</b> :	Badimon L, Royo T, Martinez-Gonzalez J, Badimon JJ.	Related Articles, Links
	[Development of coronary arteriosclerosis and its clinic Med Clin (Barc). 1995 Jan 28;104(3):105-14. Review. Spanish. N. PMID: 7877359 [PubMed - indexed for MEDLINE]	cal complications] o abstract available.
☐ <b>483</b> :	Hombach V, Waltenberger J, Voisard R, Hoher M.	Related Articles, Links
	[Recurrent stenosis following coronary angioplasty. Clibiological and molecular aspects] Z Kardiol. 1995 Jan;84(1):5-21. Review. German. PMID: 7863714 [PubMed - indexed for MEDLINE]	nical, cell
<b>484</b> :	Mann JF.	Related Articles, Links
	Hypertension and cardiovascular effectslong-term safe	ety and potential
	long-term benefits of r-HuEPO. Nephrol Dial Transplant. 1995;10 Suppl 2:80-4. PMID: 7644111 [PubMed - indexed for MEDLINE]	
□ 485:	Nephrol Dial Transplant. 1995;10 Suppl 2:80-4.	Related Articles, Links

	<b>486</b> :	Tada N.	Related Articles, Links
		[LDL receptor gene analysis and phenotypic variation of hypercholesterolemia] Nippon Rinsho. 1994 Dec;52(12):3228-35. Review. Japanese. PMID: 7853715 [PubMed - indexed for MEDLINE]	of familial
	<b>487</b> :	Schulte HM, Bamberger CM, Elsen H, Herrmann G, Bamberger AM, Barth J.	Related Articles, Links
		Systemic interleukin-1 alpha and interleukin-2 secretion acute stress and to corticotropin-releasing hormone in Eur J Clin Invest. 1994 Nov;24(11):773-7. PMID: 7890016 [PubMed - indexed for MEDLINE]	
	□ 488:	Dahlen GH.	Related Articles, Links
,		Indications of an autoimmune component in LP(a) asso Eur J Immunogenet. 1994 Oct;21(5):301-12. PMID: 9098440 [PubMed - indexed for MEDLINE]	ciated disorders.
	□ 489:	Tamamoto T, Toda T, Shimajiri S, Kiyuna M, Shingaki Y, Nakashima Y, Takei H.	Related Articles, Links
		[Expression of PDGF-A and -B in human coronary ather immunohistochemical and in situ hybridization study] Rinsho Byori. 1994 Sep;42(9):971-6. Japanese. PMID: 7967123 [PubMed - indexed for MEDLINE]	erosclerotic lesion:
	□ 490:	Denko CW, Boja B, Moskowitz RW.	Related Articles, Links
		Growth promoting peptides in osteoarthritis and diffuse hyperostosisinsulin, insulin-like growth factor-I, grow J Rheumatol. 1994 Sep;21(9):1725-30. PMID: 7799357 [PubMed - indexed for MEDLINE]	
	□ 491:	Kawai C.	Related Articles, Links
		Pathogenesis of acute myocardial infarction. Novel regionactive substances in the vessel wall.  Circulation. 1994 Aug;90(2):1033-43. Review.  PMID: 8044917 [PubMed - indexed for MEDLINE]	ulatory systems of
	□ 492:	Dzau VJ.	Related Articles, Links
		Cell biology and genetics of angiotensin in cardiovascu J Hypertens Suppl. 1994 Jul;12(4):S3-10. Review. PMID: 7965271 [PubMed - indexed for MEDLINE]	lar disease.
	□ <b>493</b> :	Hofling B, Gonschior P, Nikol S, Bauriedel G, Welsch U, Nerlich A.	Related Articles, Links
		[Pathophysiology and pathobiochemistry of restenosis] Z Kardiol. 1994 May;83(5):313-8. Review. German. PMID: 8053238 [PubMed - indexed for MEDLINE]	
	□ 494:	Nakayama T, Ohtsuru A, Enomoto H, Namba H, Ozeki S, Shibata Y, Yokota T, Nobuyoshi M, Ito M, Sekine I, et al.	Related Articles, Links
		Coronary atherosclerotic smooth muscle cells overexpreparathyroid hormone-related peptides. Biochem Biophys Res Commun. 1994 Apr 29;200(2):1028-35. PMID: 8179578 [PubMed - indexed for MEDLINE]	ess human
	T 495:	Pfeifer PB, Collins EG.	Related Articles, Links
		Cardiac allograft vasculopathy. J Cardiovasc Nurs. 1994 Apr,8(3):68-86. Review. PMID: 8207461 [PubMed - indexed for MEDLINE]	

cb

hg e e e fcg

e ch

bε

<b>496</b>	Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour Pepine CJ	<u>r M,</u>	Related Artic	les, Links
	Localization of insulin-like growth factor I and i smooth muscle cell growth by somatostatin analysmooth muscle cells. A potential treatment for recirculation. 1994 Apr;89(4):1511-7. PMID: 7908609 [PubMed - indexed for MEDLINE]	ogues i	n human co	
<b>497</b>	Luscher TF.		Related Artic	les, Links
	Endothelium in the control of vascular tone and mediators and mechanical forces. Blood Press Suppl. 1994;1:18-22. Review. PMID: 8205293 [PubMed - indexed for MEDLINE]	growth	: role of loo	cal
<b>498</b> :	Bauriedel G, Kandolf R, Welsch U, Hofling B.		Related Artic	les, Links
	[Mechanisms of re-stenosis after angioplasty] Z Kardiol. 1994;83 Suppl 4:31-41. Review. German. PMID: 7856278 [PubMed - indexed for MEDLINE]			
T 499	Yang Z. Luscher TF.		Related Artic	les, Links
	Basic cellular mechanisms of coronary bypass gr Eur Heart J. 1993 Nov;14 Suppl I:193-7. PMID: 8293775 [PubMed - indexed for MEDLINE]	raft dis	ease.	
<b>500</b> :	Wilcox JN.		Related Artic	les, Links
	Molecular biology: insight into the causes and prafter arterial intervention. Am J Cardiol. 1993 Oct 18;72(13):88E-95E. Review. PMID: 8213576 [PubMed - indexed for MEDLINE]	reventio	on of resten	osis
	Items 1-500 of 548	Page 1	l of	2 Next
Display	Summary Show: 500 Sort	<b>▼</b> ] Se	end to Text	

Write to the Help Desk

NCB! | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37








PubMed Nucleotide Protein Structure OMIM PMC Journals Book Search | PubMed for coronary artery disease AND growth factor Go Clear Limits Preview/Index History Clipboard Details About Entrez Display | Summary Show: 500 ▼ Sort Text Send to Text Version Page Items 501-548 of 548 of 2 Previous 501: Yang Z. Noll G. Luscher TF. Entrez PubMed Related Articles, Links Overview Calcium antagonists differently inhibit proliferation of human coronary Help | FAQ smooth muscle cells in response to pulsatile stretch and platelet-derived Tutorial New/Noteworthy growth factor. E-Utilities Circulation. 1993 Sep;88(3):832-6. PMID: 8353912 [PubMed - indexed for MEDLINE] PubMed Services 502: Anderson HV, Vignale SJ, Benedict CR, Willerson JT. Journals Database Related Articles, Links MeSH Database Restenosis after coronary angioplasty. Single Citation Matcher J Interv Cardiol. 1993 Sep;6(3):187-202. Review. **Batch Citation Matcher** Clinical Queries PMID: 10151016 [PubMed - indexed for MEDLINE] LinkOut Cubby 503: Klassen KJ, Nordt TK, Schneider DJ, Sobel BE. Related Articles, Links Constitutive biosynthesis of plasminogen activator inhibitor type-1 (PAI-Related Resources 1) by cultured human aortic endothelial cells independent of insulin. Order Documents Coron Artery Dis. 1993 Aug;4(8):713-9. **NLM Gateway** TOXNET PMID: 8261243 [PubMed - indexed for MEDLINE] Consumer Health Clinical Alerts 504: Johansson SR, Nilsson J, Hamsten A, Emanuelsson H. Related Articles, Links ClinicalTrials.gov PubMed Central Mitogenic activity in connection with coronary angioplasty. Eur Heart J. 1993 Jul;14(7):904-9. PMID: 8375413 [PubMed - indexed for MEDLINE] 505: Clausell N, Molossi S, Rabinovitch M. Related Articles, Links Increased interleukin-1 beta and fibronectin expression are early features of the development of the postcardiac transplant coronary arteriopathy in piglets. Am J Pathol. 1993 Jun; 142(6): 1772-86. PMID: 8506947 [PubMed - indexed for MEDLINE] 506: Ko Y, Haring R, Stiebler H, Wieczorek AJ, Vetter H, Sachinidis Related Articles, Links <u>A.</u> High-density lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. Atherosclerosis. 1993 Mar; 99(2):253-9. PMID: 8503952 [PubMed - indexed for MEDLINE] 507: Badimon JJ, Fuster V, Chesebro JH, Badimon L. Related Articles, Links Coronary atherosclerosis. A multifactorial disease. Circulation. 1993 Mar;87(3 Suppl):II3-16. Review. PMID: 8443920 [PubMed - indexed for MEDLINE] 508: Hase H, Imamura Y, Nakamura R, Inishi Y, Machii K, Related Articles, Links Yamaguchi T. Effects of rHuEPO therapy on exercise capacity in hemodialysis patients

with coronary artery disease.

Jpn Circ J. 1993 Feb;57(2):131-7. PMID: 8450597 [PubMed - indexed for MEDLINE] 509: Luscher TF. Tanner FC, Tschudi MR, Noll G. Related Articles, Links Endothelial dysfunction in coronary artery disease. Annu Rev Med. 1993;44:395-418. Review. PMID: 8476260 [PubMed - indexed for MEDLINE] Related Articles, Links 510: Lindemann A, Rumberger B. Vascular complications in patients treated with granulocyte colonystimulating factor (G-CSF) Eur J Cancer. 1993;29A(16):2338-9. No abstract available. PMID: 8110510 [PubMed - indexed for MEDLINE] 511: Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. Related Articles, Links A cascade model for restenosis. A special case of atherosclerosis progression. Circulation. 1992 Dec;86(6 Suppl):III47-52. Review. PMID: 1424051 [PubMed - indexed for MEDLINE] 512: Fuster V, Badimon JJ, Badimon L. Related Articles, Links Clinical-pathological correlations of coronary disease progression and regression. Circulation. 1992 Dec;86(6 Suppl):III1-11. Review. PMID: 1424042 [PubMed - indexed for MEDLINE] 513: Nilsson J. Volk-Jovinge S. Svensson J. Landou C. De Faire U. Related Articles, Links Hamsten A. Association between high levels of growth factors in plasma and progression of coronary atherosclerosis. J Intern Med. 1992 Nov;232(5):397-404. PMID: 1453123 [PubMed - indexed for MEDLINE] 514: Yla-Herttuala S. Related Articles, Links Gene expression in atherosclerotic lesions. Herz. 1992 Oct; 17(5):270-6. Review. PMID: 1473813 [PubMed - indexed for MEDLINE] 1 515: Bauriedel G, Heidemann P, Klingel K, Windstetter U, Hofling B. Related Articles, Links Kandolf R. In situ detection of EGF receptor mRNA in arteriosclerotic lesions in man: implications for the proliferative activity of smooth muscle cells] Z Kardiol. 1992 Oct;81(10):519-24. German. Erratum in: Z Kardiol 1992 Dec;81 PMID: 1441690 [PubMed - indexed for MEDLINE] 516: Schumacher M, Eber B, Tatzber F, Kaufmann P, Esterbauer H, Related Articles, Links Klein W. Neopterin levels in patients with coronary artery disease. Atherosclerosis. 1992 May;94(1):87-8. No abstract available. PMID: 1632862 [PubMed - indexed for MEDLINE] 517: Gordon D. Related Articles, Links Growth factors and cell proliferation in human transplant arteriosclerosis. J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S7. No abstract available. PMID: 1623005 [PubMed - indexed for MEDLINE] Wiedermann CJ, Niedermuhlbichler M, Braunsteiner H, Related Articles, Links Widermann CJ



cb

h g

e fcg

ge

	Growth factors in pathogenesis of coronary arterial rest Am J Cardiol. 1991 Nov 4;68(12):24C-33C. Review. PMID: 1951099 [PubMed - indexed for MEDLINE]	enosis.
<b>529</b>	Rosendorff C.	Related Articles, Links
	Reversal of structural changes in hypertensive arteries- for the future. S Afr Med J. 1991 Sep 21;Suppl:4-6. Review. PMID: 1925814 [PubMed - indexed for MEDLINE]	-a major prospect
<b>530</b>	Arbustini E, Grasso M, Diegoli M, Pucci A, Bramerio M, Ardissino D, Angoli L, de Servi S, Bramucci E, Mussini A, et al	Related Articles, Links
	Coronary atherosclerotic plaques with and without thro heart syndromes: a morphologic, immunohistochemica study.  Am J Cardiol. 1991 Sep 3;68(7):36B-50B.  PMID: 1892066 [PubMed - indexed for MEDLINE]	
<b>531</b>	Hermans WR, Rensing BJ, Strauss BH, Serruys PW.	Related Articles, Links
	Prevention of restenosis after percutaneous translumina angioplasty: the search for a "magic bullet".  Am Heart J. 1991 Jul;122(1 Pt 1):171-87. Review. No abstract ava PMID: 2063736 [PubMed - indexed for MEDLINE]	•
<b>532</b>	: Wilcox JN.	Related Articles, Links
	Thrombin and other potential mechanisms underlying r Circulation. 1991 Jul;84(1):432-5. No abstract available. PMID: 2060116 [PubMed - indexed for MEDLINE]	estenosis.
□ 533	Stout RW.	Related Articles, Links
	Insulin as a mitogenic factor: role in the pathogenesis of disease.  Am J Med. 1991 Feb 21;90(2A):62S-65S.  PMID: 1994720 [PubMed - indexed for MEDLINE]	f cardiovascular
□ 534	Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL.	Related Articles, Links
	Lipoprotein (a) regulates plasminogen activator inhibite endothelial cells. A potential mechanism in thrombogen J Biol Chem. 1991 Feb 5;266(4):2459-65. PMID: 1824942 [PubMed - indexed for MEDLINE]	-
<b>535</b>	DeFeudis FV.	Related Articles, Links
	Coronary atherosclerosis: current therapeutic approache trends. Life Sci. 1991;49(10):689-705. Review. PMID: 1875779 [PubMed - indexed for MEDLINE]	es and future
□ <b>536</b>	Kragel AH, Travis WD, Feinberg L, Pittaluga S, Striker LM, Roberts WC, Lotze MT, Yang JJ, Rosenberg SA.	Related Articles, Links
	Pathologic findings associated with interleukin-2-based for cancer: a postmortem study of 19 patients. Hum Pathol. 1990 May;21(5):493-502. PMID: 2338330 [PubMed - indexed for MEDLINE]	I immunotherapy
□ 537	Mustard JF, Packham MA, Kinlough-Rathbone RL.	Related Articles, Links
	Platelets, blood flow, and the vessel wall. Circulation. 1990 Jan;81(1 Suppl):I24-7; discussion I40-1. Review PMID: 2403865 [PubMed - indexed for MEDLINE]	7.

cb

hg e e

e fcg

ge

□ 538	: Popma JJ, Topol EJ	Related Articles, Links
	Factors influencing restenosis after coronary angioplas Am J Med. 1990 Jan;88(1N):16N-24N. Review. PMID: 2195881 [PubMed - indexed for MEDLINE]	ty.
<b>539</b>	: Sueishi K, Yasunaga C, Castellanos E, Kumamoto M, Tanaka K.	Related Articles, Links
	Sustained arterial injury and progression of atheroscler Ann N Y Acad Sci. 1990;598:223-31. Review. PMID: 1701074 [PubMed - indexed for MEDLINE]	osis.
<b>□</b> 540	Ouchi Y, Orimo H.	Related Articles, Links
	The role of calcium antagonists in the treatment of athe hypertension.  J Cardiovasc Pharmacol. 1990;16 Suppl 2:S1-4. Review.  PMID: 1369701 [PubMed - indexed for MEDLINE]	erosclerosis and
□ 541	Libby P.	Related Articles, Links
	The functions of blood vessel wall cells in atherogenes artery disease.  Arq Bras Cardiol. 1989 Aug;53(2):71-4. Review. No abstract avail PMID: 2696454 [PubMed - indexed for MEDLINE]	•
☐ 542	Nora R, Abrams JS, Tait NS, Hiponia DJ, Silverman HJ.	Related Articles, Links
	Myocardial toxic effects during recombinant interleuki J Natl Cancer Inst. 1989 Jan 4;81(1):59-63. PMID: 2783257 [PubMed - indexed for MEDLINE]	n-2 therapy.
□ 543	: Friedman EA.	Related Articles, Links
	Renal failure in diabetes: a substantive problem in prov	vision of health
40003	care. Verh K Acad Geneeskd Belg. 1989;51(2):81-149; discussion 149-PMID: 2678807 [PubMed - indexed for MEDLINE]	-51. Review.
□ 544	Nardoni A. Di Piazza V. Moretti V. Copetti R. Cruciatti A.	Related Articles, Links
	[Clinicopathogenetic correlations of copper and zinc ar myocardiopathy] Minerva Cardioangiol. 1987 Sep;35(9):451-5. Italian. No abstract PMID: 3500428 [PubMed - indexed for MEDLINE]	
<b>545</b>	: Nilsson J. Svensson J. Hamsten A., de Faire U.	Related Articles, Links
	Increased platelet-derived mitogenic activity in plasma with coronary atherosclerosis. Atherosclerosis. 1986 Sep;61(3):237-43. PMID: 2429675 [PubMed - indexed for MEDLINE]	of young patients
□ 546	Kottke BA.	Related Articles, Links
	Lipid markers for atherosclerosis. Am J Cardiol. 1986 Feb 12;57(5):11C-17C. Review. PMID: 3080862 [PubMed - indexed for MEDLINE]	
□ 547	Fuster V, Griggs TR.	Related Articles, Links
	Porcine von Willebrand disease: implications for the paratherosclerosis and thrombosis.  Prog Hemost Thromb. 1986;8:159-83. Review.  PMID: 3550894 [PubMed - indexed for MEDLINE]	athophysiology of
□ 548	Stuart J.	Related Articles, Links

Display

Rheological importance of acute-phase reactants.

Nouv Rev Fr Hematol. 1986;28(1):33-6.

PMID: 2423964 [PubMed - indexed for MEDLINE]

Items 501-548 of 548

Summary

Previous Page 2 of 2
Show: 500 Sort Send to Text

Write to the Help Desk
NCB! | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37







PubMed Nucleofide Protein Genome Structure OMIM PMC Journals 800 Search PubMed for VEGF AND coronary artery disease Go Clear Limits Preview/Index History Clipboard Details

About Entrez

**Text Version** 

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Show: 500 Display Summary Send to Sort Text Items 1-94 of 94 One page. 1: Depre C, Kim SJ, John AS, Hong Huang Y, Rimoldi OE, Pepper JR, Related Articles, Links Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, Camici PG, Vatner Program of Cell Survival Underlying Human and Experimental Hibernating Mvocardium. Circ Res. 2004 Jul 8 [Epub ahead of print] PMID: 15242971 [PubMed - as supplied by publisher] 1 2: Nakajima K, Tabata S, Yamashita T, Kusuhara M, Arakawa K, Related Articles, Links Ohmori R, Yonemura A, Higashi K, Ayaori M, Nakamura H, Ohsuzu F. Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease. Clin Cardiol. 2004 May;27(5):281-6. PMID: 15188944 [PubMed - in process] 3. Lemstrom KB, Nykanen AI, Tikkanen JM, Krebs R, Sihvola RK. Related Articles, Links Kallio EA, Olivier R, Koskinen PK. Role of angiogenic growth factors in transplant coronary artery disease. Ann Med. 2004;36(3):184-93. PMID: 15181974 [PubMed - in process]

Mahomed Y, March KL.

Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease.

J Am Coll Cardiol. 2004 Apr 21;43(8):1383-7.

PMID: 15093871 [PubMed - indexed for MEDLINE]

1 4. Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW,

5: Gouni-Berthold I, Sachinidis A.

Related Articles, Links

Related Articles, Links

Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseases.

Curr Pharm Des. 2004;10(11):1261-71. Review. PMID: 15078140 [PubMed - indexed for MEDLINE]

6: Perrin LA, June JE, Rosebury W, Robertson A, Kovesdi J, Bruder JT, Kessler PD, Keiser JA, Gordon D. Related Articles, Links

Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).

Gene Ther. 2004 Mar;11(6):512-21.

fcg

PMID: 14999223 [PubMed - indexed for MEDLINE]

7: Syed IS, Sanborn TA, Rosengart TK.

e

Related Articles, Links

Therapeutic angiogenesis: a biologic bypass. Cardiology. 2004;101(1-3):131-43. Review. PMID: 14988635 [PubMed - indexed for MEDLINE]


8: Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R.

Related Articles, Links

cb hg e

h

e ch



cb

h g

e fcg

e ch

cb hgee

e fcg

e ch b e

		Ü
□ 18:	Panutsopulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA	Related Articles, Links
	Peripheral monocytes from diabetic patients with corona display increased bFGF and VEGF mRNA expression. J Transl Med. 2003 Oct 06;1(1):6. PMID: 14585103 [PubMed - as supplied by publisher]	artery disease
□ 19:	Juan-Babot JO, Martinez-Gonzalez J, Berrozpe M, Badimon L.	Related Articles, Links
	[Neovascularization in human coronary arteries with less everity] Rev Esp Cardiol. 2003 Oct;56(10):978-86. Spanish. PMID: 14563292 [PubMed - indexed for MEDLINE]	ions of different
□ 20:	Nishimura S, Zaitsu M, Hara M, Yokota G, Watanabe M, Ueda Y, Imayoshi M, Ishii E, Tasaki H, Hamasaki Y.	Related Articles, Links
	A polymorphism in the promoter of the CD14 gene (CD associated with the development of coronary artery lesic Kawasaki disease.  J Pediatr. 2003 Sep;143(3):357-62. PMID: 14517520 [PubMed - indexed for MEDLINE]	
□ 21:	Fujita M, Ikemoto M, Tanaka T, Tamaki S, Yamazato A, Sawamura T, Hasegawa K, Kihara Y, Nohara R, Sasayama S.	Related Articles, Links
	Marked elevation of vascular endothelial growth factor a growth factor in pericardial fluid of patients with angina Angiogenesis. 1998;2(1):105-8. PMID: 14517380 [PubMed]	and basic fibroblast pectoris.
□ 22:	Crottogini A. Meckert PC, Vera Janavel G, Lascano E, Negroni J, Del Valle H, Dulbecco E, Werba P, Cuniberti L, Martinez V, De Lorenzi A, Telayna J, Mele A, Fernandez JL, Marangunich L, Criscuolo M, Capogrossi MC, Laguens R	Related Articles, Links
	Arteriogenesis induced by intramyocardial vascular endofactor 165 gene transfer in chronically ischemic pigs. Hum Gene Ther. 2003 Sep 20;14(14):1307-18. PMID: 14503966 [PubMed - indexed for MEDLINE]	othelial growth
□ 23:	Ruel M, Selike FW.	Related Articles, Links
	Angiogenic protein therapy. Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review. PMID: 12973700 [PubMed - indexed for MEDLINE]	*
□ 24:	Hedman M. Yla-Herttuala S.	Related Articles, Links
	Gene therapy for the treatment of peripheral vascular disartery disease.  Drugs Today (Barc). 2000 Sep;36(9):609-17.  PMID: 12847566 [PubMed]	ease and coronary
□ 25:	Chung NA, Makin AJ, Lip GY	Related Articles, Links
	Measurement of the soluble angiopoietin receptor tie-2 is coronary artery disease: development and application of Eur J Clin Invest. 2003 Jul;33(7):529-35. PMID: 12814387 [PubMed - indexed for MEDLINE]	n patients with an immunoassay.
□ 26:	Kastrup J	Related Articles, Links
	Therapeutic angiogenesis in ischemic heart disease: gene vascular growth factor protein therapy? Curr Gene Ther. 2003 Jun;3(3):197-206. Review. PMID: 12762479 [PubMed - indexed for MEDLINE]	or recombinant


h g

e fcg

cb

		8
□ 27	: Rasmussen HS, Rasmussen CS, Macko J	Related Articles, Links
	VEGF gene therapy for coronary artery disease and perdisease. Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):114-7. Review.	pheral vascular
	PMID: 12699842 [PubMed - indexed for MEDLINE]	
<b>28</b>	: Kusumanto YH, Hospers GA, Mulder NH, Tio RA,	Related Articles, Links
	Therapeutic angiogenesis with vascular endothelial grouperipheral and coronary artery disease: a review. Int J Cardiovasc Intervent. 2003;5(1):27-34. Review. PMID: 12623562 [PubMed - indexed for MEDLINE]	wth factor in
□ 29	: Sellke FW, Ruel M.	Related Articles, Links
	Vascular growth factors and angiogenesis in cardiac sur Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review. PMID: 12607713 [PubMed - indexed for MEDLINE]	gery.
□ 30	: Khan TA, Sellke FW, Laham RJ.	Related Articles, Links
	Therapeutic angiogenesis: protein-based therapy for cor	onary artery
<b>U</b> esser	disease. Expert Opin Pharmacother. 2003 Feb;4(2):219-26. Review. PMID: 12562312 [PubMed - indexed for MEDLINE]	
□ 31	Sim EK, Zhang L, Shim WS, Lim YL, Ge R.	Related Articles, Links
	Therapeutic angiogenesis for coronary artery disease. J Card Surg. 2002 Jul-Aug;17(4):350-4. Review. PMID: 12546086 [PubMed - indexed for MEDLINE]	
32	Kutryk MJ, Stewart DJ	Related Articles, Links
	Angiogenesis of the heart. Microsc Res Tech. 2003 Feb 1;60(2):138-58. Review. PMID: 12539168 [PubMed - indexed for MEDLINE]	
□ 33:	Lenihan DJ, Osman A, Sriram V, Aitsebaomo J, Patterson C.	Related Articles, Links
	Evidence for association of coronary sinus levels of hep factor and collateralization in human coronary disease. Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1507-12. Epu PMID: 12521946 [PubMed - indexed for MEDLINE]	
□ 34:	Lee CH, Smits PC.	Related Articles, Links
	Vascular growth factors for coronary angiogenesis. J Interv Cardiol. 2002 Dec;15(6):511-8. Review. PMID: 12476656 [PubMed - indexed for MEDLINE]	
□35:	Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G.	Related Articles, Links
	Angiogenic gene therapy strategies for the treatment of	cardiovascular
	disease. Curr Opin Mol Ther. 2002 Oct;4(5):476-81. Review. PMID: 12435049 [PubMed - indexed for MEDLINE]	
□ 36:	Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG.	Related Articles, Links
	Systemic interleukin-6 responses following administration gene transfer vectors to humans by different routes. Mol Ther. 2002 Aug;6(2):287-97. PMID: 12349828 [PubMed - indexed for MEDLINE]	on of adenovirus
□ 37:	Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, Isner JM.	Related Articles, Links

e ch b e



cb

h g

e fcg

e ch

ر ۾ پسو	Roreness V. Harken AH	Photograph Audiotocca Albert
1 46	Barsness K, Harken AH.	Related Articles, Links
	Clinical applications of cardiovascular angiogenesis. J Card Surg. 2001 Nov-Dec;16(6):490-7. Review. PMID: 11925031 [PubMed - indexed for MEDLINE]	•
<b>5</b> 47	Sarkar N, Ruck A, Kallner G, Y-Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C.	Related Articles, Links
	Effects of intramyocardial injection of phVEGF-A165 a patients with refractory coronary artery disease12-morangiogenic gene therapy.  J Intern Med. 2001 Nov;250(5):373-81.  PMID: 11887971 [PubMed - indexed for MEDLINE]	
48	Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY	Related Articles, Links
	Vascular endothelial growth factor and its receptor, Flt- patients with coronary or peripheral atherosclerosis, or T Clin Sci (Lond). 2002 Feb;102(2):187-94. PMID: 11834138 [PubMed - indexed for MEDLINE]	
<b>1</b> 49:	Sarkar N, Blomberg P, Wardell E, Eskandarpour M, Sylven C, Drvota V, Islam KB	Related Articles, Links
	Nonsurgical direct delivery of plasmid DNA into rat headose response, and the influence of different promoters of J Cardiovasc Pharmacol. 2002 Feb;39(2):215-24. PMID: 11791007 [PubMed - indexed for MEDLINE]	
<b>□ 50</b> :	Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann	Related Articles, Links
	C.	
		termediate-dose
□ 51:	C. Analysis of risk factors for local delivery of low- and in adenovirus gene transfer vectors to individuals with a sp comorbid conditions.  Hum Gene Ther. 2002 Jan 1;13(1):65-100.	termediate-dose
□ 51:	C. Analysis of risk factors for local delivery of low- and in adenovirus gene transfer vectors to individuals with a sp comorbid conditions. Hum Gene Ther. 2002 Jan 1;13(1):65-100. PMID: 11779413 [PubMed - indexed for MEDLINE]  Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD,	termediate-dose sectrum of Related Articles, Links denovirus gene
	C. Analysis of risk factors for local delivery of low- and intadenovirus gene transfer vectors to individuals with a sp comorbid conditions.  Hum Gene Ther. 2002 Jan 1;13(1):65-100.  PMID: 11779413 [PubMed - indexed for MEDLINE]  Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.  Safety of local delivery of low- and intermediate-dose ac transfer vectors to individuals with a spectrum of morbid Hum Gene Ther. 2002 Jan 1;13(1):15-63.	termediate-dose sectrum of Related Articles, Links denovirus gene
	Analysis of risk factors for local delivery of low- and in adenovirus gene transfer vectors to individuals with a sp comorbid conditions.  Hum Gene Ther. 2002 Jan 1;13(1):65-100.  PMID: 11779413 [PubMed - indexed for MEDLINE]  Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.  Safety of local delivery of low- and intermediate-dose actransfer vectors to individuals with a spectrum of morbid Hum Gene Ther. 2002 Jan 1;13(1):15-63.  PMID: 11779412 [PubMed - indexed for MEDLINE]	termediate-dose ectrum of Related Articles, Links denovirus gene d conditions.
☐ 52:	Analysis of risk factors for local delivery of low- and interactional adenovirus gene transfer vectors to individuals with a specomorbid conditions.  Hum Gene Ther. 2002 Jan 1;13(1):65-100.  PMID: 11779413 [PubMed - indexed for MEDLINE]  Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.  Safety of local delivery of low- and intermediate-dose at transfer vectors to individuals with a spectrum of morbid Hum Gene Ther. 2002 Jan 1;13(1):15-63.  PMID: 11779412 [PubMed - indexed for MEDLINE]  Freedman SB, Isner JM.  Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002 Jan 1;136(1):54-71. Review.	termediate-dose ectrum of Related Articles, Links denovirus gene d conditions.
☐ 52:	C. Analysis of risk factors for local delivery of low- and interpretation adenovirus gene transfer vectors to individuals with a specomorbid conditions.  Hum Gene Ther. 2002 Jan 1;13(1):65-100.  PMID: 11779413 [PubMed - indexed for MEDLINE]  Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.  Safety of local delivery of low- and intermediate-dose at transfer vectors to individuals with a spectrum of morbid Hum Gene Ther. 2002 Jan 1;13(1):15-63.  PMID: 11779412 [PubMed - indexed for MEDLINE]  Freedman SB, Isner JM.  Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002 Jan 1;136(1):54-71. Review.  PMID: 11777364 [PubMed - indexed for MEDLINE]	termediate-dose ectrum of  Related Articles, Links  denovirus gene d conditions.  Related Articles, Links
□ 52: □ 53:	C. Analysis of risk factors for local delivery of low- and in adenovirus gene transfer vectors to individuals with a sp comorbid conditions.  Hum Gene Ther. 2002 Jan 1;13(1):65-100.  PMID: 11779413 [PubMed - indexed for MEDLINE]  Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.  Safety of local delivery of low- and intermediate-dose at transfer vectors to individuals with a spectrum of morbid Hum Gene Ther. 2002 Jan 1;13(1):15-63.  PMID: 11779412 [PubMed - indexed for MEDLINE]  Freedman SB, Isner JM.  Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002 Jan 1;136(1):54-71. Review.  PMID: 11777364 [PubMed - indexed for MEDLINE]  Dulak J, Jozkowicz A, Frick M, Alber HF, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F.  Vascular endothelial growth factor: angiogenesis, athero J Am Coll Cardiol. 2001 Dec;38(7):2137-8. No abstract available.	termediate-dose ectrum of  Related Articles, Links  denovirus gene d conditions.  Related Articles, Links

Simultaneous surgical revascularization and angiogenic gene therapy in

cb

hg e e

e fcg e ch

	diffuse coronary artery disease. Eur J Cardiothorac Surg. 2001 Dec;20(6):1128-34. PMID: 11717016 [PubMed - indexed for MEDLINE]	
□ 55	: Davda J, Labhasetwar V.	Related Articles, Links
	An update on angiogenesis therapy. Crit Rev Eukaryot Gene Expr. 2001;11(1-3):1-21. Review. PMID: 11693956 [PubMed - indexed for MEDLINE]	
□ 56	Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER.	Related Articles, Links
	Intracoronary administration of recombinant human vasor growth factor to patients with coronary artery disease. Am Heart J. 2001 Nov;142(5):872-80. PMID: 11685177 [PubMed - indexed for MEDLINE]	cular endothelial
□ 57	Choukroun G.	Related Articles, Links
	[Prevention and treatment of type 1 diabetes] Presse Med. 2001 Sep 1;30(24 Pt 2):21-3. French. PMID: 11577580 [PubMed - indexed for MEDLINE]	
□ 58	Basara N.	Related Articles, Links
	AdGVVEGF121.10 (GenVec). Curr Opin Investig Drugs. 2001 Jun;2(6):792-5. Review. PMID: 11572658 [PubMed - indexed for MEDLINE]	
□ 59	Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM	Related Articles, Links
	HMG-CoA reductase inhibitors (statins) increase endoth cells via the PI 3-kinase/Akt pathway.  J Clin Invest. 2001 Aug;108(3):391-7.  PMID: 11489932 [PubMed - indexed for MEDLINE]	elial progenitor
<b>60</b>	Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N	Related Articles, Links
	Role of circulating vascular endothelial growth factor an growth factor in patients with coronary artery disease. Heart Vessels. 2000;15(3):105-11. PMID: 11289497 [PubMed - indexed for MEDLINE]	d hepatocyte
□ <b>61</b>	Ray S, Panja M.	Related Articles, Links
	Current understanding of pathogenesis of coronary artery future implications.  J Indian Med Assoc. 2000 Nov;98(11):710-1, 714, 718.  PMID: 11265801 [PubMed - indexed for MEDLINE]	y disease and its
□ 62	Brizzi MF, Formato L, Bonamini R.	Related Articles, Links
	The molecular mechanisms of angiogenesis: a new approcardiovascular diseases. Ital Heart J. 2001 Feb;2(2):81-92. Review. PMID: 11256548 [PubMed - indexed for MEDLINE]	oach to
□ 63	Morse MA.	Related Articles, Links
	Technology evaluation: VEGF165 gene therapy, Valenti Curr Opin Mol Ther. 2001 Feb;3(1):97-101. Review. PMID: 11249737 [PubMed - indexed for MEDLINE]	s Inc.
□ 64	Rosengart TK, Hillebrand K.	Related Articles, Links

cb

	Gene therapy for coronary artery disease. Adv Card Surg. 2001;13:107-20. Review. No abstract available. PMID: 11209652 [PubMed - indexed for MEDLINE]	
□ 65	Freedman SB, Isner JM.	Related Articles, Links
	Therapeutic angiogenesis for ischemic cardiovascular die J Mol Cell Cardiol. 2001 Mar;33(3):379-93. Review. PMID: 11181008 [PubMed - indexed for MEDLINE]	sease.
□ 66	Durairaj A. Mehra A. Singh RP, Faxon DP.	Related Articles, Links
	Therapeutic angiogenesis. Cardiol Rev. 2000 Sep-Oct;8(5):279-87. Review. PMID: 11174906 [PubMed - indexed for MEDLINE]	
67	Rutanen J, Rissanen TT, Kivela A, Vajanto I, Yla-Herttuala S.	Related Articles, Links
	Clinical applications of vascular gene therapy. Curr Cardiol Rep. 2001 Jan;3(1):29-36. Review. PMID: 11139796 [PubMed - indexed for MEDLINE]	
□ 68	Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM.	Related Articles, Links
	Gene therapy with vascular endothelial growth factor for coronary artery disease: anesthetic management and resures Anesth Analg. 2001 Jan;92(1):19-25. PMID: 11133594 [PubMed - indexed for MEDLINE]	_
□ 69	Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isner JM	Related Articles, Links
	Left ventricular electromechanical mapping to assess eff (165) gene transfer for therapeutic angiogenesis in chronischemia.  Circulation. 2000 Aug 29;102(9):965-74.  PMID: 10961959 [PubMed - indexed for MEDLINE]	-
<b>□</b> 70	Mukherjee D, Ellis SG.	Related Articles, Links
	New options for untreatable coronary artery disease: ang revascularization. Cleve Clin J Med. 2000 Aug;67(8):577-83. PMID: 10946453 [PubMed - indexed for MEDLINE]	iogenesis and laser
<b>□</b> 71	O'Brien T, Simari RD.	Related Articles, Links
	Gene therapy for atherosclerotic cardiovascular disease: optimism and caution.  Mayo Clin Proc. 2000 Aug;75(8):831-4. Review.  PMID: 10943238 [PubMed - indexed for MEDLINE]	a time for
□ 72	Lucassen AM, de Waal RM, Verhengt FW.	Related Articles, Links
	[Therapeutic angiogenesis as a new experimental treatmedisease] Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5. Review. Dutch PMID: 10774292 [PubMed - indexed for MEDLINE]	
□ 73	Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF	Related Articles, Links
	Adenoviral-mediated gene transfer induces sustained per expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res. 1999 Nov;44(2):294-302. PMID: 10690306 [PubMed - indexed for MEDLINE]	ricardial VEGF

hg e e e fcg e ch b e

□ 74:	Chawla PS, Keelan MH, Kipshidze N.	Related Articles, Links
	Angiogenesis for the treatment of vascular diseases. Int Angiol. 1999 Sep;18(3):185-92. Review. PMID: 10688416 [PubMed - indexed for MEDLINE]	
□ 75:	Moussa I, Moses JW.	Related Articles, Links
90000 90000 90000 90000	Angiogenesis for treatment of ischemic heart disease: shabout progression of atherosclerosis? Circulation. 1999 Nov 30;100(22):e109. No abstract available. PMID: 10578010 [PubMed - indexed for MEDLINE]	ould we worry
□ 76:	Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C.	Related Articles, Links
	Physiologically assessed coronary collateral flow and infactor concentrations in patients with 1- to 3-vessel coro Circulation. 1999 Nov 9;100(19):1945-50. PMID: 10556219 [PubMed - indexed for MEDLINE]	
□ 77:	Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG	Related Articles, Links
	Six-month assessment of a phase I trial of angiogenic getreatment of coronary artery disease using direct intramy administration of an adenovirus vector expressing the VI Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2. PMID: 10522716 [PubMed - indexed for MEDLINE]	ocardial
□ 78:	Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM.	Related Articles, Links
	Gene therapy with vascular endothelial growth factor for coronary artery disease.  Ann Thorac Surg. 1999 Sep;68(3):830-6; discussion 836-7.  PMID: 10509970 [PubMed - indexed for MEDLINE]	rinoperable
□ 79:	Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP.	Related Articles, Links
	Interindividual heterogeneity in the hypoxic regulation of significance for the development of the coronary artery of circulation.  Circulation. 1999 Aug 3;100(5):547-52.  PMID: 10430770 [PubMed - indexed for MEDLINE]	
<b>□ 80:</b>	Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szule M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG	Related Articles, Links
	Angiogenesis gene therapy: phase I assessment of direct administration of an adenovirus vector expressing VEGI individuals with clinically significant severe coronary ar Circulation. 1999 Aug 3;100(5):468-74. PMID: 10430759 [PubMed - indexed for MEDLINE]	121 cDNA to
□81:	Losordo DW, Vale PR, Isner JM,	Related Articles, Links
	Gene therapy for myocardial angiogenesis. Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. Review. PMID: 10426872 [PubMed - indexed for MEDLINE]	
□ 82:	Ikemoto M. Hasegawa K. Kihara Y. Iwakura A, Komeda M. Yamazato A, Fujita M.	Related Articles, Links
	Development of enzyme-linked immunosorbent assay for	r acidic fibroblast

cb

hg e e e fcg e ch b e

## growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.

PMID: 10404741 [PubMed - indexed for MEDLINE]

83: Patterson C. Runge MS.

Related Articles, Links



Therapeutic angiogenesis: the new electrophysiology?

Circulation. 1999 May 25;99(20):2614-6. Review. No abstract available.

PMID: 10338451 [PubMed - indexed for MEDLINE]

**84:** Okada M, Matsumori A, Ono K, Miyamoto T. Takahashi M. Sasayama S

Related Articles, Links

Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.

Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7. PMID: 10082659 [PubMed - indexed for MEDLINE]

85: Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K.

Related Articles, Links



Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries.

Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):131-9. PMID: 9888875 [PubMed - indexed for MEDLINE]

**86:** Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD. Related Articles, Links Maysky M, Ashare AB, Lathi K, Isner JM.



Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.

Circulation. 1998 Dec 22-29;98(25):2800-4.

PMID: 9860779 [PubMed - indexed for MEDLINE]

87: Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K.



Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.

Circulation. 1998 Nov 17;98(20):2108-16.

PMID: 9815864 [PubMed - indexed for MEDLINE]

88: Iwakura A, Komeda M, Fujita M.

Related Articles, Links



[Coronary stenosis and mechanisms of collateral vessel growth]

Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese. PMID: 9796310 [PubMed - indexed for MEDLINE]

89: Komatsu R, Ueda M.

Related Articles, Links



[Plaque progression and destabilization in human coronary arteries]

Nippon Rinsho. 1998 Oct;56(10):2477-82. Review. Japanese.

PMID: 9796305 [PubMed - indexed for MEDLINE]

90: Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, Related Articles, Links Carel K, Scott S, Nadler J, Sowers JR, Draznin B.



Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells.

Endocrinology. 1998 Oct;139(10):4067-72.

PMID: 9751484 [PubMed - indexed for MEDLINE]

91: Metais C, Li J, Li J, Simons M, Sellke FW.

Related Articles, Links



Effects of coronary artery disease on expression and microvascular response to VEGF.

Am J Physiol. 1998 Oct;275(4 Pt 2):H1411-8. PMID: 9746492 [PubMed - indexed for MEDLINE]

92: Brilla CG, Rybinski L, Gehrke D, Rupp H.

Related Articles, Links

[Transmyocardial laser revascularization--an innovative pathophysiologic concept]

Herz. 1997 Aug;22(4):183-9. Review. German. PMID: 9378452 [PubMed - indexed for MEDLINE]

1 93: Labarrere CA, Faulk WP.

Related Articles, Links

Antithrombin determinants of coronary artery disease in transplanted human hearts.

Semin Hematol. 1995 Oct;32(4 Suppl 2):61-6. Review. No abstract available. PMID: 8821212 [PubMed - indexed for MEDLINE]

94: Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA

Related Articles, Links

Regulation of vascular endothelial growth factor in cardiac myocytes.

Circ Res. 1995 May;76(5):758-66.

PMID: 7728992 [PubMed - indexed for MEDLINE]

Display Summary 

Show: 500 

Sort 

Send to Text 

▼

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37







			/ <b>\</b> \\		of Medici	ne Ni	M	
Entrez PubMed	Nucleotide	Protein	Genome	Structure	OMM F	MC	Journals	800
Search PubMed	×	for CPK-MB				Go	Clear	
	Limit	s Prev	iew/Index	History	Clipbo	ard	Det	ails
About Entrez	Display	Summary		ow: 500 💌 So	ort 💌	Send to	Text	
Text Version		Items 1-303			20V - 62 - 1 12			page.
Entrez PubMed Overview Help   FAQ Tutorial New/Noteworthy E-Utilifies	PL. Hem right	odynamic ef	fects of high erial ligation 4(3):232-41.	itahata H, Yellin n-frequency jet n and pulmona	ventilation	in dogs		
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut	Isola com India PMII	nakar S, Das T, o ation and part mon murrel ( n J Exp Biol. 20 D: 15233296 [Pt	Ghosh A, Dasg ial structura Channa stria 04 Mar;42(3): ubMed - index	gupta SC, Biswas l evaluation of atus L.) skin e 271-8. ed for MEDLINI	a cardiotoxixtract.	ic facto	or from In	dian
Related Resources Order Documents NLM Gateway	JD, K The bypa	Kohtz R.J. Zheng effect of elec ass: an experi	H. Hock LM. trolyte imba mental study	nlance on wear y.				Links
TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central	PMII  4: Ajan Chen	i AE, Waksman	ıbMed - index R. Sharma Ak ı M. Cha DH. l	ed for MEDLINI  Lew R. Pinnov  Leborgne L, Sath	v E. Canos DA	. Rela	ted Articles	, Links
	pred reste Am J	ict adverse or enosis. Cardiol. 2004 l	utcomes afte Feb 1;93(3):31	creatinine phoer intracoronar 3-7. ed for MEDLINI	y radiation t			ent
	5: Weis	el RD, Lipton II	H, Lyall RN, E	Baird R.J.		Rela	ted Articles	, Links
	card Circu	i <mark>oplegia.</mark> Ilation. 1978 Se	p;58(3 Pt 2):I2	ormance follo 17-26. ed for MEDLINI		tassiur	n	
	6: Jones	s JW, Richman I	BW, Baldwin .	IC, Losanoff JE.		Rela	ted Articles	, Links
	reva J Car	scularization diovase Surg (T	'orino). 2003 Г	of myocardiu Dec;44(6):681-4. ed for MEDLINI		myoca	rdial lase	r
	□ 7: <u>Kame</u> <u>J. Ha</u>	ohara K, Yoshik mada M.	ai M, Yunoki	J, Fumoto H, Ito	h T, Murayama	L Rela	ted Articles	, Links
	[Emergency coronary artery bypass grafting for acute coronary syndrome with preoperative intraaortic balloon pumping; comparative surgical							

Kyobu Geka. 2003 Dec;56(13):1075-81; discussion 1081-4. Japanese.

PMID: 14672015 [PubMed - indexed for MEDLINE]

outcome and long-term results]

	1 450 2 01 33
8: Papadopoulos CE, Karvounis HI, Gourasas IT, Parharidis GE, Louridas GE	Related Articles, Links
Evidence of ischemic preconditioning in patients experies segment elevation myocardial infarction (NSTEMI). Int J Cardiol. 2003 Dec;92(2-3):209-17. PMID: 14659855 [PubMed - indexed for MEDLINE]	encing first non-ST-
9: Rahimi AR, Marzano PM 3rd, Richard CM.	Related Articles, Links
Evaluation of lactate and C-reactive protein in the assess myocardial infarction.  South Med J. 2003 Nov;96(11):1107-12.  PMID: 14632359 [PubMed - indexed for MEDLINE]	ment of acute
10: Takigawa T. Tokioka H. Chikai T. Fukushima T. Ishizu T. Kosogabe Y.	Related Articles, Links
[A case of undiagnosed "takotsubo" cardiomyopathy du Masui. 2003 Oct;52(10):1104-6. Japanese. PMID: 14598678 [PubMed - indexed for MEDLINE]	uring anesthesia]
11: Blum A, Safori G, Hous N, Lupovitch S.	Related Articles, Links
The prognostic value of high-sensitive C-reactive prote troponin T in young and middle-aged patients with cherchanges.  Eur J Intern Med. 2003 Aug;14(5):310-314.  PMID: 13678756 [PubMed - as supplied by publisher]	
12: Sposato B. Mariotta S. Ricci A. Lucantoni G. Schmid G.	Related Articles, Links
[Legionnaire's pneumonia with rhabdomyolysis and accase report] Recenti Prog Med. 2003 Sep;94(9):391-4. Italian. PMID: 12942801 [PubMed - indexed for MEDLINE]	ute renal failure. A
13: Ibanez JI, Sobrado R, Rivero M, Olite JM, Idoate I, Berrozpe I, Arina E, Metola L, Sesma J.	Related Articles, Links
[Use of troponin-I, CPK-MB and myoglobin in the diaginfarct and processes of muscular necrosis of non-cardi An Sist Sanit Navar. 2001 Jan-Apr;24(1):15-23. Spanish. PMID: 12876598 [PubMed]	
14: Bhaskar I, Rao SB.	Related Articles, Links
New, simple and cheap alternative to troponin test for dimyocardial infarction. Indian J Exp Biol. 2002 May;40(5):628-30. PMID: 12622217 [PubMed - indexed for MEDLINE]	liagnosis of acute
15: Gandra SM, Rivetti LA.	Related Articles, Links
Experimental evidence of regional myocardial ischemia heart coronary bypass: prevention with temporary intral Heart Surg Forum. 2002;6(1):10-8. PMID: 12611726 [PubMed - indexed for MEDLINE]	
16: Doue T, Ito K, Yuba T, Tanabe T, Adachi Y, Katoh S, Azuma A, Sugihara H, Nakagawa M	Related Articles, Links
[A case of "Takotsubo" cardiomyopathy observed with scintigraphy from the acute phase] Kaku Igaku. 2002 Nov;39(4):511-8. Japanese. PMID: 12607239 [PubMed - indexed for MEDLINE]	myocardial
17: Kong QF, Song SZ, Xie XY.	Related Articles, Links

 $h \ g \quad e \quad e \quad e \quad fcg \qquad \qquad e \quad ch \qquad \qquad b \quad e$ 

cb

cb

h g

e fcg

e ch

		J
	[Clinical study on therapeutic effects of treatment accordifferentiation of traditional Chinese medicine combined severe viral myocarditis complicated heart failure] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001 Jul;21(7):513-5. Chine PMID: 12575396 [PubMed - indexed for MEDLINE]	l with captopril on
□ 18:	Meki AR, Mohamed ZM, Mohey El-deen HM.	Related Articles, Links
	Significance of assessment of serum cardiac troponin I a scorpion envenomed children. Toxicon. 2003 Feb;41(2):129-37. PMID: 12565731 [PubMed - indexed for MEDLINE]	nd interleukin-8 in
□ 19:	Pimenov LT, Dudarev MV, Eshmakov SV.	Related Articles, Links
	[Clinicofunctional characteristics of the heart in hemorrh renal syndrome] Klin Med (Mosk). 2002;80(10):28-31. Russian. PMID: 12471834 [PubMed - indexed for MEDLINE]	nagic fever with
□ 20:	Louagie Y, Jamart J, Broka S. Collard E, Scavee V, Gonzalez M.	Related Articles, Links
	Off-pump coronary artery bypass grafting: a case-match hemodynamic outcome. Eur J Cardiothorae Surg. 2002 Oct;22(4):552-8. PMID: 12297171 [PubMed - indexed for MEDLINE]	ed comparison of
□ 21:	Fernandez Portales J, Garcia Robles JA, Jimenez Candil J, Perez David E, Rey Blas JR, Perez De Isla L, Diaz Castro O, Almendral J.	Related Articles, Links
	[Utility of the serum biochemical markers CPK, CPK M myoglobin, and cardiac troponin T in a chest pain unit. V determinations should be requested and when?] Rev Esp Cardiol. 2002 Sep;55(9):913-20. Spanish. PMID: 12236920 [PubMed - indexed for MEDLINE]	•
□ 22:	Sala MF, Barcena JP, Rota JI, Roca JV, Lopez CA, Puigdevall JM, Soldevilla JG, de Luna AB.	Related Articles, Links
	Sustained ventricular tachycardia as a marker of inadeque perfusion during the acute phase of myocardial infarction Clin Cardiol. 2002 Jul;25(7):328-34. PMID: 12109866 [PubMed - indexed for MEDLINE]	-
□ 23:	Meki AR, El-Deen ZM, El-Deen HM.	Related Articles, Links
	Myocardial injury in scorpion envenomed children: sign assessment of serum troponin I and interleukin-8.  Neuro Endocrinol Lett. 2002 Apr;23(2):133-40.  PMID: 12011799 [PubMed - indexed for MEDLINE]	ificance of
□ 24:	Ji H, Liu Q, Jiang H.	Related Articles, Links
	[Clinical observation on therapeutic effect of xinyikang treating 92 patients of viral myocarditis] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Jan;20(1):22-4. Chines PMID: 11783329 [PubMed - indexed for MEDLINE]	•
□25:	Li L, Sun Z, Zhao H.	Related Articles, Links
	[Cardiac protective effects of tetramethylpyrazine in patiopen-heart operation with cardiopulmonary bypass] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Jan;20(1):13-4. Chines PMID: 11783326 [PubMed - indexed for MEDLINE]	•
	Clermont G, Vergely C, Jazayeri S, Lahet JJ, Goudeau JJ, Lecour	Related Articles, Links

		1 4 9 0 1 01 33
□ 20	5: S. David M. Rochette L. Girard C.	
	Systemic free radical activation is a major event involve oxidative stress related to cardiopulmonary bypass. Anesthesiology. 2002 Jan;96(1):80-7. PMID: 11753006 [PubMed - indexed for MEDLINE]	ed in myocardial
<b>2</b> ′	7: Stys T, Lawson WE, Liuzzo JP, Hanif B, Bragg L, Cohn PF.	Related Articles, Links
	Direct coronary stenting without balloon or device pretr success and long-term results. Catheter Cardiovasc Interv. 2001 Oct;54(2):158-63. PMID: 11590675 [PubMed - indexed for MEDLINE]	reatment: acute
□ 28	Morandi P, Ruffini PA, Benvenuto GM, La Vecchia L, Mezzena G, Raimondi R	Related Articles, Links
	Serum cardiac troponin I levels and ECG/Echo monitor patients undergoing high-dose (7 g/m(2)) cyclophospha Bone Marrow Transplant. 2001 Aug;28(3):277-82. PMID: 11535996 [PubMed - indexed for MEDLINE]	ing in breast cancer mide.
□ 29	Briassoulis G, Narlioglou M, Zavras N, Hatzis T.	Related Articles, Links
	Myocardial injury in meningococcus-induced purpura fi children. Intensive Care Med. 2001 Jun;27(6):1073-82. PMID: 11497141 [PubMed - indexed for MEDLINE]	ulminans in
□30	: Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB.	Related Articles, Links
	Differential impact on survival of electrocardiographic enzymatic myocardial infarction after percutaneous intespecific analysis of 7147 patients.  Circulation. 2001 Aug 7;104(6):642-7.  PMID: 11489768 [PubMed - indexed for MEDLINE]	
□31	: Del Rio-Navarro BE, Sienra-Monge JJ, Alvarez-Amador M, Reyes-Ruiz N, Arevalo-Salas A, Berber A.	Related Articles, Links
	Serum potassium levels, CPK-MB and ECG in children treated with beclomethasone or beclomethasone-salmete Allergol Immunopathol (Madr). 2001 Jan-Feb;29(1):16-21. PMID: 11449530 [PubMed - indexed for MEDLINE]	
□ 32	: Angus DC, Wax RS.	Related Articles, Links
	Epidemiology of sepsis: an update. Crit Care Med. 2001 Jul;29(7 Suppl):S109-16. Review. PMID: 11445744 [PubMed - indexed for MEDLINE]	
□ 33	: Matsumiya G, Ohtake S, Sawa Y, Takahashi T, Nishimura M, Kagizaki K, Katsura T, Matsue H, Matsuda H.	Related Articles, Links
	[Is routine application of off-pump coronary artery bypa warranted?] Kyobu Geka. 2001 Apr;54(4):315-20. Japanese. PMID: 11296423 [PubMed - indexed for MEDLINE]	ss grafting
□ 34	: Ulus AT, Aksoyek A. Katircioglu SF, Gokce P, Koc B.	Related Articles, Links
	Preservation of myocardial functions by pentoxyphyllin during and after cardiopulmonary bypass.  Panminerva Med. 2000 Dec;42(4):253-6.  PMID: 11294087 [PubMed - indexed for MEDLINE]	e cardioplegia
□35	Yano K, Yoshino H, Taniuchi M, Kachi E, Shimizu H, Watanuki	Related Articles, Links

cb

h g

e e e fcg

e ch

Related Articles, Links

A. Ishikawa K. Myocardial bridging of the left anterior descending coronary artery in acute inferior wall myocardial infarction. Clin Cardiol. 2001 Mar;24(3):202-8. PMID: 11288965 [PubMed - indexed for MEDLINE] 36: Zalenski RJ, Grzybowski M, Ross MA, Blaustein N, Bock B. Related Articles, Links ECG scores for a triage of patients with acute myocardial infarction transported by the emergency medical system. J Electrocardiol. 2000;33 Suppl:245-9. PMID: 11265729 [PubMed - indexed for MEDLINE] 17 37: Nagy KK, Krosner SM, Roberts RR, Joseph KT, Smith RF, Barrett Related Articles, Links Determining which patients require evaluation for blunt cardiac injury following blunt chest trauma. World J Surg. 2001 Jan;25(1):108-11. PMID: 11213149 [PubMed - indexed for MEDLINE] 38: Ranjit MS. Related Articles, Links Cardiac abnormalities in birth asphyxia. Indian J Pediatr. 2000 Mar;67(3 Suppl):S26-9. Review. PMID: 11129917 [PubMed - indexed for MEDLINE] 39. Hashimoto K. Onoguchi K, Sasaki T, Hachiya T, Takakura H, Related Articles, Links Oshiumi M, Takeuchi S. [Combined use of ante- and retrograde cardioplegia: limited efficacy in elective coronary artery bypass] Kyobu Geka. 2000 Dec;53(13):1105-9. Japanese. PMID: 11127556 [PubMed - indexed for MEDLINE] 40: Ananthanarayan C, Castro C, McKee N, Sakotic G. Related Articles, Links Compartment syndrome following intravenous regional anesthesia. Can J Anaesth. 2000 Nov;47(11):1094-8. PMID: 11097539 [PubMed - indexed for MEDLINE] 1 41: Tapia-Rombo CA, Carpio-Hernandez JC, Salazar-Acuna AH, Related Articles, Links Alvarez-Vazquez E, Mendoza-Zanella RM, Perez-Olea V, Rosas-Fernandez C. Detection of transitory myocardial ischemia secondary to perinatal asphyxia. Arch Med Res. 2000 Jul-Aug;31(4):377-83. PMID: 11068079 [PubMed - indexed for MEDLINE] 42: Ranjit MS. Related Articles, Links Cardiac abnormalities in birth asphyxia. Indian J Pediatr. 2000 Jul;67(7):529-32. PMID: 10957839 [PubMed - indexed for MEDLINE] 43: Cassin M, Nicolosi GL. Related Articles, Links The usefulness of CPK-MB and troponin I in the management of chest pain in first aid Ital Heart J. 2000 May;1(5 Suppl):705-7. Italian. No abstract available. PMID: 10834139 [PubMed - indexed for MEDLINE]

cb h g e e b e e fcg e ch

AD, Satler LF, Leon MB.

44: Lansky AJ, Popma JJ, Mintz GS, Bucher TA, Kent KM, Pichard

Frequency and Prognostic Importance of Creatine Phosphokinase

Myocardial Isoforms after Successful Balloon and New Device Coronary

	Angioplasty. J Invasive Cardiol. 1996;8 Suppl C:3C-9C. PMID: 10785773 [PubMed - as supplied by publisher]	
□ 45	5: Gunaydin B, Cakici I, Soncul H, Kalaycioglu S, Cevik C, Sancak Re B, Kanzik I, Karadenizli Y	elated Articles, Links
	Does remote organ ischaemia trigger cardiac preconditionin coronary artery surgery? Pharmacol Res. 2000 Apr;41(4):493-6. PMID: 10704275 [PubMed - indexed for MEDLINE]	ng during
<b>1</b> 46	5: Chauhan S, Wasir HS, Bhan A, Rao BH, Saxena N, Venugopal P. Re	lated Articles, Links
	Adenosine for cardioplegic induction: a comparison with St solution.  J Cardiothorac Vasc Anesth. 2000 Feb;14(1):21-4. PMID: 10698387 [PubMed - indexed for MEDLINE]	t Thomas
<b>□ 47</b>	7: Shirasawa B, Hamano K, Kawamura T, Gohra H, Katoh T. Fujimura Y, Zempo N, Esato K.	lated Articles, Links
	[Dose the serum brain natriuretic peptide (BNP) level after surgery reflect myocardial protection?] Kyobu Geka. 2000 Feb;53(2):123-6. Japanese. PMID: 10667022 [PubMed - indexed for MEDLINE]	open heart
□ 48	3: Maini CL, Tofani A. Sciuto R, Ferraironi A, Festa A, Rea S. Re	lated Articles, Links
	Myocardial 123I-MIBG kinetics in acutely hypothyroid pat differentiated thyroid carcinoma.  Nucl Med Commun. 1999 Aug;20(8):719-26.  PMID: 10451880 [PubMed - indexed for MEDLINE]	ients with
<b>1</b> 49	Stringham JC, Love RB, Welter D, Canver CC, Mentzer RM Jr. Re	lated Articles, Links
	Does University of Wisconsin solution harm the transplante J Heart Lung Transplant. 1999 Jun;18(6):587-96. PMID: 10395357 [PubMed - indexed for MEDLINE]	ed heart?
<b>50</b> :	: Aboyans V, Lacroix P, Virot P, Tapie P, Cassat C, Rambaud G, Laskar M, Bensaid J	lated Articles, Links
	Sleep apnoea syndrome and the extent of atherosclerotic les aged men with myocardial infarction. Int Angiol. 1999 Mar;18(1):70-3. PMID: 10392484 [PubMed - indexed for MEDLINE]	ions in middle-
□ 51:	: Butte MJ, Nguyen BX, Hutchison TJ, Wiggins JW, Ziegler JW.	lated Articles, Links
	Pediatric myocardial infarction after racemic epinephrine ac Pediatrics. 1999 Jul;104(1):e9. PMID: 10390295 [PubMed - indexed for MEDLINE]	lministration.
□ 52:	: Hughes GC, Landolfo KP, Lowe JE, Coleman RB, Donovan CL. Re	lated Articles, Links
	Diagnosis, incidence, and clinical significance of early poste ischemia after transmyocardial laser revascularization. Am Heart J. 1999 Jun;137(6):1163-8. PMID: 10347346 [PubMed - indexed for MEDLINE]	operative
□ 53:	: Pompilio G, Antona C, Cannata A, Lotto A, Alamanni F, Gelpi G, Rel Tartara P, Biglioli P.	lated Articles, Links
	[Coronary surgery without extracorporeal circulation: the shin high-risk patients] G Ital Cardiol. 1999 Mar;29(3):246-54. Italian. PMID: 10231669 [PubMed - indexed for MEDLINE]	ort-term results

 $h \hspace{1cm} cb \hspace{1cm} h \hspace{1cm} g \hspace{1cm} e \hspace{1cm} e \hspace{1cm} fcg \hspace{1cm} e \hspace{1cm} ch \hspace{1cm} b \hspace{1cm} e$ 

□ 54:	Czajkowski V, Marechal P, Soyeur D, Kulbertus H.	Related Articles, Links
	[Clinical case of the month. Inaugural myocardial infarc congenital coronary-cardiac fistula] Rev Med Liege. 1999 Jan;54(1):12-6. Review. French. PMID: 10081304 [PubMed - indexed for MEDLINE]	tion from a
□ 55:	Di Salvo C, Louca LL, Pattichis K, Hooper J, Walesby RK.	Related Articles, Links
	Does activated neutrophil depletion on bypass by leukoc reduce myocardial damage? A preliminary report. J Cardiovasc Surg (Torino). 1996 Dec;37(6 Suppl 1):93-100. PMID: 10064358 [PubMed - indexed for MEDLINE]	eyte filtration
□ 56:	Asano H. Kyo S. Ogiwara M. Tsunemoto M. Yokote Y. Omoto R. Koike K. Kobayashi T. Kobayashi J. Taketazu M.	Related Articles, Links
	[Single-dose and high-volume Bretschneider cardioplegicongenital heart surgery] Kyobu Geka. 1999 Jan;52(1):82-6. Japanese. PMID: 10024809 [PubMed - indexed for MEDLINE]	ic solution for
□ 57:	Katircioglu SF, Ulus AT, Iscan Z, Yamak B, Saritas Z, Birincioglu L	Related Articles, Links
	Preservation of myocardial metabolism in acute coronar with retrograde coronary sinus perfusion and iloprost. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):169-74. PMID: 9844988 [PubMed - indexed for MEDLINE]	y artery occlusions
□ 58:	Badary OA, Al-Shabanah OA, Al-Gharably NM, Elmazar MM.	Related Articles, Links
	Effect of Cremophor EL on the pharmacokinetics, antitutoxicity of doxorubicin in mice. Anticancer Drugs. 1998 Oct;9(9):809-15. PMID: 9840728 [PubMed - indexed for MEDLINE]	mor activity and
□ 59:	Le Conte P, Hulot de Collart G, Chevalier JC, Yatim D, Touze MD, Garree F, Baron D.	Related Articles, Links
	[Diagnostic difficulties of myocardial infarct in an admissemergency service: influence of age] Presse Med. 1998 Oct 24;27(32):1613-6. French. PMID: 9819598 [PubMed - indexed for MEDLINE]	ssions and
□ 60:	Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L.	Related Articles, Links
	Phase I trial of simultaneous administration of interleuki 4 subcutaneously. Clin Cancer Res. 1995 Oct;1(10):1145-52. PMID: 9815906 [PubMed - indexed for MEDLINE]	n 2 and interleukin
□ 61:	Uno Y, Horikoshi S, Emoto H, Miyamoto H, Suzuki H.	Related Articles, Links
	[Clinical advantages and myocardial protection of normocomparison with hypothermal CPB] Jpn J Thorac Cardiovasc Surg. 1998 Aug;46(8):671-6. Japanese. PMID: 9785862 [PubMed - indexed for MEDLINE]	othermal CPB
□ <b>62</b> :	Stephanopoulos DE, Monge R, Schell KH, Wyckoff P, Peterson BM	Related Articles, Links
	Continuous intravenous terbutaline for pediatric status as Crit Care Med. 1998 Oct;26(10):1744-8. PMID: 9781734 [PubMed - indexed for MEDLINE]	sthmaticus.
☐ <b>63</b> :	Gozal Y, Drenger B, Robertson JE, Davis RF.	Related Articles, Links

cb  $h \ g \quad e \quad e \quad e \quad fcg \qquad \qquad e \quad ch \qquad \qquad b \quad e$ 

cb

h g

e fcg

e ch

	ST segment changes following retinal surgery. J Clin Anesth. 1998 Jun;10(4):297-301. PMID: 9667345 [PubMed - indexed for MEDLINE]	
□ 64	: Takamasu T, Yanagawa S, Kurihara K.	Related Articles, Links
	[Isoproterenol continuous nebulization for childhood state Efficacy and side effects of high-dose method] Arerugi. 1998 May;47(5):504-10. Japanese. PMID: 9656572 [PubMed - indexed for MEDLINE]	tus asthmaticus. I.
<b>65</b>	Suzuki I, Ogoshi N, Chiba M, Komatsu T, Moizumi Y.	Related Articles, Links
	Clinical evaluation of a leucocyte-depleting blood cardio (BC1B) for elective open-heart surgery.  Perfusion. 1998 May;13(3):205-10.  PMID: 9638718 [PubMed - indexed for MEDLINE]	oplegia filter
□ 66	: Bessho R, Tanaka S.	Related Articles, Links
	Measurement of the upper limit of vulnerability during of implantation can substitute defibrillation threshold measure Int J Artif Organs. 1998 Mar;21(3):151-60. PMID: 9622114 [PubMed - indexed for MEDLINE]	
□ 67	Ishikura Y. Odagiri S, Shimazu A, Tokunaga H, Shimokawaji M, Yoshimatsu H	Related Articles, Links
	[Evaluation of myocardial protection with DBcAMP in cardioplegic solutions] Rinsho Kyobu Geka. 1989 Dec;9(6):559-63. Japanese. PMID: 9308660 [PubMed - indexed for MEDLINE]	crystalloid
□ 68	Inui K, Kobayashi M, Orita H, Shimanuki T, Kohno M, Fukasawa M, Abe K, Kuraoka S, Washio M.	Related Articles, Links
	[Effect of magnesium containing cardioplegic solution of extended aortic cross clamping] Rinsho Kyobu Geka. 1989 Oct;9(5):468-71. Japanese. PMID: 9301958 [PubMed - indexed for MEDLINE]	on the cases of
69	Kuki S. Matsuda H. Sawa Y. Ohtani M. Sasako Y. Ohtake S. Takami H. Kuratani T. Nakano S. Kawashima Y. et al.	Related Articles, Links
	[Experimental and clinical assessment of myocardial proprostacyclin analogue (OP 41483)] Rinsho Kyobu Geka. 1989 Apr;9(2):180-3. Japanese. PMID: 9301917 [PubMed - indexed for MEDLINE]	otective effect of a
□ 70:	Kuraoka S, Orita H, Shimanuki T, Kohno M, Fukasawa M, Inui K, Washio M.	Related Articles, Links
	[Comparison of cold blood cardioplegia and cold crystal with or without magnesium] Rinsho Kyobu Geka. 1989 Apr;9(2):173-5. Japanese. PMID: 9301915 [PubMed - indexed for MEDLINE]	loid cardioplegia
□ 71:	Fulda GJ, Giberson F, Hailstone D, Law A, Stillabower M.	Related Articles, Links
	An evaluation of serum troponin T and signal-averaged electrocardiography in predicting electrocardiographic alblunt chest trauma.  J Trauma. 1997 Aug;43(2):304-10; discussion 310-2.  PMID: 9291377 [PubMed - indexed for MEDLINE]	bnormalities after
77.	Trehan N, Mishra M, Bapna R, Mishra A, Maheshwari P, Karlekar	Related Articles   Links
: 1 4 a	Δ.	SAULT (COLORD DE DOMESTE

cb

h g

e fcg

	Transmyocardial laser revascularisation combined with bypass grafting without cardiopulmonary bypass. Eur J Cardiothorac Surg. 1997 Aug;12(2):276-84. PMID: 9288519 [PubMed - indexed for MEDLINE]	coronary artery
<b>73</b> :	Hayashi S, Sasaki M, Kawamoto J.	Related Articles, Links
	[Urgent coronary artery bypass surgery by only arterial amyocardial infarction] Nippon Kyobu Geka Gakkai Zasshi. 1997 Jul;45(7):935-9. Japanes PMID: 9256627 [PubMed - indexed for MEDLINE]	_
□ 74:	Garre L, Alvarez A, Rubio M, Pellegrini A, Caridi M, Berardi A, Lazzaro C, Blanco P, Menehem C, Diaz M.	Related Articles, Links
	Use of cardiac troponin T rapid assay in the diagnosis of injury secondary to electrical cardioversion. Clin Cardiol. 1997 Jul;20(7):619-21. PMID: 9220177 [PubMed - indexed for MEDLINE]	f a myocardial
□ 75:	Chiu WC, D'Amelio LF, Hammond JS.	Related Articles, Links
	Sternal fractures in blunt chest trauma: a practical algorimanagement.  Am J Emerg Med. 1997 May;15(3):252-5.  PMID: 9148979 [PubMed - indexed for MEDLINE]	thm for
□ 76:	Bouchart F, Bessou JP, Tabley A, Hecketsweiller B, Mouton-Schleifer D, Redonnet M, Arrignon J, Soyer R.	Related Articles, Links
	[What myocardial protection to select for isolated aortic replacement? A clinical prospective study of 3 cases of a Arch Mal Coeur Vaiss. 1997 Mar;90(3):345-51. French. PMID: 9232072 [PubMed - indexed for MEDLINE]	
□ <b>7</b> 7:	<u>Dwivedi SK, Kumar R, Saran RK, Narain VS, Bansal S, Puri VK, Hasan M.</u>	Related Articles, Links
	Improvement in contractility of infarct zone after dobuta predicts good (TIMI II or III) flow in infarct related arternation Heart J. 1997 Mar-Apr;49(2):147-51.  PMID: 9231544 [PubMed - indexed for MEDLINE]	
□ 78:	Kondo K, Minohara S, Sawada Y, Irie H, Okamoto K, Kinugasa S, Nakao M, Sasaki S.	Related Articles, Links
	Indications and problems of coronary artery bypass graft cardiopulmonary bypass. Surg Today. 1997;27(3):202-6. PMID: 9068098 [PubMed - indexed for MEDLINE]	ting without
□ 79:	Aronson S, Savage R, Fernandez A, Klein A, Young C, Toledano A, Lee BK, Karp RB, Lytle B, Loop F	Related Articles, Links
	Assessing myocardial perfusion with Albunex during co bypass surgery: technical considerations and safety of ac J Cardiothorac Vasc Anesth. 1996 Oct;10(6):713-8. PMID: 8910149 [PubMed - indexed for MEDLINE]	
□ 80:	Bastecky J, Palicka V, Vavrova J, Ettlerova E, Wasyliwova V.	Related Articles, Links
	[Changes in troponin T levels in patients with acute myotreated with fibrinolysis] Vnitr Lek. 1996 Aug;42(8):519-23. Czech. PMID: 8967018 [PubMed - indexed for MEDLINE]	ocardial infarct
□ 81:	<u>Irie H, Kitamura N, Ko T, Kimura S, Kumano H, Syuntou K, Noji S, Yamaguchi A.</u>	Related Articles, Links

e ch b e


cb

h g

e e

e fcg

e ch



ch

h g

e e

e fcg

Ann Chir. 1996;50(5):390-6. French. PMID: 8761109 [PubMed - indexed for MEDLINE] 91: Dowd MD, Krug S. Related Articles, Links Pediatric blunt cardiac injury: epidemiology, clinical features, and diagnosis. Pediatric Emergency Medicine Collaborative Research Committee: Working Group on Blunt Cardiac Injury. J Trauma. 1996 Jan;40(1):61-7. PMID: 8577001 [PubMed - indexed for MEDLINE] 1 92: Hoshino J, Arai H, Fukusato T, Nakamura T, Nushiro N, Sato K. Related Articles, Links Sakamaki T, Murata K Creatine phosphokinase-linked immunoglobulin associated with hypokalemic myopathy. Intern Med. 1995 Dec;34(12):1210-4. PMID: 8929653 [PubMed - indexed for MEDLINE] 73: Zou HJ, Ding Y, Huang KL, Xu ML, Tang GF, Wu MH, Wang Related Articles, Links SY. Effects of lead on systolic and diastolic cardiac functions. Biomed Environ Sci. 1995 Dec;8(4):281-8. PMID: 8719169 [PubMed - indexed for MEDLINE] 94: Aggarwal SP, Thukral R, Wander GS, Kapoor DK. Related Articles, Links Evaluation of serum lipid profile and cardiac enzyme changes in cerebrovascular accidents. J Indian Med Assoc. 1995 Sep;93(9):331-2. PMID: 8648151 [PubMed - indexed for MEDLINE] 95: Lucia P, Caiola S, Coppola A, Maroccia E, Belli M, Colliardo A, Related Articles, Links Borelli LG, De Martinis C, Buongiorno A. The physiopathological role and prognostic value of the vasoactive intestinal peptide in acute myocardial infarct] Cardiologia. 1995 Aug;40(8):579-84. Italian. PMID: 8536284 [PubMed - indexed for MEDLINE] 1 96: Berton G, Citro T, Cordiano R, Palmieri R, De Toni R, Cucchini F. Related Articles, Links <u>Palatini</u> P. Urinary albumin excretion increases during an acute myocardial infarct especially in patients who develop heart failure G Ital Cardiol. 1995 Aug;25(8):999-1009. Italian. PMID: 7498633 [PubMed - indexed for MEDLINE] 97: Amano H. Okuda M, Furuhashi K, Utsunomiya H, Nakai Y, Related Articles, Links Munevuki M. [Clinical evaluation of prophylactic nitroglycerin infusion during coronary artery bypass grafting] Masui. 1995 Apr;44(4):594-6. Japanese. PMID: 7776530 [PubMed - indexed for MEDLINE] 17 98: Moler FW, Johnson CE, Van Laanen C, Palmisano JM, Nasr SZ, Related Articles, Links Akingbola O. Continuous versus intermittent nebulized terbutaline: plasma levels and Am J Respir Crit Care Med. 1995 Mar; 151(3 Pt 1):602-6. PMID: 7881645 [PubMed - indexed for MEDLINE] 99: Lu W. Chen Y. Liu L. Related Articles, Links The injury of heart of rats sustaining delayed fluid resuscitation after burn shock]

b e

e ch

cb

h g

e fcg

Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi. 1995 Mar;11(2):112-4. Chinese. PMID: 7648496 [PubMed - indexed for MEDLINE] 100: Movahed A, Nair KG, Ashavaid TF, Kumar P. Related Articles, Links Evidence for free-radical mediated injury during coronary artery bypass surgery. Indian Heart J. 1995 Mar-Apr;47(2):107-11. PMID: 7590833 [PubMed - indexed for MEDLINE] 101: Anderson WA, Berrizbeitia LD, Ilkowski DA, Cha R, Gu J, Related Articles, Links Fernandez J, Laub GW, Adkins MS, Chen C, McGrath LB. Normothermic retrograde cardioplegia is effective in patients with left ventricular hypertrophy. A prospective and randomized study. J Cardiovasc Surg (Torino). 1995 Feb;36(1):17-24. PMID: 7721921 [PubMed - indexed for MEDLINE] 102: Spaggiari I, Cavozza C, Fesani F, D'Amico E, Menozzi E, Related Articles, Links Sciaraffia M. [Myocardial protection during extracorporeal circulation. Preliminary results with different techniques Acta Biomed Ateneo Parmense. 1995;66(5):203-7. Italian. PMID: 8928583 [PubMed - indexed for MEDLINE] 103: Efthimiadis A, Cheiridou M, Lefkos N, Doumalas A, Arampatzis Related Articles, Links P. Tsapas G. The predictive value of troponin T in patients who underwent an extracardiac surgery operation. Acta Cardiol. 1995;50(4):309-13. PMID: 8540272 [PubMed - indexed for MEDLINE] 104: Imai Y, Watanabe N, Hashimoto J, Nishiyama A, Sakuma H, Related Articles, Links Sekino H, Omata K, Abe K Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers. Eur J Clin Pharmacol. 1995;48(1):29-34. PMID: 7621844 [PubMed - indexed for MEDLINE] 105: Sousa RC, Garcia-Fernandez MA, Moreno M, Quero F. Related Articles, Links Torrecilla E, San Roman D, Delcan JL. [Value of transesophageal echocardiography in the assessment of blunt chest trauma: correlation with electrocardiogram, heart enzymes, and transthoracic echocardiogram] Rev Port Cardiol. 1994 Nov;13(11):833-43, 807-8. Portuguese. PMID: 7848654 [PubMed - indexed for MEDLINE] 106: Dingchao H. Zhiduan Q. Live H. Xiaodong F. Related Articles, Links The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass. Thorac Cardiovasc Surg. 1994 Oct; 42(5):276-8. PMID: 7863489 [PubMed - indexed for MEDLINE] 107: Yamaguchi A, Kitamura N, Kimura S, Irie H, Ko T, Shuntoh K. Related Articles, Links The efficacy of both antegrade and retrograde cardioplegia in coronary artery bypass surgery] Nippon Kyobu Geka Gakkai Zasshi. 1994 Oct;42(10):1916-24. Japanese. PMID: 7798709 [PubMed - indexed for MEDLINE] 108: Marques N, Sanchez de la Pena S, Mushiya T, Yasmineh WG. Related Articles, Links Cornelissen G, Halberg F.

Ultradian-infradian variation of cardiac creatine phosphokinase (CPK)

b e

e ch

cb

 $h\;g\quad e\quad e$ 

		_
	activity in male Holtzman rats. Chronobiologia. 1994 Jul-Dec;21(3-4):241-50. PMID: 7729240 [PubMed - indexed for MEDLINE]	
□ 109:	Kanno M, Kurihara H, Satoh H, Hamawaki M, Honda M	Related Articles, Links
	[Coronary artery spasm after mitral valve replacement: Kyobu Geka. 1994 Apr;47(4):315-8. Japanese. PMID: 8152181 [PubMed - indexed for MEDLINE]	a case report]
□ 110:	Moizumi Y. Ohsaka K, Akasaka J, Kondoh S, Shimizu M, Imai Y, Kumagai T, Uchiyama T, Abe Y, Suzuki I	Related Articles, Links
	[Advantages of combined antegrade/retrograde GIK ca coronary artery bypass surgery] Nippon Kyobu Geka Gakkai Zasshi. 1994 Feb;42(2):198-205. Jap PMID: 8138686 [PubMed - indexed for MEDLINE]	
□ 111:	Nishimaki H, Kobayashi A.	Related Articles, Links
	[Phase analysis of gated blood pool scintigraphy in traucontusion] Nippon Igaku Hoshasen Gakkai Zasshi. 1994 Jan 25;54(1):55-66. PMID: 8121771 [PubMed - indexed for MEDLINE]	·
□ 112:	Deramoudt V, Lecloirec J, Moisan A, Bourguet P, Reymann JM, Malledant Y.	Related Articles, Links
	[Role of isotopic imaging in intensive care] Ann Fr Anesth Reanim. 1994;13(3):360-72. Review. French. PMID: 7992943 [PubMed - indexed for MEDLINE]	
□ 113:	Efthymiadis A, Lefkos N, Liatsis I, Bountonas G, Styliadis IG, Aroditis K, Tsapas G.	Related Articles, Links
	The diagnostic value of the determination of troponin T of unstable angina. Acta Cardiol. 1994;49(5):419-24. PMID: 7839760 [PubMed - indexed for MEDLINE]	in the diagnosis
□ 114:	Yamamoto N, Hisamochi K, Morimoto T, Nakayama Y, Senoo Y, Teramoto S.	Related Articles, Links
	[Comparison between antegrade and retrograde cardiop blood] Nippon Kyobu Geka Gakkai Zasshi. 1993 Dec;41(12):2311-8. Jap PMID: 8288919 [PubMed - indexed for MEDLINE]	
□ 115:	Kerr LD, Spiera H.	Related Articles, Links
	Myocarditis as a complication in scleroderma patients v Clin Cardiol. 1993 Dec;16(12):895-9. PMID: 8168276 [PubMed - indexed for MEDLINE]	with myositis.
□ 116:	Minutiello L.	Related Articles, Links
	[The enzymatic and electrocardiographic changes falsel acute myocardial infarct during hypothyroidism] Minerva Cardioangiol. 1993 Dec;41(12):597-602. Italian. PMID: 8139781 [PubMed - indexed for MEDLINE]	ly indicative of an
□ 117:	Demirtas M, Dagsali S, Tarcan S, Sungu U.	Related Articles, Links
	Is continuous normothermic blood cardioplegia really a myocardial preservation? Comparison with intermittent cardioplegia. Thorac Cardiovasc Surg. 1993 Oct;41(5):284-9. PMID: 8303696 [PubMed - indexed for MEDLINE]	-

e fcg e ch b e

□ 118	: Frank R, Tonet J, Gallais Y, Lazraq S, Fellat R, Fontaine G.	Related Articles, Links
	[Treatment of ventricular tachycardia by endocardial for 686 cases] Arch Mal Coeur Vaiss. 1993 Sep;86(9):1317-24. Review. French. PMID: 8129548 [PubMed - indexed for MEDLINE]	
□ 119	: Yip AS, Chow WH, Fu KH, Cheung KL, Li JP, Lee JS.	Related Articles, Links
	Effect of percutaneous balloon mitral valvuloplasty on phosphokinase MB-isoenzyme levels. Cathet Cardiovasc Diagn. 1993 Jul;29(3):179-82. PMID: 8402839 [PubMed - indexed for MEDLINE]	serum creatinine
□ 120	Yamaguchi A, Kitamura N, Kawashima M, Miki T, Tamura H.	Related Articles, Links
	[Clinical preeminence of single aortic cross-clamping franastomoses in coronary artery bypass surgery] Nippon Kyobu Geka Gakkai Zasshi. 1993 Jul;41(7):1194-8. Japan PMID: 8376888 [PubMed - indexed for MEDLINE]	•
□ 121	Yamamoto N.	Related Articles, Links
	[A comaprative study of continuous warm blood cardic Nippon Kyobu Geka Gakkai Zasshi. 1993 Jul;41(7):1154-62. Japa PMID: 8376885 [PubMed - indexed for MEDLINE]	oplegia] anese.
□ 122	Bhave CG, Gadre KC, Gharpure BS.	Related Articles, Links
	Myoglobinuria following the use of succinylcholine. J Postgrad Med. 1993 Jul-Sep;39(3):157-9. PMID: 8051650 [PubMed - indexed for MEDLINE]	
<b>123</b>	Fourestie V, Douceron H, Brugieres P, Ancelle T, Lejone JL, Gherardi RK	Related Articles, Links
	Neurotrichinosis. A cerebrovascular disease associated injury and hypereosinophilia. Brain. 1993 Jun;116 (Pt 3):603-16. PMID: 8513394 [PubMed - indexed for MEDLINE]	with myocardial
□ 124	: Takemura T.	Related Articles, Links
	[A clinical trial of recombinant human superoxide dism myocardial protection] Nippon Kyobu Geka Gakkai Zasshi. 1993 Feb;41(2):247-53. Japa PMID: 8473790 [PubMed - indexed for MEDLINE]	
<b>125</b>	Shimoda Y, Kimura O, Miyate Y, Takata R, Terui K, Saito H, Wakusawa R.	Related Articles, Links
	[Coronary artery spasm under general and epidural ane Masui. 1993 Feb;42(2):284-7. Japanese. PMID: 8437365 [PubMed - indexed for MEDLINE]	sthesia]
<b>126</b>	Drzewiecki J. Trusz-Gluza M. Wnuk-Wojnar A. Jaklik A. Czerwinski C. Filipecki A. Szydlo K. Cienniewski Z. Giec L.	Related Articles, Links
	[Intravenous ablation of the atrio-ventricular junction in supraventricular tachyarrhythmias] Kardiol Pol. 1993 Jan;38(1):5-11; discussion 12-3. Polish. PMID: 8230978 [PubMed - indexed for MEDLINE]	n patients with
□ 127	Ladowski JS, Sullivan M, Schatzlein MH, Peterson AC, Underhill DJ, Scheeringa RH.	Related Articles, Links
	Cardiac isoenzymes following heart transplantation. Chest. 1992 Nov;102(5):1520-1. PMID: 1424875 [PubMed - indexed for MEDLINE]	

cb

h g

e fcg

e ch


□ 128	: Raga X, Vilanova MA, Bardaji A, Pastor MR, Richart C.	Related Articles, Links
	[Macrocreatine kinase, a cause of MB isoenzyme level Arch Mal Coeur Vaiss. 1992 Nov;85(11):1601-3. French. PMID: 1300958 [PubMed - indexed for MEDLINE]	s falsely elevated]
□ 129	Contini GA, Astorri E, Gavaruzzi G, Campodonico R, Albertini D, Reverberi C, Antonelli AM, Fesani F.	Related Articles, Links
	[Assessment of perioperative myocardial damage based heavy chain myosin fragments] Cardiologia. 1992 Nov;37(11):797-800. Italian. PMID: 1298552 [PubMed - indexed for MEDLINE]	d on circulating
□ 130	Attenhofer C, Vuilliomenet A, Richter M, Kaufmann U, Metzger U, Bertel O.	Related Articles, Links
	[Heart contusions: pathological findings and clinical continuous Med Wochenschr. 1992 Oct 24;122(43):1593-9. German PMID: 1439679 [PubMed - indexed for MEDLINE]	
□ 131	Bhunia BC, Basu K, Batabyal SK, Khatwa SP, Sanyal S, Banerjee S, Basu A, Sanyal S.	Related Articles, Links
	Myocardial changes in neonates dying of asphyxia neo Indian J Pathol Microbiol. 1992 Oct;35(4):308-18. PMID: 1344220 [PubMed - indexed for MEDLINE]	natorum.
□ 132	· Varani E, Pirazzini L, Casanova R, Patroncini A, Maresta A.	Related Articles, Links
	[Management and prognosis of acute myocardial infarc comparison of the cardiac intensive care unit and the ca G Ital Cardiol. 1992 Sep;22(9):1069-75. Italian. PMID: 1291424 [PubMed - indexed for MEDLINE]	
□ 133	Ishikura Y, Odagiri S, Shimazu A, Hirao D, Watanabe H, Hatooka S, Hamada M.	Related Articles, Links
	[Clinical evaluation of myocardial protection by oxyge cardioplegic solutions with DBcAMP] Nippon Geka Gakkai Zasshi. 1992 Jun;93(6):632-8. Japanese. PMID: 1321329 [PubMed - indexed for MEDLINE]	nated crystalloid
<b>134</b>	Yasu T, Nonogi H, Oshima S, Daikoku S, Haze K.	Related Articles, Links
	[A case of unstable angina pectoris associated with an a polymyositis] Kokyu To Junkan. 1992 May;40(5):491-4. Japanese. PMID: 1589649 [PubMed - indexed for MEDLINE]	active phase of
□ 135	Gokgoz L, Soncul H, Sinci V, Karasu C, Kaptanoglu M, Yener A, Ersoz A.	Related Articles, Links
	Dipyridamole induced myocardial recovery after globa Gen Pharmacol. 1992 May;23(3):435-7. PMID: 1511853 [PubMed - indexed for MEDLINE]	l ischemia.
□ 136	Antunes MJ, Bernardo JE, Oliveira JM, Fernandes LE, Andrade CM.	Related Articles, Links
	Coronary artery bypass surgery with intermittent aortic Eur J Cardiothorac Surg. 1992;6(4):189-93; discussion 193-4. PMID: 1586493 [PubMed - indexed for MEDLINE]	cross-clamping.
□ 137	Amato M, Aegerter E, Reiber W, Schneider H.	Related Articles, Links
	Creatine phosphokinase isoenzyme activity in umbilication vein and capillary blood of newborn infants at term. Arch Gynecol Obstet. 1992;251(4):171-4.  PMID: 1503508 [PubMed - indexed for MEDLINE]	l artery, umbilical

		S
□ 138	: Ohyanagi H, Saitoh Y, Uchida T, Watanabe M, Yamanouchi K, Yokoyama K, Mitsuno T.	Related Articles, Links
	Extended use of Fluosol emulsion in acute myocardial Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):94 PMID: 1391538 [PubMed - indexed for MEDLINE]	ischemia treatment. 41-9.
□ 139	: Maguire JF, O'Rourke PP, Colan SD, Geha RS, Crone R.	Related Articles, Links
	Cardiotoxicity during treatment of severe childhood as Pediatrics. 1991 Dec;88(6):1180-6. PMID: 1956735 [PubMed - indexed for MEDLINE]	sthma.
□ 140	: Bernardo JE, Antunes M, Andrade C, Fernandes LE, Ferrao JM.	Related Articles, Links
	[Aortocoronary bypass. Intermittent clamping of the accardioplegia] Rev Port Cardiol. 1991 Nov;10(11):811-5. Portuguese. PMID: 1686181 [PubMed - indexed for MEDLINE]	orta versus
<b>141</b>	Tsukube T, Yamaguchi M, Hosokawa Y, Ohashi H, Imai M, Oshima Y, Obo H, Nishikawa Y, Maeda H, Tachibana H.	Related Articles, Links
	[Results of open heart surgery in neonatescomparison hypothermia with circulatory arrest and deep hypother Nippon Kyobu Geka Gakkai Zasshi. 1991 Oct;39(10):1831-8. Jap PMID: 1960423 [PubMed - indexed for MEDLINE]	mic bypass]
□ 142	Gustafson DL., Swanson JD, Pritsos CA.	Related Articles, Links
	Role of xanthine oxidase in the potentiation of doxorul cardiotoxicity by mitomycin C. Cancer Commun. 1991 Sep;3(9):299-304. PMID: 1911046 [PubMed - indexed for MEDLINE]	bicin-induced
<b>143</b>	McLean RF, Devitt JH, Dubbin J, McLellan BA	Related Articles, Links
	Incidence of abnormal RNA studies and dysrhythmias blunt chest trauma.  J Trauma. 1991 Jul;31(7):968-70.  PMID: 2072436 [PubMed - indexed for MEDLINE]	in patients with
□ 144	Gunnar WP, Martin M, Smith RF, Manglano R, Resnick DJ, Lopez V, Barrett JA	Related Articles, Links
	The utility of cardiac evaluation in the hemodynamical with suspected myocardial contusion.  Am Surg. 1991 Jun;57(6):373-7.  PMID: 2048849 [PubMed - indexed for MEDLINE]	lly stable patient
□ 145	Fabian TC, Cicala RS, Croce MA, Westbrook LL, Coleman PA, Minard G, Kudsk KA	Related Articles, Links
	A prospective evaluation of myocardial contusion: consignificant arrhythmias and cardiac output with CPK-N J Trauma. 1991 May;31(5):653-9; discussion 659-60. PMID: 2030512 [PubMed - indexed for MEDLINE]	
□ 146	Matsumura H, Iwai F, Ichikizaki K.	Related Articles, Links
	[Ischemic myocardial disorder in acute phase subarach clinical study of 52 patients] No Shinkei Geka. 1991 Apr;19(4):349-57. Japanese.	noid hemorrhage:
	PMID: 2046849 [PubMed - indexed for MEDLINE]	
□ 147		Related Articles, Links

cb

h g

e fcg e ch



Jpn Circ J. 1990 Apr;54(4):354-60. PMID: 2398616 [PubMed - indexed for MEDLINE] 157: Hamano K, Mori F, Miyamoto M, Tsuboi H, Fujimura Y, Noda Related Articles, Links H. Matsumoto N. Nishida K, Esato K. [Significance of measuring Cu, Zn-superoxide dismutase (SOD) levels in open heart surgery] Nippon Kyobu Geka Gakkai Zasshi. 1990 Mar;38(3):412-5. Japanese. PMID: 2348122 [PubMed - indexed for MEDLINE] 158: Koike R. Related Articles, Links The protective effect of diltiazem, a calcium channel blocker on myocardial ischemia during open heart surgery--an analysis of electrolyte changes in myocardial cells] Nippon Kyobu Geka Gakkai Zasshi. 1990 Mar;38(3):358-69. Japanese. PMID: 2348117 [PubMed - indexed for MEDLINE] 159: Ozaki S. Sugiura Y. Ozeki Y. Okuda E. Yoshizu H. Shima S. Related Articles, Links Tanaka S, Suzuki M. [Cardiac arrest episodes by cardiomyopathy following total pancreatectomy, a case report Kokyu To Junkan. 1990 Mar;38(3):265-8. Japanese. PMID: 2330460 [PubMed - indexed for MEDLINE] 160: Colantonio D, Pasqualetti P, Casale R, Bucci V, Natali G. Related Articles, Links [Differentiated circadian chrono-risk of acute myocardial infarct] Cardiologia. 1990 Mar;35(3):243-52. Italian. PMID: 2245425 [PubMed - indexed for MEDLINE] 161: Kinoshita Y, Okamoto K, Yahata K, Yoshioka T, Sugimoto T, Related Articles, Links Kawaguchi N, Onishi S Clinical and pathological changes of the heart in brain death maintained with vasopressin and epinephrine. Pathol Res Pract. 1990 Feb; 186(1):173-9. PMID: 2315211 [PubMed - indexed for MEDLINE] 162: Li CC. Related Articles, Links [Changes of creatine phosphokinase and malondialdehyde in the serum and clinical use of large doses of vitamin C following open heart surgery Zhonghua Wai Ke Za Zhi. 1990 Jan; 28(1):16-7, 60-1. Chinese. PMID: 2364809 [PubMed - indexed for MEDLINE] 163: Bonchek LI, Burlingame MW, Vazales BE, Ferdinand NJ. Related Articles, Links Coronary bypass with substrate-enhanced cardioplegia versus noncardioplegic technique for early revascularization in acute infarction. Eur J Cardiothorac Surg. 1990;4(3):124-9. PMID: 2334551 [PubMed - indexed for MEDLINE] 164: Aronson DC, Heymans HS, la Riviere AV, Naeff MS. Related Articles, Links Nontransmural myocardial infarction as a complication of untreated cystic fibrosis. J Pediatr Gastroenterol Nutr. 1990 Jan;10(1):126-30. PMID: 2324873 [PubMed - indexed for MEDLINE] 1 165: Baxter BT, Moore EE, Moore FA, McCroskey BL, Ammons LA. Related Articles, Links A plea for sensible management of myocardial contusion. Am J Surg. 1989 Dec;158(6):557-61; discussion 561-2. PMID: 2589589 [PubMed - indexed for MEDLINE]

h

cb

<b>1</b> 166	: Cheng DC, Chung F, Burns RJ, Houston PL, Feindel CM.	Related Articles, Links
	Postoperative myocardial infarction documented by tec pyrophosphate scan using single-photon emission com significance of intraoperative myocardial ischemia and control.	chnetium puted tomography:
	Anesthesiology. 1989 Dec;71(6):818-26. PMID: 2556063 [PubMed - indexed for MEDLINE]	•
□ 167	Gohra H, Kaneda Y, Furukawa S, Oda T, Miyamoto M, Mori F, Esato K.	Related Articles, Links
	[The effect of pulsatile perfusion on aortocoronary byp Kyobu Geka. 1989 Nov;42(12):974-9; discussion 979-81. Japanes PMID: 2593408 [PubMed - indexed for MEDLINE]	
□ 168	Tamura T, Yokoyama K, Sato H, Kato K, Taneda M, Hayashi A, Jounokoshi H, Ueda Y, Kawana Y, Araki Y.	Related Articles, Links
	[Coronary artery spasm under thoracic epidural anesthe Masui. 1989 Oct;38(10):1369-77. Japanese. PMID: 2585706 [PubMed - indexed for MEDLINE]	esia]
<b>169</b>	Lovreglio V, Bartucci G, Simini P, Leuce U.	Related Articles, Links
	[Cardiac enzymes in acute cerebrovascular diseases: the relation to ECG] Minerva Med. 1989 Sep;80(9):1003-10. Italian. PMID: 2812474 [PubMed - indexed for MEDLINE]	eir behavior in
□ 170	Hadi HA, Albazzaz SJ.	Related Articles, Links
	Cardiac isoenzymes and electrocardiographic changes tocolysis.  Am J Obstet Gynecol. 1989 Aug;161(2):318-21.  PMID: 2764051 [PubMed - indexed for MEDLINE]	during ritodrine
<b>171</b>	Helling TS, Duke P, Beggs CW, Crouse LJ.	Related Articles, Links
	A prospective evaluation of 68 patients suffering blunt evidence of cardiac injury.  J Trauma. 1989 Jul;29(7):961-5; discussion 965-6.  PMID: 2746707 [PubMed - indexed for MEDLINE]	chest trauma for
☐ 172	Kohata T, Ono Y, Yoshibayashi M, Fukushima H, Yamada O, Kamiya T, Nishimura T, Takamiya M, Yutani C	Related Articles, Links
	[Gallium-67 imaging in patients with myocarditis in ch J Cardiol. 1989 Jun;19(2):445-53. Japanese. PMID: 2636626 [PubMed - indexed for MEDLINE]	ildhood and youth]
173	Fernandez-Quero Bonilla L, Jardon Contreras F, Lajara Montell A, Manzanos Luna A.	Related Articles, Links
	[A controversial entity: myocardial contusion in 51 pat trauma] Rev Esp Anestesiol Reanim. 1989 May-Jun;36(3):145-8. Spanish. PMID: 2762608 [PubMed - indexed for MEDLINE]	
□174:	Rubin RB, Neugarten J.	Related Articles, Links
	Cocaine-induced rhabdomyolysis masquerading as my Am J Med. 1989 May;86(5):551-3. PMID: 2712062 [PubMed - indexed for MEDLINE]	ocardial ischemia.
□ 175:	Ramondo A, Isabella G, Fracasso A, Sorbara C, Razzolini R, Maddalena F, Mazzucco A, Corbara F, Chioin R	Related Articles, Links
	[Results of emergency aortocoronary bypass in complication of the	cated coronary

 $h\,g\quad e\quad e\quad e\quad fcg\qquad \qquad e\quad ch\qquad \qquad b\quad e$ 

		C
	angioplasty] G Ital Cardiol. 1989 May;19(5):379-84. Italian. PMID: 2527774 [PubMed - indexed for MEDLINE]	
□ 176:	Cortadellas J, Figueras J, Curos A, Cinca J, Moya A, Angel J, Salas A, Roma F.	Related Articles, Links
	[Intravenous streptokinase in acute myocardial infarcti early in-hospital mortality] Rev Esp Cardiol. 1989 Apr,42(4):254-61. Spanish. PMID: 2781119 [PubMed - indexed for MEDLINE]	on. Reduction of
□ 177:	Dazai Y, Katoh I, Sueda S, Katoh T, Yoshida R, Fujii M, Kazatani S.	Related Articles, Links
	[Report of a case of lung cancer with metastasis to the showed electrocardiographic findings similar to acute a infarction and intramyocardial mass on echocardiographic Kokyu To Junkan. 1989 Apr;37(4):461-5. Japanese. PMID: 2740646 [PubMed - indexed for MEDLINE]	nyocardial
□ 178:	Campbell JB, Baker J, Morris DM.	Related Articles, Links
	Cardiac complications of aneurysm repair. South Med J. 1989 Apr;82(4):458-61. PMID: 2705072 [PubMed - indexed for MEDLINE]	
□ 179:	Desai RN, Joshi SV, Vaidya P, Magotra RA, Parulkar GB.	Related Articles, Links
	Blood cardioplegiaa comparative clinical and laborate Indian Heart J. 1989 Mar-Apr;41(2):134-6. PMID: 2787289 [PubMed - indexed for MEDLINE]	ory study.
<b>180</b> :	Bianchi L. Bertocchi C. Felci U. Ferrario G. Giani P. Mariani L. Medolago G. Sarti E.	Related Articles, Links
	[Cardiomyopathy due to adriamycin: the possibility of Monitoring by noninvasive technics] Minerva Med. 1989 Mar;80(3):215-26. Italian. PMID: 2717043 [PubMed - indexed for MEDLINE]	its prevention.
□181:	Yonenaga K, Yasui H, Kado H, Andou H, Nakano E, Fukumura F, Nishimura Y, Zaitsu M, Shin T, Merimoto A	Related Articles, Links
	[Retrograde coronary sinus perfusion of cardioplegic so operation in neonates and infants] Nippon Kyobu Geka Gakkai Zasshi. 1989 Feb;37(2):274-80. Japa PMID: 2768906 [PubMed - indexed for MEDLINE]	
□ 182:	O'Connor JP, Ramsay JG, Wynands JE, Ralley FE, Casey WF, Smith CE, Robbins GR, Bilodeau J, Sami MH.	Related Articles, Links
	The incidence of myocardial ischemia during anesthesi artery bypass surgery in patients receiving pancuronium Anesthesiology. 1989 Feb;70(2):230-6. PMID: 2563317 [PubMed - indexed for MEDLINE]	
□ 183:	Tondeur M, Haentjens M, Piepsz A, Ham HR.	Related Articles, Links
	Muscular injury in a child diagnosed by 99mTc-MDP t Eur J Nucl Med. 1989;15(6):328-9. PMID: 2767083 [PubMed - indexed for MEDLINE]	oone scan.
□ 184:	Burke GL, Edlavitch SA, Crow RS.	Related Articles, Links
	The effects of diagnostic criteria on trends in coronary morbidity: the Minnesota Heart Survey.  J Clin Epidemiol. 1989;42(1):17-24.  PMID: 2643674 [PubMed - indexed for MEDLINE]	heart disease

cb

hg e e

e fcg e ch

cb

hg e e

		rage 21 01 33
□ 185:	Tabatabai M, Segal R, Amidi M, Stremple JF, Caines M, Kirimli B	Related Articles, Links
	Serum creatine phosphokinase, lactic dehydrogenase, a isoenzymes in the perioperative period.  J Clin Anesth. 1989;1(4):277-83.  PMID: 2627401 [PubMed - indexed for MEDLINE]	and their
□ 186:	Magnani B, Melandri G.	Related Articles, Links
	The role of infarct size in early and late mortality. J Cardiovasc Pharmacol. 1989;14 Suppl 9:S25-8. PMID: 2483228 [PubMed - indexed for MEDLINE]	
□ 187:	Vinogradov AV, Aloev RS, Zhuravleva IA, Kharlap GV, Glazunov AS.	Related Articles, Links
	[Possibilities of electrocardiography in the evaluation of process in posterior myocardial infarction] Kardiologiia. 1988 Nov;28(11):58-61. Russian. PMID: 3230778 [PubMed - indexed for MEDLINE]	of necrotization
□ 188:	Lindenbaum GA, Carroll SF, Block EF, Kapusnick RA.	Related Articles, Links
	Value of creatine phosphokinase isoenzyme determinated diagnosis of myocardial contusion.  Ann Emerg Med. 1988 Sep;17(9):885-9.  PMID: 3415059 [PubMed - indexed for MEDLINE]	tions in the
□ 189:	Bluzhas IN, Gribauskene RA, Gribauskas PS, Rastianene DM.	Related Articles, Links
	[Atypical creatine phosphokinase isoenzyme fraction in acute myocardial infarction] Kardiologiia. 1988 Sep;28(9):46-8. Russian. PMID: 3236643 [PubMed - indexed for MEDLINE]	n the diagnosis of
□ 190:	Gibler WB, Blanton J.	Related Articles, Links
	Early identification of patients with acute myocardial in Compr Ther. 1988 Aug;14(8):41-4. PMID: 3168429 [PubMed - indexed for MEDLINE]	nfarction.
□ 191:	Rizk SL, Roseman DL, Bonomi P, Sky-Peck H, Clark J, Lee I, Gould VE.	Related Articles, Links
	Elevated creatine phosphokinase MB in a patient with a carcinoma of the colonevidence for a tumor marker. It Dis Colon Rectum. 1988 Apr;31(4):318-22. PMID: 3359901 [PubMed - indexed for MEDLINE]	
□ 192:	Keller KD, Shatney CH.	Related Articles, Links
	Creatine phosphokinase-MB assays in patients with sus contusion: diagnostic test or test of diagnosis?  J Trauma. 1988 Jan;28(1):58-63.  PMID: 3339664 [PubMed - indexed for MEDLINE]	spected myocardial
□ 193:	Fabian TC, Mangiante EC, Patterson CR, Payne LW, Isaacson ML.	Related Articles, Links
	Myocardial contusion in blunt trauma: clinical charactediagnosis, and implications for patient management. J Trauma. 1988 Jan;28(1):50-7. PMID: 3339663 [PubMed - indexed for MEDLINE]	ristics, means of
□ 194:	Gerrish SP, Goiti JJ, Hunsley JE	Related Articles, Links
	A comparison of blood, crystalloid and oxygenated crys	stalloid

b e

e fcg e ch

	cardioplegia solutions on myoglobin and creatine kinas cardiac surgery. Eur J Cardiothorac Surg. 1988;2(6):438-41. PMID: 3272252 [PubMed - indexed for MEDLINE]	se release following
<b>195</b> :	Tellez DW, Hardin WD Jr, Takahashi M, Miller J, Galvis AG, Mahour GH.	Related Articles, Links
	Blunt cardiac injury in children. J Pediatr Surg. 1987 Dec;22(12):1123-8. PMID: 3440897 [PubMed - indexed for MEDLINE]	
<b>196</b> :	Czarnecki A, Hinek A.	Related Articles, Links
	Protective effect of inosine against adrenaline toxicity in Pol J Pharmacol Pharm. 1987 Nov-Dec;39(6):675-82. PMID: 3503988 [PubMed - indexed for MEDLINE]	in rats.
<b>197</b> :	Pauletto P, Piccolo D, Scannapieco G, Paolini R, Caroli M, Corbara F, Cuman G, Chioin R, Casiglia E, Maddalena F, et al.	Related Articles, Links
	[Changes in plasma levels of myoglobin, CPK and CPI subjected to percutaneous coronary angioplasty] Cardiologia. 1987 Oct;32(10):1125-9. Italian. No abstract available PMID: 2961442 [PubMed - indexed for MEDLINE]	•
□ 198:	Gibler WB, Gibler CD, Weinshenker E, Abbottsmith C, Hedges IR, Barsan WG, Sperling M, Chen IW, Embry S, Kereiakes D.	Related Articles, Links
	Myoglobin as an early indicator of acute myocardial in Ann Emerg Med. 1987 Aug;16(8):851-6. PMID: 3619163 [PubMed - indexed for MEDLINE]	farction.
□ 199:	Livatino L, Schiatti R, Guidi L, Ignesti C.	Related Articles, Links
	[Evaluation of isoenzymes of creatine kinase and lactat	
	cases of suspected acute myocardial infarct] Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian. PMID: 3441595 [PubMed - indexed for MEDLINE]	e dehydrogenase in
□ 200:	cases of suspected acute myocardial infarct] Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian.	Related Articles, Links
☐ 200: ☐	cases of suspected acute myocardial infarct] Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian. PMID: 3441595 [PubMed - indexed for MEDLINE]	Related Arlicles, Links elevation in
	cases of suspected acute myocardial infarct] Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian. PMID: 3441595 [PubMed - indexed for MEDLINE]  Maguire JF. Geha RS, Umetsu DT.  Myocardial specific creatine phosphokinase isoenzyme children with asthma treated with intravenous isoproter J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):631-6.	Related Arlicles, Links elevation in
	cases of suspected acute myocardial infarct] Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian. PMID: 3441595 [PubMed - indexed for MEDLINE]  Maguire JF, Geha RS, Umetsu DT.  Myocardial specific creatine phosphokinase isoenzyme children with asthma treated with intravenous isoproter J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):631-6. PMID: 3771954 [PubMed - indexed for MEDLINE]	Related Articles, Links elevation in renol.  Related Articles, Links
☐ 201: ☐	cases of suspected acute myocardial infarct] Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian. PMID: 3441595 [PubMed - indexed for MEDLINE]  Maguire JF, Geha RS, Umetsu DT.  Myocardial specific creatine phosphokinase isoenzyme children with asthma treated with intravenous isoproter J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):631-6. PMID: 3771954 [PubMed - indexed for MEDLINE]  Glinz W.  Problems caused by the unstable thoracic wall and by c to blunt injury. Injury. 1986 Sep;17(5):322-6.	Related Articles, Links elevation in renol.  Related Articles, Links
☐ 201: ☐	cases of suspected acute myocardial infarct] Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian. PMID: 3441595 [PubMed - indexed for MEDLINE]  Maguire JF, Geha RS, Umetsu DT.  Myocardial specific creatine phosphokinase isoenzyme children with asthma treated with intravenous isoproter J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):631-6. PMID: 3771954 [PubMed - indexed for MEDLINE]  Glinz W.  Problems caused by the unstable thoracic wall and by c to blunt injury. Injury. 1986 Sep;17(5):322-6. PMID: 3770934 [PubMed - indexed for MEDLINE]	Related Articles, Links elevation in enol.  Related Articles, Links ardiac injury due
☐ 201: ☐ 202:	cases of suspected acute myocardial infarct] Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian. PMID: 3441595 [PubMed - indexed for MEDLINE]  Maguire JF. Geha RS. Umetsu DT.  Myocardial specific creatine phosphokinase isoenzyme children with asthma treated with intravenous isoproter J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):631-6. PMID: 3771954 [PubMed - indexed for MEDLINE]  Glinz W.  Problems caused by the unstable thoracic wall and by c to blunt injury. Injury. 1986 Sep;17(5):322-6. PMID: 3770934 [PubMed - indexed for MEDLINE]  Flancbaum L. Wright J. Siegel JH.  Emergency surgery in patients with post-traumatic myof J Trauma. 1986 Sep;26(9):795-803.	Related Articles, Links elevation in enol.  Related Articles, Links ardiac injury due
☐ 201: ☐ 202:	cases of suspected acute myocardial infarct] Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian. PMID: 3441595 [PubMed - indexed for MEDLINE]  Maguire JF, Geha RS, Umetsu DT.  Myocardial specific creatine phosphokinase isoenzyme children with asthma treated with intravenous isoproter J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):631-6. PMID: 3771954 [PubMed - indexed for MEDLINE]  Glinz W.  Problems caused by the unstable thoracic wall and by c to blunt injury. Injury. 1986 Sep;17(5):322-6. PMID: 3770934 [PubMed - indexed for MEDLINE]  Flancbaum L, Wright J, Siegel JH.  Emergency surgery in patients with post-traumatic myof J Trauma. 1986 Sep;26(9):795-803. PMID: 3746954 [PubMed - indexed for MEDLINE]	Related Articles, Links elevation in enol.  Related Articles, Links ardiac injury due  Related Articles, Links ocardial contusion.

hg e e

e fcg

e ch

b e

h

cb

ch

h g

e

e

e fcg



b e

e ch


	[Transient appearance of asynergy on the echocardiographic changes simulating acute myocard following non-cardiac surgery] J Cardiogr. 1985 Sep;15(3):639-53. Japanese. PMID: 3837059 [PubMed - indexed for MEDLINE]	
□ 214:	Dewar ML, Rosengarten MD, Blundell PE, Chiu RC.	Related Articles, Links
	Perioperative Holter monitoring and computer analysis cardiac surgery. Chest. 1985 May;87(5):593-7. PMID: 3872775 [PubMed - indexed for MEDLINE]	of dysrhythmias in
□ 215:	Possati F, Calafiore AM, Luciani N, Falcone F, Scesi M.	Related Articles, Links
	[Variations in CPK-MB during extracorporeal circulati Minerva Cardioangiol. 1985 Mar;33(3):123-6. Italian. No abstract PMID: 4010978 [PubMed - indexed for MEDLINE]	
<b>1</b> 216:	Hines GL, Wehbe U, Mele V	Related Articles, Links
	Papaverine hydrochloride as an adjunct to asanguinous beneficial? J Cardiovase Surg (Torino). 1985 Mar-Apr;26(2):196-9. PMID: 3872304 [PubMed - indexed for MEDLINE]	cardioplegia, is it
□ 217:	Rasmussen LH, Madsen HN, Ladefoged SD.	Related Articles, Links
<b>.</b>	Creatine phosphokinase MB and lactate dehydrogenase polymyositis. Scand J Rheumatol. 1985;14(4):427-30. PMID: 4081664 [PubMed - indexed for MEDLINE]	•
1 218:	Gianrossi R, Marruzzo M, Torrielli A, Azzolini A, Nizzo MC, Montemanni M, Mottola G.	Related Articles, Links
	Left ventricular thrombus and myocardial infarction. Acta Cardiol. 1985;40(6):599-612. PMID: 3879418 [PubMed - indexed for MEDLINE]	
□ 219:	Georgiades C, Cokkinos DV, Kalofoutis A, Miras C.	Related Articles, Links
	Deoxycytidylate deaminase in the diagnosis of acute m infarction.  Acta Cardiol. 1985;40(2):247-54.  PMID: 3873159 [PubMed - indexed for MEDLINE]	yocardial
□ 220:	Burlina A, Rizzotti P, Plebani M, Cocco C, Vassanelli C, Menegatti G	Related Articles, Links
	CPK and CPK-MB in the early diagnosis of acute myon and prediction of infarcted area. Clin Biochem. 1984 Dec;17(6):356-61. PMID: 6518651 [PubMed - indexed for MEDLINE]	cardial infarction
□ 221:	Douste-Blazy P, Delay M, Douste-Blazy MY, Fauvel M, Marco J, Bernadet P.	Related Articles, Links
	[Systemic fibrinolytic treatment in the acute phase of minfarction. Effects on coronary repermeation and left ve Arch Mal Coeur Vaiss. 1984 Nov;77(12):1322-8. French. PMID: 6439157 [PubMed - indexed for MEDLINE]	
□ 222:	Graeber GM, Cafferty PJ, Wolf RE, Harmon JW.	Related Articles, Links
	An analysis of creatine phosphokinase in the mucosa ar of the gastrointestinal tract. J Surg Res. 1984 Nov;37(5):376-82.	nd the muscularis

cb

 $h\,g\quad e\quad e$ 

e fcg

e ch



h g


e fcg

e ch

cb

h

□ 232	: Hicks GL, Arnold W, DeWall RA.	Related Articles, Links
	Fluorocarbon cardioplegia and myocardial protection. Ann Thorac Surg. 1983 May;35(5):500-3. PMID: 6847286 [PubMed - indexed for MEDLINE]	
□ 233	: Kumar SA, Puri VK, Mittal VK, Cortez J.	Related Articles, Links
	Myocardial contusion following nonfatal blunt chest tr J Trauma. 1983 Apr;23(4):327-31. PMID: 6302297 [PubMed - indexed for MEDLINE]	auma.
□ 234	: Titov VN, Krauze EG, Filippov IK, Rabich G, Filippova VA.	Related Articles, Links
	[Glycogen phosphorylase activity in acute myocardial Kardiologiia. 1983 Mar;23(3):51-5. Russian. PMID: 6855063 [PubMed - indexed for MEDLINE]	infarction]
□ 235	: Grenadier E, Keidar S, Kahana L, Alpan G, Marmur A, Palant A.	Related Articles, Links
	The roles of serum myoglobin, total CPK, and CK-ME acute phase of myocardial infarction.  Am Heart J. 1983 Mar;105(3):408-16.  PMID: 6829403 [PubMed - indexed for MEDLINE]	s isoenzyme in the
<b>1</b> 236	: Takimoto M, Matsuoka S, Hirohata T, Suzuki Y, Enomoto K, Ohta H, Okada N.	Related Articles, Links
	Myocardial protection during cardiac ischemia by cord cold lactated Ringer's solution plus mannitol. Jpn Heart J. 1983 Mar;24(2):199-213. PMID: 6406721 [PubMed - indexed for MEDLINE]	nary perfusion with
□ 237	: Kakihana M, Shino A, Nagaoka A.	Related Articles, Links
	Cardiovascular responses to cerebral ischemia followir artery occlusion in SHRSP, SHRSR and WKY rats. Jpn J Pharmacol. 1983 Feb;33(1):17-26. PMID: 6876514 [PubMed - indexed for MEDLINE]	ng bilateral carotid
4	artery occlusion in SHRSP, SHRSR and WKY rats. Jpn J Pharmacol. 1983 Feb;33(1):17-26.	ng bilateral carotid  Related Articles, Links
4	artery occlusion in SHRSP, SHRSR and WKY rats. Jpn J Pharmacol. 1983 Feb;33(1):17-26. PMID: 6876514 [PubMed - indexed for MEDLINE]	Related Articles, Links
□ 238 □	artery occlusion in SHRSP, SHRSR and WKY rats. Jpn J Pharmacol. 1983 Feb;33(1):17-26. PMID: 6876514 [PubMed - indexed for MEDLINE]  : Yazaki Y, Nagai R, Yamaoki K, Ueda S.  Myocardial infarct size from serum cardiac myosin ligand experimental studies. Adv Myocardiol. 1983;4:489-95.	Related Articles, Links
□ 238 □	artery occlusion in SHRSP, SHRSR and WKY rats. Jpn J Pharmacol. 1983 Feb;33(1):17-26. PMID: 6876514 [PubMed - indexed for MEDLINE]  : Yazaki Y, Nagai R, Yamaoki K, Ueda S.  Myocardial infarct size from serum cardiac myosin light and experimental studies. Adv Myocardiol. 1983;4:489-95. PMID: 6856976 [PubMed - indexed for MEDLINE]	Related Articles, Links ht chain. Clinical  Related Articles, Links
□ 238 □ 239 □	artery occlusion in SHRSP, SHRSR and WKY rats. Jpn J Pharmacol. 1983 Feb;33(1):17-26. PMID: 6876514 [PubMed - indexed for MEDLINE]  : Yazaki Y, Nagai R, Yamaoki K, Ueda S.  Myocardial infarct size from serum cardiac myosin light and experimental studies. Adv Myocardiol. 1983;4:489-95. PMID: 6856976 [PubMed - indexed for MEDLINE]  : Mirhoseini M, Fisher JC, Cayton M.  Myocardial revascularization by laser: a clinical report Lasers Surg Med. 1983;3(3):241-5.	Related Articles, Links ht chain. Clinical  Related Articles, Links
□ 238 □ 239 □	artery occlusion in SHRSP, SHRSR and WKY rats.  Jpn J Pharmacol. 1983 Feb;33(1):17-26.  PMID: 6876514 [PubMed - indexed for MEDLINE]  : Yazaki Y, Nagai R, Yamaoki K, Ueda S.  Myocardial infarct size from serum cardiac myosin ligiand experimental studies.  Adv Myocardiol. 1983;4:489-95.  PMID: 6856976 [PubMed - indexed for MEDLINE]  : Mirhoseini M, Fisher JC, Cayton M.  Myocardial revascularization by laser: a clinical report Lasers Surg Med. 1983;3(3):241-5.  PMID: 6608040 [PubMed - indexed for MEDLINE]  : Gualandi G, Facchin L, Anastasio R, Raho L, Peroni L, Caturelli	Related Articles, Links ht chain. Clinical  Related Articles, Links .  Related Articles, Links ershock: analysis of
□ 238 □ 239 □ 240	artery occlusion in SHRSP, SHRSR and WKY rats.  Jpn J Pharmacol. 1983 Feb;33(1):17-26.  PMID: 6876514 [PubMed - indexed for MEDLINE]  : Yazaki Y, Nagai R, Yamaoki K, Ueda S.  Myocardial infarct size from serum cardiac myosin light and experimental studies.  Adv Myocardiol. 1983;4:489-95.  PMID: 6856976 [PubMed - indexed for MEDLINE]  : Mirhoseini M, Fisher JC, Cayton M.  Myocardial revascularization by laser: a clinical report Lasers Surg Med. 1983;3(3):241-5.  PMID: 6608040 [PubMed - indexed for MEDLINE]  : Gualandi G, Facchin L, Anastasio R, Raho L, Peroni L, Caturelli G.  [Possible myocardial damage caused by electric counter CPK MB isoenzyme variations]  Cardiologia. 1982 Dec;27(12):1177-85. Italian. No abstract availa	Related Articles, Links ht chain. Clinical  Related Articles, Links .  Related Articles, Links ershock: analysis of



cb

hg e e

,	Y 1 170	Photos A. J. N. Markey and J. Co.
1 252:	Wasaki T.	Related Articles, Links
	[Studies on myocardial infarct size and the release of n in experimental infarction: correlation of infarct size ar myocardial enzymes after coronary artery ligation and special reference to CPK-MB]  Jpn Circ J. 1981 Dec;45 Suppl 3:477-82. Japanese. No abstract av PMID: 7310986 [PubMed - indexed for MEDLINE]	nd released reperfusion with
<b>253</b> :	Ward RE, Woo J, Pace P.	Related Articles, Links
	Increased release of beta thromboglobulin during acute infarction. Cardiovasc Dis. 1981 Sep;8(3):372-378. PMID: 15216194 [PubMed - as supplied by publisher]	myocardial
<b>254</b> :	Graeber GM, Reardon MJ, Fleming AW, Head HD, Zajtchuk R, Brott WH, Foster JH	Related Articles, Links
	An analysis of the isoenzymes of creatine phosphokina dehydrogenase in the esophagus. Ann Thorac Surg. 1981 Sep;32(3):230-4. PMID: 7283514 [PubMed - indexed for MEDLINE]	se and lactic
<b>255</b> :	Graeber GM, Cafferty PJ, Reardon MJ, Curley CP, Ackerman NB, Harmon JW.	Related Articles, Links
	Changes in serum total creatine phosphokinase (CPK) caused by experimental ligation of the superior mesent Ann Surg. 1981 Apr;193(4):499-505. PMID: 7212812 [PubMed - indexed for MEDLINE]	
□ 256:	Soffer O. Fellner SK, Rush RL.	Related Articles, Links
	Creatine phosphokinase in long-term dialysis patients. Arch Intern Med. 1981 Feb;141(2):181-8. PMID: 7458513 [PubMed - indexed for MEDLINE]	
<b>257</b> :	Besson C, Rocheongar P, Beauverger Y, Dassonville J, Aubree M, Catheline M	Related Articles, Links
	[Study of the valuations of serum muscular enzymes ar maximal exercise test and during the next 24 hours (au Eur J Appl Physiol Occup Physiol. 1981;47(1):47-56. French. PMID: 7197623 [PubMed - indexed for MEDLINE]	
<b>258</b> :	Michelson WB.	Related Articles, Links
	CPK-MB isoenzyme determinations: diagnostic and prevaluation of blunt chest trauma.  Ann Emerg Med. 1980 Nov;9(11):562-7.  PMID: 7436065 [PubMed - indexed for MEDLINE]	ognostic value in
□ <b>259</b> :	Graeber GM, Snyder RJ, Zajtchuk R, Brott WH.	Related Articles, Links
	A comparison of serum isoenzyme levels of creatine phactic dehydrogenase in patients undergoing thoracic oppatients admitted to a coronary care unit.  Ann Thorac Surg. 1980 Oct;30(4):364-9.  PMID: 7425715 [PubMed - indexed for MEDLINE]	
<b>260</b> :	$\underline{\text{Mikaeloff P, Amouroux C, Boivin J, Guidollet J, Vial C, El Kirat}}  \underline{M.}$	Related Articles, Links
	[Myocardial metabolism during coronary perfusion at 1 or without cardioplegia associated with potassium] Arch Mal Coeur Vaiss. 1980 Sep;73(9):1075-85. French.	0 degrees C with

e fcg e ch b e

Related Articles, Links

PMID: 6776926 [PubMed - indexed for MEDLINE] 261: Maklari E, Dekany P, Keltai M, Gabor G. Related Articles, Links [Determination of free CPK and CPK/MB isoenzyme in myocardial infarctl Orv Hetil. 1980 Feb 24;121(8):441-5. Hungarian. No abstract available. PMID: 7383681 [PubMed - indexed for MEDLINE] 262: Ofir D, Morag A. Related Articles, Links [Isoenzyme CPK-MB in myocardial infarction] Harefuah. 1980 Feb 1;98(3):129-32. Hebrew. No abstract available. PMID: 7429355 [PubMed - indexed for MEDLINE] 263: Suzuki T, Kashimura S, Umetsu K. Related Articles, Links Creatine phosphokinase and malate dehydrogenase isozymes in heart muscle of sudden death cases. Tohoku J Exp Med. 1980 Feb;130(2):175-82. PMID: 7385226 [PubMed - indexed for MEDLINE] 264: Bradner WT, Schurig JE, Huftalen JB, Doyle GJ. Related Articles, Links Evaluation of antitumor drug side effects in small animals. Cancer Chemother Pharmacol. 1980;4(2):95-101. PMID: 7389061 [PubMed - indexed for MEDLINE] **265:** Bauman DJ. Related Articles, Links Creatine phosphokinase isoenzymes and the diagnosis of myocardial infarction. Postgrad Med. 1980 Jan;67(1):103-6, 109-12, 115-6. PMID: 7350557 [PubMed - indexed for MEDLINE] **266:** Cosic V. Related Articles, Links [Improvements in the diagnosis of acute myocardial infarct. Diagnostic values of CPK-MB isoenzymes] Vojnosanit Pregl. 1979 Nov-Dec;36(6):464-6. Serbian. No abstract available. PMID: 538893 [PubMed - indexed for MEDLINE] **267:** Lin CS, Shih MC. Related Articles, Links Reappraisal of enzyme diagnosis in acute myocardial infarction-with special reference to CPK-MB isoenzyme. Taiwan Yi Xue Hui Za Zhi. 1979 Sep;78(9):789-94. No abstract available. PMID: 292754 [PubMed - indexed for MEDLINE] 268: Reynolds M. Jones JW. Related Articles, Links CPK-MB isoenzume determinations in blunt chest trauma. JACEP. 1979 Aug;8(8):304-6. PMID: 459188 [PubMed - indexed for MEDLINE] 269: Marmor A. Grenadir E, Keidar S, Edward S, Palant A. Related Articles, Links The MB fraction of creatine phosphokinase. An indicator of myocardial involvement in acute pericarditis. Arch Intern Med. 1979 Jul;139(7):819-20. PMID: 454073 [PubMed - indexed for MEDLINE]

cb h g e e e fcg e ch b e

h

270: Oda T, Hamamoto K, Morinaga H.

Jpn Circ J. 1979 May;43(5):433-40.

PMID: 470104 [PubMed - indexed for MEDLINE]

Clinical aspects of nonrheumatic myocarditis in children.

	· ·
271: Val-Mejias J. Lee WK, Weisse AB, Regan TJ.	Related Articles, Links
Left ventricular performance during and after sickle of Am Heart J. 1979 May;97(5):585-91. PMID: 433733 [PubMed - indexed for MEDLINE]	cell crisis.
272: Wakabayashi A, Nishi T, Mihranian M, Ito Y, Guilmette JE, Connolly JE.	Related Articles, Links
Experimental evaluation of hypothermic intermittent J Thorac Cardiovasc Surg. 1979 May;77(5):641-6. PMID: 431097 [PubMed - indexed for MEDLINE]	coronary perfusion.
273: Witherspoon LR, Shuler SE, Garcia MM, Zollinger LA.	Related Articles, Links
Assessment of serum myoglobin as a marker for acut infarction.  J Nucl Med. 1979 Feb;20(2):115-9. PMID: 430183 [PubMed - indexed for MEDLINE]	e myocardial
274: Sordahl LA.	Related Articles, Links
Role of mitochondria in heart cell function. Tex Rep Biol Med. 1979;39:5-18. PMID: 553325 [PubMed - indexed for MEDLINE]	
275: Mercado Tl. Garbus J.	Related Articles, Links
Creatine phosphokinase isoenzymes and Trypanosom Comp Biochem Physiol B. 1979;64(1):11-5. PMID: 45531 [PubMed - indexed for MEDLINE]	na cruzi infections.
<b>7. 276:</b> Maggs PR.	Related Articles, Links
CPK MB elevations in hypothermia. Am Heart J. 1978 Nov;96(5):703. No abstract available. PMID: 263405 [PubMed - indexed for MEDLINE]	
277: D'Souza JP, Sine HE, Horvitz RA, Kubasik NP, Brody BB, Barold SS.	Related Articles, Links
The significance of the MB isoenzyme in patients wit cardiovascular disease with a normal or borderline tot Clin Biochem. 1978 Oct;11(5):204-9. PMID: 729162 [PubMed - indexed for MEDLINE]	th acute tal CPK activity.
278: Harwood SJ, Catrou PG, Cole GW.	Related Articles, Links
Creatine phosphokinase isoenzyme fractions in the se struck by lightning. Arch Intern Med. 1978 Apr;138(4):645-6. PMID: 637650 [PubMed - indexed for MEDLINE]	rum of a patient
279: Fiolet JW, Willebrands AF, Lie KI, Ter Welle HF, Durrer D.	Related Articles, Links
[The isoenzyme creatine phosphokinase-MB (CPK-M diagnosis of acute heart infarct] Ned Tijdschr Geneeskd. 1978 Mar 25;122(12):393-8. Dutch. No PMID: 643093 [PubMed - indexed for MEDLINE]	,
280: Carlson CJ, Emilson B, Rapaport E.	Related Articles, Links
Creatine phosphokinase MB isoenzyme in hypotherm experimental studies.  Am Heart J. 1978 Mar;95(3):352-8. PMID: 622978 [PubMed - indexed for MEDLINE]	ia: case reports and
281: Delva E, Maille JG, Solymoss BC, Chabot M, Grondin CM, Bourassa MG	Related Articles, Links

	Evaluation of myocardial damage during coronary arteserial determinations of serum CPK MB isoenzyme. J Thorac Cardiovasc Surg. 1978 Mar;75(3):467-75. PMID: 305508 [PubMed - indexed for MEDLINE]	ery grafting with
<b>282</b>	: Guzy PM.	Related Articles, Links
	Creatine phosphokinase-MB (CPK-MB) and the diagninfarction. West J Med. 1977 Dec;127(6):455-60. Review. No abstract availant PMID: 339548 [PubMed - indexed for MEDLINE]	•
□ 283	: Wirz P, Blum J, Brunner HH.	Related Articles, Links
	[Effect of droperidol on the creatine phosphokinase ac myocardial infarct] Schweiz Med Wochenschr. 1977 Nov 5;107(44):1595-6. German PMID: 918632 [PubMed - indexed for MEDLINE]	·
284	· Codd JE, Sullivan RG, Weins RD, Barner HB, Kaiser GC, Willman VL.	Related Articles, Links
	Myocardial injury following myocardial revascularizatisoenzyme analysis. Circulation. 1977 Sep;56(3 Suppl):II49-53. PMID: 884827 [PubMed - indexed for MEDLINE]	ion. Detection by
□ 285	Atzeni E, Dessalvi F, Binaghi F, Corti D, Pitzus F.	Related Articles, Links
	[The specificity of the CPK MB enzyme kinetic test fo acute myocardial infarction (author's transl)] G Ital Cardiol. 1977 Aug;7(8):770-5. Italian. PMID: 913934 [PubMed - indexed for MEDLINE]	r the diagnosis of
□ 286	Klausner SC, Botvinick EH, Shames D, Ullyot DJ, Fishman NH, Roe BB, Ebert PA, Chatterjee K, Parmley WW.	Related Articles, Links
	The application of radionuclide infarct scintigraphy to perioperative myocardial infarction following revascul Circulation. 1977 Aug;56(2):173-81. PMID: 872307 [PubMed - indexed for MEDLINE]	diagnose arization.
□ 287	Dinovo EC, McIntosh ME, Lynn JK.	Related Articles, Links
	Erroneously low creatine kinase activity measurements Calbiochem CPK-MB kit with the Beckman TR Enzyn Clin Chem. 1977 Jul;23(7):1362-3. No abstract available. PMID: 872391 [PubMed - indexed for MEDLINE]	with use of the ne Analyzer.
288	Lell WA, Walker DR, Blackstone EH, Kouchoukos NT, Allarde R, Roe CR.	Related Articles, Links
	Evaluation of myocardial damage in patients undergoin bypass procedures with halothane-N2O anesthesia and Anesth Analg. 1977 Jul-Aug;56(4):556-63. PMID: 301724 [PubMed - indexed for MEDLINE]	ng coronary-artery ajuvants.
<b>289</b> :	Yasmineh WG, Pyle RB, Cohn JN, Nicoloff DM, Hanson NQ, Steele BW	Related Articles, Links
	Serial serum creatine phosphokinase MB isoenzyme ac myocardial infarction. Studies in the baboon and man. Circulation. 1977 May;55(5):733-7. PMID: 403031 [PubMed - indexed for MEDLINE]	tivity after
□ 290:	Baker J, Wagner GS, Greenfield JC Jr.	Related Articles, Links
	The management of acute coronary insufficiency.	

	Dis Mon. 1977 May;23(8):1-39. Review. PMID: 324738 [PubMed - indexed for MEDLINE]	
□ 291	: Roe CR.	Related Articles, Links
	Diagnosis of myocardial infarction by serum isoenzyn Ann Clin Lab Sci. 1977 May-Jun;7(3):201-9. Review. PMID: 324344 [PubMed - indexed for MEDLINE]	ne analysis.
□ 292	• Willerson JT, Stone MJ, Ting R, Mukherjee A, Gomez-Sanchez CE, Lewis P, Hersh LB.	Related Articles, Links
	Radioimmunoassay of creatine kinase-B isoenzyme in in patients with acute myocardial infarction.  Proc Natl Acad Sci U S A. 1977 Apr;74(4):1711-5.  PMID: 266211 [PubMed - indexed for MEDLINE]	human sera: results
<b>293</b>	: Roe CR, Cobb FR, Starmer CF.	Related Articles, Links
	The relationship between enzymatic and histologic est of myocardial infarction in conscious dogs with perma occlusion.  Circulation. 1977 Mar;55(3):438-49.  PMID: 837480 [PubMed - indexed for MEDLINE]	
□ 294	: Warren SG, Wagner GS, Bethea CF, Roe CR, Oldham HN, Kong	Z Related Articles, Links
	Diagnostic and prognostic significance of electrocardic isoenzyme changes following coronary bypass surgery findings at one year.  Am Heart J. 1977 Feb;93(2):189-96.  PMID: 299973 [PubMed - indexed for MEDLINE]	
F** 00 =		
1 295	· Cipressi F, Nardini M, Zennaro R, Mattioli G.	Related Articles, Links
1 295	: Cipressi F, Nardini M, Zennaro R, Mattioli G.  [CPK-MB enzyme changes in coronary disease patientypes of algogenic treatment]  Boll Soc Ital Cardiol. 1977;22(10):1875-6. Italian. No abstract av PMID: 753320 [PubMed - indexed for MEDLINE]	ts given various
2000 2000 2000 2000 2000 2000	[CPK-MB enzyme changes in coronary disease patientypes of algogenic treatment] Boll Soc Ital Cardiol. 1977;22(10):1875-6. Italian. No abstract av	ts given various
2000 2000 2000 2000 2000 2000	[CPK-MB enzyme changes in coronary disease patientypes of algogenic treatment] Boll Soc Ital Cardiol. 1977;22(10):1875-6. Italian. No abstract av PMID: 753320 [PubMed - indexed for MEDLINE] Atzeni E. Meleddu GE, Bande A, Binaghi F, Corti D, Sanna A,	ts given various railable. Related Articles, Links myocardial infarct
□ 296 □	[CPK-MB enzyme changes in coronary disease patientypes of algogenic treatment]  Boll Soc Ital Cardiol. 1977;22(10):1875-6. Italian. No abstract av PMID: 753320 [PubMed - indexed for MEDLINE]  Atzeni E, Meleddu GE, Bande A, Binaghi F, Corti D, Sanna A, Pitzus F.  [Evaluation of the theoretical size of the area of acute by observation of the CPK and CPK-MB enzyme flow (preliminary experiments)]  Boll Soc Ital Cardiol. 1977;22(8):1359-68. Italian. No abstract av	ts given various railable. Related Articles, Links myocardial infarct
□ 296 □	[CPK-MB enzyme changes in coronary disease patient types of algogenic treatment]  Boll Soc Ital Cardiol. 1977;22(10):1875-6. Italian. No abstract av PMID: 753320 [PubMed - indexed for MEDLINE]  Atzeni E. Meleddu GE, Bande A, Binaghi F, Corti D, Sanna A, Pitzus F.  [Evaluation of the theoretical size of the area of acute by observation of the CPK and CPK-MB enzyme flow (preliminary experiments)]  Boll Soc Ital Cardiol. 1977;22(8):1359-68. Italian. No abstract av PMID: 618270 [PubMed - indexed for MEDLINE]	ts given various railable.  Related Articles, Links myocardial infarct r curves railable.  Related Articles, Links determination of the
□ 296 □ 297 □	[CPK-MB enzyme changes in coronary disease patient types of algogenic treatment]  Boll Soc Ital Cardiol. 1977;22(10):1875-6. Italian. No abstract av PMID: 753320 [PubMed - indexed for MEDLINE]  Atzeni E. Meleddu GE, Bande A, Binaghi F, Corti D, Sanna A, Pitzus F.  [Evaluation of the theoretical size of the area of acute by observation of the CPK and CPK-MB enzyme flow (preliminary experiments)]  Boll Soc Ital Cardiol. 1977;22(8):1359-68. Italian. No abstract av PMID: 618270 [PubMed - indexed for MEDLINE]  Noble J, Garcia-Pascual B, Fathi M, Rosenbusch CA.  [Diagnosis of myocardial infarct by means of a quick of MB fraction of serum creatinephosphokinase]  Schweiz Med Wochenschr. 1976 Dec 18;106(51):1867-70. Frence	ts given various railable.  Related Articles, Links myocardial infarct r curves railable.  Related Articles, Links determination of the
□ 296 □ 297 □	[CPK-MB enzyme changes in coronary disease patient types of algogenic treatment]  Boll Soc Ital Cardiol. 1977;22(10):1875-6. Italian. No abstract av PMID: 753320 [PubMed - indexed for MEDLINE]  **Atzeni E, Meleddu GE, Bande A, Binaghi F, Corti D, Sanna A, Pitzus F.  [Evaluation of the theoretical size of the area of acute by observation of the CPK and CPK-MB enzyme flow (preliminary experiments)]  Boll Soc Ital Cardiol. 1977;22(8):1359-68. Italian. No abstract av PMID: 618270 [PubMed - indexed for MEDLINE]  **Noble J, Garcia-Pascual B, Fathi M, Rosenbusch CA.  [Diagnosis of myocardial infarct by means of a quick of MB fraction of serum creatinephosphokinase]  Schweiz Med Wochenschr. 1976 Dec 18;106(51):1867-70. Frence PMID: 1013716 [PubMed - indexed for MEDLINE]	ts given various railable.  Related Articles, Links myocardial infarct r curves railable.  Related Articles, Links determination of the h.  Related Articles, Links analysis of creatine

	Diagnosis of acute myocardial infarction in a communi significance of CPK-MB determination. Circulation. 1976 Jun;53(6):965-9. PMID: 1269133 [PubMed - indexed for MEDLINE]	ty hospital:
□ 300:	Pyle RB, Blomberg DJ, Burke MD, Lindsay WG, Nicoloff DM.	Related Articles, Links
	CPK-MB isoenzyme: use in diagnosis of acute myocarthe early postoperative period. J Thorac Cardiovasc Surg. 1976 Jun;71(6):884-90. PMID: 1271838 [PubMed - indexed for MEDLINE]	dial infarction in
□ 301:	Jarmakani JM, Limbird L, Graham TC, Marks RA.	Related Articles, Links
	Effect of reperfusion on myocardial infarct, and the accestimating infarct size from serum creatine phosphokin Cardiovasc Res. 1976 Mar;10(2):245-53. PMID: 938992 [PubMed - indexed for MEDLINE]	
□ 302:	Wong R, Swallen TO.	Related Articles, Links
	Cellulose acetate electrophoresis of creatine phosphoki the diagnosis of myocardial infarction. Am J Clin Pathol. 1975 Aug;64(2):209-16. PMID: 1155383 [PubMed - indexed for MEDLINE]	nase isoenzymes in
□ 303:	Tonkin AM, Lester RM, Guthrow CE, Roe CR, Hackel DB, Wagner GS.	Related Articles, Links
	Persistence of MB isoenzyme of creatine phosphokinas after minor iatrogenic cardiac trauma. Absence of postr myocardial infarction.  Circulation. 1975 Apr;51(4):627.  PMID: 1116253 [PubMed - indexed for MEDLINE]	
Display	Summary Show: 500 Sort S	end to Text 💌

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37

## **WEST Search History**

Hide Items Restore Clear Cancel

DATE: Friday, August 13, 2004

Hide?	<u>Set</u> Name	Query	<u>Hit</u> Count
	DB=PG	SPB, USPT, USOC, EPAB, JPAB, DWPI; PLUR=YES; OP=ADJ	
	L28	L23 AND 514/2.CCLS.	29
	L27	= 2000	33
	L26	L23 AND inhalation	377
	L25	L23 AND CPK-MB	4
$\Box$	L24	L23 AND acute coronary artery disease	2
	L23	L22 AND coronary artery disease	793
	L22	(FGF-1 OR aFGF OR acidic FGF OR FGF-2 OR bFGF OR basic FGF OR VEGF)	12334
	L21	= 2000	44
	L20	L19 AND treatment	810
	L19	L17 AND nasal	811
	L18	L17 AND inhala?	0
	L17	L14 AND growth factor	2032
	L16	L14 AND growth-factor	41
	L15	L14 AND growth fator	3
	L14	coronary artery disease	7647
	L13	L12 AND growth factor	83
	L12	L11 AND coronary artery disease	143
	L11	530/300,324,399.CCLS.	8009
	L10	L9 AND coronary artery disease	28
	L9	424/9.1.CCLS.	. 907
	L8	L7 AND coronary artery disease	67
	L7	L6 AND growth factor	2399
	L6	(514/2.CCLS.)	6208
	L5	Franco-W-P.IN.	3
	L4	Franco-Wayne-P.IN.	6
	L3	Franco.IN.	6436
	L2	Franco-W.IN.	4
	L1	(Franco-Wayne.IN.)	0

#### END OF SEARCH HISTORY

Entrez PubMed Page 1 of 2






1: Ann Thorac Surg. 1998 Jun;65(6):1540-4.

KI SUYILI MARKA

FULL TEXT ARTICLE



Related Articles, Links

				, ,,					
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	866
Search Pu	ıbMed	for					Go	Clear	
		Limits	Previ	ew/Index	History	Cli	pboard		etails
About Entrez		Display Abstra	ct	Sho	w 20 <b>▼</b>	Sort *	Send	to Text	

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.

Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M.

Angiogenesis Research Center, Department of Surgery at Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. fsellke@bidmc.harvard.edu

BACKGROUND: Patients not amenable to complete myocardial revascularization by conventional methods present a difficult clinical problem. Here we present the early results and technical considerations of the administration of basic fibroblast growth factor for the induction of collateral growth using heparin-alginate slow-release devices in patients undergoing coronary artery bypass grafting. METHODS: Eight patients were enrolled. Patients were candidates if they had at least one graftable obstructed coronary artery and at least one major arterial distribution not amenable to revascularization, a serum creatinine level less than 3 mg/dL, ejection fraction greater than 0.20, and estimated operative mortality of less than 25%. During conventional coronary artery bypass grafting, 10 heparin-alginate devices, each containing either 1 microg or 10 microg of basic fibroblast growth factor, were implanted in the epicardial fat in multiple regions of the unrevascularizable territory and also in the distal distribution of a grafted or patent artery. RESULTS: There was no mortality and no evidence of renal, hematologic, or hepatic toxicity during follow-up. Three months after the operation, all patients remain free of angina. Seven patients were examined with stress perfusion scans. Three patients had clear enhancement of perfusion to the unrevascularized myocardium, 1 patient had a new fixed defect, and 3 had minimal overall change but had evidence of new small, fixed perfusion defects. Seven patients had improved or similar myocardial contractile function (ejection fraction at 3-month follow-up = 0.53 + -0.22versus 0.47 +/- 0.14 preoperatively). One patient suffered a perioperative myocardial infarction in the area of basic fibroblast growth factor administration. CONCLUSIONS: This preliminary study demonstrates the safety and technical feasibility of therapeutic angiogenesis with basic fibroblast growth factor delivered by heparin-alginate slow-release devices. Further studies examining the safety, clinical efficacy, and long-term results are ongoing.

#### **Publication Types:**

Clinical Trial

#### • Clinical Trial, Phase I

#### PMID: 9647055 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk

NCBI | NLM | NIH


Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37







Send to

				,				-	
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	800
	PubMed						Go	Clear	
		Limits	Previ	ew/Index	History	Cli	pboard	Deta	ils

▼ Show: 20

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts Clinical Trials.gov PubMed Central 1: Am Heart J. 1999 Aug; 138(2 Pt 2): S132-41.

Related Articles, Links

Am Heart J

**Abstract** 

Display

Gene therapy for myocardial angiogenesis.

Losordo DW, Vale PR, Isner JM.

St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135, USA.

**▼** Sort

In patients in whom antianginal medications fail to provide sufficient symptomatic relief, additional interventions such as angioplasty or bypass surgery may be required. Although both types of intervention have been shown to be effective for various types of patients, a certain group of patients may not be candidates for either intervention because of the diffuse nature of their coronary artery disease. Moreover, there are many patients in whom recurrent narrowing and/or occlusion of bypass conduits after initially successful surgery has left the patient again symptomatic with no further angioplasty or surgical option. Ischemic muscle represents a promising target for gene therapy with naked plasmid DNA. Intramuscular transfection of genes encoding angiogenic cytokines, particularly those naturally secreted by intact cells, may constitute an alternative treatment strategy for patients with extensive tissue ischemia in whom contemporary therapies (antianginal medications, angioplasty, bypass surgery) have previously failed or are not feasible. This strategy is designed to promote the development of supplemental collateral blood vessels that will constitute endogenous bypass conduits around occluded native arteries, a strategy termed "therapeutic angiogenesis." Preclinical animal studies from our laboratory have established that intramuscular gene transfer may be used to successfully accomplish therapeutic angiogenesis. More recently, phase 1 clinical studies from our institution have established that intramuscular gene transfer may be used to safely and successfully accomplish therapeutic angiogenesis in patients with critical limb ischemia. The notion that this concept could be extrapolated to the treatment of chronic myocardial ischemia was demonstrated in our laboratory by administering recombinant human vascular endothelial growth factor (VEGF) to a porcine model of chronic myocardial ischemia. Recent experiments performed in this same porcine model of myocardial ischemia have shown that direct intramyocardial gene transfer of naked plasmid DNA encoding VEGF (phVEGF(165), the identical plasmid used in our previous animal and human clinical trials) can be safely and successfully achieved through a minimally invasive chest wall incision. Finally, initial results have supported the concept that intramyocardial injection of naked plasmid DNA encoding VEGF can achieve therapeutic angiogenesis, as demonstrated by clinical improvement in patient symptoms and improved myocardial

perfusion shown by single-photon emission computed tomography-sestamibi imaging.

#### **Publication Types:**

- Review
- Review, Tutorial

PMID: 10426872 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37







Entrez PubMed Nucleotide Protein Genome OMIM **PMC** Structure Journals 300 Search PubMed Go ¥ Clear for Limits Preview/Index History Clipboard Details Display Abstract Show: 20 Send to

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher **Clinical Queries** LinkOut Cubby

Related Resources Order Documents **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov **PubMed Central** 

**1:** Am J Cardiol. 1999 Aug 15;84(4):430-3.

Related Articles, Links

۳

KLSKYRK WARNER FULL TEXT ARTICLE

Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.

Spallarossa P, Rossettin P, Minuto F, Caruso D, Cordera R, Battistini M, Barreca A, Masperone MA, Brunelli C.

Department of Internal Medicine, University of Genoa, Italy.

We have examined the effects of 6 months of treatment with growth hormone (GH) (0.02 U/kg/day) in 10 patients with chronic postischemic cardiac failure. Ten patients matched for age, body mass index, functional class, and ejection fraction served as a control group. In the GH group, 1 patient died and 2 were withdrawn from the study because of arrhythmia or worsening of heart failure. In the control group, 1 patient died and 1 patient was withdrawn from the study because of progressive heart failure. Among GH patients, those with an unfavorable outcome had a greater left ventricular end-diastolic diameter (79, 82, and 88 mm) on entry to the study than patients without adverse events (range 62 to 72 mm). At the end of the study, the seven GH patients reported a feeling of well-being and had a significant increase in their exercise test duration (462 +/- 121 vs 591 +/- 105 seconds, p <0.05). Low baseline insulin-like growth factor-I values were increased with GH treatment (189 + - 52 vs 100 + - 22 ng/ml, p < 0.01). GH did not change left ventricular diameters or wall thickness. A trend toward decreased serum triglyceride levels and adipose body tissue associated with an increase in high-density lipoproteins was observed in the GH group. In conclusion, our present data support previous suggestions that GH treatment exerts some beneficial effects in patients with chronic, stabilized, moderately severe heart failure, but may have deleterious effects in patients with more severe heart failure.

#### **Publication Types:**

- Clinical Trial
- Controlled Clinical Trial


PMID: 10468082 [PubMed - indexed for MEDLINE]

Show: 20 Display Abstract Send to

> Write to the Help Desk NCBI | NLM | NIH







Nucleofide PubMed Protein Genome Structure OMIM PMC Journals 300 Search | PubMed × for CPK-MB AND coronary artery disease Go Clear Limits Preview/Index History Clipboard Details About Entrez Display Summary ▼ Show: 500 ▼ Sort Send to Text Items 1-12 of 12 One page. Text Version 1: Sala MF, Barcena JP, Rota JI, Roca JV, Lopez CA, Puigdevall JM. Related Articles, Links Soldevilla JG, de Luna AB Entrez PubMed Overview Sustained ventricular tachycardia as a marker of inadequate myocardial Help | FAQ perfusion during the acute phase of myocardial infarction. Tutorial Clin Cardiol. 2002 Jul;25(7):328-34. New/Noteworthy E-Utilities PMID: 12109866 [PubMed - indexed for MEDLINE] 2: Chauhan S. Wasir HS, Bhan A, Rao BH, Saxena N, Venugopal P. Related Articles, Links PubMed Services Journals Database Adenosine for cardioplegic induction: a comparison with St Thomas MeSH Database solution. Single Citation Matcher J Cardiothorac Vasc Anesth. 2000 Feb;14(1):21-4. **Batch Citation Matcher** PMID: 10698387 [PubMed - indexed for MEDLINE] Clinical Quenes LinkOut 1 3. Trehan N, Mishra M, Bapna R, Mishra A, Maheshwari P, Karlekar Related Articles, Links Cubby <u>A.</u> Related Resources Transmyocardial laser revascularisation combined with coronary artery Order Documents bypass grafting without cardiopulmonary bypass. **NLM Gateway** Eur J Cardiothorac Surg. 1997 Aug;12(2):276-84. TOXNET PMID: 9288519 [PubMed - indexed for MEDLINE] Consumer Health Clinical Alerts 4. Kondo K, Minohara S, Sawada Y, Irie H, Okamoto K, Kinugasa S, Related Articles, Links ClinicalTrials.gov Nakao M, Sasaki S. PubMed Central Indications and problems of coronary artery bypass grafting without cardiopulmonary bypass. Surg Today. 1997;27(3):202-6. PMID: 9068098 [PubMed - indexed for MEDLINE] 5: Aggarwal SP, Thukral R, Wander GS, Kapoor DK. Related Articles, Links Evaluation of serum lipid profile and cardiac enzyme changes in cerebrovascular accidents. J Indian Med Assoc. 1995 Sep;93(9):331-2. PMID: 8648151 [PubMed - indexed for MEDLINE] 6: Kanno M, Kurihara H, Satoh H, Hamawaki M, Honda M. Related Articles, Links [Coronary artery spasm after mitral valve replacement: a case report] Kyobu Geka. 1994 Apr;47(4):315-8. Japanese. PMID: 8152181 [PubMed - indexed for MEDLINE]. 7: Moizumi Y, Ohsaka K, Akasaka J, Kondoh S, Shimizu M, Imai Y, Related Articles, Links Kumagai T, Uchiyama T, Abe Y, Suzuki I. [Advantages of combined antegrade/retrograde GIK cardioplegia for coronary artery bypass surgery] Nippon Kyobu Geka Gakkai Zasshi. 1994 Feb;42(2):198-205. Japanese. PMID: 8138686 [PubMed - indexed for MEDLINE]

Cardiac isoenzymes following heart transplantation.

8: Ladowski JS, Sullivan M, Schatzlein MH, Peterson AC, Underhill

DJ, Scheeringa RH.

Related Articles, Links

Chest. 1992 Nov;102(5):1520-1. PMID: 1424875 [PubMed - indexed for MEDLINE]	
9: McLean RF, Devitt JH, Dubbin J, McLellan BA.	Related Articles, Links
Incidence of abnormal RNA studies and dysrhythmias in chest trauma.  J Trauma. 1991 Jul;31(7):968-70. PMID: 2072436 [PubMed - indexed for MEDLINE]	patients with blunt
10: Campbell JB, Baker J, Morris DM.	Related Articles, Links
Cardiac complications of aneurysm repair. South Med J. 1989 Apr;82(4):458-61. PMID: 2705072 [PubMed - indexed for MEDLINE]	
11: Roberts AJ, Faro RS, Williams LA, Cohen JA, Knauf DK, Alexander JA.	Related Articles, Links
Relative efficacy of left ventricular venting and venous commonly used during coronary artery bypass graft sur Ann Thorac Surg. 1983 Oct;36(4):444-52. PMID: 6605127 [PubMed - indexed for MEDLINE]	
12: Mirhoseini M, Fisher JC, Cayton M.	Related Articles, Links
Myocardial revascularization by laser: a clinical report. Lasers Surg Med. 1983;3(3):241-5. PMID: 6608040 [PubMed - indexed for MEDLINE]	
Display Summary ★ Show: 500 ★ Sort +	end to Text 💌

Write to the Help Desk

NCBI | NLM | NIH


Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37







Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	800
Search	PubMed	for					Go	Clear	
·		Limits	Previev	w/Index	History	Cli	oboard	D(	etails

About Entrez

Text Version

Entrez PubMed Overview Heip | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts Clinical Trials.gov PubMed Central Display Abstract ★ Show: 20 ★ Sort ★ Send to

1: Cardiovasc Res. 1999 Nov;44(2):294-302.

Related Articles, Links

Text

FULL TEXT ARTICLE

Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.

Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF.

Experimental Physiology and Pharmacology Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA. dlazarou@welch.jhu.edu

OBJECTIVE: Angiogenic peptides like VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor) have entered clinical trials for coronary artery disease. Attempts are being made to devise clinically relevant means of delivery and to effect site-specific delivery of these peptides to the cardiac tissue, in order to limit systemic side-effects. We characterized the response of the pericardium to delivery of a replicationdeficient adenovirus carrying the cDNA for AdCMV.VEGF165, and assessed the effect of pericardial VEGF165 on myocardial collateral development in a canine model of progressive coronary occlusion. METHODS: Ameroid constrictors were placed on the proximal left circumflex coronary artery of mongrel dogs. Ten days later,  $6 \times 10(9)$  pfu AdCMV.VEGF165 (n = 9). AdRSV.beta-gal (n = 9), or saline (n = 7) were injected through an indwelling pericardial catheter. Transfection efficiency was assessed by X-gal staining. Pericardial and serum VEGF levels were measured serially by ELISA. Maximal myocardial collateral perfusion was quantified with radiolabeled or fluorescent microspheres 28 days after treatment. RESULTS: In AdRSV.betagal-treated dogs, there was extensive beta-gal staining in the pericardium and epicardium, with minimal beta-gal staining in the mid-myocardium and endocardium. Pericardial delivery of AdCMV. VEGF165 resulted in sustained (8-14 day) pericardial transgene expression, with VEGF levels peaking 3 days after infection (> 200 ng/ml) and decreasing thereafter. There was no detectable increase in serum VEGF levels. Maximal collateral perfusion, a principal correlate of collateral development and angiogenesis, was equivalent in all groups. CONCLUSION: Adenoviral-mediated gene transfer is capable of inducing sustained VEGF165 expression in the pericardium; however, locally targeted pericardial VEGF delivery failed to improve myocardial collateral perfusion in this model.

PMID: 10690306 [PubMed - indexed for MEDLINE]

b

Text Version

Help | FAQ Tutorial

E-Utilities

Entrez PubMed Overview

New/Noteworthy

**PubMed Services** 

Journals Database MeSH Database Single Citation Matcher

**Clinical Queries** 

LinkOut Cubby

Batch Citation Matcher

Related Resources

Order Documents

Consumer Health

ClinicalTrials.gov PubMed Central

NLM Gateway TOXNET

Clinical Alerts







PubMed Nucleotide Protein OMIM **FMC** Structure Journals 800 Search | PubMed Clear for Go Limits Preview/Index History Clipboard Details About Entrez Display Abstract Show: |20 Send to

1: Am J Cardiol. 1991 Nov 4;68(12):24C-33C.

Related Articles, Links

### Growth factors in pathogenesis of coronary arterial restenosis.

Cercek B, Sharifi B, Barath P, Bailey L, Forrester JS.

Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California 90048.

Restenosis occurs in 25% to 55% of patients within 6 months of successful angioplasty. The major histologic component of the restenotic lesion is intimal hyperplasia, which is almost certainly driven by growth factors. After vascular injury, smooth muscle cells proliferate, reaching a maximum rate at day 2. Smooth muscle cell proliferation diminishes as the vessel surface is reendothelialized at about day 7, and by week 4 the smooth muscle cell mitotic rate returns to baseline of less than 1% per day. The events of the histologic evolution of arterial injury can be used to create a hypothetical paradigm for the role of growth factors in restenosis. Restenosis might logically be prevented by an inhibitory intervention at any of the various steps in the healing process.

**Publication Types:** 

- Review
- Review, Academic

PMID: 1951099 [PubMed - indexed for MEDLINE]

Display Abstract ★	DILOW.	20 💌	Sort	Send to	Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37

h

cb

ng e e e fcg c

e e e l

. .







				*					
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMM	PMC	Journals	800
Search P	ubMed	for				***************************************	Go	Clear	
		Limits	Previe	w/Index	History	Clij	oboard	Det	ails
About Entre	z	Display Abstra	ct	Sho	w: 20 <b>▼</b> Sc	ort •	Send	to Text	
Text Version	1	1: J Thorac C	ardiovas	c Surg. 197	6 Jun:71(6):8	84-90	Re	lated Articles	••••••

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Refated Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

CPK-MB isoenzyme: use in diagnosis of acute myocardial infarction in the early postoperative period.

Pyle RB, Blomberg DJ, Burke MD, Lindsay WG, Nicoloff DM.

The diagnosis of acute myocardial infarction (AMI) in the early postoperative period may be quite difficult in certain patients. Electrocardiograms fail to be diagnostic of AMI in as many as one third of patients with myocardial injury found at autopsy. Enzyme patterns commonly used to diagnose AMI in patients admitted to coronary care units are obscured by muscle injury, medications, cardioversion, surgical manipulation, and blood transfusion. The MB isoenzyme of creatinine phosphokinase (CPK) has been described as a specific indicator of myocardial injury. Therefore the CPK-MB isoenzyme level was evaluated as a potential aid in the diagnosis of AMI in the early postoperative period. Thirty patients undergoing cardiac surgery and 7 patients undergoing thoracic surgery not involving the heart were studied. CPK-MB isoenzyme was present in the serum in 10 of 30 patients after cardiac surgery but in none of 7 patients after thoracic surgery. The presence of CPK-MB isoenzyme was found to be a valuable adjunctive indicator in the diagnosis of AMI in the early postoperative period.

PMID: 1271838 [PubMed - indexed for MEDLINE]

44.		
Wisptav Abstract	ct 120 will Sort will Sandisa Il Tout	:0000
	Show: 120 John Shows Text	

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37

h

cb

hgeeefcgc

e e e

h he

.

Related Articles, Links







***************************************	***************************************	,	w.x. 1-w	Annual III	~~~	or mea	manne. 📾	A. W. A. S.	
	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Boo
1	∕led	for					Go	Clear	
		Limits	Previe	w/Index	History	Cli	pboard	De	tails
About Entrez		Display Abst	ract	Sho	w: 20 <b>▼</b> Sor	t j	Send	to Text	×

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy

Text Version

E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Diagnosis of acute myocardial infarction in a community hospital: significance of CPK-MB determination.

Roark SF, Wagner GS, Izlar HL Jr, Roe CR.

1: Circulation. 1976 Jun;53(6):965-9.

Twice-daily CPK-MB determinations were performed but not made availabe to the physicians of 179 consecutive patients with precordial pain admitted to a community hospital to evaluate the diagnostic importance of this isoenzyme. Physician decision was based upon history and once-daily ECG and total enzymes (CPK, SGOT, LDH). Following hospital discharge, each patient's clinical record was reviewed to determine the physician diagnostic decision. The patients were subdivided into three groups. The first group consisted of 46 patients with diagnostic QRS changes and elevated total enzymes. All 46 had physician diagnosis of acute myocardial infarction and CPK-MB was present in 44 (96%). The second group included 55 patients with nondiagnostic QRS but elevated total enzymes. Physician diagnosis was acute myocardial infarction in 28 (51%) but 16 (57%) of these had no CPK-MB. The third group contained 50 patients with nondiagnostic QRS and normal enzyme levels. Six (12%) had physician diagnosis of acute myocardial infarction but none had CPK-MB. Thus, absence of CPK-MB failed to confirm physician diagnosis of acute myocardial infarction when based upon history and total enzymes in the absence of QRS changes in 22 of 34 (65%) patients.

PMID: 1269133 [PubMed - indexed for MEDLINE]

Display Abstract ▼	Show: 20 💌	Sort •	Send to Text ▼

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37

h

ch

hg e e e fcg c

e e e b


C

Related Articles, Links





1: Cancer Chemother Pharmacol. 1980;4(2):95-101.



		•		, , , , , , , , , , , , , , , , , , ,		*******			
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMM	PMC	Journals	800
Search F	ubMed	for			***************************************		Go	Clear	
		Limits	Previ	ew/Index	History	Clip	pboard	Det	ails
About Entre	Z	Display Abst		Sho	100 ***********	rt 💌			¥
Text Version	1							- <del>-</del>	

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

#### Evaluation of antitumor drug side effects in small animals.

Bradner WT, Schurig JE, Huftalen JB, Doyle GJ.

This is an initial report on the development of screening tests for side effects of antitumor drugs, with small amounts of compound and short time intervals. These tests are based on acute dosing of mice and various blood or serum measurements: (a) total white blood cell count for leukopenia; (b) BUN for kidney toxicity; (c) SGPT for liver toxicity; and (d) creatine phosphokinase MB isozyme (CPK-MB) for cardiotoxicity. A correlation with the toxicity observed in other species is developed by establishing the effect of a prototype compound for each toxicity and tests of one or more compounds expected to lack such toxicity. On the basis of the limited number of compounds studied all four tests, although varying in sensitivity, seem to correlate with the results of tests in other species and with known effects in man. Final validation of these acute tests, especially the CPK-MB, will require both further study of histopathologic effects and correlation with results from clinical trials of an extended list of agents.

PMID: 7389061 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 🕶	Sort <b>→ Sen</b> d to Text <b>→</b>

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37

h

cb

hg e e e fcg c

e e e b b

) с







Send to

Entrez	PubMed	Nucleotide		Benome	Structure	OMM	PMC	Journals	800
~ 1	PubMed	33333			***************************************		Gol	Clear	
		Limits	Preview/I	ndex	History	Clin	board	ne	tails

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central 1: Clin Cancer Res. 1995 Oct;1(10):1145-52.

Display

Abstract

Related Articles, Links

Ψ

# Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.

**▼** | Sort

#### Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L.

▼ Show: 20

Texas Tech University Health Sciences Center, Lubbock, Texas 79430, USA.

Interleukin (IL) 2 plays an important role in enhancing the immune response, whereas IL-4 has pluripotent activities which include affecting immune function. Preclinical data suggest that the combination might have enhanced immunomodulatory activity. In this Phase I trial in patients with advanced solid tumors, both IL-2 and IL-4 were given by separate s.c. injections simultaneously daily, 5 days in a row, Monday through Friday, for 3 consecutive weeks, followed by a 1-week break from treatment. Cycles could be repeated. The dose of IL-2 was kept constant at 9 x 10(6) IU/m2/injection while the dose of IL-4 was escalated beginning at 100 microgram/m2/injection and increasing by 100-microgram/m2 increments to a planned level of 400 microgram/m2/injection. Sixteen patients were entered in this study, with one patient being ineligible because of the presence of brain metastases. Of the 15 eligible patients, there were 14 males and 1 female, with a median age of 54 (range, 38-67) years and initial performance status of 0 in 5 patients and 1 in 10 patients. Patients were treated at levels of up to 300 microgram/m2/injection of IL-4 before the study was closed due to withdrawal of the drug by the manufacturer. The most commonly observed toxicities were fatigue, fever and chills, local reaction, nausea/vomiting and anorexia, headache and nasal stuffiness, and coughing, sometimes with the production of clear white sputum, more common in smokers. Duodenal ulcers occurred in one patient and one patient had grade 4 cardiac toxicity consisting of an asymptomatic minimal elevation of the creatinine phosphokinase MB isoenzyme (CPK-MB). Grade 3 hyponatremia occurred in two patients, and elevated liver function tests and creatinine occurred but were not dose limiting. Eosinophilia of unknown significance occurred in all patients. There were statistically significant elevations in absolute numbers of most T-cell subsets examined, without changes in circulating B cells. No antibodies to the IL-4 were found after one cycle. One patient with renal cell carcinoma showed a significant decrease in tumor burden after one cycle of treatment. Because of the IL-4 withdrawal, the maximum tolerated dose for this combination of drugs given by the route and schedule used here was not determined and will require additional testing. Subcutaneous IL-2 and IL-4 given simultaneously show important immunomodulatory and antitumor effects and should be tested further in cancer patients.

Related Articles, Links





1: J Invasive Cardiol. 1996;8 Suppl C:3C-9C.



***************************************	***************************************		A		OX SATES	THE THE PARTY		
	Med Nucleotide	Protein	Genome	Structure	MIMO	PMC	Journals	900
Search PubMe	(00000	for		************		Go	Clear	
	Limits	Previ	ew/Index	History	Clip	ppoard	Det	ails
About Entrez	Display A	bstract	Sho	w: 20 🔻 So	rt 💽	Sendt	0 Text	

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts Clinical Trials.gov PubMed Central Frequency and Prognostic Importance of Creatine Phosphokinase Myocardial Isoforms after Successful Balloon and New Device Coronary Angioplasty.

Lansky AJ, Popma JJ, Mintz GS, Bucher TA, Kent KM, Pichard AD, Satler LF, Leon MB.

Director, Angiographic Core Laboratory, 110 Irving Street, N.W., Suite 4B-1, Washington, D.C., 20010, USA.

The frequency and prognostic importance of subclinical myocardial necrosis after new device coronary intervention is not known. To identify the frequency of CPK-MB release after balloon and single new device angioplasty in native coronary arteries, we reviewed the course of 810 patients who underwent successful single lesion, native vessel angioplasty using balloon angioplasty (N=174), Gianturco-Roubin stent placement for suboptimal angioplasty results (N=31), Palmaz-Schatz stent deployment (N=320), directional coronary atherectomy (N=102), or rotational atherectomy (N=183). All patients had serial measurements of CPK-MB isoenzymes 6 and 18Eth24 hours after coronary intervention; absolute CPK-MB levels were determined by radioimmunoassay (normal assay < 4 ng/ml). CPK-MB isoenzymes were > 2 times normal (> 8 ng/dl) in 15.6% of procedures, > 3 times normal ((3) 12 ng/ml) in 11.5% of procedures, > 4 times normal ((3) 16 ng/ml) in 8.6% of procedures, and  $\geq$  5 times normal ((3) 20 ng/ml) in 7.7% of procedures. CPK-MB elevation > 2 times normal was more common in those undergoing directional atherectomy (20.8%) and Gianturco-Roubin stent placement (34,4%) than in those undergoing balloon angioplasty (11.7%). No significant differences were noted in patients undergoing rotational atherectomy (13.2%) or Palmaz-Schatz stent placement (15.6%) than in those undergoing balloon angioplasty. CPK-MB > 5 times normal occurred after 7.7% of procedures, but did not vary significantly among the devices used in this study. We conclude that CPK-MB elevations > 2 times normal are highest in patients undergoing directional coronary atherectomy and ObailoutO use of the Gianturco-Roubin stent. No significant differences in CPK-MB elevation were seen in patients undergoing balloon angioplasty, Palmaz-Schatz stent deployment, or rotational atherectomy. Identification of the prognostic importance of these CPK-MB elevations is currently under study.

PMID: 10785773 [PubMed - as supplied by publisher]

b







Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	860
Search F	<sup>o</sup> ubMed	for					Go	Clear	
-		Limits	Previ	ew/Index	History	Cli	pboard	Det	ails
About Entre	z	Display Abstr	act	Sho	w: 20 <b>★</b> Se	ort *	Cand	to Text	<b>*</b>

.

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Gueries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts Clinical Trials.gov PubMed Central ☐ 1: Cardiovasc Res. 1996 Sep;32(3):570-9.

Related Articles, Links

FULL TEXT ARTICLE

The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo.

Ito A, Shimokawa H, Fukumoto Y, Kadokami T, Nakaike R, Takayanagi T, Egashira K, Sueishi K, Takeshita A.

Research Institute of Angiocardiology and Cardiovascular Clinic, Kyushu University School of Medicine, Fukuoka, Japan.

OBJECTIVE: We recently demonstrated that chronic treatment with interleukin-1 beta (IL-1 beta), a major inflammatory cytokine found in atherosclerotic lesions, induces coronary arteriosclerotic changes and vasospastic responses to serotonin and histamine in pigs in vivo and that those responses are partially mediated by platelet-derived growth factor (PDGF). This study was designed to examine, first, whether the effects of IL-1 beta are also partially mediated by fibroblast growth factor-2 (FGF-2), which is another important growth factor in atherosclerotic lesions, and, secondly, whether chronic treatment with FGF-2 per se also induces histological and functional changes in porcine coronary arteries in vivo. METHODS: Porcine coronary arteries were aseptically wrapped with cotton mesh absorbing IL-1 beta with or without neutralizing antibody to FGF-2. In a separate series of experiments porcine coronary arteries were chronically treated with FGF-2 itself in the same manner. Coronary vascular responses in vivo and histological changes were examined 2 weeks after the operation. RESULTS: Coronary vasospastic responses to serotonin and histamine and neointimal formation were induced at the site of the coronary artery where IL-1 beta was chronically and locally applied. These responses were significantly suppressed by co-treatment with a neutralizing antibody to FGF-2 but not by that with non-immune IgG. Immunostaining revealed the presence of FGF-2 in the endothelial cells, the thickened intima and the media at the IL-1 betatreated site. Furthermore, chronic treatment with FGF-2 also induced coronary vasospastic responses to serotonin and histamine and neointimal formation. CONCLUSIONS: These results suggest that the vascular effects of IL-1 beta may also be mediated by FGF-2 in our swine model and that chronic treatment with FGF-2 also causes coronary arteriosclerotic changes and vasospastic responses in vivo.

PMID: 8881517 [PubMed - indexed for MEDLINE]







Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	800
Search	PubMed	for					Go	Clear	
		Limits	Previ	ew/Index	History	Cli	pboard	Deta	ils
Okana da eta antaria		***************************************							

About Entrez

**Text Version** 

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts Clinical Trials gov PubMed Central 1: J Am Coll Cardiol. 2000 Mar 1;35(3):647-54.

Related Articles, Links

 $\overline{\phantom{a}}$ 

FULL-TEXT ARTICLE

Display Abstract

Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.

▼ Show: 20 ▼ Sort

Ruotolo G, Bavenholm P, Brismar K, Efendic S, Ericsson CG, de Faire U, Nilsson J, Hamsten A.

Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, Sweden.

OBJECTIVES: We investigated whether the effect of bezafibrate on progression of coronary atherosclerosis in the BEzafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was related to insulin-like growth factor (IGF)-I and glucose-insulin homeostasis. BACKGROUND: BECAIT, the first double-blind, placebo-controlled, randomized, serial angiographic trial of a fibrate compound, demonstrated that progression of focal coronary atherosclerosis in young patients after infarction could be retarded by bezafibrate treatment. METHODS: The treatment effects on serum concentrations of IGF-I and insulin-like growth factor binding protein (IGFBP)-1, as well as on basal and postload glucose and insulin levels, were examined, and on-trial determinations were related to the angiographic outcome measurements. RESULTS: Bezafibrate treatment resulted in a significant reduction of serum IGF-I levels, both at two and five years, and on-trial serum IGF-I levels were directly related to changes in both minimal lumen diameter (r = 0.25, p < 0.05) and mean segment diameter (r = 0.29, p <0.05). In contrast, none of the available indexes of insulin resistance (homeostasis model assessment estimate, basal and postload plasma insulin concentrations and serum IGFBP-1 levels) were related to the angiographic changes, nor were they significantly affected by bezafibrate treatment. Multiple stepwise regression analysis showed that the relation between ontrial serum IGF-I level and coronary artery disease (CAD) progression was independent of baseline angiographic score, age, body mass index, serum lipoprotein and plasma fibrinogen concentrations and measures of glucoseinsulin homeostasis. CONCLUSIONS: IGF-I could be implicated in the progression of premature CAD, and a reduction of serum IGF-I concentration could account partly for the effect of bezafibrate on progression of focal coronary atherosclerosis.

### Publication Types:

Clinical Trial







Ennez PubMed Nucleotide OMIM Protein Genome Structure PMC Journals Boo. Search PubMed Go Clear for Limits Preview/Index Clipboard History Details

About Entrez

**Text Version** 

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central 1: Am J Cardiol. 1999 Aug 15;84(4):430-3.

Related Articles, Links

Text

¥

FULL TEXT ARTICLE

Display Abstract

Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.

Spallarossa P, Rossettin P, Minuto F, Caruso D, Cordera R, Battistini M, Barreca A, Masperone MA, Brunelli C.

Department of Internal Medicine, University of Genoa, Italy.

Show: |20

We have examined the effects of 6 months of treatment with growth hormone (GH) (0.02 U/kg/day) in 10 patients with chronic postischemic cardiac failure. Ten patients matched for age, body mass index, functional class, and ejection fraction served as a control group. In the GH group, 1 patient died and 2 were withdrawn from the study because of arrhythmia or worsening of heart failure. In the control group, 1 patient died and 1 patient was withdrawn from the study because of progressive heart failure. Among GH patients, those with an unfavorable outcome had a greater left ventricular end-diastolic diameter (79, 82, and 88 mm) on entry to the study than patients without adverse events (range 62 to 72 mm). At the end of the study, the seven GH patients reported a feeling of well-being and had a significant increase in their exercise test duration (462 +/- 121 vs 591 +/- 105 seconds, p <0.05). Low baseline insulin-like growth factor-I values were increased with GH treatment (189 +/- 52 vs 100 +/- 22 ng/ml, p <0.01). GH did not change left ventricular diameters or wall thickness. A trend toward decreased serum triglyceride levels and adipose body tissue associated with an increase in high-density lipoproteins was observed in the GH group. In conclusion, our present data support previous suggestions that GH treatment exerts some beneficial effects in patients with chronic, stabilized, moderately severe heart failure, but may have deleterious effects in patients with more severe heart failure.

## **Publication Types:**

- Clinical Trial
- Controlled Clinical Trial

PMID: 10468082 [PubMed - indexed for MEDLINE]

Display Abstract ▼ Show: 20 ▼ Sort ▼ Send to Text ▼

Write to the Help Desk NCBI | NLM | NIH







Entres Publised Nucleotide Protein Genome Structure OMIM **FMC** Journals See: Search PubMed for FGF-1 AND coronary artery disease Go Clear Limits Preview/Index History Clipboard Details About Entrez Display Summary ★ Show: 500 ★ Send to Text Items 1-7 of 7 One page. **Text Version** 1: Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R. Related Articles, Links Entrez PubMed Ethanol inhibits fibroblast growth factor-induced proliferation of aortic Overview Help | FAQ smooth muscle cells. Tutoria: Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 07. New/Noteworthy PMID: 12907464 [PubMed - indexed for MEDLINE] E-Utilities 2: Ananyeva N, Tjurmin A, Saenko E, Haudenschild C. Related Articles, Links **PubMed Services** Low density lipoproteins interact with acidic fibroblast growth factor and Journals Database MeSH Database modify its function. Single Citation Matcher Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 06. **Batch Citation Matcher** PMID: 12692004 [PubMed - indexed for MEDLINE] Clinical Queries LinkOut 3: Sellke FW, Ruel M. Related Articles, Links Cubby Vascular growth factors and angiogenesis in cardiac surgery. Ann Thorac Surg. 2003 Feb;75(2):S685-90, Review. Related Resources Order Documents PMID: 12607713 [PubMed - indexed for MEDLINE] **NLM Gateway** TOXNET 4: Schumacher B, Hannekum A, Pecher P. Related Articles, Links Consumer Health Neoangiogenesis by local gene therapy: a new therapeutic concept in the Clinical Alerts ClinicalTrials.gov treatment of coronary diseasel PubMed Central Z Kardiol. 2000;89 Suppl 7:23-30. German. PMID: 11098556 [PubMed - indexed for MEDLINE] 5: Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker Related Articles, Links LC, Anversa P, Capogrossi MC Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart. Microvasc Res. 1999 Nov;58(3):238-49. PMID: 10527767 [PubMed - indexed for MEDLINE] 6. Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Related Articles, Links Yamazato A, Fujita M. Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application. Clin Chim Acta. 1999 May;283(1-2):171-82. PMID: 10404741 [PubMed - indexed for MEDLINE] 7: Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M. Related Articles, Links Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery. 1996 Aug;120(2):182-8. PMID: 8751581 [PubMed - indexed for MEDLINE]

> Write to the Help Desk NCBI | NLM | NIH

Show: 500 Sort

Summary

Display

Send to

Text





Display Abstract



Send to

C

Text

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	MIMO	FMC	Journals	800
Search F	PubMed	for					Go	Clear	
		Limits	Previ	ew/Index	History	Cli	pboard	Deta	ails

Show: 20

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilifies

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Surgery. 1996 Aug;120(2):182-8. Related Articles, Links

Sort

Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.

Department of Surgery, Beth Israel Hospital, Boston, MA 02215, USA.

BACKGROUND: The effect of periadventitial administration of acidic fibroblast growth factor (FGF) on coronary microvascular reactivity and blood flow was examined in the collateral-dependent and normally perfused myocardium. METHODS: Ameroid constrictors were placed on the proximal left circumflex (LCx) coronary artery in 14 pigs. In seven pigs acidic FGF (10 micrograms) was administered into the perivascular space of the proximal LCx artery by using an ethylene vinyl acetate copolymer slow release device. After 7 to 9 weeks coronary arterial microvessels (70 to 150 microns) were studied in a pressurized (40 mm Hg) no-flow state with video microscopy. RESULTS: Relaxation mediated by beta-adrenoceptors and induced by isoproterenol ( $p \le 0.05$ ), and endothelium-dependent relaxation induced by adenosine 5' diphosphate (ADP) (p < 0.05) of isolated microvessels from the collateral-dependent LCx region were markedly reduced compared with the respective responses of vessels from the normally perfused left anterior descending (LAD) artery region. Relaxation induced by the adenylate cyclase activator forskolin and the guanylate cyclase activator sodium nitroprusside were unaltered. Chronic treatment with acidic FGF normalized responses to isoproterenol (p < 0.001 versus nontreated LCx) and ADP (p < 0.001 versus nontreated LCx) in the collateral-dependent LCx region, whereas responses to forskolin and sodium nitroprusside were not changed. Blood flow in the collateral-dependent LCx region (0.49 +/- 0.24 ml/min/gm) was less than that in the normally perfused LAD region (0.80 +/- 0.24 ml/min/gm, p < 0.05). Treatment with acidic FGF improved perfusion in the LCx region (0.80 +/-0.06 ml/min/gm, p < 0.05) but did not significantly affect blood flow in the LAD territory (0.89 +/- 0.09 ml/min/gm). CONCLUSIONS: The periadventitial delivery of acidic FGF normalizes vasomotor regulation by beta-adrenergic and endothelium-dependent mechanisms and improves myocardial perfusion to the collateral-dependent myocardium. This may have implications regarding the treatment of patients with severe coronary artery disease who are not ameneable to conventional methods of revascularization.

PMID: 8751581 [PubMed - indexed for MEDLINE]







Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	866
Search	PubMed	for		<del>-</del> -			Go	Clear	
		Limits	Previe	ew/Index	History	Clip	oboard	Deta	ails

▼ Show: 20

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials gov PubMed Central 1: Microvasc Res. 1999 Nov;58(3):238-49.

Related Articles, Links

 $\sim$ 

FULL TEXT ARTICLE

Abstract

Display

Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.

▼ Sort

Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC.

Laboratory of Cardiovascular Science, National Institutes of Health, Baltimore, Maryland 21224, USA.

Most patients with severe coronary artery disease have normal baseline myocardial blood flow. Therefore, interventions aimed at inducing therapeutic angiogenesis in these patients should cause new blood vessel growth in the heart in the absence of chronic ischemia. It was examined whether adenovirus-mediated gene transfer of recombinant, secreted acidic fibroblast growth factor (sp+aFGF(1-154)), next to a major epicardial artery, may induce neovascularization and reduce the risk region for myocardial infarction upon coronary ligation near the injection site. Fifteen days prior to coronary artery occlusion, rabbits were treated with intramyocardial injections of AdCMV.sp+aFGF(1-154), the control vector AdCMV.NLSbetagal (1 x 10 (9) plaque-forming units), or saline. Messenger RNA transcripts for aFGF(1-154) were present up to 12 days after injection in the tissues exposed to AdCMV.aFGF(1-154). Following coronary artery occlusion rabbits treated with AdCMV. sp+aFGF(1-154) showed a 50% reduction of the risk region for myocardial infarction ( $P \le 0.01$  vs control). Histologic analysis showed a twofold increase in length density of intramural coronary arterioles ( $P \le 0.01$ vs control) and a 17% increase in length density of the capillary network (P < 0.001) in the myocardium exposed to AdCMV sp+aFGF(1-154). Thus, gene therapy with AdCMV. sp+aFGF(1-154) can induce angiogenesis in the absence of chronic ischemia. The newly formed collateral blood vessels provide an anatomical basis for the reduction in the risk region for myocardial infarction upon subsequent occlusion of the coronary artery in proximity of the site where angiogenesis was induced. Copyright 1999 Academic Press.

PMID: 10527767 [PubMed - indexed for MEDLINE]

Display Abstract	Show:	20 👻	Sort ¥	Send to	Text <b>▼</b>

Write to the Help Desk NCBI | NLM | NIH







**PubMed** Nucleotide Protein Genome Structure OMIM PMC Journals 300 Search PubMed for aFGF AND coronary artery disease Go Clear Preview/Index Clipboard Details Limits History About Entrez Display | Summary ▼ Show: |500 ▼ |Sort Send to Text Items 1-7 of 7 One page. Text Version 1: Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R. Related Articles, Links Entrez PubMed Ethanol inhibits fibroblast growth factor-induced proliferation of aortic Overview smooth muscle cells. Help | FAQ Tutorial Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 07. New/Noteworthy PMID: 12907464 [PubMed - indexed for MEDLINE] E-Utilities 2: Ananyeva N, Tjurmin A, Saenko E, Haudenschild C. Related Articles, Links **PubMed Services** Low density lipoproteins interact with acidic fibroblast growth factor and Journals Database modify its function. MeSH Database Single Citation Matcher Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 06. **Batch Citation Matcher** PMID: 12692004 [PubMed - indexed for MEDLINE] Clinical Queries LinkOut **3:** Sellke FW, Ruel M. Related Articles, Links Cubby Vascular growth factors and angiogenesis in cardiac surgery. Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review. Related Resources PMID: 12607713 [PubMed - indexed for MEDLINE] Order Documents **NLM Gateway** 4: Schumacher B. Hannekum A. Pecher P. Related Articles, Links TOXNET Consumer Health [Neoangiogenesis by local gene therapy: a new therapeutic concept in the Clinical Alerts ClinicalTrials.gov treatment of coronary disease PubMed Central Z Kardiol. 2000;89 Suppl 7:23-30. German. PMID: 11098556 [PubMed - indexed for MEDLINE] 5: Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker Related Articles, Links LC. Anversa P. Capogrossi MC Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart. Microvasc Res. 1999 Nov;58(3):238-49. PMID: 10527767 [PubMed - indexed for MEDLINE] 6: Ikemoto M. Hasegawa K. Kihara Y. Iwakura A. Komeda M. Related Articles, Links Yamazato A, Fujita M. Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application. Clin Chim Acta. 1999 May;283(1-2):171-82. PMID: 10404741 [PubMed - indexed for MEDLINE] 7: Sellke FW, Li J. Stamler A. Lopez JJ. Thomas KA, Simons M. Related Articles, Links Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery. 1996 Aug;120(2):182-8. PMID: 8751581 [PubMed - indexed for MEDLINE]

> Write to the Help Desk NCBI | NLM | NIH

Sort

b e

Send to

Text

**★** Show: 500

Summary

Display







Go

Entres PubMed Nucleotide

Protein Genome Structure

OMIM

PMC

Journals

Clear

See:

Search PubMed

for acidic FGF AND coronary artery disease Limits

Preview/Index

History

Clipboard

Details

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries LinkOut Cubby

Related Resources Order Documents **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Display Summary ▼ Show: 500 ▼ Sort Send to Text Items 1-2 of 2 One page.

1: Ananyeva N. Tjurmin A. Saenko E. Haudenschild C.

Related Articles, Links

Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 06. PMID: 12692004 [PubMed - indexed for MEDLINE]

2: Sellke FW, Li J. Stamler A. Lopez JJ. Thomas KA, Simons M.

Related Articles, Links

Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

Surgery. 1996 Aug;120(2):182-8.

PMID: 8751581 [PubMed - indexed for MEDLINE]

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37

Related Articles, Links







PubMed Nucleotide OMIM PMC Entrez Protein Genome Structure Journals Sec. Search PubMed for FGF-2 AND coronary artery disease Go Clear Limits Preview/Index Clipboard Details History About Entrez Display **★** Show: 500 ★ Send to Summary Text Items 1-36 of 36 One page. **Text Version** 1: van Royen N. Voskuil M. Hoefer I, Jost M. de Graaf S, Hedwig F. Related Articles, Links Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Entrez PubMed Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST. Overview Help | FAQ CD44 regulates arteriogenesis in mice and is differentially expressed in Tutoria! patients with poor and good collateralization. New/Noteworthy Circulation. 2004 Apr 6;109(13):1647-52. Epub 2004 Mar 15. E-Utilities PMID: 15023889 [PubMed - indexed for MEDLINE] **PubMed Services** 1 2: Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Related Articles, Links Journals Database Gielen S, Emmrich F, Schuler G, Hambrecht R. MeSH Database Single Citation Matcher Increase of circulating endothelial progenitor cells in patients with coronary **Batch Citation Matcher** artery disease after exercise-induced ischemia. **Clinical Queries** Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26. LinkOut PMID: 14988094 [PubMed - indexed for MEDLINE] Cubby 3: Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato Related Articles, Links Related Resources L. Smith ML. Landolfo C. Lowe JE, Annex BH, Landolfo KP. Order Documents Intramyocardial and intracoronary basic fibroblast growth factor in porcine **NLM Gateway** TOXNET hibernating myocardium: a comparative study. Consumer Health J Thorac Cardiovasc Surg. 2004 Jan; 127(1):34-43. Clinical Alerts PMID: 14752410 [PubMed - indexed for MEDLINE] ClinicalTrials.gov PubMed Central 4: Aviles RJ, Annex BH, Lederman RJ. Related Articles, Links Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2). Br J Pharmacol. 2003 Oct;140(4):637-46. PMID: 14534147 [PubMed - in process] 5: Ruel M, Sellke FW. Related Articles, Links Angiogenic protein therapy. Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review. PMID: 12973700 [PubMed - indexed for MEDLINE] 6: Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham Related Articles, Links RJ, Sellke FW Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation. 2003 Sep 9,108 Suppl 1:II335-40. PMID: 12970256 [PubMed - indexed for MEDLINE] 7: Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R. Related Articles, Links Ethanol inhibits fibroblast growth factor-induced proliferation of a ortic smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 07.

cb hg e e e fcg e ch b e

Nishimura K, Tabata Y, Komeda M.

PMID: 12907464 [PubMed - indexed for MEDLINE]

8: Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M,

cb

hg e e

e fcg

e ch

	Toward surgical angiogenesis using slow-released basic fi factor. Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112. PMID: 12853053 [PubMed - indexed for MEDLINE]	ibroblast growth
<b>-</b> 9: ]	Sellke FW, Ruel M.	Related Articles, Links
	Vascular growth factors and angiogenesis in cardiac surge Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review. PMID: 12607713 [PubMed - indexed for MEDLINE]	ery.
<b>I</b> 10:	Zhang C, Yang J, Feng J, Jennings LK.	Related Articles, Links
	Short-term administration of basic fibroblast growth fact coronary collateral development without exacerbating at balloon injury-induced vasoproliferation in atherosclerot acute myocardial infarction.  J Lab Clin Med. 2002 Aug;140(2):119-25. PMID: 12228768 [PubMed - indexed for MEDLINE]	herosclerosis and
□11:	Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P.	Related Articles, Links
	Basic fibroblast growth factor changes in response to conin patients with stable angina. Int J Cardiol. 2002 Aug;84(2-3):195-9. PMID: 12127372 [PubMed - indexed for MEDLINE]	ronary angioplasty
□ 12:	Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M.	Related Articles, Links
	The effect of intracoronary fibroblast growth factor-2 on primary angioplasty or stent placement in a pig model of Clin Cardiol. 2002 Jun;25(6):271-8. PMID: 12058790 [PubMed - indexed for MEDLINE]	
□ 13:	Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P.	Related Articles, Links
	Serum basic fibroblast growth factor levels in exercise-in ischemia more likely a marker of endothelial dysfunction ischemia? Eur J Med Res. 2002 Mar 28;7(3):93-7. PMID: 11953278 [PubMed - indexed for MEDLINE]	•
□14:	Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA.	Related Articles, Links
	Pharmacological treatment of coronary artery disease wifibroblast growth factor-2: double-blind, randomized, cotrial.  Circulation. 2002 Feb 19;105(7):788-93.  PMID: 11854116 [PubMed - indexed for MEDLINE]	
□ 15:	Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA.	Related Articles, Links
	Pharmacokinetics and pharmacodynamics of recombinar I trial in coronary artery disease.  J Clin Pharmacol. 2001 Apr;41(4):378-85.  PMID: 11304894 [PubMed - indexed for MEDLINE]	nt FGF-2 in a phase
<b>16</b> :	Rosengart TK, Hillebrand K	Related Articles, Links
	Gene therapy for coronary artery disease.  Adv Card Surg. 2001;13:107-20. Review. No abstract available.  PMID: 11209652 [PubMed - indexed for MEDLINE]	

ch

h g

e fcg

e ch

b e

17: Lambiase P, Edwards R, Bucknall CA, Marber MS. Related Articles, Links Physiologically assessed collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation. 2001 Jan 30;103(4):E22. No abstract available. PMID: 11157734 [PubMed - indexed for MEDLINE] 18: Schumacher B, Hannekum A, Pecher P. Related Articles, Links [Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease] Z Kardiol. 2000;89 Suppl 7:23-30. German. PMID: 11098556 [PubMed - indexed for MEDLINE] 19: Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais Related Articles, Links M. Galt JR, Pike M. Yoshizawa C, Simons M. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation. 2000 Oct 3;102(14):1605-10. PMID: 11015335 [PubMed - indexed for MEDLINE] 20: Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Related Articles, Links Cannon RO 3rd, Quyyumi AA. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol. 2000 Jun 15;85(12):1414-9. PMID: 10856385 [PubMed - indexed for MEDLINE] 21: Lucassen AM, de Waal RM. Verheugt FW. Related Articles, Links Therapeutic angiogenesis as a new experimental treatment for vascular disease Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5. Review. Dutch. PMID: 10774292 [PubMed - indexed for MEDLINE] 122: Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Related Articles, Links Fishbein MC, Meehan WP, Hsueh WA. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 2000 Mar 21;101(11):1311-8. PMID: 10725292 [PubMed - indexed for MEDLINE] 1 23. Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Related Articles, Links Seiler C. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation. 1999 Nov 9;100(19):1945-50. PMID: 10556219 [PubMed - indexed for MEDLINE] 124: Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Related Articles, Links Yamazato A, Fujita M. Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application. Clin Chim Acta. 1999 May;283(1-2):171-82. PMID: 10404741 [PubMed - indexed for MEDLINE] 1 25: Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Related Articles, Links Sasayama S. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.

PMID: 10082659 [PubMed - indexed for MEDLINE] 26: Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW. Related Articles, Links Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation. J Thorac Cardiovasc Surg. 1998 Dec;116(6):1022-8. PMID: 9832695 [PubMed - indexed for MEDLINE] Related Articles, Links 27: Iwakura A, Komeda M, Fujita M. [Coronary stenosis and mechanisms of collateral vessel growth] Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese. PMID: 9796310 [PubMed - indexed for MEDLINE] 28: Selike FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Related Articles, Links Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg. 1998 Jun;65(6):1540-4. PMID: 9647055 [PubMed - indexed for MEDLINE] 129: Hasdai D, Barak V, Leibovitz E, Herz I, Sclarovsky S, Eldar M, Related Articles, Links Scheinowitz M. Serum basic fibroblast growth factor levels in patients with ischemic heart Int J Cardiol. 1997 Apr 18;59(2):133-8. PMID: 9158164 [PubMed - indexed for MEDLINE] 130: Ito A. Shimokawa H. Fukumoto Y. Kadokami T. Nakaike R. Related Articles, Links Takayanagi T, Egashira K, Sueishi K, Takeshita A. The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo. Cardiovasc Res. 1996 Sep;32(3):570-9. PMID: 8881517 [PubMed - indexed for MEDLINE] 31: Taylor AJ, Farb AA, Angello DA, Burwell LR, Virmani R. Related Articles, Links Proliferative activity in coronary atherectomy tissue. Clinical, histopathologic, and immunohistochemical correlates. Chest. 1995 Sep;108(3):815-20. PMID: 7656639 [PubMed - indexed for MEDLINE] 132: Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Related Articles, Links Pepine C.J. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation. 1994 Apr, 89(4):1511-7. PMID: 7908609 [PubMed - indexed for MEDLINE] 33: Wilcox JN. Related Articles, Links Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. Am J Cardiol. 1993 Oct 18;72(13):88E-95E. Review. PMID: 8213576 [PubMed - indexed for MEDLINE] 34: Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. Related Articles, Links A cascade model for restenosis. A special case of atherosclerosis

h cb h g e ch e e e fcg

Circulation. 1992 Dec;86(6 Suppl):III47-52. Review. PMID: 1424051 [PubMed - indexed for MEDLINE]

progression.

□ 35:	Gordon D.	Related Articles, Links								
0.00000 0.00000 0.00000 0.00000	Growth factors and cell proliferation in human transplant arteriosclerosis.  J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S7. No abstract available.  PMID: 1623005 [PubMed - indexed for MEDLINE]									
□36:	Heidemann P, Hofling B, Heimerl J, Emberger C, Meyer G, Kandolf R, Bauriedel G	Related Articles, Links								
	[Proliferative response of smooth muscle cells from hur lesions to PDGF, bFGF and EGF] Vasa Suppl. 1992;35:137-9. German. No abstract available. PMID: 1481019 [PubMed - indexed for MEDLINE]	man arteriosclerosis								
Displa	y Summary 💌 Show: 500 💌 Sort 💌	Send to Text ▼								

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37







				•					
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMM	PMC	Journals	Box
Search	PubMed	for					Go	Clear	
		Limits	Previe	w/Index	History	Clip	preodo		Details

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials gov PubMed Central 1: J Thorac Cardiovasc Surg. 1998 Dec;116(6):1022-8.

J Thorac Cardiovasc Surg.

Display Abstract

Related Articles, Links

Text

Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-

▼ Sort

Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW.

Show: 20

Cardiovascular Angiogenesis Center of the Department of Medicine and Surgery, Harvard Medical School and Beth Research Division, Chiron Corporation, Emeryville, CA, USA.


induced reduction in endothelium-dependent vasodilatation.

OBJECTIVES: The present study was designed to study the effects of a single intrapericardial injection of basic fibroblast growth factor on myocardial vascular resistance and endothelium-dependent microvascular dilatation in a porcine model of chronic myocardial ischemia and to investigate the mechanism of ischemia-induced impairment of endothelium-dependent vasodilatation. METHODS: Yorkshire pigs underwent ameroid constrictor placement on the left circumflex coronary artery. At 3 weeks, animals were randomized to a single intrapericardial injection of saline solution (n = 10), 30 micrograms basic fibroblast growth factor (n = 10), or 2 mg basic fibroblast growth factor (n = 10). Myocardial vascular resistance in the normal (left anterior descending) and ischemic collateral-dependent (left circumflex artery) territories (using colored microspheres) and microvascular reactivity to adenosine diphosphate and sodium nitroprusside were measured before treatment and 4 weeks after treatment. The expression of inducible and endothelial nitric oxide synthase was determined in normal and ischemic myocardium by means of reverse transcriptase-polymerase chain reaction and Western analysis, and the effect of nitric oxide on endothelium-dependent vasodilatation was determined. RESULTS: Compared with results in the control group, treatment with basic fibroblast growth factor resulted in significant improvement in left circumflex artery resistance and endotheliumdependent vasodilatation, reflecting increased collaterals. Myocardial ischemia was associated with increased expression of inducible nitric oxide synthase with no change in endothelial nitric oxide synthase. However, the nitric oxide donor sodium nitroprusside did not affect endothelium-dependent vasodilatation to adenosine diphosphate. CONCLUSIONS: A single intrapericardial bolus of basic fibroblast growth factor may be a useful therapeutic strategy for the treatment of myocardial ischemia in patients with coronary artery disease. Although chronic myocardial ischemia is associated with increased expression of inducible nitric oxide synthase, it does not appear to be the cause of altered endothelial function.

Related Articles, Links







of Medicine PubMed Nucleotide Protein Genome Structure OMIM PMC Journals მიი: Search PubMed for bFGF AND coronary artery disease Go Clear Y Details Limits Preview/Index History Clipboard About Entrez Display Summary ★ Show: |500 ★ | Sort Send to Text Items 1-42 of 42 One page. Text Version 1: van Royen N, Voskuil M, Hoefer I, Jost M, de Graaf S, Hedwig F. Related Articles, Links Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Entrez PubMed Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST. Overview Help | FAQ CD44 regulates arteriogenesis in mice and is differentially expressed in Tutorial patients with poor and good collateralization. New/Noteworthy Circulation. 2004 Apr 6;109(13):1647-52. Epub 2004 Mar 15. E-Utilities PMID: 15023889 [PubMed - indexed for MEDLINE] **PubMed Services** 1 2: Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Related Articles, Links Journals Database Gielen S, Emmrich F, Schuler G, Hambrecht R MeSH Database Single Citation Matcher Increase of circulating endothelial progenitor cells in patients with coronary **Batch Citation Matcher** artery disease after exercise-induced ischemia. Clinical Queries Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26. LinkOut PMID: 14988094 [PubMed - indexed for MEDLINE] Cubby 13: Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato Related Articles, Links Related Resources L, Smith ML, Landolfo C, Lowe JE, Annex BH, Landolfo KP Order Documents Intramyocardial and intracoronary basic fibroblast growth factor in porcine **NLM Gateway** TOXNET hibernating myocardium: a comparative study. Consumer Health J Thorac Cardiovasc Surg. 2004 Jan;127(1):34-43. Clinical Alerts PMID: 14752410 [PubMed - indexed for MEDLINE] ClinicalTrials.gov PubMed Central 1 4: Panutsopulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE. Related Articles, Links Igoumenidis NE, Spandidos DA. Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression. J Transl Med. 2003 Oct 06;1(1):6. PMID: 14585103 [PubMed - as supplied by publisher] 5: Fujita M, Ikemoto M, Tanaka T, Tamaki S, Yamazato A, Sawamura Related Articles, Links T, Hasegawa K, Kihara Y, Nohara R, Sasayama S. Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris. Angiogenesis. 1998;2(1):105-8. PMID: 14517380 [PubMed] 6: Ruel M, Sellke FW. Related Articles, Links Angiogenic protein therapy. Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review. PMID: 12973700 [PubMed - indexed for MEDLINE] 7: Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham Related Articles, Links RJ, Sellke FW Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation. 2003 Sep 9;108 Suppl 1:II335-40.

cb hg e e e fcg e ch b

h

PMID: 12970256 [PubMed - indexed for MEDLINE]

8: Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.

cb

h g

e fcg

e



b e

e ch


hg e e

cb

h

		fibroblast growth factor-2: double-blind, randomized, co trial.	ntrolled clinical
		Circulation. 2002 Feb 19;105(7):788-93. PMID: 11854116 [PubMed - indexed for MEDLINE]	
1	17:	Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA.	Related Articles, Links
		Pharmacokinetics and pharmacodynamics of recombinar I trial in coronary artery disease.  J Clin Pharmacol. 2001 Apr;41(4):378-85.  PMID: 11304894 [PubMed - indexed for MEDLINE]	nt FGF-2 in a phase
	18:	Rosengart TK, Hillebrand K.	Related Articles, Links
		Gene therapy for coronary artery disease. Adv Card Surg. 2001;13:107-20. Review. No abstract available. PMID: 11209652 [PubMed - indexed for MEDLINE]	
1	19:	Lambiase P, Edwards R, Bucknall CA, Marber MS.	Related Articles, Links
		Physiologically assessed collateral flow and intracoronar concentrations in patients with 1- to 3-vessel coronary ar Circulation. 2001 Jan 30;103(4):E22. No abstract available. PMID: 11157734 [PubMed - indexed for MEDLINE]	
Ī	20:	Schumacher B, Hannekum A, Pecher P.	Related Articles, Links
		[Neoangiogenesis by local gene therapy: a new therapeutreatment of coronary disease] Z Kardiol. 2000;89 Suppl 7:23-30. German. PMID: 11098556 [PubMed - indexed for MEDLINE]	tic concept in the
	21:	Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M.	Related Articles, Links
		Therapeutic angiogenesis with recombinant fibroblast grimproves stress and rest myocardial perfusion abnormali with severe symptomatic chronic coronary artery disease Circulation. 2000 Oct 3;102(14):1605-10. PMID: 11015335 [PubMed - indexed for MEDLINE]	ties in patients
	22:	Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA.	Related Articles, Links
E		Effects of a single intracoronary injection of basic fibrob in stable angina pectoris.  Am J Cardiol. 2000 Jun 15;85(12):1414-9.  PMID: 10856385 [PubMed - indexed for MEDLINE]	last growth factor
	23:	Lucassen AM, de Waal RM, Verheugt FW.	Related Articles, Links
		[Therapeutic angiogenesis as a new experimental treatmedisease] Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5. Review. Dutch. PMID: 10774292 [PubMed - indexed for MEDLINE]	•
	24:	Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Mechan WP, Hsuch WA	Related Articles, Links
		Expression and function of PPARgamma in rat and huma muscle cells. Circulation. 2000 Mar 21;101(11):1311-8. PMID: 10725292 [PubMed - indexed for MEDLINE]	an vascular smooth
	25:	Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF.	Related Articles, Links

e fcg e ch b e




cb

hg e e e fcg

e ch

b e



Write to the Help Desk NCBI | NLM | NIH







				•					
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	MIMO	FMC	Journals	800
Search F	PubMed	for					Go	Clear	
		Limits		ew/Index	History	Clip	oboard	Det	ails
About Entre	Z	Display Abstra	ct	Sho	20 <b>▼</b>	Sort *	Sond	to Text	

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

**PubMed Services** Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

**1:** Life Sci. 1991;49(10):689-705.

Related Articles, Links

## Coronary atherosclerosis: current therapeutic approaches and future trends.

#### DeFeudis FV.

Institute for BioScience, Grafton, MA 01519.

Invasive cardiovascular procedures, such as percutaneous translumenal coronary angioplasty (PTCA) and aorto-coronary bypass surgery (ACBS), that are currently employed in treating the coronary stenosis or occlusion caused by atherosclerosis represent a major therapeutic advance for managing coronary heart disease (CHD). However, the cellular proliferative response and associated intimal hyperplasia that can follow the damage to blood vessels that occurs with these procedures leads to late complications which cannot be effectively controlled by presently available drugs. Hence, a new approach is required for managing these complications, termed "restenosis" (in the case of PTCA) or "stenosis" (in the case of ACBS). Existing drug therapy is reviewed and some new approaches to this problem are provided herein. Further studies of growth factors and other substances that influence the cellular proliferative response that follows injury to the blood vessel wall could lead to the development of effective therapy. Inhibition of intimal hyperplasia and/or acceleration of endothelial cell regrowth provide a basis for such new approaches. Platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF), as well as endothelium-derived relaxing factor(s) (EDRF) and calcitonin gene-related peptide (CGRP) are among the substances discussed. Modification of certain currently available drugs (e.g. Ca(2+)-antagonists) could also be of value in meeting this therapeutic demand.

## Publication Types:

- Review
- Review, Academic

PMID: 1875779 [PubMed - indexed for MEDLINE]

,				
Display Abstract ▼	ct 120 🔞	Sort •	Send to Text	

Write to the Help Desk NCBI | NLM | NIH







Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo! Search PubMed for basic FGF AND coronary artery disease Go ~ Clear Preview/Index Clipboard Limits History Details About Entrez Show: 500 \* Display Send to Text Summary Items 1-4 of 4 One page. **Text Version** 1: Aviles RJ, Annex BH, Lederman RJ. Related Articles, Links Entrez PubMed Testing clinical therapeutic angiogenesis using basic fibroblast growth factor Overview (FGF-2). Help | FAQ Tutorial Br J Pharmacol. 2003 Oct; 140(4):637-46. New/Noteworthy PMID: 14534147 [PubMed - in process] E-Utilities 1 2: Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Related Articles, Links Nishimura K, Tabata Y, Komeda M. **PubMed Services** Journals Database Toward surgical angiogenesis using slow-released basic fibroblast growth MeSH Database Single Citation Matcher Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112. Batch Citation Matcher PMID: 12853053 [PubMed - indexed for MEDLINE] **Clinical Queries** LinkOut 3. Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A. Related Articles, Links Cubby Castro JM, Fernandez-Ayerdi A, Cuevas P. Related Resources Serum basic fibroblast growth factor levels in exercise-induced myocardial Order Documents ischemia more likely a marker of endothelial dysfunction than a marker of **NLM Gateway** ischemia? TOXNET Eur J Med Res. 2002 Mar 28;7(3):93-7. Consumer Health PMID: 11953278 [PubMed - indexed for MEDLINE] Clinical Alerts ClinicalTrials.gov 4: Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M. PubMed Central Related Articles, Links Pepine CJ Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?

Circulation. 1994 Apr, 89(4):1511-7.

PMID: 7908609 [PubMed - indexed for MEDLINE]

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37

h cb hg e e e fcg

e ch

b e







				*					
Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	864
Search	PubMed	for					Go	Clear	
		Limits	Preview.	Index	History	Cli	oboard		etails

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
Clinical Trials gov
PubMed Central

Related Articles, Links

•

1: Am J Physiol. 1998 Oct;275(4 Pt 2):H1411-8.

Abstract

Display

Effects of coronary artery disease on expression and microvascular response to VEGF.

▼ Show: 20

Metais C, Li J, Li J, Simons M, Sellke FW.

Division of Cardiothoracic Surgery, Department of Surgery, Department of Medicine of Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.

Sort

The effects of coronary artery disease (CAD) on human coronary microvascular responses to vascular endothelial growth factor (VEGF) and the alterations of the myocardial expressions of VEGF and its flk-1 and flt-1 receptors were examined in 48 patients. Microvascular studies were performed in vitro with video microscopy. The expressions of VEGF and its receptors were examined using Northern analysis of total mRNA, and the expressions of constitutive nitric oxide synthase (cNOS) and inducible nitric oxide synthase (iNOS) were examined by RT-PCR. VEGF and hepatocyte growth factor (HGF) caused potent relaxations of microvessels. These responses were reduced in the presence of NG-nitro-L-arginine and the tyrosine kinase inhibitor genistein or in microvessels from patients with CAD. Relaxations to substance P and sodium nitroprusside were similar in both groups. The substance P response was abolished in the presence of NG-nitro-L-arginine. The expression of VEGF and its receptors and the expression of cNOS and iNOS were not altered in patients with CAD. In conclusion, VEGF and HGF elicit the release of nitric oxide through activation of tyrosine kinase receptors. CAD is associated with reduced vascular responses to both VEGF and HGF; this is not likely due to a reduced expression of VEGF or flt-1 or flk-1 receptors and not due to a generalized endothelium dysfunction despite the presence of mild hypercholesterolemia in these patients with CAD. These findings may have important implications regarding the efficacy of endogenous and exogenous VEGF in patients with risk factor for CAD.

PMID: 9746492 [PubMed - indexed for MEDLINE]

Display Abstract ✓	Show:	20	Sort	Send to	Text •
	DIIO II.	3		 	الننند

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services







Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	FMC	Journals	800
Search F	PubMed	for					Go	Clear	
		Limits	Previ	ew/Index	History	Cli	oboard	Detail	ş

Show: |20

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Circulation. 1998 Dec 22-29;98(25):2800-4.

Related Articles, Links

Text

fatt uit es article a circ ahajournals org

Display Abstract

Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.

Sort

Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM.

Departments of Medicine, Biomedical Research, Surgery, and Anesthesiology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass 02135, USA.


BACKGROUND: We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of vascular endothelial growth factor (VEGF) as sole therapy for patients with symptomatic myocardial ischemia. METHODS AND RESULTS: VEGF gene transfer (GTx) was performed in 5 patients (all male, ages 53 to 71) who had failed conventional therapy; these men had angina (determined by angiographically documented coronary artery disease). Naked plasmid DNA encoding VEGF (phVEGF165) was injected directly into the ischemic myocardium via a mini left anterior thoracotomy. Injections caused no changes in heart rate (pre-GTx=75+/-15/min versus post-GTx=80+/-16/min, P=NS), systolic BP (114+/-7 versus 118+/-7 mm Hg, P=NS), or diastolic BP (57+/-2 versus 59+/-2 mm Hg, P=NS). Ventricular arrhythmias were limited to single unifocal premature beats at the moment of injection. Serial ECGs showed no evidence of new myocardial infarction in any patient. Intraoperative blood loss was 0 to 50 cm<sup>3</sup>, and total chest tube drainage was 110 to 395 cm<sup>3</sup>. Postoperative cardiac output fell transiently but increased within 24 hours (preanesthesia=4.8+/-0.4 versus postanesthesia=4.1+/-0.3 versus 24 hours postoperative=6. 3+/-0.8, P=0.02). Time to extubation after closure was 18.4+/-1.4 minutes; average postoperative hospital stay was 3.8 days. All patients had significant reduction in angina (nitroglycerin [NTG] use=53.9+/-10.0/wk pre-GTx versus 9.8+/-6.9/wk post-GTx, P<0.03). Postoperative left ventricular ejection fraction (LVEF) was either unchanged (n=3) or improved (n=2, mean increase in LVEF=5%). Objective evidence of reduced ischemia was documented using dobutamine single photon emission computed tomography (SPECT)-sestamibi imaging in all patients. Coronary angiography showed improved Rentrop score in 5 of 5 patients. CONCLUSIONS: This initial experience with naked gene transfer as sole therapy for myocardial ischemia suggests that direct myocardial injection of naked plasmid DNA, via a minimally invasive chest wall incision, is safe and

may lead to reduced symptoms and improved myocardial perfusion in selected patients with chronic myocardial ischemia.

## **Publication Types:**

- Case Reports
- Clinical Trial
- Clinical Trial, Phase I

PMID: 9860779 [PubMed - indexed for MEDLINE]




Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Jul 27 2004 06:47:37







Entrez PubMed Nucleotide Protein Genome Structure MIMO PMC Journals Boot Search PubMed Go Clear for Limits Preview/Index Clipboard Details History About Entrez Display Abstract Show: 20 Send to Sort Text Text Version 1: Circulation. 1999 May 25;99(20):2614-6. Related Articles, Links Entrez PubMed Overview Comment on: Help | FAQ • Circulation, 1999 May 25;99(20):2682-7. Tutorial FREE full text article of New/Noteworthy circ.ahajournals.org E-Utilities Therapeutic angiogenesis: the new electrophysiology? **PubMed Services** Journals Database MeSH Database Patterson C, Runge MS. Single Citation Matcher Batch Citation Matcher **Publication Types:** Clinical Queries LinkOut

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts

ClinicalTrials.gov PubMed Central

Cubby

h

- Comment
- Editorial
- Review
- · Review, Tutorial

PMID: 10338451 [PubMed - indexed for MEDLINE]

Display Abstract Sort Send to ★ Show: 20

> Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer

> > Tel: 27 2004 06:47:37







PubMed Nucleotide Protein OMIM PMC Journals 800 Structure Search PubMed Go Clear for Limits Clipboard Details Preview/Index History

Show: |20

About Entrez

**Text Version** 

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Gueries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials gov
PubMed Central

**1:** Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.

Related Articles, Links

Text



Abstract

Display

Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.

Sort

Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG.

Department of Cardiothoracic Surgery, Weill Medical College of Cornell University-New York Presbyterian Hospital, New York City 10021, USA.

OBJECTIVE. To summarize the 6-month follow-up of a cohort of patients with clinically significant coronary artery disease who received direct myocardial injection of an E1-E3- adenovirus (Ad) gene transfer vector (Ad (GV)VEGF121.10) expressing the human vascular endothelial growth factor (VEGF) 121 cDNA to induce therapeutic angiogenesis. BACKGROUND: Therapeutic angiogenesis describes a novel approach to the treatment of vascular occlusive disease that uses the administration of growth factors known to induce neovascularization of ischemic tissues. METHODS: Direct myocardial injection of Ad(GV)VEGF121.10 into an area of reversible ischemia was carried out in 21 patients as an adjunct to conventional coronary artery bypass grafting (group A, n = 15) or as sole therapy using a minithoracotomy (group B, n = 6). RESULTS: No evidence of systemic or cardiac-related adverse events related to vector administration was observed up to 6 months after therapy. Trends toward improvement in angina class and exercise treadmill testing at 6-month follow-up in the sole therapy group suggest the effects of this therapy are persistent for > or =6 months. CONCLUSIONS: This study suggests that direct myocardial administration of Ad(GV)VEGF121.10 appears to be well tolerated in patients with clinically significant coronary artery disease. Initiation of phase II evaluation of this therapy appears warranted.

## **Publication Types:**

- Clinical Trial
- Clinical Trial, Phase I

PMID: 10522716 [PubMed - indexed for MEDLINE]







OMBM PMC Journals 300 Nucleofide Protein Genome Structure PubMed Search PubMed Clear Go for Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Gueries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials gov PubMed Central

h

cb

1: Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.

Show: 20

Related Articles, Links

 $\sim$ 



**Abstract** 

Display

Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.

Sort

Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG.

Department of Cardiothoracic Surgery, Weill Medical College of Cornell University-New York Presbyterian Hospital, New York City 10021, USA.

OBJECTIVE: To summarize the 6-month follow-up of a cohort of patients with clinically significant coronary artery disease who received direct myocardial injection of an E1-E3- adenovirus (Ad) gene transfer vector (Ad (GV)VEGF121.10) expressing the human vascular endothelial growth factor (VEGF) 121 cDNA to induce therapeutic angiogenesis. BACKGROUND: Therapeutic angiogenesis describes a novel approach to the treatment of vascular occlusive disease that uses the administration of growth factors known to induce neovascularization of ischemic tissues. METHODS: Direct myocardial injection of Ad(GV)VEGF121.10 into an area of reversible ischemia was carried out in 21 patients as an adjunct to conventional coronary artery bypass grafting (group A, n = 15) or as sole therapy using a minithoracotomy (group B, n = 6). RESULTS: No evidence of systemic or cardiac-related adverse events related to vector administration was observed up to 6 months after therapy. Trends toward improvement in angina class and exercise treadmill testing at 6-month follow-up in the sole therapy group suggest the effects of this therapy are persistent for > or =6 months. CONCLUSIONS: This study suggests that direct myocardial administration of Ad(GV)VEGF121.10 appears to be well tolerated in patients with clinically significant coronary artery disease. Initiation of phase II evaluation of this therapy appears warranted.

## **Publication Types:**

- Clinical Trial
- Clinical Trial, Phase I

PMID: 10522716 [PubMed - indexed for MEDLINE]

# Untitled

US20030109420 US20040116349 US20040023863 US20020058612 US20020156001 US20040143103 US20030181379

GB2090528B

514/2

424/9.1

530/300,324,399

Untitled

+	WO2000013710
	5057494
	5358959
~~	5665382
_	5710175
	5750351
¥	5773209
	5773231
_	5785965
	5807884
	5811449
FT.	5846959
	5925375
	5955624
	6040157

CPK-MB 4328396

```
elcome to STN international! Enter x:x

* * * * * * * * * * Welcome to STN International

* * * * * * * * * * * * * STN Columbus * * * * *
ILE 'HOME' ENTERED AT 13:05:23 ON 13 AUG 2004
> file BIOSCIENCE
ILE 'ADISCTI' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 Adis Data Information BV
ILE 'ADISINSIGHT' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 Adis Data Information BV
ILE 'ADISNEWS' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 Adis Data Information BV
ILE 'AGRICOLA' ENTERED AT 13:05:33 ON 13 AUG 2004
ILE 'AQUALINE' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
ILE 'ANABSTR' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)
ILE 'ANTE' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
ILE 'AOUASCI' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.
ILE 'BIOBUSINESS' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)
ILE 'BIOCOMMERCE' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:
ILE 'BIOENG' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
ILE 'BIOSIS' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)
ILE 'BIOTECHABS' ACCESS NOT AUTHORIZED
ILE 'BIOTECHDS' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION
ILE 'BIOTECHNO' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.
ILE 'CABA' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)
ILE 'CANCERLIT' ENTERED AT 13:05:33 ON 13 AUG 2004
ILE 'CAPLUS' ENTERED AT 13:05:33 ON 13 AUG 2004 SE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
LEASE SEE "HELP USAGETERMS" FOR DETAILS.
OPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
ILE 'CEABA-VTB' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (c) 2004 DECHEMA eV
ILE 'CEN' ENTERED AT 13:05:33 ON 13 AUG 2004
OPYRIGHT (C) 2004 American Chemical Society (ACS)
ILE 'CIN' ENTERED AT 13:05:33 ON 13 AUG 2004
SE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
LEASE SEE "HELP USAGETERMS" FOR DETAILS.
OPYRIGHT (C) 2004 American Chemical Society (ACS)
ILE 'CONFSCI' ENTERED AT 13:05:33 ON 13 AUG 2004
```

OPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

ILE 'CROPB' ENTERED AT 13:05:33 ON 13 AUG 2004

```
FILE 'CROPU' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'DISSABS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve
FILE 'DDFB' ACCESS NOT AUTHORIZED
FILE 'DDFU' ACCESS NOT AUTHORIZED
FILE 'DGENE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'DRUGB' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'DRUGMONOG2' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd
FILE 'IMSDRUGNEWS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd
FILE 'DRUGU' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
FILE 'IMSRESEARCH' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd
FILE 'EMBAL' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.
FILE 'EMBASE' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.
FILE 'ESBIOBASE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'FEDRIP' ENTERED AT 13:05:33 ON 13 AUG 2004
FILE 'FOMAD' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association
FILE 'FOREGE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association
FILE 'FROSTI' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association
FILE 'FSTA' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service
FILE 'GENBANK' ENTERED AT 13:05:33 ON 13 AUG 2004
FILE 'HEALSAFE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
FILE 'IFIPAT' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)
FILE 'IMSPRODUCT' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd
FILE 'JICST-EPLUS' ENTERED AT 13:05:33 ON 13 AUG 2004
```

COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemi:

FILE 'LIFESCI' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'KOSMET' ENTERED AT 13:05:33 ON 13 AUG 2004

FILE 'MEDICONF' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'NIOSHTIC' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 13:05:33 ON 13 AUG 2004 Compiled and distributed by the NTIS, U.S. Department of Commerce. It contains copyrighted material. All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 13:05:33 ON 13 AUG 2004 Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 13:05:33 ON 13 AUG 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 13:05:33 ON 13 AUG 2004 Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 13:05:33 ON 13 AUG 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:05:33 ON 13 AUG 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 13:05:33 ON 13 AUG 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

```
=> s coronary artery disease
  14 FILES SEARCHED ...
  25 FILES SEARCHED...
  43 FILES SEARCHED...
  55 FILES SEARCHED...
        291193 CORONARY ARTERY DISEASE
=> S growth factor OR FGF-1 OR aFGF OR acidic FGF OR FGF-2 OR bFGF OR basic FGF
  12 FILES SEARCHED...
  16 FILES SEARCHED...
  25 FILES SEARCHED...
     FILES SEARCHED...
     FILES SEARCHED...
  52 FILES SEARCHED...
  63 FILES SEARCHED...
  69 FILES SEARCHED...
       1757190 GROWTH FACTOR OR FGF-1 OR AFGF OR ACIDIC FGF OR FGF-2 OR BFGF
                OR BASIC FGF OR VEGF
=> S L1 AND L2
  46 FILES SEARCHED...
          6283 L1 AND L2
=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY PROCESSING IS APPROXIMATELY PROCESSING IS APPROXIMATELY
                              23% COMPLETE FOR L3
                              45% COMPLETE FOR L3
                              67% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY
                              83% COMPLETE FOR L3
PROCESSING COMPLETED FOR L3
           4731 DUP REM L3 (1552 DUPLICATES REMOVED)
=> S nasal OR inhalation OR inhale
  42 FILES SEARCHED...
        811503 NASAL OR INHALATION OR INHALE
=> S L4 AND L5
  29 FILES SEARCHED...
  61 FILES SEARCHED...
  64 FILES SEARCHED...
          1011 L4 AND L5
=> DUP REM L6
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L6
           1011 DUP REM L6 (0 DUPLICATES REMOVED)
=> S L7 AND PY<=2000
'2000' NOT A VALID FIELD CODE
   6 FILES SEARCHED...
   8 FILES SEARCHED...
  12 FILES SEARCHED...
  16 FILES SEARCHED...
  20 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
  24 FILES SEARCHED...
  32 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
  43 FILES SEARCHED..
'2000' NOT A VALID FIELD CODE
  47 FILES SEARCHED...
  52 FILES SEARCHED..
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
  60 FILES SEARCHED...
  63 FILES SEARCHED...
  64 FILES SEARCHED...
```

LВ

L8

TITLE:

SOURCE:

ANSWER 7 OF 98

ACCESSION NUMBER:

PROMT

2000:40040

PROMT

=> D L8 1-98 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN ANSWER 1 OF 98 L8 ANPHARMAML 1641161 Genentech Starts Trials Of Recombinant \*\*\*VEGF\*\*\* TI SO Marketletter April 3, 1998 DT Newsletter WC 750 PHIN COPYRIGHT 2004 PJB on STN L8ANSWER 2 OF 98 AN97:13715 PHIN DN S00546366 DED 3 Jul 1997 ΤI Genentech earnings down, sales flat \*\*\*1997\*\*\* ) No. 2253 p12 SO Scrip ( Newsletter DT FS FULL L8 ANSWER 3 OF 98 PHIN COPYRIGHT 2004 PJB on STN AN95:11703 PHIN DNS00450122 DED 29 Jun 1995 Bristol-Myers Squibb Company Profile (1995) Scrip-Online-plus ( \*\*\*1995\*\*\* ) TISO DT Newsletter FS FULL ANSWER 4 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN L8ACCESSION NUMBER: 2000:713716 PROMT CHIRON PAYING \$700M IN CASH FOR PATHOGENESIS TITLE: ACQUISITION. (Brief Article) AUTHOR(S): Osborne, Randall BIOWORLD Today, ( \*\*\*15 Aug 2000\*\*\* ) Vol. 11, No. 157. SOURCE: American Health Consultants, Inc. PUBLISHER: Newsletter DOCUMENT TYPE: LANGUAGE: English 62Ŏ WORD COUNT: \*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\* PROMT COPYRIGHT 2004 Gale Group on STN L8 ANSWER 5 OF 98 2000:169616 PROMT ACCESSION NUMBER: Muted progress. TITLE: Truelove, Christiane AUTHOR(S): \*\*\*Sept 1999\*\*\* ) Vol. 18, No. 9, pp. 172. SOURCE: Med Ad News, ( ISSN: 1067-733X. Engel Publishing Partners PUBLISHER: DOCUMENT TYPE: Newsletter LANGUAGE: English WORD COUNT: 2537 \*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\* PROMT COPYRIGHT 2004 Gale Group on STN L8 ANSWER 6 OF 98 2000:169609 ACCESSION NUMBER: PROMT TITLE: Gene genies. AUTHOR(S): Truelove, Christiane \*\*\*Sept 1999\*\*\* ) Vol. 18, No. 9, pp. 122. Med Ad News, ( SOURCE: ISSN: 1067-733X. Engel Publishing Partners PUBLISHER: Newsletter DOCUMENT TYPE: LANGUAGE: English WORD COUNT: 2599 \*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

COPYRIGHT 2004 Gale Group on STN

/FIRST AND FINAL ADD -- NYTU059B -- Pfizer Inc/.

PR Newswire, ( \*\*\*18 Jan 2000\*\*\* ) pp. 3285.

Newsletter DOCOMENT. LABE: LANGUAGE: English 5191

WORD COUNT:

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

PROMT COPYRIGHT 2004 Gale Group on STN L8ANSWER 8 OF 98

ACCESSION NUMBER: 1999:802479 PROMT TITLE: Novartis Group. Krajnak, Mark AUTHOR(S):

\*\*\*Sept 1997\*\*\* ) Vol. 16, No. 9, pp. 130. Med Ad News, SOURCE:

ISSN: 0745-0907. Engel Publishing Partners PUBLISHER:

DOCUMENT TYPE: Newsletter English LANGUAGE: WORD COUNT: 6433

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L8ANSWER 9 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

1999:162782 PROMT ACCESSION NUMBER:

Megabios and GeneMedicine Complete Merger.
PR Newswire, ( \*\*\*19 Mar 1999\*\*\* ) pp. 8437. TITLE: SOURCE:

PR Newswire Association, Inc. PUBLISHER:

Newsletter DOCUMENT TYPE: English LANGUAGE:

WORD COUNT: 636

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

ANSWER 10 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN L8

PROMT ACCESSION NUMBER: 1998:175708

DEVELOPMENTS IN BIOTECHNOLOGY : GeneMedicine-Cationic Lipid TITLE: Gene Delivery System In Two Phase II Gene Therapy Angioplasty Clinical Trials
BioAccess, ( \*\*\*1 Apr 1998\*\*\* ) pp. N/A.

SOURCE:

ISSN: 1356-3432.

English LANGUAGE: WORD COUNT: 712

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

ANSWER 11 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN L8

ACCESSION NUMBER: 1998:173353 PROMT

Genentech Starts Trials Of Recombinant \*\*\*VEGF\*\*\* TITLE:

Marketletter, ( \*\*\*13 Apr 1998\*\*\* ) pp. N/A. SOURCE:

ISSN: 0951-3175.

English 756 LANGUAGE: WORD COUNT:

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

ANSWER 12 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:143219 PROMT

TITLE: GENEMEDICINE Proprietary Cationic Lipid Gene Delivery

System Is Employed in Two Phase II Gene Therapy Angioplasty Clinical Trials.

Business Wire, ( \*\*\*19 Mar 1998\*\*\* ) pp. 3190068. SOURCE:

English LANGUAGE: 900 WORD COUNT:

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

COPYRIGHT 2004 Gale Group on STN L8 ANSWER 13 OF 98 PROMT

ACCESSION NUMBER: 1998:41293 PROMT

Genentech's Year-End Results Show Growth Plan on Track: TITLE:

Earnings Increase Nine Percent on Revenues Exceeding \$1

Billion.

\*\*\*22 Jan 1998\*\*\* Business Wire, ( ) pp. 01220134. SOURCE:

LANGUAGE: English WORD COUNT: Ž029

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

L8ANSWER 14 OF 98 USPATFULL on STN

AN2003:228145 USPATFULL

```
management
         Ajami, Alfred M., Brookline, MA, United States
IN
         Xanthus Life Sciences, Inc., Cambridge, MA, United States (U.S.
PA
         corporation)
         US 6610270
                                  B1
                                         20030826
PΙ
                             20000106
         WO 200000636
                                                                                           <--
                                         20001218 (9)
         US 2000-719956
ΑI
         WO 1999-US14725
                                         19990629
         Continuation-in-part of Ser. No. US 1998-107965, filed on 30 Jun 1998,
RLI
         now patented, Pat. No. US 6284219, issued on 4 Sep 2001
         Utility
DT
         GRANTED
FS
LN.CNT 3873
         INCLM: 424/009.200
INCLS: 424/001.810; 424/001.110; 435/004.000
NCLM: 424/009.200
INCL
NCL
                  424/001.110; 424/001.810; 435/004.000
         NCLS:
         [7]
IC
         ICM: A61K049-00
         424/1.11; 424/1.53; 424/1.65; 424/1.81; 424/9.2; 424/9.1; 435/4;
EXF
         435/183; 435/188; 435/814; 250/472.1; 600/9
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 15 OF 98 USPATFULL on STN
L8
         2002:209740 USPATFULL
NA
         Transgenic models of inflammatory disease
Duff, Gordon W., Sheffield, UNITED KINGDOM
Nicklin, Martin, Sheffield, UNITED KINGDOM
Interleukin Genetics Inc., Waltham, MA, United States (U.S. corporation)
TI
IN
PA
                                         20020820
                                  В1
PΙ
         US 6437216
         WO 9925857
                         19990527
         US 2001-647826
                                          20010312
                                                      (9)
AΙ
                                          19981113
         WO 1998-US24287
                                                       PCT 371 date
                                          20010312
         GB 1997-23835
                                    19971113
PRAI
DT
         Utility
FS
         GRANTED
LN.CNT
         3230
INCL
         INCLM: 800/021.000
         INCLS: 800/018.000; 800/003.000; 435/320.100; 435/325.000; 536/023.100 NCLM: 800/021.000
NCL
                   435/320.100; 435/325.000; 536/023.100; 800/003.000; 800/018.000
         NCLS:
IC
         ICM: C12N015-00
         800/3; 800/8; 800/21; 800/18; 435/320.1; 435/325; 536/23.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                            USPATFULL on STN
L8
       ANSWER 16 OF 98
         2002:160701 USPATFULL
ΜA
         Benzimidazole derivatives for the treatment of viral infections
Tidwell, Jeffrey H., Raleigh, NC, United States
Chamberlain, Stanley D., Research Triangle Park, NC, United States
Freeman, George A., Research Triangle Park, NC, United States
TI
IN
         Chan, Joseph H., Research Triangle Park, NC, United States
Koszalka, George W., Research Triangle Park, NC, United States
Townsend, Leroy B., Ann Arbor, MI, United States
Drach, John C., Ann Arbor, MI, United States
The Regents of the University of Michigan, Ann Arbor, MI, United States
PA
          (U.S. corporation)
         Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S.
         corporation)
PI
         US 6413938
                                          20020702
                         19980820
                                                                                            < - -
         WO 9835977
         US 1999-367260
                                          19990825 (9)
AΙ
         WO 1998-GB448
                                          19980213
                                          19990825
                                                       PCT 371 date
         GB 1997-3134
US 1997-37992P
                                    19970214
PRAI ·
                                    19970213 (60)
DT
         Utility
FS
          GRANTEĎ
LN.CNT
         3484
          INCLM: 514/043.000
INCL
          INCLS: 514/394.000; 514/934.000; 536/024.100; 536/028.900; 548/304.700
NCL
                   514/043.000
                   514/394.000; 514/934.000; 536/024.100; 536/028.900; 548/304.700
         NCLS:
```

```
ICM: A6IKU3I-70
         ICS: A61K031-415; C07H019-04; C07D235-04
         514/43; 514/934; 514/394; 536/28.9; 536/24; 548/304.7
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 17 OF 98 USPATFULL on STN
L8
AN
         2000:164487
                         USPATFULL
TI
         Polypeptide composition for oral administration
IN
         Grass, George M., Mountain View, CA, United States
         Sweetana, Stephanie A., Indianapolis, IN, United States
         G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)
PA
                                         20001205
PI
         US 6156731
         US 1995-567501
                                         19951205
                                                     (8)
AI
         Continuation of Ser. No. US 1989-350067, filed on 10 May 1989, now
RLI
         abandoned
DT
         Utility
FS
         Granted
LN.CNT
         1014
INCL
         INCLM: 514/015.000
         INCLS: 514/002.000; 514/014.000; 514/013.000; 514/016.000; 514/012.000; 530/300.000; 530/311.000; 530/313.000; 530/324.000; 530/327.000; 530/328.000; 424/464.000; 424/185.100
NCL
         NCLM:
                   514/015.000
                  424/185.100; 424/464.000; 514/002.000; 514/012.000; 514/013.000; 514/014.000; 514/016.000; 530/300.000; 530/311.000; 530/313.000; 530/324.000; 530/326.000; 530/327.000; 530/328.000
         NCLS:
IC
         ICM: A61K038-00
ICS: A61K039-00; C07K005-00; C07K007-00

EXF 514/2; 514/3; 514/12; 514/13; 514/14; 514/15; 514/16; 530/300; 530/311; 530/313; 530/324; 530/326; 530/327; 530/328; 424/464; 424/185.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 18 OF 98 USPATFULL on STN
L_8
AN
         2000:153882 USPATFULL
ΤI
         Compounds and methods for the inhibition of the expression of VCAM-1
         Somers, Patricia K., Atlanta, GA, United States
AtheroGenics, Inc., Alpharetta, GA, United States (U.S. corporation)
IN
PA
ΡI
         US 6147250
                                         20001114
            1998-79213
                                         19980514 (9)
AI
         US
         US 1997-47020P
PRAI
                                    19970514 (60)
         Utility
DT
FS
         Granted
LN.CNT
         3089
INCL
         INCLM: 560/130.000
         INCLS: 560/138.000; 514/548.000
NCLM: 560/130.000
NCLS: 560/138.000
NCL
IC
          [7]
         ICM: C07C069-00
         ICS: A01N037-02
EXF
         560/130; 560/138; 514/548
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 19 OF 98 USPATFULL on STN
         2000:153824 USPATFULL
ΑN
         Tub interactor (TI) polypeptides and uses therefor Gimeno, Carlos J., Wellesley, MA, United States
TΙ
IN
         Errada, Patrick R., Cambridge, MA, United States
         Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
PA
         corporation)
PI
         US 6147192
                                         20001114
                                         19990218 (9)
AΙ
         US 1999-252329
         Division of Ser. No. US 1997-897340, filed on 21 Jul 1997, now patented, Pat. No. US 5955306 which is a continuation-in-part of Ser. No. US
RLI
         1996-715032, filed on 17 Sep 1996, now abandoned
DT
         Utility
FS
         Granted
         3795
LN.CNT
INCL
         INCLM: 530/350.000
NCL
         NCLM:
                   530/350.000
IC
          [7]
         ICM: C07K014-00
EXF
         530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
ANSWER 20 OF 98 USPATFULL ON STN
Ь8
AN
          2000:145865 USPATFULL
TI
          Targeted contrast agents for diagnostic and therapeutic use
         Unger, Evan C., Tucson, AZ, United States
IN
         Fritz, Thomas A., Tucson, AZ, United States
Gertz, Edward W., Paradise Valley, AZ, United States
PA
          ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
                                          20001031
         US 6139819
PI
                                          19970917 (8)
AI
         US 1997-932273
         Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996,
RLI
         now abandoned which is a continuation-in-part of Ser. No. US
         1996-640464, filed on 1 May 1996, now abandoned which is a continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995, now abandoned And a continuation-in-part of Ser. No. US 1996-666129, filed on 19 Jun 1996, now patented, Pat. No. US 6033645
DT
         Utility
FS
         Granted
LN.CNT
         7523
INCL
         INCLM: 424/009.520
         INCLS: 424/009.510; 424/450.000
NCL
                   424/009.520
         NCLM:
         NCLS:
                   424/009.510; 424/450.000
IC
          [7]
         ICM: A61B008-00
         ICS: A61K009-127
         424/9.52; 424/9.51; 424/9.5; 424/450; 424/812; 600/441; 600/458; 264/4.1; 427/2.14; 427/213.3; 428/402.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 21 OF 98
                            USPATFULL on STN
         2000:138360 USPATFULL
AN
ΤI
         Hydroxyl-containing bicyclic compounds
Underiner, Gail E., Brier, WA, United States
IN
         Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
PA
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 6133274 20001017 <--
         US 6133274 US 1996-756703
PΙ
         US 1996-756703 19961126 (8)
Continuation of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353,
ΑI
RLI
         filed on 16 Nov 1992, now patented, Pat. No. US 5473070
DT
         Utility
FS
         Granted
         1646
LN.CNT
         INCLM: 514/263.000
INCLS: 544/267.000
NCLM: 514/263.360
NCLS: 544/267.000
INCL
NCL
IC
          [7]
         ICM: C07D473-04
         ICS: A61K031-52
         544/267; 514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 22 OF 98 USPATFULL on STN
         2000:137814 USPATFULL
AN
ΤI
         Allelic polygene diagnosis of reward deficiency syndrome and treatment
IN
         Blum, Kenneth, San Antonio, TX, United States
         City of Hope National Medical Center, Duarte, CA, United States (U.S.
PA
         corporation)
         The University of Texas System AMD Board of Regents, Austin, TX, United
         States (U.S. corporation)
         US 6132724
US 1998-69886
PΙ
                                         20001017
                                                                                           < - -
ΑI
                                         19980429 (9)
DT
         Utility
FS
         Granted
LN.CNT
         20845
INCL
         INCLM: 424/195.100
         INCLS: 514/188.000; 514/561.000
                   424/725.000
NCL
         NCLM:
                   514/188.000; 514/561.000
         NCLS:
IC
          [7]
         ICM: A61K035-78
EXF
         514/188; 514/561; 424/195.1
```

```
Ь8
      ANSWER 23 OF 98
                           USPATFULL on STN
         2000:128465 USPATFULL
\mathbf{A}\mathbf{N}
         Compositions and methods for treatment and diagnosis of cardiovascular
ΤI
         disease
         Falb, Dean A., Wellesley, MA, United States
IN
         Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA
        Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
        Brigham and Women's Hospital, Boston, MA, United States (U.S.
         corporation)
        US 6124433
US 1997-944496
PΙ
                                       20000926
AΙ
                                       19971006 (8)
        Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser.
RLI
        No. US 1995-386844, filed on 10 Feb 1995
DT
        Utility
FS
        Granted
LN.CNT
        5924
         INCLM: 530/350.000
INCL
         INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100;
                 435/320.100; 435/325.000
530/350.000
435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000; 536/023.100; 536/023.500
NCL
        NCLM:
        NCLS:
IC
         [7]
         ICM: C07K016-00
         ICS: C12N015-00
        536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/69.1; 435/7.1; 435/172.3; 435/320.1; 435/325; 935/32; 935/52; 530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 24 OF 98
L8
                          USPATFULL on STN
        2000:125096 USPATFULL
\mathbf{A}\mathbf{N}
TI
        Monoesters of probucol for the treatment of cardiovascular and
        inflammatory disease
IN
        Somers, Patricia K., Atlanta, GA, United States
PA
        AtheroGenics, Inc., Alpharetta, GA, United States (U.S. corporation)
                                       20000919
PI
        US 6121319
ΑI
        US
            1998-78935
                                       19980514 (9)
        US 1997-47020P
PRAI
                                  19970514 (60)
        Utility
DT
FS
        Granted
LN.CNT 992
INCL
        INCLM: 514/548.000
        INCLS: 514/712.000; 514/824.000; 514/825.000; 514/826.000; 514/855.000
                 514/548.000
514/712.000; 514/824.000; 514/825.000; 514/826.000; 514/855.000
NCL
        NCLM:
        NCLS:
IC
         [7]
        ICM: A01N037-02
        ICS: A61K031-10; A61K031-225
EXF
         514/548; 514/712; 514/824; 514/855; 514/826; 514/825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 25 OF 98 USPATFULL on STN
                        USPATFULL
ΑN
        2000:121539
TI
        Methods for regulating transcription factors
IN
        Qabar, Maher N., Redmond, WA, United States
        McMillan, Michael K., Bellevue, WA, United States
        Kahn, Michael S., Kirkland, WA, United States
        Tulinsky, John E., Seattle, WA, United States
Ogbu, Cyprian O., Bellevue, WA, United States
Mathew, Jessymol, Bellevue, WA, United States
PA
        Molecumetics Ltd., Bellevue, WA, United States (U.S. corporation)
        US 6117896
US 1998-22934
PΙ
                                       20000912
                                                                                     <---
        US 1998-22934 19980212 (9)
Continuation-in-part of Ser. No. US 1997-797915, filed on 10 Feb 1997, now abandoned And a continuation-in-part of Ser. No. US 692420
ΑI
RLI
PRAI
        US 1997-47067P
                                  19970519 (60)
DT
        Utility
FS
        Granted
LN.CNT 4501
INCL
        INCLM: 514/384.000
        INCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400
NCL
        NCLM:
                 514/384.000
```

```
TC
         ICM: A61K031-41
         ICS: C07K005-00; C07K007-00; C07K016-00; C07D249-12
         514/248; 514/384; 530/332; 530/323; 548/263.4
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 26 OF 98 USPATFULL on STN
L8
AN
         2000:105913
                         USPATFULL
         Amine substituted compounds
ΤI
         Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
IN
PA
                                         20000815
PΙ
         US 6103730
         US 1995-486264
                                        19950607
                                                     (8)
ΑI
         Continuation of Ser. No. US 1994-217051, filed on 24 Mar 1994, now
RLI
         abandoned
DT
         Utility
FS
         Granted
LN.CNT
         1702
         INCLM: 514/263.000
INCLS: 514/265.000; 544/268.000; 544/269.000; 544/270.000; 544/271.000;
544/272.000
INCL
                  514/263.200
NCL
         NCLM:
                  514/151.000; 514/210.210; 514/263.210; 514/263.220; 514/263.230; 514/263.240; 514/263.350; 544/268.000; 544/269.000; 544/270.000; 544/271.000; 544/272.000
         NCLS:
IC
         [7]
         ICM: A61K031-522
         ICS: C07D473-10
         544/268; 544/269; 544/220; 544/271; 544/272; 514/263; 514/265
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 27 OF 98 USPATFULL on STN
         2000:102304 USPATFULL
AN
TI
         Therapeutic compounds containing xanthinyl
         Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
IN
         Kumar, Anil M., Seattle, WA, United States
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 6100271 20000808 <--
PA
ΡI
                                         19950607
                                                    (8)
AΙ
         US 1995-483871
RLI
         Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
         now abandoned
DT
         Utility
FS
         Granted
LN.CNT
         1986
INCL
         INCLM:
                  514/263.000
                  514/265.000; 544/268.000; 544/269.000; 544/271.000
         INCLS:
         NCLM:
NCL
                  514/263.200
                  514/210.210; 514/234.200; 514/263.220; 514/263.230; 514/263.240; 514/263.350; 544/268.000; 544/269.000; 544/271.000
         NCLS:
IC
         ICM: A61K031-522
         ICS: C07D473-10
         544/271; 544/268; 544/269; 514/263; 514/265
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 28 OF 98
                            USPATFULL on STN
         2000:95042 USPATFULL
AN
ΤI
         Therapeutic methods employing disulfide derivatives of dithiocarbamates
         and compositions useful therefor
         Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
Medinox Inc., San Diego, CA, United States (U.S. corporation)
IN
PA
                                        20000725
         US 6093743
PΙ
AΙ
         US 1998-103639
                                        19980623 (9)
DT
         Utility
FS
         Granted
LN.CNT
         2691
INCL
         INCLM: 514/599.000
         INCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
                  514/866.000; 514/909.000; 514/912.000
```

```
514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000; 514/866.000; 514/909.000; 514/912.000
C
        [7]
        ICM: A61K031-16
        ICS: A61K031-095; A61K031-105
        514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909;
CXF
        514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 29 OF 98
38
                          USPATFULL on STN
I.
       2000:91763
                      USPATFULL
        SV-40 derived DNA constructs comprising exogenous DNA sequences
N
       Oppenheim, Ariella, Jerusalem, Israel
       Dalyot, Nava, Jerusalem, Israel
Ben-Nun-Shaul, Orly, Jerusalem, Israel
Rund, Deborah, Jerusalem, Israel
Sandalon, Ziv, Jerusalem, Israel
Chajek-Shaul, Toba, Jerusalem, Israel
Metzger, Shulamit, Jerusalem, Israel
       Metzger, Shulamit, Jerusalem, Israel
       Yissum Research Development Company of the Hebrew University of Jerusalem, Jerusalem, Israel (non-U.S. corporation)
PΑ
       Hadasit Medical Research Services and Development Company Limited, Jerusalem, Israel (non-U.S. corporation)
                                       20000718
Ι
       US 6090608
       WO 9530762
                       19951116
                                                                                       <---
       US 1997-737047
I
                                       19970115 (8)
       WO 1995-US5595
                                       19950504
                                                    PCT 371 date
                                       19970115
                                       19970115
                                                   PCT 102(e) date
       IL 1994-109558
RAI
                                 19940504
       Utility
т
'S
       Granted
N.CNT
       1838
NCL
       INCLM: 435/235.100
       INCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.500
ICL
       NCLM:
                435/235.100
       NCLS:
                435/320.100; 435/325.000; 435/455.000; 536/023.500
C
        [7]
       ICM: C12N007-01
       ICS: C12N015-86; C12N005-10 536/23.1; 536/23.5; 435/320.1; 435/235.1; 435/325; 514/44; 424/93.1;
XF
       424/93.21
AS INDEXING IS AVAILABLE FOR THIS PATENT.
8
     ANSWER 30 OF 98
                          USPATFULL on STN
I.
       2000:57545
                       USPATFULL
       Human transferases
       Lal, Preeti, Santa Clara, CA, United States
Bandman, Olga, Mountain View, CA, United States
Ν
       Hillman, Jennifer L., Mountain View, CA, United States
       Guegler, Karl J., Menlo Park, CA, United States
       Gorgone, Gina A., Boulder Creek, CA, United States
Corley, Neil C., Mountain View, CA, United States
Patterson, Chandra, Mountain View, CA, United States
       Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
       corporation)
       US 6060250
                                       20000509
       US 1998-109204
I
                                       19980630 (9)
       Utility
'S
       Granted
N.CNT
       3615
       INCLM: 435/006.000
NCL
       INCLS: 435/193.000; 435/252.300; 435/325.000; 435/320.100; 536/023.100;
                 536/023.200
                435/006.000
435/193.000; 435/252.300; 435/320.100; 435/325.000; 536/023.100;
536/023.200
ICL
       NCLM:
       NCLS:
C
        [7]
       ICM: C12N015-54
       ICS: C12N009-10; C12Q001-68
        536/23.1; 536/23.2; 435/6; 435/193; 435/252.3; 435/325; 435/320.1
AS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 31 OF 98 USPATFULL on STN
N
       2000:40874 USPATFULL
```

NCLS:

```
Lar, Preetr, Santa Crara, CA, United States
Yue, Henry, Sunnyvale, CA, United States
Corley, Neil C., Mountain View, CA, United States
TM
         Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
PA
         corporation)
                                      20000404
PΙ
         US 6046029
AI
         US 1997-977001
                                      19971124 (8)
DT
         Utility
         Granted
FS
LN.CNT
         2270
INCL
         INCLM: 435/069.100
         INCLS: 435/070.100; 435/183.000; 435/320.100; 435/325.000; 435/252.300;
                 435/419.000; 435/254.200; 530/350.000; 536/023.310; 536/023.500
                 435/069.100
NCL
         NCLM:
                 435/070.100; 435/183.000; 435/252.300; 435/254.200; 435/320.100;
         NCLS:
                 435/325.000; 435/419.000; 530/350.000; 536/023.500; 536/024.310
IC
         [7]
         ICM: C12P021-06
         ICS: C12P021-04; C07H021-04; C07K001-00
         536/23.5; 536/24.31; 435/320.1; 435/325; 435/252.3; 435/419; 435/254.2; 435/69.1; 435/70.1; 435/183; 530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 32 OF 98
                           USPATFULL on STN
         2000:37806
                      USPATFULL
AN
        Methods for using therapeutic compounds containing xanthinyl Klein, J. Peter, Vashon, WA, United States
TI
IN
        Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Rice, Glenn C., Seattle, WA, United States
        Rice, Glenn C., Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
10 6043250 20000328 <---
PA
PI
ΑI
        US 1995-472296
                                      19950607 (8)
         Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
RLI
         now abandoned
DT
        Utility
FS
         Granted
LN.CNT
        2052
INCL
         INCLM: 514/263.000
        NCLM:
                 514/234.200
NCL
                 514/210.210; 514/263.200; 514/263.220; 514/263.230; 514/263.350
         NCLS:
IC
         [7]
         ICM: A61K003-52
         514/263
EXF
L8
      ANSWER 33 OF 98 USPATFULL on STN
                      USPATFULL
         2000:34403
AN
                                     ***growth***
TI
         Vascular endothelial
                                                          ***factor***
        Hu, Jing-Shan, Sunnyvale, CA, United States
Rosen, Craig A., Laytonsville, MD, United States
IN
         Cao, Liang, South Horizons, Hong Kong
PA
         Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
         corporation)
ΡI
         US 6040157
                                      20000321
         US 1998-42105
ΑI
                                      19980313 (9)
         Continuation-in-part of Ser. No. US 1997-999811, filed on 24 Dec 1997,
RLI
         now patented, Pat. No. US 5932540 which is a continuation-in-part of
         Ser. No. US 1997-824996, filed on 27 Mar 1997 And a continuation-in-part
         of Ser. No. US 1995-465968, filed on 6 Jun 1995 which is a
         continuation-in-part of Ser. No. US 1994-207550, filed on 8 Mar 1994
DT
         Utility
FS
         Granted
LN.CNT
         5292
INCL
         INCLM: 435/069.400
                 435/007.100; 435/325.000; 435/243.000; 435/320.100; 536/023.510;
         INCLS:
                 530/399.000
                 435/069.400
NCL
         NCLM:
         NCLS:
                 435/007.100; 435/243.000; 435/320.100; 435/325.000; 530/399.000;
                 536/023.510
IC
         [7]
         ICM: C12N015-18
         ICS: C12N015-63; C12N001-21; C12N005-00 435/69.4; 435/320.1; 435/325; 435/243; 536/23.51; 530/399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
USPATFULL on STN
r_8
          ANSWER 34 OF 98
              2000:31222 USPATFULL
ΑN
              MTBX protein and nucleic acid molecules and uses therefor
TI
              Khodadoust, Mehran, Chestnut Hill, MA, United States
Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
IN
PA
               corporation)
PI
              US 6037148
                                                                 20000314
                                                                 19981109 (9)
ΑI
              US 1998-188811
              Continuation-in-part of Ser. No. US 1998-163116, filed on 29 Sep 1998
RLI
PRAI
              US 1998-89467P
                                                        19980616 (60)
DT
              Utility
FS
              Granted
LN.CNT
             4497
              INCLM: 435/069.100
INCL
              INCLS: 435/320.100; 435/325.000; 435/252.300; 536/023.100
                             435/069.100
NCL
              NCLM:
                             435/252.300; 435/320.100; 435/325.000; 536/023.100
              NCLS:
IC
              ICM: C12P021-06
              ICS: C12N015-00; C07H017-00
               435/69.1; 435/320.1; 435/325; 435/252.3; 536/23.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
          ANSWER 35 OF 98
                                            USPATFULL on STN
1.8
              2000:24752
                                      USPATFULL
AN
              MTbx protein and nucleic acid molecules and uses therefor
TI
              Khodadoust, Mehran, Chestnut Hill, MA, United States
IN
              Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
PA
              corporation)
                                                                 20000229
PΙ
              US 6031078
                                                                 19981110 (9)
              US 1998-189760
_{
m AI}
              Continuation-in-part of Ser. No. US 1998-163116, filed on 29 Sep 1998 And a continuation-in-part of Ser. No. US 1998-188811, filed on 9 Nov
RLI
               1998
              US 1998-89467P
                                                        19980616 (60)
PRAI
DT
              Utility
FS
              Granted
LN.CNT
              4457
              INCLM: 530/350.000
INCL
              INCLS: 530/300.000
NCLM: 530/350.000
NCLS: 530/300.000
NCL
               [7]
IC
               ICM: C07K014-00
               530/350; 530/300
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
          ANSWER 36 OF 98
                                            USPATFULL on STN
              2000:15642 USPATFULL
Use of hyaluronic acid and forms to prevent arterial restenosis
ΑN
TI
               Falk, Rudolf Edgar, Toronto, Canada
IN
              Asculai, Samuel Simon, Toronto, Canada
               Turley, Eva Anne, Winnipeg, Canada
              Hyal Pharmaceutical Corporation, Mississauga, Canada (non-U.S.
PA
               corporation)
PI
                                                                 20000208
                                                                                                                                               <--
              US 6022866
              WO 9407505
                                       19940414
                                                                                                                                               <--
               US 1995-403766
                                                                 19950324 (8)
ΑI
                                                                 19930922
               WO 1993-CA388
                                                                 19950324
                                                                                      PCT 371 date
                                                                                      PCT 102(e) date
                                                                 19950324
              Continuation-in-part of Ser. No. US 1994-285764, filed on 3 Aug 1994, now patented, Pat. No. US 5614506, issued on 25 Mar 1997 which is a
RLI
              continuation-in-part of Ser. No. US 1992-952095, filed on 28 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-675908, filed on 3 Jul 1991 And Ser. No. US 1992-838675, filed on 3 Jul 1991 And Ser. No. US 1992-838675, filed on 3 Jul 1991 And Ser. No. US 1992-838675, filed on 1992-83
                                        now patented, Pat. No. US 5639738, issued on 17 Jun 1997
               21 Feb 1992,
PRAI
               CA 1992-2079205
                                                         19920925
DT
               Utility
FS
               Granted
LN.CNT
               1554
INCL
               INCLM: 514/054.000
                              514/023.000; 514/025.000; 514/028.000; 514/032.000; 514/042.000;
               INCLS:
                              514/056.000; 514/060.000; 514/062.000; 536/055.000
NCL
               NCLM:
                              514/054.000
```

```
514/056.000; 514/060.000; 514/062.000; 536/055.000
IC
          [6]
         ICM: A61K031-70
         424/180; 514/23; 514/25; 514/28; 514/32; 514/33; 514/42; 514/54; 514/56; 514/60; 514/62; 536/55
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8.
       ANSWER 37 OF 98 USPATFULL on STN
AN
         2000:12926
                        USPATFULL
         Compositions and methods for the treatment and diagnosis of
TI
         cardiovascular disease using rchd523 as a target
Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
IN
PA
         corporation)
         Brigham and Women's Hospital, Boston, MA, United States (U.S.
         corporation)
         US 6020463
                                          20000201
ΡI
                                          19971006 (8)
         US 1997-944423
ΑI
         Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995, now patented, Pat. No. US 5968770 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10
RLI
         Feb 1995
Utility
DT
FS
         Granted
LN.CNT
         5972
INCL
         INCLM: 530/350.000
         INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100
NCL
         NCLM:
                   530/350.000
                   435/069.100; 435/320.100; 435/325.000; 536/023.100
         NCLS:
IC
          [6]
         ICM: C07K016-00
         ICS: C12N015-00
         435/320.1; 435/325; 435/69.1; 435/6; 536/23.1; 530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
       ANSWER 38 OF 98 USPATFULL on STN
         2000:12800 USPATFULL
ΑN
         Electronegative-substituted long chain xanthine compounds
TI
IN
         Leigh, Alistair J., Brier, WA, United States
         Michnick, John, Seattle, WA, United States
         Kumar, Anil M., Seattle, WA, United States
         Klein, J. Peter, Vashon, WA, United States
Underiner, Gail, Malvern, PA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 6020337
20000201
<--
PA
         US 6020337 US 1997-950810
ΡI
ΑI
                                          19970916 (8)
         Continuation-in-part of Ser. No. US 1993-42946, filed on 5 Apr 1993, now
RLI
         patented, Pat. No. US 5670506 And a continuation-in-part of Ser. No. US
         1997-910579, filed on 26 Jul 1997
DT
         Utility
         Granted
FS
LN.CNT
         1376
         INCLM: 514/258.000
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCLM: 514/263.340
NCLS: 514/210.210; 514/263.360; 544/267.000; 544/272.000; 544/277.000
INCL
NCL
         NCLS:
IC
          [6]
          ICM: A61K031-52
          ICS: C07D473-00
          514/258; 544/267; 544/272; 544/277
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 39 OF 98 USPATFULL 2000:10014 USPATFULL
L8
                             USPATFULL on STN
ΑN
TI
          Compositions and methods for the treatment and diagnosis of
          cardiovascular disease using rchd528 as a target
         Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
IN
PA
         Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
          corporation)
         Brigham and Women's Hospital, Boston, MA, United States (U.S.
          corporation)
PI
                                          20000125
         US 6018025
                                                                                            < - -
```

```
Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US
K\Gamma T
        1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser.
        No. US 1995-386844, filed on 10 Feb 1995
DT
        Utility
FS
        Granted
LN.CNT 6133
        INCLM: 530/350.000
INCL
        INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100;
                 435/320.100; 435/325.000
530/350.000
NCL
        NCLM:
                 435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000;
        NCLS:
                 536/023.100; 536/023.500
IC
        [6]
        ICM: C07K016-00
        ICS: C12N015-00
        536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/810; 435/69.1;
EXF
        435/7.1; 435/172.3; 435/320.1; 435/325; 436/501; 436/63; 935/32; 935/52; 935/77; 530/350; 530/325; 530/326
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 40 OF 98
L8
                          USPATFULL on STN
        2000:4941 USPATFULL
ΑN
                        .sub.145 expression vectors
TI
           ***VEGF***
IN
        Neufeld, Gera, Haifa, Israel
        Keshet, Eli, Kiryat Yam, Israel
        Vlodavsky, Israel, Mevaseret Zion, Israel
Poltorak, Zoya, Jerusalem, Israel
PA
        Technion Research & Development Co. Ltd., Haifa, Israel (non-U.S.
        corporation)
PI
        US 6013780
                                     20000111
                                     19970121 (8)
AΙ
        US 1997-784551
PRAI
        US 1996-25537P
                                19960906 (60)
DT
        Utility
FS
        Granted
LN.CNT 2158
        INCLM: 536/023.100
INCL
        INCLS: 435/320.100
NCLM: 536/023.100
NCL
        NCLS:
                435/320.100
IC
        [6]
        ICM: C07H021-04
        ICS: C12N015-11; C12N015-63
514/44; 435/172.3; 435/320.1; 536/23.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 41 OF 98 USPATFULL on STN
L8
ΑN
        1999:166794 USPATFULL
        Human S1-5 ECMP-like protein
TI
IN
        Yue, Henry, Sunnyvale, CA, United States
        Guegler, Karl J., Menlo Park, CA, United States
        Shah, Purvi, Sunnyvale, CA, United States
Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
PA
        corporation)
PΙ
                                     19991221
        US 6004753
                                                                                 <---
        US 1997-980514
ΑI
                                    19971201 (8)
        Utility
DT
FS
        Granted
LN.CNT 2285
INCL
        INCLM: 435/006.000
        INCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100
NCL
                435/006.000
        NCLM:
        NCLS:
                435/320.100; 435/325.000; 435/455.000; 536/023.100
IC
        [6]
        ICM: C12Q001-68
        ICS: C12N015-00; C12N005-00; C07H021-02
EXF
        536/23.1; 435/69.1; 435/320.1; 435/325; 435/455; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 42 OF 98 USPATFULL on STN
        1999:151198 USPATFULL
AN
TI
        Use of hyaluronic acid and forms to prevent arterial restenosis
        Falk, Rudolf Edgar, Toronto, Canada
Ascuali, Samuel Simon, Toronto, Canada
Turley, Eva Anne, Winnipeg, Canada
IN
```

```
corporation)
PI
        US 5990095
                                     19991123
                                                                                  <--
        US 1995-448503
ΑI
                                     19950726
                                                (8)
                                     19940325
        WO 1994-CA188
                                                 PCT 371 date
                                     19950726
                                                 PCT 102(e) date
                                     19950726
        Continuation-in-part of Ser. No. US 1991-675908, filed on 3 Jul 1991 And
RLI
        a continuation-in-part of Ser. No. US 1992-838674, filed on 21 Feb 1992,
        now abandoned Ser. No. Ser. No. US 1992-838675, filed on 21 Feb 1992,
        now patented, Pat. No. US 5639738 Ser. No. Ser. No. US 1992-952095
        filed on 28 Sep 1992, now abandoned And Ser. No. US 1993-125398, filed on 23 Sep 1993, now patented, Pat. No. US 5834444
DT
        Utility
FS
        Granted
        1906
LN.CNT
        INCLM: 514/054.000
INCL
NCL
        NCLM:
                 514/054.000
IC
         [6]
        ICM: A61K031-70
EXF
        536/55.1; 536/55.2; 514/54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 43 OF 98 USPATFULL on STN
ΑN
        1999:151195
                       USPATFULL
TI
        GATA-6 transcription factor: compositions and methods
IN
        Walsh, Kenneth, Carlisle, MA, United States
        St. Elizabeth's Medical Center, Boston, MA, United States (U.S.
PA
        corporation)
US 5990092
US 1997-927394
ΡI
                                     19991123
                                                                                  <--
AΙ
                                     19970827 (8)
DT
        Utility
FS
        Granted
LN.CNT
        2449
INCL
        INCLM: 514/044.000
        INCLS: 435/320.100; 536/023.500
NCL
                 514/044.000
        NCLM:
                 435/320.100; 536/023.500
        NCLS:
IC
        [6]
        ICM: A61K048-00
        ICS: C12N015-12; C12N015-85
435/320.1; 435/375; 435/377; 514/44; 536/23.5
EXF
    INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
L8
      ANSWER 44 OF 98 USPATFULL on STN
AN
        1999:150906 USPATFULL
TI
        Method for treating a subject suffering from a condition associated with
        an extracellular zinc sphingomyelinase
Tabas, Ira, New City, NY, United States
Schissel, Scott L., Teaneck, NJ, United States
Williams, Kevin Jon, Wynnewood, PA, United States
The Trustees of Columbia University in the City of New York, New York,
IN
PA
        NY, United States (U.S. corporation)
        Thomas Jefferson University, Philadelphia, PA, United States (U.S.
        corporation) US 5989803
PΙ
                                     19991123
                                                                                 <--
        US 1997-937234
ΑI
                                     19970908 (8)
DT
        Utility
FS
        Granted
LN.CNT
        3580
INCL
        INCLM: 435/004.000
        INCLS: 424/094.100; 424/094.600; 435/007.100; 435/007.210; 435/008.000;
                435/018.000
NCL
        NCLM:
                435/004.000
                424/094.100; 424/094.600; 435/007.100; 435/007.210; 435/008.000; 435/018.000
        NCLS:
IC
        [6]
        ICM: C12Q001-00
        ICS: C12Q001-66; C12Q001-34
EXF
        424/94.1; 424/94.6; 435/4; 435/7.1; 435/18; 435/7.72; 435/8
CAS
    INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 45 OF 98 USPATFULL on STN
\mathbf{N}\mathbf{A}
        1999:117455 USPATFULL
ΤI
        Compositions and methods for treating erectile dysfunction
IN
        Kifor, Imre, Methuen, MA, United States
```

```
PΑ
          The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S.
          corporation)
          US 5958884
PI
                                           19990928
          US 1998-47594
                                           19980325 (9)
ΑI
                                      19970411 (60)
PRAI
          US 1997-41875P
DT
          Utility
FS
          Granted
LN.CNT
         692
INCL
          INCLM: 514/016.000
          INCLS: 514/048.000; 514/381.000; 514/396.000; 514/397.000; 514/400.000
NCL
          NCLM:
                    514/016.000
                    514/048.000; 514/381.000; 514/396.000; 514/397.000; 514/400.000
          NCLS:
IC
          [6]
          ICM: A61K031-41
          ICS: A61K031-70; A61K038-08
          514/16; 514/48; 514/381; 514/396; 514/397; 514/400; 530/316; 548/252;
EXF
          548/253; 548/312.7; 548/323.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                             USPATFULL on STN
L8
       ANSWER 46 OF 98
                           USPATFULL
AN
          1999:113909
         Growth stimulating factors
Nudelman, Edward, Seattle, WA, United States
Hakomori, Sen-Itiroh, Mercer Island, WA, United States
TI
IN
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5955624 19990921
PA
PΙ
AI
          US 1995-473901
                                           19950607
                                                       (8)
RLI
          Continuation of Ser. No. US 1994-285153, filed on 3 Aug 1994, now
          abandoned
DT
          Utility
FS
          Granted
LN.CNT
         1036
INCL
          INCLM: 554/227.000
          INCLS: 514/546.000; 514/547.000; 514/549.000; 514/552.000; 514/715.000;
                   514/722.000; 514/723.000
NCL
          NCLM:
                   554/227.000
IC
          [6]
          ICM: C07C057-00
          554/227; 514/546; 514/547; 514/549; 514/552; 514/715; 514/722; 514/723
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 47 OF 98
L8
                              USPATFULL on STN
ΑN
          1999:113869
                          USPATFULL
TI
          Atherosclerotic plaque specific antigens, antibodies thereto, and uses
          thereof
         Ditlow, Charles C., Fremont, CA, United States
Chen, Francis W., San Francisco, CA, United States
Calenoff, Emanuel, Chicago, IL, United States
Charter Ventures, Palo Alto, CA, United States (U.S. corporation)
IN
PA
PΙ
          US 5955584
                                           19990921
AΙ
         US 1993-53451
                                           19930426 (8)
RLI
         Continuation-in-part of Ser. No. US 1992-828860, filed on 31 Jan 1992,
         now abandoned which is a continuation-in-part of Ser. No. US
         now abandoned which is a continuation-in-part of Ser. No. US 1989-388129, filed on 31 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-67995, filed on 29 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-67993, filed on 29 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-67986, filed on 29 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-876741, filed on 20 Jun 1986, now abandoned which is a continuation-in-part of Ser. No. US
         1986-871811, filed on 6 Jun 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-846401, filed on 31 Mar 1986,
         now abandoned
DT
         Utility
FS
         Granted
LN.CNT
         14947
INCL
          INCLM: 530/388.200
          INCLS:
                   530/391.100; 530/391.300; 436/543.000; 435/011.000; 522/544.000
NCL
                   530/388.200
         NCLM:
         NCLS:
                   435/011.000; 436/543.000; 530/391.100; 530/391.300
IC
          [6]
          ICM: C07K016-18
          ICS: C12P021-08
EXF
          530/388.2; 530/389.5; 530/391.1; 530/391.3; 530/359; 424/133.1;
          424/141.1; 424/152.1; 424/172.1; 424/178.1; 424/184.1; 435/11; 436/543;
```

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 48 OF 98
L8
                              USPATFULL on STN
          1999:113594 USPATFULL
AN
TI
          Genes encoding proteins that interact with the tub protein
         Gimeno, Carlos J., Wellesley, MA, United States
IN
          Errada, Patrick R., Cambridge, MA, United States
         Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
PA
ΡI
         US 5955306
                                           19990921
         US 1997-897340
                                           19970721 (8)
AI
RLI
         Continuation-in-part of Ser. No. US 1996-715032, filed on 17 Sep 1996,
         now abandoned
DT
         Utility
FS
          Granted
LN.CNT 4240
INCL
          INCLM: 435/069.100
          INCLS: 435/071.100; 435/320.100; 435/325.000; 435/252.300; 435/254.110;
                   536/023.500; 536/024.300; 536/024.310
NCL
         NCLM:
                   435/069.100
         NCLS:
                   435/071.100; 435/252.300; 435/254.110; 435/320.100; 435/325.000;
                   536/023.500; 536/024.300; 536/024.310
IC
          [6]
          ICM: C12N015-12
          ICS: C12P021-00; C07K014-435; C07K014-47
         536/23.5; 536/24.3; 536/24.31; 435/320.1; 435/325; 435/252.3; 435/69.1; 435/71.1; 435/254.11
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 49 OF 98 USPATFULL on STN
L8
         1999:113557 USPATFULL
\mathbf{M}\mathbf{A}
         Methods of screening foods for nutraceuticals
Ghai, Geetha, Murray Hill, NJ, United States
Boyd, Charles, New Brunswick, NJ, United States
TI
IN
         Csiszar, Katalin, New Brunswick, NJ, United States
         Ho, Chi-Tang, East Brunswick, NJ, United States
Rosen, Robert T., Pottersville, NJ, United States
         Rutgers, The State University of New Jersey, New Brunswick, NJ, United States (U.S. corporation)
PA
PΙ
         US 5955269
                                           19990921
                                                                                               <--
         US 1996-670826
ΑI
                                           19960620 (8)
         Utility
DT
FS
         Granted
LN.CNT
         2189
INCL
          INCLM: 435/006.000
          INCLS: 435/091.200; 435/004.000; 426/478.000
                   435/006.000
NCL
         NCLM:
         NCLS:
                   426/478.000; 435/004.000; 435/091.200
IC
          [6]
          ICM: C12Q001-68
          ICS: C12P019-34; A23L001-00
          435/91.1; 435/91.2; 435/91.51; 435/6; 435/7.1; 435/4; 426/478
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 50 OF 98 USPATFULL on STN 1999:92656 USPATFULL
L8
\mathbf{A}\mathbf{N}
         Compositions and methods for modulating growth of a tissue in a mammal Weisz, Paul B., State College, PA, United States
Trustees of the University of Pennsylvania, Philadelphia, PA, United
TI
IN
PA
         States (U.S. corporation)
ΡI
         US 5935940
                                           19990810
                                                                                               <--
AΙ
                                           19970805 (8)
         US 1997-906500
         Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented,
RLI
         Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592,
         filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned, said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented. Bet No. US 5183808
```

now patented, Pat. No. US 5183809
DT Utility
FS Granted
LN.CNT 1497
INCL INCLM: 514/058.000

```
NCL
             NCLM:
                          514/058.000
             NCLS:
                          514/021.000; 530/810.000; 530/812.000; 530/813.000
IC
             [6]
             ICM: A61K031-715
             ICS: A61K038-00
             514/58; 514/21; 530/810; 530/812; 530/813
EXF
       INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
L8
         ANSWER 51 OF 98 USPATFULL on STN
AN
             1999:81567 USPATFULL
            Therapeutic use of multilamellar liposomal prostaglandin formulations Lenk, Robert P., The Woodland, TX, United States Tomsho, Michelle L., Levittown, PA, United States Suddith, Robert L., Wilmington, NC, United States Klimchak, Robert J., Flemington, NJ, United States Janoff, Andrew S., Yardley, PA, United States Minchey, Sharma R., Monmouth Junction, NJ, United States
TI
ΙN
             Ostro, Marc J., Pennington, NJ, United States
PA
             The Liposome Company, Inc., Princeton, NJ, United States (U.S.
            corporation)
US 5925375
US 1994-333770
PI
                                                        19990720
                                                                                                                           < - -
            US 1994-333770

US 1994-333770

Continuation-in-part of Ser. No. US 1993-152852, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-821648, filed on 16 Jan 1992, now patented, Pat. No. US 5262168 which is a continuation of Ser. No. US 1988-195228, filed on 18 May 1988, now patented, Pat. No. US 5082664 which is a continuation-in-part of Ser. No. US 1987-52305 filed on 2 May 1987 now abandoned said
AI
RLI
            of Ser. No. US 1987-53305, filed on 2 May 1987, now abandoned , said
             Ser. No. US 152852 which is a continuation-in-part of Ser. No. US
            1993-147898, filed on 4 Nov 1993, now abandoned which is a continuation of Ser. No. US 1992-876200, filed on 30 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-697314, filed on 7 May 1991,
             now abandoned
DT
             Utility
FS
             Granted
LN.CNT 1206
INCL
             INCLM: 424/450.000
             INCLS: 514/573.000
                         424/450.000
514/573.000
NCL
             NCLM:
            NCLS:
             [6]
IC
             ICM: A61K009-127
             ICS: A61K009-133
             424/450; 514/573
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
         ANSWER 52 OF 98 USPATFULL on STN 1999:75518 USPATFULL
L8
ΑN
            Polynucleotides encoding cytokine inducible regulatory protein Hillman, Jennifer L., Mountain View, CA, United States Guegler, Karl J., Menlo Park, CA, United States Corley, Neil C., Mountain View, CA, United States
ΤI
IN
            Shah, Purvi, Sunnyvale, CA, United States
Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
PA
            corporation)
US 5919661
ΡĮ
                                                        19990706
            US 1997-918206
ΑI
                                                       19970825 (8)
            Utility
DT
            Granted
LN.CNT
            2184
INCL
             INCLM: 435/069.100
            INCLS: 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.500; 536/024.310; 530/350.000; 514/044.000
NCL
            NCLM:
                         435/069.100
                         435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 514/044.000; 530/350.000; 536/023.500; 536/024.310
            NCLS:
IC
             [6]
             ICM: C12N015-12
             ICS: C12N015-63; C07K014-47
            536/23.1; 536/23.5; 536/24.3; 536/24.31; 435/69.1; 435/71.1; 435/71.2; 435/172.3; 435/325; 435/252.3; 435/320.1; 435/471; 530/350; 514/44
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
         ANSWER 53 OF 98 USPATFULL on STN
AN
             1999:72602 USPATFULL
```

```
uses therefore
           Lai, Ching-San, Encinitas, CA, United States
Medinox, Inc., San Diego, CA, United States (U.S. corporation)
US 5916910 19990629 <
 IN
PA
PI
ΑI
           US 1997-869158
                                                19970604 (8)
DT
           Utility
FS
           Granted
LN.CNT
           1842
INCL
           INCLM: 514/423.000
           INCLS: 514/514.000; 548/564.000; 548/573.000; 558/235.000
NCL
                      514/423.000
           NCLM:
           NCLS:
                      514/514.000; 548/564.000; 548/573.000; 558/235.000
IC
            [6]
           ICM: C07D207-04
           ICS: C07D207-30; A61K031-27; A61K031-40
           514/514; 514/423; 548/565; 548/573; 558/235
EXF
      INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
L8
        ANSWER 54 OF 98
                                USPATFULL on STN
           1999:56471
AΝ
                            USPATFULL
TI
           Methods of modulating tissue growth and regeneration
IN
           Herrmann, Howard C., Bryn Mawr, PA, United States
           Barnathan, Elliot, Havertown, PA, United States
           Weisz, Paul B., State College, PA, United States
The Trustees of the University of Pennsylvania, Philadelphia, PA, United
PA
           States (U.S. corporation)
PI.
           US 5902799
                                                19990511
ΑI
           US 1997-906501
                                                19970805 (8)
           Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592,
RLI
           filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned, said Ser. No. US 900592 which is a continuation of Ser. No. US 900592 which is a continuation in part of Ser. No. US 900592 which is a continuation in part of Ser. No. US 900592 which is a continuation in part of Ser. No. US 900592 which is a continuation in part of Ser. No. US 900592 which is a continuation in part of Ser. No. US 900592 which is a continuation in part of Ser. No. US 1880 480407 filed on 15 Feb 1880
           continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990,
           now patented, Pat. No. US 5183809
DT
           Utility
FS
           Granted
LN.CNT
           1703
           INCLM: 514/058.000
INCL
           INCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000
                     514/058.000
NCL
           NCLM:
           NCLS:
                      514/021.000; 530/810.000; 530/813.000; 530/817.000
IC
           [6]
           ICM: A61K031-715
           ICS: A61K031-735
EXF 514/58; 514/21; 514/56; 530/810; 530/812; 530/813; 530/817 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
        ANSWER 55 OF 98
                                 USPATFULL on STN
NA
           1999:40428 USPATFULL
TI
           Substituted amino alkyl compounds
           Klein, J. Peter, Vashon Island, WA, United States
IN
          Underiner, Gail E., Brier, WA, United States
Leigh, Alistair J., Brier, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5889011
19990330
---
PA
PΙ
                                               19970627 (8)
AΙ
           US 1997-884037
           Continuation of Ser. No. US 1993-149681, filed on 9 Nov 1993, now
RLI
           abandoned which is a continuation-in-part of Ser. No. US 1992-973804,
           filed on 9 Nov 1992, now patented, Pat. No. US 5340813
DT
           Utility
FS
           Granted
LN.CNT
           1351
INCL
                     514/263.000
514/261.000; 544/267.000; 544/264.000; 544/265.000
514/263.350
           INCLM:
           INCLS:
NCL
           NCLM:
           NCLS:
                     544/264.000; 544/265.000; 544/267.000
IC
           [6]
           ICM: C07D473-00
           ICS: A61K031-52
EXF
           544/257; 544/267; 544/263; 544/285; 544/287; 514/263; 514/261
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
AΝ
          1999:34025 USPATFULL
TI
          Compositions and methods for treating and preventing pathologies
          including cancer
          Samid, Dvorit, Rockville, MD, United States
The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
IN
PA
ΡI
                                            19990316
          US 5883124
          US 1995-484615
ΑI
                                            19950607 (8)
          Division of Ser. No. US 1994-207521, filed on 7 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993
RLI
          which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21
          Oct 1991, now abandoned
DT
          Utility
          Granted
FS
LN.CNT
          7729
          INCLM:
                    514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000; 514/725.000
INCL
          INCLS:
                    514/538.000
NCL
          NCLM:
                    514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000;
          NCLS:
                    514/725.000
IC
          [6]
          ICM: A01N037-12
     ICS: A01N037-44; A61K031-24
514/538; 514/557; 514/563; 514/567; 514/568; 514/570; 514/725
INDEXING IS AVAILABLE FOR THIS PATENT.
EXF
CAS
L8 .
       ANSWER 57 OF 98
                               USPATFULL on STN
\mathbf{AN}
          1999:33831
                          USPATFULL
          Compositions and method for the treatment and diagnosis of
TI
          cardiovascular disease using rchd502 as a target
IN
          Falb, Dean A., Wellesley, MA, United States
          Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
PA
          corporation)
          US 5882925
PΙ
                                            19990316
ΑI
         US 1996-599654
                                            19960209 (8)
RLI
          Continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995
          which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10
          Feb 1995
DT
          Utility
FS
          Granted
LN.CNT
          5758
INCL
          INCLM: 435/325.000
          INCLS: 536/023.100; 536/024.100; 536/024.300; 435/006.000; 435/069.100;
                    435/320.100; 435/455.000
NCL
                    435/325.000
         NCLM:
                   435/006.000; 435/069.100; 435/320.100; 435/455.000; 536/023.100; 536/024.100; 536/024.300
         NCLS:
IC
          [6]
          ICM: C12N015-12
536/23.1; 536/24.1; 536/24.3; 435/6; 435/69.1; 435/325; 435/320.1;
EXF
          435/455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
       ANSWER 58 OF 98
                              USPATFULL on STN
AN
          1999:24638 USPATFULL
          Compositions and methods for modulating growth of a tissue in a mammal
TI
         Herrmann, Howard C., Bryn Mawr, PA, United States
Barnathan, Elliot, Havertown, PA, United States
Weisz, Paul B., State College, PA, United States
The Trustees of the University of Pennsylvania, Philadelphia, PA, United
IN
PA
          States (U.S. corporation)
PI
         US 5874419
                                            19990223
                                                                                                 <---
AΙ
         US 1997-905612
                                            19970804 (8)
RLI
         Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented,
         Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592,
         filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned, said Ser. No. US 20 -900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented. Pat No. US 5182808 iggued on 2 Feb 1992
         now patented, Pat. No. US 5183809, issued on 2 Feb 1993
DT
          Utility
FS
         Granted
```

```
INCLM: 514/058.000
TNCL
                514/021.000; 514/023.000; 514/054.000; 514/060.000; 514/769.000;
        INCLS:
                424/652.000; 424/682.000; 424/617.000; 536/103.000
                514/058.000
NCL
        NCLM:
        NCLS:
                424/617.000; 424/652.000; 424/682.000; 514/021.000; 514/023.000;
                514/054.000; 514/060.000; 514/769.000; 536/103.000
IC
        [6]
        ICM: A61K031-735
        ICS: A61K047-02; C08B037-16
        514/21; 514/23; 514/54; 514/58; 514/60; 514/769; 536/103; 424/652;
EXF
424/682; 424/617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 59 OF 98 USPATFULL on STN 1999:7227 USPATFULL
L8
AN
        Methods for identifying compounds that modulate mammalian tub protein
TI
        activity
        Kleyn, Patrick W., Cambridge, MA, United States
IN
        Moore, Karen J., Maynard, MA, United States
Kapeller, Rosana, Chestnut Hill, MA, United States
        Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
PA
        corporation)
US 5861239
US 1997-922267
                                   19990119
PΙ
                                                                              <--
                                   19970902 (8)
ΑI
        Continuation-in-part of Ser. No. US 1997-829553, filed on 28 Mar 1997,
RLI
        now patented, Pat. No. US 5817762 which is a division of Ser. No. US
        1996-631200, filed on 12 Apr 1996, now patented, Pat. No. US 5646040,
        issued on 8 Jul 1997
        US 1995-604P
                              19950630
PRAI
                                         (60)
        US 1995-1273P
                               19950720
                                         (60)
           1995-1444P
        US
                               19950726
                                         (60)
        US 1995-2759P
                               19950824
                                         (60)
        US 1995-4424P
                               19950928
                                         (60)
        US 1996-15396P
                              19960409
                                         (60)
DT
        Utility
FS
        Granted
LN.CNT
       4705
INCL
        INCLM: 435/004.000
        NCLM:
               435/004.000
NCL
        [6]
IC
        ICM: C12Q001-00
        ICS: C12Q001-02
        435/4
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 60 OF 98 USPATI
1999:4647 USPATFULL
L8
                        USPATFULL on STN
AN
ΤI
        Fas ligand compositions for treatment of proliferative disorders
        Walsh, Kenneth, Carlisle, MA, United States
IN
PA
        St. Elizabeth's Medical Center, Boston, MA, United States (U.S.
        corporation)
PΙ
        US 5858990
                                   19990112
                                                                              <--
ΑI
        US 1997-810453
                                   19970304 (8)
        Utility
DT
FS
        Granted
LN.CNT
        3038
INCL
        INCLM: 514/044.000
        INCLS: 435/006.000; 435/172.100; 435/320.100; 435/069.100; 435/375.000;
                435/377.000
NCL
        NCLM:
                514/044.000
        NCLS:
                435/006.000; 435/069.100; 435/320.100; 435/375.000; 435/377.000
IC
        [6]
        ICM: A61K048-00
        ICS: C12N015-11
        435/6; 435/172.1; 435/172.3; 435/320.1; 435/325; 435/69.1; 435/31.1; 435/375; 435/377; 536/23.1; 536/23.5; 514/2; 514/44
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
^{18}
                        USPATFULL on STN
     ANSWER 61 OF 98
AN
        1998:159986 USPATFULL
TI
        Phenylacetate and derivatives alone or in combination with other
        compounds against neoplastic conditions and other disorders
IN
        Samid, Dvorit, Rockville, MD, United States
        The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PA
```

```
WO 9510271 199
US 1996-633833
                        19950420
AΙ
                                       19960410 (8)
         WO 1994-US11492
                                       19941012
                                       19960410
                                                    PCT 371 date
                                                    PCT 102(e) date
                                       19960410
         Continuation of Ser. No. US 1994-207521, filed on 7 Mar 1994, now
RLI
         patented, Pat. No. US 5605930 And Ser. No. US 1993-135661, filed on 12
         Oct 1993, now patented, Pat. No. US 5635532, each Ser. No. US
         is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct
         1991, now abandoned
DT
         Utility
         Granted
FS
LN.CNT
        5051
INCL
         INCLM: 514/510.000
         INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                  514/567.000
                  514/510.000
NCL
         NCLM:
         NCLS:
                  514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                  514/567.000
IC
         [6]
         ICM: A01N037-12
         ICS: A01N037-44; A61K031-195; A61K031-24
     514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567 INDEXING IS AVAILABLE FOR THIS PATENT.
EXF
CAS
                            USPATFULL on STN
Г8
      ANSWER 62 OF 98
AN
         1998:157185
                        USPATFULL
         Compositions and methods for the treatment and diagnosis of
TI
         cardiovascular using RCHD528 as a target
IN
         Falb, Dean A., Massachusetts, MA, United States
PA
         Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
         corporation)
         US 5849578
PI
                                       19981215
         US 1996-616844
ΑI
                                       19960315 (8)
        Division of Ser. No. US 1996-599654, filed on 9 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-458873, filed on 7 Jun 1995
RLI
         which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10
         Feb 1995
DT
         Utility
FS
         Granted
LN.CNT
        5753
INCL
         INCLM: 435/325.000
         INCLS: 536/023.100; 536/024.100; 536/024.300; 435/006.000; 435/069.100;
                  435/320.100; 435/455.000
NCL
                  435/325.000
         NCLM:
         NCLS:
                  435/006.000; 435/069.100; 435/320.100; 435/455.000; 536/023.100;
                  536/024.100; 536/024.300
IC
         [6]
         ICM: C12N015-12
         536/23.1; 536/24.1; 536/24.3; 435/6; 435/69.1; 435/7.1; 435/325; 435/320.1; 435/455; 436/201; 436/63; 514/44
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 63 OF 98 USPATFULL on STN
L8
AN
         1998:154266 USPATFULL
TI
         Treatment for atherosclerosis and other cardiovascular and inflammatory
         diseases
IN
         Medford, Russell M., Atlanta, GA, United States
Alexander, R. Wayne, Atlanta, GA, United States
         Parthasarathy, Sampath, Atlanta, GA, United States
         Khan, Bobby V., Dunwoody, GA, United States
PΑ
         Emory University, Atlanta, GA, United States (U.S. corporation)
         US 5846959
                                       19981208
PI
AΙ
         US 1995-471537
                                       19950606 (8)
         Continuation of Ser. No. US 1994-317399, filed on 4 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-969934, filed on 30 Oct 1992, now patented, Pat. No. US 5380747
RLI
DT
         Utility
FS
         Granted
LN.CNT
         2167
INCL
         INCLM: 514/165.000
         INCLS: 424/009.100; 424/009.200; 424/006.000; 424/007.200; 424/007.210; 424/007.240; 424/007.940; 424/007.950; 436/071.000; 436/086.000; 436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000;
```

```
514/45/.000; 514/4/8.000; 514/4/9.000
                              514/165.000
NCL
               NCLM:
               NCLS:
                              424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210;
                              435/007.240; 435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000; 514/171.000; 514/211.070; 514/423.000; 514/457.000;
                              514/478.000; 514/479.000
IC
                [6]
               ICM: A61K031-60
               ICS: A61K031-56; A61K031-40; A61K031-37
               424/9.1; 424/0.2; 436/71; 436/86; 436/129; 514/18; 514/423; 514/478; 514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513; 514/824; 514/825; 514/826; 514/861; 514/863; 530/331; 548/431; 558/230;
EXF
               558/235;
                                  564/76; 565/21; 565/25
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
          ANSWER 64 OF 98 USPATFULL on STN
L8
               1998:150994 USPATFULL
AN
               Compositions and methods for treating and preventing pathologies
TI
               including cancer
               Samid, Dvorit, Rockville, MD, United States
The United States of America as representeed by the Department of Health
IN
PA
               and Human Services, Washington, DC, United States (U.S. government)
PΙ
               US 5843994
                                                                   19981201
AΙ
               US 1995-478264
                                                                   19950607 (8)
               Division of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented,
RLI
               Pat. No. US 5605930 which is a continuation-in-part of Ser. No. US
               1993-135661, filed on 12 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991,
               now abandoned
DT
               Utility
               Granted
FS
LN.CNT
               7935
               INCLM: 514/510.000
INCL
               INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                              514/567.000
NCL
               NCLM:
                              514/510.000
                              514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
               NCLS:
                              514/567.000
IC
                [6]
               ICM: A61K031-21
               ICS: A01N047-40
               514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
           ANSWER 65 OF 98
                                             USPATFULL on STN
L8
               1998:144102 USPATFULL
\mathbf{A}\mathbf{N}
TI
               Amino-alcohol substituted cyclic compounds
              Kumar, Anil M., Seattle, WA, United States
Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States
(U.S. corporation)
IN
PA
               US 5837703
                                                                   19981117
PI
AI
               US 1993-152650
                                                                   19931112 (8)
               Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
RLI
               now abandoned
DT
               Utility
FS
               Granted
               2596
LN.CNT
               INCLM: 514/183.000
INCLS: 514/211.000; 514/228.800; 514/241.000; 514/242.000; 514/249.000; 514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000; 514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000; 514/309.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000; 514/312.000;
INCL
                               514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
                               540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
                              544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000; 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000; 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
NCL
                               514/183.000
               NCLM:
                              514/211.150; 514/228.800; 514/241.000; 514/242.000; 514/249.000; 514/256.000; 514/266.200; 514/266.300; 514/270.000; 514/274.000; 514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000; 514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
               NCLS:
```

```
544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000; 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000; 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
IC
           [6]
          ICM: A61K031-55
          ICS: A61K031-515; A61K031-445; A61K031-52
          544/276; 544/272; 544/216; 544/257; 544/285; 544/286; 544/301; 544/311;
EXF
          544/335; 514/263; 514/183; 514/211; 514/228.8; 514/241; 514/242;
          514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315; 514/348; 514/357; 514/374; 514/400; 514/418; 514/425; 514/427; 540/467; 540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334; 548/215; 548/340.1; 548/485; 548/561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                               USPATFULL on STN
L8
       ANSWER 66 OF 98
          1998:128265
                            USPATFULL
AN
ΤI
          Substituted amino alcohol compounds
          Klein, J. Peter, Vashon, WA, United States
IN
          Underiner, Gail E., Brier, WA, United States
          Kumar, Anil M., Seattle, WA, United States
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5824677 19981020 <--
PA
PΙ
          US 1995-474816
ΑI
                                             19950607
                                                           (8)
          Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented, Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US
RLI
          1993-152650, filed on 12 Nov 1993, now patented, Pat. No. US 5801181 And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878, said Ser. No. US -152650 And Ser. No. US -164081, each
                              - which is a continuation-in-part of Ser. No. US
          Ser. No. US
          1993-40820, filed on 31 Mar 1993, now abandoned
          Utility
DT
FS
          Granted
LN.CNT
          3136
          INCLM:
INCL
                    514/222.500
          INCLS:
                    514/223.500;
                                       514/224.500; 514/226.800; 514/227.500; 514/228.800;
                    514/229.200; 514/230.500;
                                                          514/230.800; 514/237.800; 514/258.000; 514/274.000;
                                                                                                514/248.000;
                    514/249.000; 514/255.000;
                                                                                               514/301.000;
                    514/303.000;
                                      514/311.000;
                                                         514/351.000; 514/360.000;
                                                                                                514/361.000;
                                       514/363.000;
514/373.000;
514/379.000;
                                                          514/364.000;
514/374.000;
514/380.000;
                                                                             514/365.000;
514/375.000;
514/387.000;
514/425.000;
                                                                                               514/367.000;
514/376.000;
514/395.000;
514/433.000;
                    514/362.000;
                    514/372.000;
514/378.000;
                                       514/418.000;
                    514/415.000;
                                                          514/424.000;
                    514/452.000;
                                       514/432.000;
                                                          514/438.000;
                                                                             346/113.000;
                                                                                                346/114.000;
                    346/164.000;
                                       346/300.000;
                                                          549/014.000;
                                                                             549/050.000;
                                                                                                549/075.000;
                    549/367.000;
                                      549/368.000;
                                                          544/002.000;
                                                                             544/003.000;
                                                                                                544/005.000;
                                                                                                544/066.000;
                    544/008.000;
                                       544/053.000;
                                                         544/063.000;
                                                                             544/065.000;
                                       544/090.000;
544/215.000;
544/255.000;
548/123.000;
                                                          544/091.000;
544/219.000;
544/278.000;
548/125.000;
                                                                             544/127.000;
544/229.000;
544/311.000;
548/131.000;
                                                                                               544/128.000;
544/235.000;
544/353.000;
548/134.000;
548/207.000;
                    544/067.000;
                    544/162.000;
544/237.000;
                    544/385.000;
                    548/143.000;
                                       548/146.000;
                                                          548/153.000;
                                                                             548/174.000;
                    548/214.000;
                                       548/215.000;
                                                          548/217.000;
                                                                             548/221.000; 548/228.000;
                    548/229.000;
                                       548/237.000;
                                                          548/240.000;
                                                                             548/241.000; 548/243.000;
                    548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000;
                    548/486.000; 548/543.000; 548/546.000
                    514/222.500

514/223.500; 514/224.500; 514/226.800;

514/229.200; 514/230.500; 514/230.800;

514/249.000; 514/255.020; 514/260.100;

514/251.000; 514/251.000; 514/260.100;
NCL
          NCLM:
                                                                             514/227.500; 514/228.800;
514/237.800; 514/248.000;
514/274.000; 514/301.000;
          NCLS:
                                                         514/351.000;
                    514/303.000; 514/311.000;
                                                                             514/360.000;
                                                                                                514/361.000;
                    514/362.000; 514/363.000; 514/364.000;
                                                                             514/365.000;
                                                                                                514/367.000;
                    514/372.000; 514/373.000; 514/374.000;
                                                                                                514/376.000;
                                                                             514/375.000;
                    514/378.000; 514/379.000; 514/380.000;
                                                                             514/387.000; 514/395.000;
                    514/415.000;
                                       514/418.000; 514/424.000;
                                                                             514/425.000; 514/432.000;
                                       514/438.000;
544/008.000;
544/067.000;
                                                          514/452.000;
544/053.000;
                                                                                                544/003.000;
                    514/433.000;
                                                                             544/002.000;
                                                                             544/063.000;
                    544/005.000;
                                                                                                544/065.000;
                                                                             544/091.000;
544/219.000;
544/278.000;
                                                                                                544/127.000;
544/229.000;
544/311.000;
                                                          544/090.000;
                    544/066.000;
                                       544/162.000;
544/237.000;
                                                          544/215.000;
544/255.000;
                    544/128.000;
                    544/235.000;
                                       544/385.000;
                    544/353.000;
                                                          546/113.000;
                                                                             546/114.000;
                                                                                                546/164.000;
                    546/300.000;
                                       548/123.000; 548/125.000;
                                                                             548/131.000; 548/134.000;
                                       548/146.000; 548/153.000; 548/174.000; 548/207.000;
                    548/143.000;
                    548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000;
                    548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000;
```

```
549/075.000; 549/367.000; 549/368.000
IC
            [6]
            ICM: A61K031-385
           ICS: A61K031-445; A61K031-47; A61K031-505
549/75; 549/50; 549/14; 549/367; 549/368; 514/432; 514/438; 514/222.5;
514/223.5; 514/224.5; 514/226.8; 514/227.5; 514/228.8; 514/229.2;
514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258;
EXF
            514/274; 514/301; 514/303; 514/311; 514/351; 514/360; 514/361; 514/362; 514/363; 514/364; 514/365; 514/367; 514/372; 514/373; 514/374; 514/375;
            514/376; 514/378; 514/379; 514/380; 514/387; 514/395; 514/415; 514/418;
           514/424; 514/425; 514/433; 514/452; 544/2; 544/3; 544/5; 544/8; 544/53;
           514/424; 514/425; 514/433; 514/452; 544/2; 544/3; 544/5; 544/6; 544/53; 544/63; 544/65; 544/66; 544/67; 544/90; 544/91; 544/127; 544/128; 544/162; 544/215; 544/219; 544/229; 544/235; 544/237; 544/255; 544/278; 544/311; 544/353; 544/385; 546/113; 546/114; 546/164; 546/300; 548/123; 548/125; 548/131; 548/134; 548/145; 548/146; 548/153; 548/174; 548/207; 548/214; 548/215; 548/217; 548/221; 548/228; 548/229; 548/237; 548/240; 548/241; 548/243; 548/247; 548/267.2; 548/303.7; 548/307.1; 548/453;
            548/486;
                          548/543; 548/546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
        ANSWER 67 OF 98 USPATFULL on STN
            1998:122413 USPATFULL
AN
ΤI
            Substituted amino alkyl compounds
           Klein, J. Peter, Vashon Island, WA, United States
Underiner, Gail E., Brier, WA, United States
Leigh, Alistair J., Brier, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5817662
19981006
---
IN
PA
PΙ
           US 1995-468656
AΙ
                                                    19950606 (8)
           Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned
RLI
           which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9
           Nov 1992, now patented, Pat. No. US 5340813
DT
           Utility
           Granted
FS
LN.CNT
           1358
INCL
           INCLM: 514/263.000
            INCLS: 424/824.000; 424/825.000; 424/885.000; 424/921.000
NCL
                       514/263.350
           NCLM:
           NCLS:
                       424/824.000; 424/825.000
IC
            [6]
     ICM: A61K031-52
514/397; 514/263; 424/824; 424/825; 424/885; 424/921
INDEXING IS AVAILABLE FOR THIS PATENT.
EXF
CAS
L8
        ANSWER 68 OF 98
                                   USPATFULL on STN
ΑN
           1998:115764 USPATFULL
TI
           Treatment for atherosclerosis and other cardiovascular and inflammatory
           diseases
           Medford, Russell M., Atlanta, GA, United States
Alexander, R. Wayne, Atlanta, GA, United States
Parthasarathy, Sampath, Atlanta, GA, United States
Khan, Bobby V., Dunwoody, GA, United States
IN
PA
           Emory University, Altanta, GA, United States (U.S. corporation)
                                                    19980922
PI
           US 5811449
AΙ
           US 483335&
                                                    19950607 (8)
RLI
           Division of Ser. No.
                                                    317399, filed on 4 Oct 1994 which is a
           continuation-in-part of Ser. No. 240858, filed on 10 May 1994, now abandoned which is a continuation-in-part of Ser. No. 969934, filed
                                                                                                           969934, filed
           on 30 Oct 1992, now patented, Pat. No. Utility
                                                                                  5380747
DT
FS
           Granted
LN.CNT
           2106
            INCLM: 514/423.000
INCL
           INCLS: 514/863.000; 530/331.000; 548/431.000; 548/531.000; 549/010.000; 558/230.000; 558/234.000; 558/235.000; 558/250.000; 562/026.000; 562/027.000; 564/076.000
                        514/423.000
NCL
           NCLM:
                       424/009.100; 424/009.200; 436/071.000; 436/086.000; 436/129.000; 514/018.000; 514/226.200; 514/477.000; 514/478.000; 514/479.000; 514/485.000; 514/487.000; 514/488.000; 514/489.000;
           NCLS:
                        514/506.000; 514/513.000; 514/517.000; 514/518.000; 514/553.000;
                        514/561.000; 514/824.000; 514/825.000; 514/826.000; 514/861.000;
                        514/863.000; 530/331.000; 548/431.000; 548/531.000; 549/010.000;
                       558/230.000; 558/234.000; 558/235.000; 558/250.000; 562/026.000; 562/027.000; 564/076.000; 568/021.000; 568/025.000
```

```
ICM: A61KU31-40
            ICS: A61K031-54; A61K031-265; A61K031-185
424/9.1; 424/9.2; 436/71; 436/86; 436/129; 514/18; 514/423; 514/478;
514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513;
514/824; 514/825; 514/826; 514/861; 514/863; 530/331; 548/431; 558/230;
558/235; 564/76; 568/21; 568/25
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
         ANSWER 69 OF 98
                                     USPATFULL on STN
L8
            1998:115565
AN
                                  USPATFULL
TI
            Atherosclerotic plaque specific antiqens, antibodies thereto, and uses
            Ditlow, Charles C., Fremont, CA, United States
Chen, Francis W., San Francisco, CA, United States
Calenoff, Emanuel, Chicago, IL, United States
Charter Ventures, Palo Alto, CA, United States (U.)
IN
PA
                                                                      United States (U.S. corporation)
                                                      19980922
PI
            US 5811248
            US 1995-480434
                                                      19950607 (8)
ΑI
            Division of Ser. No. US 1994-336525, filed on 9 Nov 1994, now abandoned
RLI
            which is a continuation-in-part of Ser. No. US 1993-53451, filed on 26
            Apr 1993 which is a continuation-in-part of Ser. No. US 1992-828860,
            filed on 31 Jan 1992, now abandoned which is a continuation-in-part of
            Ser. No. US 1989-388129, filed on 31 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-67995, filed on 29 Jun 1987, now abandoned which is a continuation of Ser. No. US 1987-67993, filed on 29 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-67986, filed on 29 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-876841, filed on 20 Jun 1986, now abandoned which is a continuation-in-part of Ser. No. US
            1986-871811, filed on 6 Jun 1986, now abandoned which is a
            continuation-in-part of Ser. No. US 1986-846401, filed on 31 Mar 1986,
            now abandoned
DT
            Utility
FS
            Granted
            4729
LN.CNT
INCL
            INCLM: 435/007.900
            INCLS: 435/007.100; 435/011.000; 435/007.920; 435/007.930; 424/009.600; 424/133.100; 424/134.100; 424/135.100; 424/178.100; 530/388.100; 530/388.900; 530/391.100; 530/391.300
NCL
            NCLM:
                        435/007.900
                        424/009.600; 424/133.100; 424/134.100; 424/135.100; 424/178.100; 435/007.100; 435/007.920; 435/007.930; 435/011.000; 530/387.300; 530/388.100; 530/388.900; 530/391.100; 530/391.300
            NCLS:
IC
            ICM: G01N033-574
ICS: G01N033-53; C07K016-18

EXF 435/7.1; 435/11; 435/7.9; 435/7.92; 435/7.93; 530/387.3; 530/388.1; 530/388.9; 530/391.1; 530/391.3; 530/391.7; 436/518; 424/9.6; 424/133.1; 424/134.1; 424/135.1; 424/178.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
         ANSWER 70 OF 98 USPATFULL on STN
ΑN
            1998:111964 USPATFULL
TI
            Treatment for atherosclerosis and other cardiovascular and inflammatory
            diseases
            Medford, Russell M., Atlanta, GA, United States
Alexander, R. Wayne, Atlanta, GA, United States
Parthasarathy, Sampath, Atlanta, GA, United States
Khan, Bobby V., Dunwoody, GA, United States
IN
PA
            Emory University, Atlanta, GA, United States (U.S. corporation)
PΙ
            US 5807884
                                                      19980915
ΑI
            US 1994-317399
                                                      19941004 (8)
            Continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994,
RLI
            now abandoned which is a continuation-in-part of Ser. No. US
            1992-969934, filed on 30 Oct 1992, now patented, Pat. No. US 5380747
DT
            Utility
FS
            Granted
LN.CNT
            2089
INCL
            INCLM: 514/423.000
            INCLS: 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210; 435/007.240; 435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000;
                        514/018.000; 514/226.200; 514/477.000; 514/478.000; 514/479.000;
                        514/484.000; 514/485.000; 514/487.000
NCL
            NCLM:
                        514/423.000
```

```
514/518.000; 514/553.000; 514/561.000; 514/824.000; 514/825.000;
                    514/826.000; 514/861.000; 514/863.000; 530/331.000; 548/431.000;
                    549/016.000
IC
          [6]
          ICM: A61K031-40
          ICS: A61K031-54; A61K031-265; A61K031-185
424/9.1; 424/9.2; 436/71; 436/86; 436/129; 514/18; 514/423; 514/478;
514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513;
EXF
          514/824; 514/825; 514/826; 514/861; 514/863; 514/226.2; 514/477; 514/517; 514/518; 514/553; 514/561; 530/331; 548/431; 548/531; 558/230; 558/235; 558/234; 558/250; 564/76; 568/21; 568/25; 562/26; 562/27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 71 OF 98
                             USPATFULL on STN
L8
ΑN
          1998:111942 USPATFULL
ΤI
          Therapeutic compounds containing pyrimidinyl moieties
         Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
IN
          Kumar, Anil M., Seattle, WA, United States
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5807862 19980915 <--
PA
          US 5807862
US 1995-478112
PΙ
AΙ
                                           19950607 (8)
RLI
          Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
          now abandoned Utility
DT
FS
          Granted
LN.CNT 2190
          INCLM: 514/269.000
INCL
          INCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
                   514/269.000
NCL
          NCLM:
                   544/309.000; 544/310.000; 544/311.000; 544/312.000
          NCLS:
IC
          [6]
          ICM: A61K031-505
          ICS: C07D239-54
          514/269; 514/274; 544/309; 544/310; 544/311; 544/312
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
       ANSWER 72 OF 98 USPATFULL on STN
          1998:111941 USPATFULL
\mathbf{AN}
TI
          Amine substituted xanthinyl compounds
         Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
IN
         Rice, Glenn C., Seattle, WA, United States
Leung, David W., Mercer Island, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
ΡI
          US 5807861
                                           19980915
          US 1995-476911
ΑI
                                           19950607 (8)
          Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,
RLI
          now abandoned
DT
          Utility
FS
          Granted
LN.CNT 1713
INCL
          INCLM: 514/263.000
                   514/263.350
514/081.000; 514/151.000; 514/210.210; 514/263.200; 514/263.220;
NCL
          NCLM:
          NCLS:
                   514/263.230
IC
          [6]
          ICM: A61K031-52
          514/263
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
       ANSWER 73 OF 98
                             USPATFULL on STN
ΑN
          1998:108415
                           USPATFULL
TI
          Therapeutic compounds containing a monocyclic five- to six- membered
          ring structure having one to two nitrogen atoms Underiner, Gail E., Brier, WA, United States
IN
          Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
          Woodson, Paul, Edmonds, WA, United States
          Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5804584 19980908 <--
PA
PΙ
ΑI
          US 1995-468659
                                           19950606 (8)
```

```
which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16
         Nov 1992, now patented, Pat. No. US 5473070
DT
         Utility
FS
         Granted
LN.CNT
        1554
         INCLM: 514/269.000
INCL
         INCLS: 544/298.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000
NCL
         NCLM:
                 514/269.000
         NCLS:
                 514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000
IC
         [6]
         ICM: C07D239-54
         ICS: A61K031-52
EXF 514/242; 514/243; 514/269; 544/298; 544/299 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 74 OF 98
                          USPATFULL on STN
        1998:104752
                        USPATFULL
AN
TI
        Amine substituted compounds
        Klein, J. Peter, Vashon, WA, United States
IN
        Underiner, Gail E., Brier, WA, United States
        Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
PI
        US 5801182
                                       19980901
        US 1995-485777
ΑI
                                      19950607 (8)
        Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,
RLI
        now abandoned
DT
        Utility
FS
        Granted
LN.CNT
        1706
        INCLM: 514/269.000
INCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
NCLM: 514/269.000
NCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
INCL
NCL
        NCLM:
        NCLS:
IC
         [6]
         ICM: A61K031-505
        ICS: C07D239-02
EXF
         544/312; 514/269; 514/274; 514/310; 514/311
CAS
    INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 75 OF 98
L8
                           USPATFULL on STN
        1998:88470
AN
                      USPATFULL
TI
           ***VEGF***
                           qene transfer into endothelial cells for vascular
        prosthesis
        Pratt, Richard E., Palo Alto, CA, United States
Dzau, Victor J., Los Altos Hills, CA, United States
The Board of Trustees of the Leland Stanford Junior Univ., Palo Alto,
IN
PA
        CA, United States (U.S. corporation)
US 5785965 19980728
PI
AΙ
        US 1996-647821
                                      19960515 (8)
        Utility
DT
FS
        Granted
LN.CNT
        905
INCL
        INCLM: 424/093.210
        INCLS: 424/093.100; 424/093.200; 435/172.300; 435/325.000
                 424/093.210
NCL
        NCLM:
        NCLS:
                 424/093.100; 424/093.200; 435/325.000; 435/455.000; 435/456.000
IC
         [6]
        ICM: A01N063-00
         ICS: C12N015-00
EXF
        600/36; 623/1; 623/11; 623/12; 435/172.3; 435/240.2; 435/320.1; 435/325;
         424/93.21; 424/93.1; 424/93.2; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
      ANSWER 76 OF 98
                          USPATFULL on STN
                      USPATFULL
ИA
        1998:82763
TI
        Hydroxyl-containing xanthine compounds
Underiner, Gail E., Brier, WA, United States
IN
        Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
        Woodson, Paul, Edmonds, WA, United States
PA
        Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PΙ
        US 5780476
                                      19980714
                                                                                    <--
AΙ
        US 1995-468660
                                      19950606 (8)
RLI
        Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned
```

```
NOV 1992, now patented, Pat. No. US 54/30/0
DT
         Utility
FS
         Granted
LN.CNT
         1672
         INCLM: 514/263.000
INCLS: 544/267.000
INCL
                   514/263.360
NCL
         NCLM:
IC
         [6]
         ICM: A61K031-52
         ICS: C07D473-04
         514/263; 514/256; 514/257; 514/258; 514/259; 514/261; 514/269; 514/270
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 77 OF 98 USPATFULL 1998:79344 USPATFULL
                            USPATFULL on STN
L8
AN
         Method for preparing substituted amino alcohol compounds
ΤI
         Klein, J. Peter, Vashon, WA, United States
IN
         Underiner, Gail E., Brier, WA, United States
         Kumar, Anil M., Seattle, WA, United States
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
         US 5777117
                                          19980707
PΙ
                                                                                             < - -
         US 1995-472569
AΙ
                                          19950607 (8)
         Division of Ser. No. US 1994-303842, filed on 8 Sep 1994 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And Ser. No. US 1993-164081, filed on 8 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned for Ser. No. US 1993-40820, filed on 31 Mar 1993,
RLI
         now abandoned , said Ser. No. US -152650 which is a
         continuation-in-part of Ser. No. US
DT
         Utility
FS
         Granted
LN.CNT
         3153
                  544/267.000
544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000;
546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
         INCLM:
INCL
         INCLS:
                   544/267.000
544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000;
544/257.000; 544/285.000; 544/286.000; 548/546.000
NCL
         NCLM:
         NCLS:
                   546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
IC
          [6]
         ICM: C07D473-10
         ICS: C07D239-80; C07D211-94; C07D209-48
544/267; 544/257; 544/285; 544/286; 544/287; 544/311; 546/141; 546/243; 546/246; 548/477; 548/546
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
       ANSWER 78 OF 98
                             USPATFULL on STN
                        USPATFULL
\mathbf{A}\mathbf{N}
         1998:79342
TI
         Acetal-and ketal-substituted pyrimidine compounds
         Leigh, Alistair, Brier, WA, United States
Underiner, Gail, Brier, WA, United States
IN
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5777115 19980707 <--
PA
PΙ
AΙ
         US 1994-193331
                                          19940207 (8)
RLI
         Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now
         abandoned
DT
         Utility
FS
         Granted
LN.CNT
         1632
INCL
         INCLM: 544/242.000
INCLS: 544/267.000; 514/269.000; 514/270.000; 514/256.000
                   544/242.000
         NCLM:
NCL
         NCLS:
                   544/267.000
IC
          [6]
          ICM: C07D239-26
          ICS: A61K031-505
          544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 79 OF 98 USPATFULL 1998:75382 USPATFULL
L8
                             USPATFULL on STN
NA
          Treatment for atherosclerosis and other cardiovascular and inflammatory
TI
         diseases
IN
         Medford, Russell M., Atlanta, GA, United States
         Alexander, R. Wayne, Atlanta, GA, United States
Parthasarathy, Sampath, Atlanta, GA, United States
         Khan, Bobby V., Dunwoody, GA, United States
```

```
ЬΤ
               US 5773231
                                                                    TAA80630
AΙ
               US 1995-473272
                                                                    19950607 (8)
               Continuation of Ser. No. US 1994-317399, filed on 4 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-969934, filed on 30 Oct 1992, now patented, Pat. No. US 5380747
RLI
DT
               Utility
FS
               Granted
LN.CNT
               2092
               INCLM: 435/007.240
INCL
               INCLM: 435/007.240
INCLS: 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210; 435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000; 514/423.000; 514/478.000; 514/479.000; 514/484.000; 514/485.000; 514/487.000; 514/488.000; 514/489.000; 514/506.000; 514/513.000; 514/824.000; 514/825.000; 514/826.000; 514/861.000; 514/863.000; 530/331.000; 548/431.000; 558/230.000; 558/235.000; 564/076.000;
                               568/021.000; 568/025.000
                               435/007.240
NCL
               NCLM:
               NCLS:
                              514/489.000; 514/506.000; 514/513.000; 514/824.000; 514/825.000;
                              514/826.000; 514/861.000; 514/863.000; 530/331.000; 548/431.000; 558/230.000; 558/235.000; 564/076.000; 568/021.000; 568/025.000
IC
                [6]
               ICM: G01N033-53
               124. Golfinos 33 33 424/9.1; 436/86; 514/18; 514/423; 514/478; 514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513; 514/824; 514/825; 514/826; 514/861; 514/863; 530/331; 540/431; 558/230; 558/235;
EXF
               564/76; 568/21; 568/25
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
          ANSWER 80 OF 98
1998:75361 US
L8
                                             USPATFULL on STN
                                       USPATFULL
AN
TI
               Treatment for atherosclerosis and other cardiovascular and inflammatory
              Medford, Russell M., Atlanta, GA, United States
Alexander, R. Wayne, Atlanta, GA, United States
Parthasarathy, Sampath, Atlanta, GA, United States
Khan, Bobby V., Dunwoody, GA, United States
Emory University, Atlanta, GA, United States
Emory University, Atlanta, GA, United States (U.S. corporation)
US 5773209
19980630
2-US 1995-484059
19950607 (8)
IN
PA
PΙ
ΑI
               Continuation of Ser. No. US 1994-317399, filed on 4 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994 which is a continuation-in-part of Ser. No. US 1992-969934, filed on 30
RLI
               Oct 1992, now patented, Pat. No. US 5380747
DT
               Utility
FS
               Granted
               2115
LN.CNT
INCL
               INCLM: 435/007.240
                              424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210; 435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000;
               INCLS:
                               514/423.000; 514/478.000; 514/479.000; 514/484.000; 514/485.000;
                              514/487.000; 514/488.000; 514/489.000; 514/506.000; 514/513.000; 514/824.000; 514/825.000; 514/826.000; 514/861.000; 514/863.000; 530/331.000; 548/431.000; 558/230.000; 558/235.000; 564/076.000;
                              568/021.000; 568/025.000
435/007.240
424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210;
NCL
               NCLM:
               NCLS:
                              435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000; 514/423.000; 514/478.000; 514/479.000; 514/484.000; 514/485.000;
                               514/487.000; 514/488.000
IC
               ICM: G01N033-53
               424/9.1; 424/9.2; 436/71; 436/86; 436/129; 514/18; 514/423-478; 514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513; 514/824; 514/825; 514/826; 514/861; 514/863; 530/331; 548/431; 558/230; 558/235; 564/76; 568/21; 568/25
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
           ANSWER 81 OF 98 USPATFULL on STN
AN
               1998:72620 USPATFULL
TI
               Oxime substituted therapeutic compounds
IN
               Klein, J. Peter, Vashon, WA, United States
```

```
PΑ
                  Cell Therapeutics, inc., Seattle, WA, United States (U.S. corporation)
                 US 5770595
ΡI
                                                                             19980623
                 US 1994-193344
AΙ
                                                                             19940207 (8)
                 Continuation of Ser. No. US 1993-6083, filed on 19 Jan 1993, now
RLI
                 abandoned
DT
                 Utility
FS
                 Granted
LN.CNT
                 2183
                  INCLM: 514/263.000
INCL
                  INCLS: 544/271.000; 544/273.000
                                   514/263.350
NCL
                 NCLM:
                                   514/151.000; 544/271.000; 544/273.000
                 NCLS:
IC
                  [6]
                  ICM: M61K031-52
                  514/263; 544/271; 544/273
EXF
            ANSWER 82 OF 98 USPATFULL on STN 1998:51651 USPATFULL
rs
ΑN
                 Substituted amino alcohol compounds
TI
                 Klein, J. Peter, Vashon, WA, United States
IN
                 Underiner, Gail E., Brier, WA, United States
                 Kumar, Anil M., Seattle, WA, United States
                 Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5750575 19980512 <--
PA
                 US 5750575
US 1995-475721
ΡI
ΑI
                                                                             19950607 (8)
                 Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented, Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And a continuation-in-part of Ser. No. 1993-152650, filed on 12 Nov 1993 and a continuation-in-part of Ser. No. 1993-152650, filed on 12 Nov 1993 and a continuation-in-part of Ser. No. 1993-152650, filed on 12 Nov 1993-1
RLI
                 US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878
                 which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31
                 Mar 1993, now abandoned
                 Utility
DT
FS
                 Granted
LN.CNT
                 3115
                 INCLM:
INCL
                                   514/617.000
                 INCLS:
                                   514/653.000; 564/182.000; 564/355.000; 564/361.000
NCL
                 NCLM:
                                   514/617.000
                                   514/653.000; 564/182.000; 564/355.000; 564/361.000
                 NCLS:
IC
                  [6]
                  ICM: A61K031-165
                 ICS: A61K031-135; C07C233-35; C07C215-20 564/355; 564/182; 564/361; 514/617; 514/653
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
            ANSWER 83 OF 98
                                                     USPATFULL on STN
                 1998:51434 USPATFULL
\mathbf{AN}
TI
                 Treatment for atherosclerosis and other cardiovascular and inflammatory
                 diseases
                 Medford, Russell M., Atlanta, GA, United States
Alexander, R. Wayne, Atlanta, GA, United States
Parthasarathy, Sampath, Atlanta, GA, United States
Khan, Bobby V., Dunwoody, GA, United States
IN
                 Emory University, Atlanta, GA, United States (U.S. corporation) US 5750351 19980512 <-
PA
                                                                             19980512
PI
ΑI
                 US 1995-474530
                                                                             19950607 (8)
                 Continuation of Ser. No. US 1994-317399, filed on 4 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994, now abandoned which is a continuation-in-part of Ser. No. US
RLI
                  1992-969934, filed on 30 Oct 1992, now patented, Pat. No. US 5380747
DT
                 Utility
FS
                 Granted
LN.CNT
                 2126
                  INCLM: 435/007.210
INCL
                 INCLM: 435/007.210
INCLS: 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.240; 435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000; 514/226.200; 514/423.000; 514/477.000; 514/478.000; 514/479.000; 514/484.000; 514/485.000; 514/487.000; 514/488.000; 514/489.000; 514/506.000; 514/513.000; 514/517.000; 514/518.000; 514/553.000; 514/561.000; 514/824.000; 514/825.000; 514/826.000; 514/863.000; 530/331.000; 548/431.000; 549/016.000; 558/230.000; 558/234.000; 558/235.000; 558/250.000; 562/026.000; 562/027.000
                                   558/234.000; 558/235.000; 558/250.000; 562/026.000; 562/027.000;
                                   564/076.000
NCL
                 NCLM:
                                   435/007.210
                 NCLS:
                                   424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.240;
```

```
436/1/2.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000; 514/226.200; 514/423.000; 514/477.000; 514/478.000; 514/479.000; 514/484.000; 514/485.000; 514/487.000; 514/488.000; 514/489.000; 514/506.000; 514/513.000; 514/517.000; 514/518.000; 514/553.000; 514/561.000; 514/824.000; 514/825.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000; 514/826.000;
                              514/863.000; 530/331.000; 548/431.000; 549/016.000; 558/230.000;
                             558/234.000; 558/235.000; 558/250.000; 562/026.000; 562/027.000;
                              564/076.000
IC
               [6]
               ICM: G01N033-53
              ICS: A61K031-40; A61K031-54; A61K031-265
424/9.1; 424/9.2; 436/71; 436/86; 436/129; 514/1S; 514/423; 514/478;
514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513;
514/824; 514/825; 514/826; 514/861; 514/863; 530/331; 548/431; 558/230;
558/235; 564/76; 568/21; 568/25
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
          ANSWER 84 OF 98 USPATFULL on STN
L8
              1998:7093 USPATFULL
ИA
TI
              Growth stimulating factors
              Nudelman, Edward, Seattle, WA, United States
Hakomori, Sen-Itiroh, Mercer Island, WA, United States
IN
              Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5710175 19980120 <--
PA
ΡI
                                                                 19960404 (8)
AΙ
              US 1996-627623
              Continuation of Ser. No. US 1994-285153, filed on 3 Aug 1994, now
RLI
              abandoned
DT
              Utility
FS.
              Granted
LN.CNT
              999
              INCLM: 514/547.000
INCLS: 514/549.000; 514/723.000
NCLM: 514/547.000
INCL
NCL
              NCLS:
                             514/549.000; 514/723.000
IC
               [6]
               ICM: A01N037-02
              ICS: A01N037-06; A61K031-72
EXF
              514/547; 514/549; 514/723
        INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
          ANSWER 85 OF 98
                                             USPATFULL on STN
L8
              97:86614 USPATFULL
AN
              Halogen, isothiocyanate or azide substituted xanthines
ΤI
              Leigh, Alistair, Brier, WA, United States
IN
              Michnick, John, Seattle, WA, United States
Kumar, Anil, Seattle, WA, United States
Underiner, Gail, Brier, WA, United States
              Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
US 5670506 19970923 <--
PA
              US 5670506
ΡI
              US 1993-42946
ΑI
                                                                 19930405 (8)
DT
              Utility
FS
              Granted
LN.CNT
              1994
INCL
              INCLM: 514/258.000
              INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCLM: 514/141.000
NCL
                             544/267.000; 544/272.000; 544/277.000
              NCLS:
IC
               [6]
               ICM: A61K031-52
               ICS: C07D473-00
EXF
               544/267; 544/276; 544/272; 544/277; 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
          ANSWER 86 OF 98 USPATFULL on STN
               97:80936 USPATFULL
AΝ
              Methods for the preparation of immunostimulating agents for in vivo
ΤI
               delivery
IN
              Grinstaff, Mark W., Pasadena, CA, United States
               Soon-Shiong, Patrick, Los Angeles, CA, United States
              Wong, Michael, Champagne, IL, United States
Sandford, Paul A., Los Angeles, CA, United States
Suslick, Kenneth S., Champagne, IL, United States
Desai, Neil P., Los Angeles, CA, United States
PΑ
              Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S.
              corporation)
```

```
US 1995-488804
\mathbf{L}\mathbf{A}
                                          T9950607 (8)
         Continuation-in-part of Ser. No. US 1994-200235, filed on 22 Feb 1994,
RLI
         now patented, Pat. No. US 5498421 which is a continuation-in-part of Ser. No. US 1993-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 1993-35150, filed on
         26 Mar 1993, now patented, Pat. No. US 5362478
DT
         Utility
FS
         Granted
LN.CNT
         3278
INCL
         INCLM: 424/450.000
         INCLS: 424/451.000; 424/465.000; 424/489.000
                   424/450.000
NCL
         NCLM:
         NCLS:
                   424/451.000; 424/465.000; 424/489.000
IC
          [6]
         ICM: A61K009-127
424/451; 424/450; 424/465; 424/489
EXF
     INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
       ANSWER 87 OF 98 USPATFULL on STN
L8
AΝ
         97:80935
                      USPATFULL
         Methods for the preparation of pharmaceutically active agents for in
TI
         vivo delivery
IN
         Grinstaff, Mark W., Pasadena, CA, United States
         Soon-Shiong, Patrick, Los Angeles, CA, United States Wong, Michael, Champaign, IL, United States Sandford, Paul A., Los Angeles, CA, United States Suslick, Kenneth S., Champaign, IL, United States Desai, Neil P., Los Angeles, CA, United States
PA
         Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S.
         corporation)
         US 5665382
US 1995-485448
                                         19970909
PΙ
                                                                                            <---
         US 1995-485448 19950607 (8)
Continuation-in-part of Ser. No. US 1994-200235, filed on 22 Feb 1994, now patented, Pat. No. US 5498421 which is a continuation-in-part of
AΙ
RLI
         Ser. No. US 1993-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 1993-35150, filed on
         26 Mar 1993, now patented, Pat. No. US 5362478
DT
         Utility
FS
         Granted
LN.CNT
         3304
INCL
         INCLM: 424/450.000
         INCLS: 424/009.100; 424/488.000
                   424/450.000
NCL
         NCLM:
         NCLS:
                   424/009.100; 424/488.000
IC
          [6]
         ICM: A61K009-127
EXF
         424/9; 424/9.1; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 88 OF 98 USPATFULL on STN
L8
         97:73601 USPATFULL
AN
TI
         Compositions for inhibiting restenosis
         Weisz, Paul B., State College, PA, United States
IN
         The Trustees of the University of Pennsylvania, Philadephia, PA, United
PA
         States (U.S. corporation)
         US 5658894
PI
                                         19970819
         US 1994-345011
AΙ
                                         19941123 (8)
         Continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser.
RLI
         No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a
         continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now
                                                  -900592 which is a continuation-in-part
         abandoned , said Ser. No. US
         of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No.
         US 5183809, issued on 2 Feb 1993
DT
         Utility
FS
         Granted
LN.CNT
         1449
INCL
         INCLM:
                  514/058.000
                   514/021.000; 514/023.000; 514/054.000; 514/060.000; 536/103.000;
         INCLS:
                   530/810.000; 530/812.000; 530/813.000
NCL
         NCLM:
                   514/058.000
         NCLS:
                   514/021.000; 514/023.000; 514/054.000; 514/060.000; 530/810.000;
                   530/812.000; 530/813.000; 536/103.000
IC
          [6]
```

```
ICS: C08B037-16
                      514/21; 514/23; 514/54; 514/58; 514/60; 536/103; 530/810; 530/812;
EXF
                       530/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
               ANSWER 89 OF 98
                                                                    USPATFULL on STN
ΑN
                      97:63766 USPATFULL
ΤI
                      Methods for in vivo delivery of nutriceuticals and compositions useful
                      therefor
IN
                      Grinstaff, Mark W., Pasadena, CA, United States
                      Soon-Shiong, Patrick, Los Angeles, CA, United States
                     Wong, Michael, Champagne, IL, United States
Sandford, Paul A., Los Angeles, CA, United States
Suslick, Kenneth S., Champagne, IL, United States
Desai, Neil P., Los Angeles, CA, United States
Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S.
PA
                      corporation)
                                                                                                  19970722
PΙ
                      US 5650156
AΙ
                      US 1995-482272
                                                                                                  19950607 (8)
                      Continuation-in-part of Ser. No. US 1994-200235, filed on 22 Feb 1994,
RLI
                     now patented, Pat. No. US 5498421 which is a continuation-in-part of Ser. No. US 1993-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And Ser. No. US 1993-35150, filed on 26 Mar 1993, now patented,
                      Pat. No. US 5362478 Utility
DT
FS
                      Granted
LN.CNT
                     3310
INCL
                      INCLM: 424/400.000
                      INCLS: 424/450.000; 424/451.000; 424/056.000; 424/009.400; 424/009.500;
                                            424/009.300
                      NCLM:
NCL
                                            424/400.000
                                            424/009.300; 424/009.400; 424/009.500; 424/056.000; 424/450.000; 424/451.000
                      NCLS:
                       [6]
IC
                      ICM: A61K009-00
EXF
                      424/400; 424/450; 424/451; 424/9
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
               ANSWER 90 OF 98 USPATFULL on STN
                      97:54233 USPATFULL
AN
TI
                      Substituted amino alcohol compounds
                      Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
IN
                     PA
PΙ
                     US 1994-303842 19940908 (8)
Continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993
And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No.
ΑI
RLI
                      US 5470878
                      Utility
DT
                      Granted
FS
LN.CNT
                      3206
INCL
                      INCLM: 514/263.000
                      INCLS: 514/283.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/241.000; 514/242.000; 514/243.000; 514/246.000; 514/247.000; 514/248.000; 514/249.000; 514/255.000; 514/256.000; 514/259.000; 514/261.000; 514/262.000; 514/263.000; 514/270.000; 514/274.000; 514/297.000; 514/300.000; 514/301.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000; 514/302.000
                                            514/302.000; 514/303.000; 514/306.000; 514/307.000; 514/311.000;
                                             514/312.000; 514/315.000; 514/345.000; 514/351.000; 514/357.000;
                                            514/312.000; 514/315.000; 514/345.000; 514/351.000; 514/357.000; 514/359.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000; 514/369.000; 514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000; 514/381.000; 514/383.000; 514/389.000; 514/394.000; 514/395.000; 514/398.000; 514/406.000; 514/406.000; 514/415.000; 514/415.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000; 514/416.000;
                                             514/418.000; 514/423.000; 514/424.000; 514/425.000; 514/427.000; 514/428.000; 544/001.000; 544/002.000; 544/003.000; 544/008.000;
                                             544/053.000; 544/063.000; 544/065.000; 544/066.000; 544/067.000;
                                             544/090.000; 544/091.000; 544/162.000; 544/215.000; 544/216.000;
                                            544/219.000; 544/220.000; 544/224.000; 544/235.000; 544/239.000; 544/254.000; 544/255.000; 544/257.000; 544/262.000; 544/272.000; 544/277.000; 544/278.000; 544/280.000; 544/283.000; 544/286.000;
```

```
544/353.000; 544/385.000; 544/401.000; 546/102.000; 546/113.000; 546/114.000; 546/115.000; 546/117.000; 546/118.000; 546/119.000;
                                   546/115.000;
546/138.000;
546/164.000;
546/246.000;
                  546/114.000;
                                                    546/139.000;
                                                                     546/150.000; 546/153.000;
                  546/122.000;
                                                    546/176.000;
                                                                     546/178.000; 546/242.000;
                  546/157.000;
                  546/243.000;
                                                    546/264.000;
                                                                     546/300.000; 546/334.000;
                                   548/123.000;
                                                                     548/127.000; 548/128.000;
                  548/100.000;
                                                    548/125.000;
                                                                     548/153.000; 548/179.000;
                                                    548/146.000;
                  548/131.000;
                                   548/134.000;
                                                                     548/215.000; 548/217.000;
                  548/186.000;
                                   548/207.000;
                                                    548/214.000;
                                                                     548/229.000; 548/235.000;
                  548/221.000;
                                   548/225.000;
                                                    548/228.000;
                                                                                      548/247.000;
548/306.400;
548/340.100;
548/375.100;
                                                                     548/243.000;
548/303.700;
548/323.500;
548/370.100;
                                                    548/241.000;
                                   548/240.000;
                  548/237.000;
                                                    548/267.800;
548/319.100;
548/356.100;
548/453.000;
                                   548/267.200;
                  548/252.000;
                  548/307.100;
                                   548/309.700;
                                   548/349.100;
                  548/348.100;
548/379.400;
                                                                     548/470.000;
                                                                                      548/482.000;
                                   548/452.000;
                                   548/486.000; 548/491.000; 548/503.000; 548/532.000
548/546.000; 548/550.000; 548/565.000; 548/566.000
                                                                                      548/532.000;
                  548/485.000;
                  548/543.000;
                  514/263.350
NCL
         NCLM:
                  514/183.000;
                                   514/222.500; 514/223.500; 514/224.200; 514/226.800;
         NCLS:
                                   514/228.800; 514/229.200; 514/230.500; 514/230.800;
                  514/227.500;
                                                                     514/243.000;
                                                                                      514/246.000;
                  514/237.800;
                                   514/241.000; 514/242.000;
                                                                                      514/256.000;
514/274.000;
514/303.000;
514/315.000;
514/360.000;
                                                    514/249.000;
                                                                     514/252.160;
                  514/247.000;
                                   514/248.000;
                                                    514/266.300;
514/301.000;
514/311.000;
514/357.000;
                                                                     514/270.000;
514/302.000;
514/312.000;
514/359.000;
                  514/259.500;
                                   514/264.100;
                  514/297.000;
514/306.000;
514/345.000;
                                   514/300.000;
514/307.000;
514/351.000;
514/362.000;
                  514/361.000;
                                                                     514/364.000;
                                                                                      514/365.000;
                                                    514/363.000;
                                                                     514/373.000;
                  514/367.000;
                                   514/369.000;
                                                    514/372.000;
                                                                                      514/374.000;
                                                                     514/379.000;
                                                                                      514/380.000;
                                   514/376.000;
                                                    514/378.000;
                  514/375.000;
                                                    514/389.000;
                                                                     514/394.000;
                                                                                      514/395.000;
                                   514/383.000;
                  514/381.000;
                                                                                      514/406.000;
514/423.000;
544/001.000;
                  514/398.000;
                                   514/399.000;
                                                    514/401.000;
                                                                     514/404.000;
                                   514/415.000;
                                                    514/416.000;
514/427.000;
                                                                     514/418.000;
                  514/413.000;
                                                                     514/428.000;
                                   514/425.000;
                  514/424.000;
                                                                                      544/063.000;
                                   544/003.000;
                                                    544/008.000;
                  544/002.000;
                                                                     544/053.000;
                                                                     544/090.000;
                                   544/066.000;
                                                    544/067.000;
                                                                                      544/091.000;
                  544/065.000;
                  544/162.000;
                                   544/215.000;
                                                    544/216.000;
                                                                     544/219.000;
544/254.000;
                                                                                      544/220.000;
                                   544/235.000;
                                                    544/239.000;
                                                                                      544/255.000;
                  544/224.000;
                                                                                      544/278.000;
544/311.000;
544/385.000;
546/115.000;
                                                                     544/277.000;
                                                    544/272.000;
                  544/257.000;
                                   544/262.000;
                                                                     544/301.000;
544/353.000;
546/114.000;
                                                    544/286.000;
544/350.000;
546/113.000;
                                   544/283.000;
                  544/280.000;
                                   544/336.000;
546/102.000;
546/118.000;
                  544/335.000;
                  544/401.000;
                                                                                      546/138.000;
                                                    546/119.000;
                                                                     546/122.000;
                  546/117.000;
                                                                                      546/164.000;
                  546/139.000;
                                   546/150.000;
                                                    546/153.000;
                                                                     546/157.000;
                  546/176.000;
                                                                     546/243.000; 546/246.000;
                                   546/178.000;
                                                    546/242.000;
                                                                     548/100.000; 548/123.000;
                  546/264.000;
                                   546/300.000;
                                                    546/334.000;
                                                                                      548/134.000;
548/207.000;
548/225.000;
548/240.000;
                                   548/127.000;
                                                    548/128.000;
                                                                     548/131.000;
                  548/125.000;
                                                    548/179.000;
548/217.000;
548/235.000;
548/247.000;
                                                                     548/186.000;
548/221.000;
548/237.000;
548/252.000;
                                   548/153.000;
                  548/146.000;
                                   548/215.000;
548/229.000;
548/243.000;
548/303.700;
                  548/214.000;
                  548/228.000;
548/241.000;
                                                                                      548/267.200;
                                                                     548/307.100;
                  548/267.800;
                                                    548/306.400;
                                                                                      548/309.700;
                  548/319.100;
                                   548/323.500;
                                                    548/340.100;
                                                                     548/348.100; 548/349.100;
                                                                     548/379.400; 548/452.000;
                                   548/370.100;
                                                    548/375.100;
                  548/356.100;
                                                    548/482.000; 548/485.000; 548/486.000;
                  548/453.000; 548/470.000;
                  548/491.000; 548/503.000; 548/532.000; 548/543.000; 548/546.000;
                  548/550.000; 548/565.000; 548/566.000
IC
          [6]
         ICM: A61K031-415
         ICS: A61K031-42; A61K031-425; A61K031-52
         544/272; 514/263
EXF
     INDEXING IS AVAILABLE FOR THIS PATENT.
CAS
L8
       ANSWER 91 OF 98
                           USPATFULL on STN
         97:16085
                     USPATFULL
_{
m AN}
         Compositions and methods for treating and preventing pathologies
TI
         including cancer
         Samid, Dvorit, Rockville, MD, United States
The United States of America as represented by the Department of Health
IN
PA
         and Human Services, Washington, DC, United States (U.S. government)
                                         19970225
PI
         US 5605930
                                                    (8)
AΙ
         US 1994-207521
                                         19940307
         Continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993
RLI
         which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21
         Oct 1991
         Utility
DT
FS
         Granted
```

```
TNCT
          INCLM:
                   514/510.000
                   514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
          INCLS:
                    514/567.000
          NCLM:
                   514/510.000
NCL
          NCLS:
                   514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
                   514/567.000
IC
          [6]
          ICM: A61K031-21
          ICS: A01N037-00; A01N047-40; A01N047-46
          514/538; 514/563; 514/567; 514/510; 514/513; 514/515; 514/529
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 92 OF 98 USPATFULL on STN
L8
          96:46169
                       USPATFULL
ΑN
          Olefin substituted long chain compounds
TI
         Underiner, Gail, Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon, WA, United States
Eiseman, Elisa, Seattle, WA, United States
Leigh, Alistair, Brier, WA, United States
IN
         Kumar, Anil, Seattle, WA, United States
Michnick, John, Seattle, WA, United States
         Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation) US 5521315 19960528 <--
PA
ΡI
         US 5521315
         US 1993-59697
ΑI
                                           19930510 (8)
RLI
          Continuation-in-part of Ser. No. US 1993-3372, filed on 12 Jan 1993, now
          patented, Pat. No. US 5354756
DT
          Utility
FS
          Granted
LN.CNT
         2761
         INCLM: 546/243.000
INCLS: 546/242.000; 544/285.000
NCLM: 546/243.000
INCL
NCL
         NCLM:
         NCLS:
                   544/285.000; 546/242.000
IC
          [6]
          ICM: C07D211-88
          ICS: C07D239-80
     548/545; 548/546; 548/547; 546/243; 544/285 INDEXING IS AVAILABLE FOR THIS PATENT.
EXF
CAS
L8
       ANSWER 93 OF 98 USPATFULL on STN
          96:19104 USPATFULL
ΑN
TI
          Inhibition of insulin-induced adiposis
         Alexander-Bridges, Maria C., Newtonville, MA, United States Zhao, Hui-Fen, Brookline, MA, United States
IN
PA
          The General Hospital Corporation, Boston, MA, United States (U.S.
          corporation)
         US 5496831
PI
                                           19960305
                                                                                              <--
         US 1994-242409
ΑI
                                           19940513 (8)
DT
         Utility
FS
          Granted
LN.CNT
         1269
INCL
          INCLM: 514/290.000
         INCLS: 514/294.000
NCLM: 514/290.000
NCLS: 514/294.000
NCL
         NCLM:
         NCLS:
IC
          [6]
          ICM: A01N043-42
          514/290; 514/294
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 94 OF 98 USPATFULL 95:105868 USPATFULL
L8
                             USPATFULL on STN
AN
          Cell signaling inhibitors
TI
         Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
IN
         Rice, Glenn C., Seattle, WA, United States (U.S. corporation)
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PA
PI
AΙ
         US 1993-164081
                                           19931208 (8)
RLI
          Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
         now abandoned
DT
          Utility
FS
          Granted
```

```
TNCL
          INCLM: 514/558.000
          INCLS: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000;
                    514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000;
                    544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000;
                    548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000;
                    554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000; 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000
NCL
          NCLM:
                    514/558.000
                   514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000
          NCLS:
IC
          [6]
          ICM: A61K031-20
          ICS: C07C233-00
         554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/506; 564/198; 564/215; 564/201; 564/197; 514/625; 514/629; 514/613; 514/558; 514/552; 514/529; 514/561; 514/626; 514/669; 560/130; 560/145; 562/553; 562/567
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 95 OF 98 USPATFULL on STN
L8
                        USPATFULL
AN
          94:113002
ΤI
          Methods for treating renin-related disorders with amylin antagonists
         Young, Andrew A., San Diego, CA, United States Rink, Timothy J., La Jolla, CA, United States
IN
PA
          Amylin Pharmaceuticals, Inc., San Diego, CA, United States (U.S.
          corporation)
         US 5376638
US 1992-939106
Utility
ΡI
                                            19941227
                                                                                                  < -- -
ΑI
                                            19920901 (7)
DT
FS
          Granted
LN.CNT
         1037
INCL
          INCLM: 514/012.000
          INCLS: 514/011.000; 514/013.000
NCL
                   514/012.000
          NCLM:
         NCLS:
                   514/011.000; 514/013.000
          [5]
IC
          ICM: A61K037-02
          ICS: C07K007-10
514/11-13
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L8
       ANSWER 96 OF 98 USPATFULL on STN
                       USPATFULL
AN
          94:93338
         Methods for treating arteriosclerosis
Halperin, Jose, Brookline, MA, United States
Brugnara, Carlo, Newton Highlands, MA, United States
President and Fellows of Harvard University, Cambridge, MA, United
TI
IN
PA
          States (U.S. corporation)
PΙ
                                            19941025
          US 5358959
          US 1993-18835
AΙ
                                            19930218 (8)
DT
          Utility
FS
          Granted
LN.CNT
          539
INCL
          INCLM: 514/396.000
          INCLS: 514/399.000; 514/824.000
          NCLM:
                    514/396.000
NCL
          NCLS:
                    514/399.000; 514/824.000
IC
          [5]
          ICM: A61K031-415
          514/396; 514/399; 514/824
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 97 OF 98 USPATFULL on STN
L8
          91:84437 USPATFULL
AN
          Method for preventing tissue damage after an ischemic episode Sheffield, Warren D., Lebanon, NJ, United States
TI
IN
          Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
PA
PI
          US 5057494
                                            19911015
ΑI
          US 1988-227579
                                            19880803 (7)
DT
          Utility
FS
          Granted
LN.CNT 487
INCL
          INCLM: 514/012.000
```

```
NCLS:
                514/021.000
IC
        [5]
        ICM: A61K037-02
        ICS: A61K037-36
        514/12; 514/21
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                                COPYRIGHT 2004 THOMSON DERWENT on STN
     ANSWER 98 OF 98 WPIDS
L8
     2000-256866 [22]
                          WPIDS
AN
     C2000-078440
DNC
     Hydrogel compositions useful for controlled delivery of ***growth** ***factors*** e.g. in treatment of ischemia and in wound healing.
                                                                        ***arowth***
ΤI
     A11 A25 A96 B04 B07
DC
     JENNINGS, R N; PROTTER, A A; WANG, Y J; YANG, B
IN
      (SCIO-N) SCIOS INC
PA
CYC
     87
                                                       27
                                                              A61K047-10
     WO 2000013710
                        A2 20000316 (200022)* EN
ΡI
         RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
             OA PT SD SE SL SZ UG ZW
          W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
                                     IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
             GD GE GH GM HR HU
                                  ID
             LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
             TT UA UG US UZ VN YU
                                     ZA ZW
                           20000327
     AU 9959095
                                     (200032)
                                                                               <--
                        A
                                                             A61K047-10
                        A2 20010620 (200135)
                                                 EN
     EP 1107791
          R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
             RO SE SI
                                     (200205)
                        B1 20011218
                                                              A61F013-00
     US 6331309
     JP 2002524425
                        W
                           20020806
                                      (200266)
                                                       33
                                                              A61K038-22
                           20030320 (200329)
                                                              A61K047-10
                        В
     AU 758178
     WO 2000013710 A2 WO 1999-US20382 19990903; AU 9959095 A AU 1999-59095
ADT
     19990903; EP 1107791 A2 EP 1999-946759 19990903, WO 1999-US20382 19990903;
     US 6331309 B1 Provisional US 1998-99168P 19980904, US 1999-390164
     19990903; JP 2002524425 W WO 1999-US20382 19990903, JP 2000-568516
      19990903; AU 758178 B AU 1999-59095 19990903
     AU 9959095 A Based on WO 2000013710; EP 1107791 A2 Based on WO 2000013710; JP 2002524425 W Based on WO 2000013710; AU 758178 B Previous Publ. AU
FDT
9959095, Based on WO 2000013710
PRAI US 1998-99168P 19980904;
                              19980904; US 1999-390164
                                                                 19990903
           A61F013-00; A61K038-22; A61K047-10
IC
      ICM
           A61K009-10; A61K009-70; A61K038-18; A61K047-26; A61K047-32;
      ICS
           A61K047-34; A61K047-36; A61P009-10; A61P017-02
=> S CPK-MB
  43 FILES SEARCHED...
L9
           1514 CPK-MB
=> S L1 AND L9
  60 FILES SEARCHED...
L10
            120 L1 AND L9
=> DUP REM L10
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'. ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L10
               90 DUP REM L10 (30 DUPLICATES REMOVED)
L11
=> D L11 1-90
      ANSWER 1 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L11
      DUPLICATE 1
AN
      2004:323387
                    BIOSIS
      PREV200400325165
DN
      Methods of use of fibroblast growth factor, vascular endothelial growth
TI
      factor and related proteins in the treatment of acute and chronic heart
      disease.
               Wayne P. [Inventor, Reprint Author]
ΑU
      500 Cold Spring Rd., No. E217, Rocky Hill, CT, 06067, USA
CS
      US 6759386 July 06, 2004
Official Gazette of the United States Patent and Trademark Office Patents,
PI
SO
      (July 6 2004) Vol. 1284, No. 1. http://www.uspto.gov/web/menu/patdata.html
```

NCL

NCLM:

514/012.000

```
ISSN: 0098-1133 (ISSN print).
DT
       Patent
LΑ
       English
ED
       Entered STN: 21 Jul 2004
       Last Updated on STN: 21 Jul 2004
       ANSWER 2 OF 90 USPATFULL on STN 2004:203948 USPATFULL
L11
AN
         Rifalazil compositions and therapeutic regimens
ΤI
         Cabana, Bernard E., Montgomery Village, MD, UNITED STATES Michaelis, Arthur F., Devon, PA, UNITED STATES Magnant, Gary P., Topsfield, MA, UNITED STATES Sayada, Chalom B., Luxembourg City, LUXEMBOURG
IN
                                          2004Ŏ812
PΙ
         US 2004157840
                                   Α1
         US 2003-668792
                                          20030923 (10)
AI
                                   A1
         US 2002-412958P
PRAI
                                    20020923 (60)
DT
         Utility
FS
         APPLICATION
LN.CNT
         1369
INCL
          INCLM: 514/229.500
                  514/229.500
NCL
         NCLM:
IC
          [7]
         ICM: A61K031-538
L11
      ANSWER 3 OF 90 USPATFULL on STN
         2004:152127 USPATFULL
AN
TI
         Methods of use of fibroblast growth factor, vascular endothelial growth
         factor and related proteins in the treatment of acute and chronic heart
         disease
IN
                   Wayne P., Rocky Hill, CT, UNITED STATES
         Franco,
PI
         US 2004116349
                                         20040617
                                  A1
AΙ
         US 2003-730831
                                  Α1
                                         20031209 (10)
         Division of Ser. No. US 2001-828330, filed on 6 Apr 2001, PENDING
RLI
PRAI
         US 2000-195624P
                                    20000406 (60)
         Utility
DT
FS
         APPLICATION
LN.CNT
         2885
INCL
         INCLM: 514/012.000
         NCLM: 514/012.000
NCL
IC
         [7]
         ICM: A61K038-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 4 OF 90 USPATFULL on STN 2004:101741 USPATFULL
L11
AN
         Triple therapy of angiotensin converting enzyme inhibitor epoxy-steroidal aldosterone antagonist and diuretic or digoxin for
TI
         treatment of cardiovascular disease
         Alexander, John C., Princeton, NJ, UNITED STATES
Roniker, Barbara, Chicago, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
C. Chicago, II, (II & Corporation
IN
         G.D. Searle & Co., Chicago, IL (U.S. corporation)
PA
PI
         US 2004077611
                                         20040422
                                  Α1
         US 2003-440691
AΙ
                                  A1
                                         20030519
                                                     (10)
         Continuation of Ser. No. US 2000-518854, filed on 3 Mar 2000, ABANDONED US 1999-122997P 19990305 (60)
RLI
PRAI
         US 1999-122998P
                                    19990305 (60)
DT
         Utility
FS
         APPLICATION
LN.CNT 4409
INCL
         INCLM: 514/171.000
         INCLS: 514/423.000
NCLM: 514/171.000
NCLS: 514/423.000
NCL
         NCLM:
         NCLS:
IC
         [7]
         ICM: A61K031-58
         ICS: A61K031-401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L11
      ANSWER 5 OF 90 USPATFULL on STN
AN
         2004:83262 USPATFULL
TI
         Targeted therapeutics and uses thereof
         Michaelis, Arthur F., Devon, PA, UNITED STATES Maulding, Hawkins V., Mendham, NJ, UNITED STATES Sayada, Chalom, Luxembourg City, LUXEMBOURG
IN
```

```
PI
         US 2004063718
                                A_{\perp}
                                      20040401
ΑI
         US 2002-302409
                                Α1
                                      20021121 (10)
PRAI
         US 2002-358881P
                                20020222 (60)
         US 2001-332264P
                                 20011121 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT
        1997
INCL
         INCLM: 514/252.130
         INCLS: 540/457.000
                 514/252.130
540/457.000
NCL
         NCLM:
        NCLS:
IC
         [7]
         ICM: A61K031-496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L11
      ANSWER 6 OF 90 USPATFULL on STN
AN
         2004:45028 USPATFULL
TI
         Intravenous rifalazil formulation and methods of use thereof
        Michaelis, Arthur F., Devon, PA, UNITED STATES
Sayada, Chalom, Luxembourg City, LUXEMBOURG
Cabana, Bernard E., Montgomery Village, MD, UNITED STATES
US 2004034021 A1 20040219
IN
PΙ
ΑI
        US 2003-453155
                                      20030603 (10)
                                A1
PRAI
        US 2002-385532P
                                 20020603
                                            (60)
        US 2002-406873P
                                 20020829
                                            (60)
        US 2002-412958P
                                 20020923
                                            (60)
        US 2003-444570P
                                 20030203
                                            (60)
DT
        Utility
FS
        APPLICÂTION
LN.CNT
        1942
INCL
        INCLM: 514/229.500
        NCLM:
NCL
                 514/229.500
IC
         [7]
        ICM: A61K031-538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L11
      ANSWER 7 OF 90 USPATFULL on STN
AN
        2004:31721
                      USPATFULL
        Methods of use growth factors for treating heart disease
TI
        Franco, Wayne P., Rocky Hill, CT, UNITED STATES
IN
                                      20040205
PΙ
        US 2004023863
                               A1
ΑI
        US 2003-239902
                               A1
                                      20030123
                                                 (10)
        WO 2001-US11205
US 2000-60195624
                                      20010406
PRAI
                                 20000406
        Utility
DT
        APPLICATION
FS
LN.CNT
        2837
INCL
        INCLM: 514/012.000
NCL
        NCLM:
                 514/012.000
IC
         [7]
        ICM: A61K038-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L11
      ANSWER 8 OF 90 USPATFULL on STN
AN
                      USPATFULL
        2004:19446
ΤI
        Metal complexes and formulations of rifamycin analogues and uses thereof
        Michaelis, Arthur F., Devon, PA, UNITED STATES Maulding, Hawkins V., Mendham, NJ, UNITED STATES
IN
        Sayada, Chalom, Luxembourg City, MA, UNITED STATES Eisenstein, Barry, Chestnut Hill, MA, UNITED STATES
PI
        US 2004014750
                                      20040122
                               Α1
ΑI
        US
            2002-318998
                               Α1
                                      20021212
                                                 (10)
PRAI
        US
            2001-341591P
                                 20011213
                                            (60)
        US
            2002-382805P
                                 20020523
                                            (60)
        US 2002-385532P
                                 20020603
                                            (60)
        US 2002-406873P
                                 20020829
                                            (60)
        US 2002-412958P
                                 20020923
                                            (60)
DT
        Utility
        APPLICATION
FS
LN.CNT
        2451
INCL
        INCLM:
                 514/224.500
        INCLS:
                 514/229.500
                 514/224.500
514/229.500
NCL
        NCLM:
        NCLS:
IC
         [7]
```

```
ICS: A61KU31-538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L11
       ANSWER 9 OF 90 USPATFULL on STN
ΑN
          2004:19445
                         USPATFULL
ΤI
          Sulfhydryl rifamycins and uses thereof
         Michaelis, Arthur F., Devon, PA, UNITED STATES
Maulding, Hawkins V., Mendham, NJ, UNITED STATES
Sayada, Chalom, Luxembourg City, LUXEMBOURG
Eisenstein, Barry, Chestnut Hill, MA, UNITED STATES
Geiss, William B., Athens, NY, UNITED STATES
Raker, Joseph, Delmar, NY, UNITED STATES
IN
PΙ
         US 2004014749
                                           20040122
                                    Α1
AΙ
         US 2002-318582
                                    Α1
                                           20021212
PRAI
         US 2001-341130P
                                      20011213 (60)
         US 2002-382805P
                                      20020523
                                                   (60)
         US 2002-385532P
                                      20020603
                                                   (60)
         US 2002-406873P
US 2002-412958P
Utility
APPLICATION
                                      20020829
                                                   (60)
                                      20020923 (60)
DT
FS
LN.CNT
         2259
         INCLM: 514/224.500
INCLS: 514/229.800; 540/457.000
NCLM: 514/224.500
INCL
NCL
         NCLS:
                   514/229.800; 540/457.000
IC
          [7]
          ICM: A61K031-542
          ICS: A61K031-538; C07D498-14; C07D491-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L11
       ANSWER 10 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
                      JICST-EPlus
ΑN
       1040203293
TI
       Plain Computed Tomography Is Useful for Assessment of Coronary
       Microvascular Damage in Infarction Area After Recanalization Therapy
AU
       KATO M; DOTE K; SAŠAKI S; TAKEMOTO H; HABARA S; HASEGAWA D
      Hiroshima City Asa Hospital, Hiroshima
Circ J, (2004) vol. 68, no. Supplement 1, pp. 543. Journal Code: F0908A
ISSN: 1346-9843
CS
SO
CY
       Japan
DT
       Journal; Preprint
LΑ
       English
STA
       New
      ANSWER 11 OF 90 BI
2004:244431 BIOSIS
L11
                             BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN
       PREV200400243343
DN
ΤI
       Should patients with severe aortic stenosis and
                                                                             ***coronary***
          ***artery***
                                 ***disease*** undergoing percutaneous coronary
       intervention prior to aortic valve replacement?.
      Kuchulakanti, Pramod K. [Reprint Author]; Rha, Seung-Woon [Reprint Author]; Gevorkian, Natalie [Reprint Author]; Abbott, Maureen C. [Reprint Author]; Pichard, Augusto D. [Reprint Author]; Satler, Lowell F. [Reprint Author]; Kent, Kenneth M. [Reprint Author]; Suddath, William O. [Reprint Author]; Waksman, Ron [Reprint Author]
AU
      Washington Hospital Center, Washington, DC, USA
Journal of the American College of Cardiology, (March 3 2004) Vol. 43, No.
CS
SO
      5 Supplement A, pp. 440A. print.
Meeting Info.: 53rd Annual Scientific Session of the American College of
       Cardiology. New Orleans, LA, USA. March 07-10, 2004. American College of
      Cardiology. ISSN: 0735-1097 (ISSN print).
DT
       Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA
       English
ED
       Entered STN: 6 May 2004
       Last Updated on STN: 6 May 2004
L11
       ANSWER 12 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
ÀΝ
       1040202388 JICST-EPlus
TI
       The relationships between coexisting inflammation and no/slow-flow
       phenomenon during directional coronary atherectomy
ΑU
       MIURA E; HIROSAKĀ A; TAKEDA H; NIITSUMA T; UEKITA H; ENDOH N
       OHWADA K
       MARUYAMA Y
```

```
Onta Memorial Hospital Onta General Hospital Foundation, Koriyama
      Fukushima Medical Coll., Fukushima
      Circ J, (2004) vol. 68, no. Supplement 1, pp. 317. Journal Code: F0908A
SO
      ISSN: 1346-9843
CY
      Japan
DT
      Journal; Preprint
LΑ
      English
STA
      New
L11
      ANSWER 13 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
                    JICST-EPlus
      1040387728
AN
      Nocturnal Hypoxemic Episodes After Acute Myocardial Infarction
TI
      SASAMOTO SHUTCHI; SASÃO KEN'ICHIRO; UNO NAŘIAKI; HONDA MITSURU; IGARASHI
AU
      MASAKI; YOSHIHARA KATSUNORI; KOYAMA NOBUYA
      Toho Univ., Omori Hosp.
CS
      Nippon Kyukyu Igakkai Zasshi (Journal of Japanese Association for Acute
SO
      Medicine), (2004) vol. 15, no. 4, pp. 135-140. Journal Code: L1136A (Fig. 2, Tbl. 3, Ref. 8)
      ISSN: 0915-924X
CY
      Japan
DT
      Journal; Article
LΑ
      Japanese
STA
      New
L11
      ANSWER 14 OF 90 USPATFULL on STN
\mathbf{A}\mathbf{N}
        2003:283399
                        USPATFULL
        Screening test and procedure using apocrine sweat Berlin, Stuart M., Thousand Oaks, CA, UNITED STATES
TI
IN
        US 2003199743
US 2003-463465
PI
                                A1
                                      20031023
ΑI
                                      20030616
                                A1
                                                 (10)
RLI
        Continuation-in-part of Ser. No. US 2001-994535, filed on 26 Nov 2001,
        GRANTED, Pat. No. US 6585646
PRAI-
        US 2000-250206P
                                 20001129 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT
        822
INCL
        INCLM: 600/346.000
                 600/346.000
NCL
        NCLM:
IC
        ICM: A61B005-05
L11
      ANSWER 15 OF 90 USPATFULL on STN
AN
        2003:244880 USPATFULL
TI
        Dose of an angiogenic factor and method of administering to improve
        myocardial blood flow
        Myocardial blood flow
Hung, David T., Belmont, CA, UNITED STATES
Annex, Brian H., Durham, NC, UNITED STATES
Landolfo, Kevin P., Chapel Hill, NC, UNITED STATES
Kavanaugh, W. Michael, Mill Valley, CA, UNITED STATES
Chiron Corporation, Emeryville, CA, UNITED STATES
US 2003171294
Al 20030911
IN
PA
        US 2003171294
US 2003-395541
ΡI
ΑI
                                      20030324 (10)
                                Α1
        Continuation of Ser. No. US 2000-637471, filed on 11 Aug 2000, PENDING
RLI
        US 1999-148746P
Utility
PRAI
                                 19990813 (60)
DT
        APPLICATION
FS
LN.CNT 2868
INCL
        INCLM: 514/012.000
NCL
        NCLM:
                 514/012.000
IC
         [7]
        ICM: A61K038-18
L11
      ANSWER 16 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
      1040000525
                    JICST-EPlus
ΑN
      Emergency Coronary Artery Bypass Grafting for Acute Coronary Syndrome with Preoperative Intraaortic Balloon Pumping; Comparative Surgical Outcome and
TI
      Long-term Results
ΑU
      KAMOHARA KEIJI; YOSHIKAI MASARU; YUNOKI JUNJI; FUMOTO HIDEMASA
      ITO TSUBASA; MURAYAMA JUN'ICHI; HAMADA MASAKATSU
CS
      Tenjinkai Shinkogabyoin Shinzokekkangeka
      Sagadai Kyobugeka
SO
      Kyobu Geka (Japanese Journal of Thoracic Surgery), (2003) vol. 56, no. 13,
      pp. 1075-1084. Journal Code: Z0662A (Fig. 2, Tbl. 4, Ref. 22) ISSN: 0021-5252
CY
      Japan
```

```
LА
       Japanese
STA
       New
L11
       ANSWER 17 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
       on STN
                                                                                DUPLICATE 2
AN
       2003358169 EMBASE
ΤI
       A case of acute myocardial infarction due to vasospasm related to marked
       coronary inflammation.

Kawakami H.; Matsuoka H.; Koyama Y.; Matsunaka T.; Aono J.; Ito T.

Respiration and Circulation, (1 Sep 2003) 51/9 (943-948).
ΑU
SO
       Refs: 7
       ISSN: 0452-3458 CODEN: KOJUA
CY
       Japan
DT
       Journal; Article
FS
                  Cardiovascular Diseases and Cardiovascular Surgery
       037
                  Drug Literature Index
LA
       Japanese
SL
       English; Japanese
L11
       ANSWER 18 OF 90 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
       2004:195912 SCISEARCH
\mathbf{A}\mathbf{N}
       The Genuine Article (R) Number: 773UF
GΑ
       Noninvasive characterization of myocardium after transmyocardial laser
TI
       revascularization
      Jones J W (Reprint); Richman B W; Baldwin J C; Losanoff J E Univ Missouri, Sch Med, Hlth Sci Ctr M580, Dept Surg, 1 Hosp Dr, Columbia, MO 65212 USA (Reprint); Univ Missouri, Sch Med, Hlth Sci Ctr M580, Dept Surg, Columbia, MO 65212 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA
ΑU
CS
CYA
       USA
       JOURNAL OF CARDIOVASCULAR SURGERY, (DEC 2003) Vol. 44, No. 6, pp. 681-684. Publisher: EDIZIONI MINERVA MEDICA, CORSO BRAMANTE 83-85 INT JOURNALS
SO
       DEPT., 10126 TURIN, ITALY. ISSN: 0021-9509.
DT
       Article; Journal
LΑ
       English
REC
       Reference Count: 20
       *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
       ANSWER 19 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L11
AN
       2004:17492
                       BIOSIS
DN
       PREV200400014437
TI
       Diagnostic implications of release of myocardial necrosis markers in
       patients with acute pulmonary edema.
Pena-Gil, C. [Reprint Author]; Figueras, J.; Ferreira, I.; Soler-Soler,
Cardiology, Hospital Clinico de Santiago, Santiago de Compostela, Spain
European Heart Journal, (August-September 2003) Vol. 24, No. Abstract
ΑU
CS
SO
       Supplement, pp. 260. print.
       Meeting Info.: Congress of the European Society of Cardiology. Vienna,
       Austria. August 30-September 03, 2003. European Society of Cardiology. ISSN: 0195-668X (ISSN print).
       Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
DT
LA
       English
ED
       Entered STN: 24 Dec 2003
       Last Updated on STN: 24 Dec 2003
L11
       ANSWER 20 OF 90 USPATFULL on STN
                                                                               DUPLICATE 3
\mathbf{A}\mathbf{N}
          2002:214528
                           USPATFULL
         Screening test and procedure using skin patches Berlin, Stuart, Thousand Oaks, CA, UNITED STATES
TI
IN
          US 2002115921
PI
                                    Α1
                                            20020822
         US 6585646
                                            20030701
                                    B2
AΙ
         US 2001-994535
                                    Α1
                                            20011126 (9)
                                      20001129 (60)
PRAI
          US 2000-250206P
DT
          Utility
          APPLICATION
FS
LN.CNT
         854
INCL
          INCLM: 600/362.000
NCL
          NCLM:
                    600/362.000
                    600/306.000; 600/309.000; 600/573.000
          NCLS:
IC
```

ICM: A61B005-00

```
ΑN
       2002:112871 USPATFULL
       Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart
TI
IN
       Franco, Wayne P., Rocky Hill, CT, UNITED STATES
       US 2002058612
                                20020516
PI
                           Α1
       US 6759386
                           B2
                                20040706
       US 2001-828330
                           A1
                                20010406 (9)
ΑI
       US 2000-195624P
PRAI
                            20000406 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT
       2636
       INCLM: 514/002.000
INCL
       INCLS: 424/043.000
       NCLM:
              514/002.000
NCL
       NCLS:
              514/002.000; 514/008.000; 514/012.000; 514/014.000; 530/300.000
IC
       [7]
       ICM: A61L009-04
       ICS: A61K038-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 22 OF 90
L11
                       EMBASE
                               COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
     2003058936
ΑN
                 EMBASE
TI
     [Use of a combination of enoxaparin or unfractionated Heparin and
     abciximab during percutaneous coronary interventions: A randomized pilot
     UTILIZACION DE ENOXAPARINA O HEPARINA NO FRACCIONADA EN COMBINACION CON
     ABCIXIMAB DURANTE LA INTERVENCION CORONARIA PERCUTANEA: ESTUDIO PILOTO
     ALEATORIZADO.
ΑU
     Galeote G.; Hussein M.; Sobrino N.; Calvo L.; Sanchez-Recalde A.; Sobrino
     J.A.
CS
     Dr. G. Galeote, Unidad Med.-Quirurgica Cardiologia, Hospital Universitario
     La Paz, P de la Castellana 261, 28046 Madrid, Spain.
     quiqaleote@teleline.es
SO
     Řevísta Espanola de Cardiologia, (1 Dec 2002) 55/12 (1261-1266).
     Refs: 23
     ISSN: 0300-8932 CODEN: RCDOAM
CY
     Spain
DT
     Journal; Article
             Internal Medicine
     006
     018
             Cardiovascular Diseases and Cardiovascular Surgery
     037
             Drug Literature Index
     038
             Adverse Reactions Titles
LA
     Spanish
     Spanish; English
SL
                       EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
L11
     ANSWER 23 OF 90
     on STN
                                                           DUPLICATE 5
AN
     2002233738 EMBASE
     Sustained ventricular tachycardia as a marker of inadequate myocardial
TI
     perfusion during the acute phase of myocardial infarction.
ΑU
     Fiol Sala M.; Perez Barcena J.; Ayestaran Rota J.I.; Velasco Roca J.;
     Carrilo Lopez A.; Raurich Puigdevall J.M.; Guindo Soldevilla J.; Bayes de
     Luna A.
CS
     Dr. J. Perez Barcena, Calle Andrea Doria 55, 07014 Palma de Mallorca,
     Spain. ucoro@hsd.es
SO
     Clinical Cardiology, (2002) 25/7 (328-334).
     Refs: 35
     ISSN: 0160-9289
                       CODEN: CLCADC
CY
     United States
DT
     Journal; Article
FS
     018
             Cardiovascular Diseases and Cardiovascular Surgery
LA
     English
SL
     English
L11
     ANSWER 24 OF 90
                      BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
     2001:190135 BIOSIS
NA
DN
     PREV200100190135
TI
     Coronary artery calcification in patients with acute chest pain.
AU
     Alexopoulos, Dimitris [Reprint author]; Stathopoulos, Christos [Reprint
     author]; Hahalis, George [Reprint author]; Chiladakis, John A. [Reprint
     author]; Kotsaridis, Abraham [Reprint author]; Manolis, Antonis S.
     [Reprint author]
CS
     Patras University, Patras, Greece
```

```
No. 2 Supplement A, pp. 377A. print.
Meeting Info.: 50th Annual Scientific Session of the American College of
      Cardiology. Orlando, Florida, USA. March 18-21, 2001. American College of
      Cardiology.
      CODEN: JĂĆCDI. ISSN: 0735-1097.
      Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
DT
LΑ
      English
ED
      Entered STN: 20 Apr 2001
     Last Updated on STN: 18 Feb 2002
     ANSWER 25 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
L11
      on STN
      2001088181 EMBASE
ΑN
     Myocardial bridging of the left anterior descending coronary artery in
TI
     acute inferior wall myocardial infarction.
      Yano K.; Yoshino H.; Taniuchi M.; Kachi E.; Shimizu H.; Watanuki A.;
ΑU
      Ishikawa K.
     Dr. K. Ishikawa, Second Dept. of Internal Medicine, Kyorin University
CS
     School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan Clinical Cardiology, (2001) 24/3 (202-208).
SO
     Refs: 37
ISSN: 0160-9289 CODEN: CLCADC
CY
      United States
DT
      Journal; Article
FS
      006
               Internal Medicine
      014
               Radiology
               Cardiovascular Diseases and Cardiovascular Surgery
      018
      037
               Drug Literature Index
LА
      English
     English
SL
     ANSWER 26 OF 90
                         EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
L11
                                                                  DUPLICATE 6
     on STN
ΑN
      2001360365 EMBASE
     Direct coronary stenting without balloon or device pretreatment: Acute
TI
      success and long-term results.
     Stys T.; Lawson W.E.; Liuzzo J.P.; Hanif B.; Bragg L.; Cohn P.F. Dr. W.E. Lawson, Division of Cardiology, State Univ. New York at Stony Brook, HSC T-17-020, Stony Brook, NY 11794, United States.
ΑU
CS
      wlawson@ts.uh.sunysb.edu
      Catheterization and Cardiovascular Interventions, (2001) 54/2 (158-163).
SO
      Refs: 19
      ISSN: 1522-1946 CODEN: CARIF2
CY
      United States
DT
      Journal; Article
               Cardiovascular Diseases and Cardiovascular Surgery
FS
      018
               Health Policy, Economics and Management
      036
LΑ
      English
SL
      English
L11
      ANSWER 27 OF 90 USPATFULL on STN
AN
        2000:161050 USPATFULL
        Method of improving outcome of cardiopulmonary bypass surgery Holtz, Russell R., 3305 N. 18.sup.th St., Tacoma, WA, United States
ΤI
IN
        98406
        US 6153654
                                     20001128
PI
        WO 9824381
                      19980611
        US 1999-319405
                                     19990604 (9)
ΑI
        WO 1997-US22103
                                     19971204
                                                PCT 371 date
PCT 102(e) date
                                     19990604
                                     19990604
DT
        Utility
FS
        Granted
LN.CNT
        557
        INCLM: 514/652.000
INCL
        NCLM:
NCL
               514/652.000
        [7]
IC
        ICM: A61K031-135
EXF
        514/652
      ANSWER 28 OF 90 BIOSIS 2001:189978 BIOSIS
                                   COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L11
AΝ
      PREV200100189978
DN
                                                                               ***artery***
                                                        ***coronary***
TI
      Profile of patients with nonobstructive
```

ΑU Manı, A. [keprint author]; Karatepe, M. [keprint author]; Kreps, E. [Reprint author]; Collins, M. [Reprint author]; Moses, J. [Reprint author]; Coplan, N. [Reprint author]; Moussa, I. [Reprint author] Lenox Hill Heart and Vascular Institute, New York, NY, USA American Journal of Cardiology, (October 16, 2000) Vol. 86, No. Suppl. 8A, SO pp. 100i-101i. print. Meeting Info.: Twelfth Annual Symposium on Transcatheter Cardiovascular Therapeutics. Washington, D. C., USA. October 17-22, 2000. CODEN: AJCDAG. ISSN: 0002-9149. Conference; (Meeting)
Conference; Abstract; (Meeting Abstract) DT T.A English Entered STN: 20 Apr 2001 ED Last Updated on STN: 18 Feb 2002 ANSWER 29 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN L111000366354 JICST-EPlus ANAn autopsy case of the incarceration of a free-floating ball thrombus in the left atrium into mitral valve. TI KAWABE TETSUYA; YAMAMOTO KATSUHIRO; SHIOTANI MASAHIKO; SATANI OSAMU; HANO TAKUZO; NISHIO ICHIRO ΑU Wakayama Med. Coll. Wakayama Igaku (Journal of the Wakayama Medical Society), (2000) vol. 51, SO no. 1, pp. 73-77. Journal Code: F0546A (Fig. 5, Tbl. 1, Ref. 14) CODEN: WKMIAO; ISSN: 0043-0013 CYJapan DT Journal; Short Communication LΑ Japanese STA New L11 ANSWER 30 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 7 AN 2000077979 EMBASE TTAdenosine for cardioplegic induction: A comparison with St Thomas solution. Chauhan S.; Wasir H.S.; Bhan A.; Rao B.H.; Saxena N.; Venugopal P. Dr. S. Chauhan, Department of Cardiac Anaesthesia, Cardiothoracic Centre, All India Inst. of Medical Sciences, New Delhi 110029, India CS Journal of Cardiothoracic and Vascular Anesthesia, (2000) 14/1 (21-24). SO Refs: 13 ISSN: 1053-0770 CODEN: JCVAEK CYUnited States DT Journal; Article FS 018 Cardiovascular Diseases and Cardiovascular Surgery 024 Anesthesiology 030 Pharmacology Drug Literăture Index 037 English LА English SLL11 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. ANSWER 31 OF 90 on STN AN 2000126248 EMBASE The effects of endotracheal intubation and laryngeal mask airway on the TI risk of myocardial ischemia in cardiac patients. Ay B.; Eti Z.; Fak A.S.; Umuroglu T.; Gogus F.Y. ΑU B. Ay, Dept. Anesthesiology Reanimation, School of Medicine, Marmara CS University, Istanbul, Turkey SO Marmara Medical Journal, (2000) 13/1 (15-18). Refs: 20 ISSN: 1019-1941 CODEN: MMJOF4 CY Turkey DT Journal; Article FS Cardiovascular Diseases and Cardiovascular Surgery 018 024 Anesthesiology 037 Drug Literature Index English LΑ  $\mathtt{SL}$ English L11 ANSWER 32 OF 90 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN 1999:419986 SCISEARCH ANGA The Genuine Article (R) Number: 199XY Sleep apnoea syndrome and the extent of atherosclerotic lesions in ΤI

Aboyans V (Reprint); Lacroix P; Virot P; Tapie P; Cassat C; Rambaud G;

middle-aged men with myocardial infarction

AU

```
HOP DUPUYTREN, SERV CTCV & ANGIOL, 2 AVE MARTIN LUTHER, F-87042 LIMOGES, FRANCE (Reprint); SUPUYTRENS UNIV HOSP, DEPT THORAC & CARDIOVASC SURG &
CS
       ANGIOL, LIMOGES, FRANCE
CYA
      FRANCE
       INTERNATIONAL ANGIOLOGY, (MAR 1999) Vol. 18, No. 1, pp. 70-73. Publisher: EDIZIONI MINERVA MEDICA, CORSO BRAMANTE 83-85 INT JOURNALS
SO
       DEPT., 10126 TURIN, ITALY.
       ISSN: 0392-9590.
DT
      Article; Journal
FS
       CLIN
      English
LΑ
REC
      Reference Count: 17
       *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
      ANSWER 33 OF 90 USPATFULL on STN
L11
         1998:122391 USPATFULL
AN
         Methods of preventing tissue damage associated with decreased blood flow by administration of AICA riboside compounds
TI
         Gruber, Harry E., Rancho Santa Fe, CA, United States
Mullane, Kevin M., Del Mar, CA, United States
Laikind, Paul K., San Diego, CA, United States
Gensia Pharmaceuticals, San Diego, CA, United States (U.S. corporation)
IN
PA
         US 5817640
PΙ
                                          19981006
                                          19950516 (8)
ΑI
         US 1995-443245
         Continuation of Ser. No. US 1994-296266, filed on 25 Aug 1994, now abandoned which is a continuation of Ser. No. US 1992-949101, filed on 21 Sep 1992, now abandoned which is a continuation-in-part of Ser. No.
RLI
             1991-770023, filed on 30 Sep 1991, now abandoned
DT
         Utility
         Granted
FS
LN.CNT
         1645
INCL
         INCLM: 514/046.000
                   514/045.000; 514/821.000; 514/822.000; 514/824.000; 514/885.000;
         INCLS:
                   514/886.000; 435/975.000
NCL
         NCLM:
                   514/046.000
                   435/975.000; 514/045.000; 514/821.000; 514/822.000; 514/824.000; 514/885.000; 514/886.000
         NCLS:
IC
          [6]
         ICM: A61K031-70
         514/45; 514/46; 514/821; 514/822; 514/824; 514/861; 514/885; 514/886;
EXF
         435/975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                             JICST-EPlus COPYRIGHT 2004 JST on STN
L11
      ANSWER 34 OF 90
       990445094 JICST-EPlus
AN
ΤI
       Surgical Results of Postinfarction Ventricular Septal Rupture.
ΑU
       FUNĂKI SHIGEKI; KOYAMA TERUYUKI; OKADA TADAHIKO; TAKEI HIROSHI; YAMATE
      NOBORU
      KAWADA TADANORI
      HIEKATA TOMIZO; OGAWA NOBORU; ABE HIROYUKI
CS
      St. Marianna Univ.
      Showa Univ., Sch. of Med.
Yokohama-shi Seibu Hosp., St. Marianna Univ.
Sei Marianna Ika Daigaku Zasshi (St. Marianna Medical Journal), (1998)
vol. 26, no. 6, pp. 755-760. Journal Code: Z0605A (Fig. 3, Tbl. 4, Ref.
SO
       18)
       ISSN: 0387-2289
CY
       Japan
DT
      Journal; Article
       Japanesė
LА
STA
      New
                             JICST-EPlus COPYRIGHT 2004 JST on STN
L11
      ANSWER 35 OF 90
ΑN
       980876199
                     JICST-EPlus
TI
       Clinical advantages and myocardial protection of normothermal CPB.
       Comparison with hypothermal CPB.
       UNO YOSHIMASA; HORĪKOSHI SHIGEKI; EMOTO HIDETO; MIYAMOTO HISAKI; SUZUKI
ΑU
      HIROYUKI
       Jikei Univ. Kashiwa Hosp.
      Jpn J Thorac Cardiovasc Surg, (1998) vol. 46, no. 8, pp. 671-676. Journal Code: Z0767A (Fig. 6, Tbl. 1, Ref. 12)
SO
       ISSN:
               0369-4739
CY
       Japan
DT
       Journal; Article
```

LA

Japanese

```
ANSWER 36 OF 90
                         JICST-EPlus COPYRIGHT 2004 JST on STN
      990111671 JICST-EPlus
AN
TI
      The Clinical Assessment of the Nutritional and the Metabolic Changes in
      Patients with AMI.
ΑU
      SUGIMOTO KATSUHIKO; ARUGA TOORU
      KATO CHII; AOKI YAYOI; KONDO ETSUKO; AOYAMA NAOYOSHI; ASARI YASUSHI; OWADA
      TAKASHI; KUROSAWA TOSHIRO
      Showa Univ., Sch. of Med.
CS
      Kitasato Univ., Hosp.
Geka to Taisha, Eiyo (Japanese Journal of Surgical Metabolism and
SO
     Nutrition), (1998) vol. 32, no. 6, pp. 343-350. Journal Code: Y0699A (Fig. 5, Tbl. 4, Ref. 23)
      ISSN: 0389-5564
CY
      Japan
DT
      Journal; Article
LΑ
      Japanese
STA
     New
      ANSWER 37 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
                  JICST-EPlus
      980739086
AN
      Intra-coronary Shunt for Coronary Artery Revascularization in the Beating
TI
      SOGAWA MASAKAZU; SAITO AKIRA; NAMURA OSAMU; OZEKI HAJIME; MORO HISANAGA;
ΑU
      HAYASHI JUN'ICHI
     Niigata Univ., Sch. of Med.
Nippon Shinzo Kekkan Geka Gakkai Zasshi (Japanese Journal of
Cardiovascular Surgery), (1998) vol. 27, no. 4, pp. 222-226. Journal Code:
CS
SO
      Y0192A (Fig. 4, Ref.
      ISSN: 0285-1474
CY
      Japan
DT
      Journal; Article
LΑ
      Japanese
STA
     New
      ANSWER 38 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
                   JICST-EPlus
AN
TI
      Urgent coronary artery bypass surgery by only arterial graft for acute
      myocardial infarction.
      HÁYASHI SAIHO; SASAKI MASARU; KAWAMOTO JUN
Chugoku Rosai Hosp.
ΑU
CS
     Nippon Kyobu Geka Gakkai Zasshi (Journal of the Japanese Association for Thoracic Surgery), (1997) vol. 45, no. 7, pp. 935-939. Journal Code: Z0767A (Tbl. 1, Ref. 27)
SO
      ISSN: 0369-4739
CY
      Japan
DT
      Journal; Article
LA
      Japanese
STA
     New
      ANSWER 39 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN 970699865 JICST-EPlus
L11
AN
      A Case of Acute Myocardial Infarction during Intravenous Ritodrine Treatment for Preterm Labor.
TI
      SAIJO YASUAKI; MATSUZAKA TOMOYUKI; HONDA HAJIME; NORO TADATAKA; KOMORI
ΑU
      HARUMI; NAKATA TOSHIYUKI
      Enaru Kosei Hosp.
      Kokyu to Junkan (Respiration and Circulation), (1997) vol. 45, no. 8, pp. 825-828. Journal Code: Z0660A (Fig. 4, Tbl. 1, Ref. 9)
SO
      ISSN: 0452-3458
CY
      Japan
DT
      Journal; Short Communication
LΑ
      Japanese
STA
      New
L11
      ANSWER 40 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
                                                                   DUPLICATE 8
      on STN
      97267119 EMBASE
MA
DN
      1997267119
ΤI
     Transmyocardial laser revascularisation combined with coronary artery
```

bypass grafting without cardiopulmonary bypass.
Trehan N.; Mishra M.; Bapna R.; Mishra A.; Maheshwari P.; Karlekar A.
M. Mishra, Escorts Heart Inst, Research Centre, Okhla Road, New Delhi-110

European Journal of Cardio-thoracic Surgery, (1997) 12/2 (276-284).

CS

SO

025, India

ISSN: 1010-7940 CODEN: EJCSE7 PUI S 1010-7940(97)00098-5 CY Netherlands DT Journal; Article FS 009 Surgery 018 Cardiovascular Diseases and Cardiovascular Surgery LΑ English SLEnglish ANSWER 41 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN L11 DUPLICATE 9 1997:176416 BIOSIS ANDN PREV199799468129 Indications and problems of coronary artery bypass grafting without ΤI cardiopulmonary bypass.

Kondo, Keiichiro [Reprint author]; Minohara, Seiichiro; Sawada, Yoshihide;
Irie, Hiroshi; Okamoto, Ken; Kinugasa, Seiji; Nakao, Masatomo; Sasaki, ΑU Shinjiro Dep. Thoracic Surgery, Osaka Med. College, 2-7 Daigaku-cho, Takatsuki CS City, Osaka 569, Japan Surgery Today (Tokyo), (1997) Vol. 27, No. 3, pp. 202-206. SO DT Article English LΑ Entered STN: 24 Apr 1997 ED Last Updated on STN: 24 Apr 1997 ANSWER 42 OF 90 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN L11SCISEARCH  $\mathbf{A}\mathbf{N}$ 97:211222 GA The Genuine Article (R) Number: WM022 Indications and problems of coronary artery bypass grafting without ΤI cardiopulmonary bypass Kondo K (Reprint); Minohara S; Sawada Y; Irie H; Okamoto K; Kinugasa S; ΑU Nakao M; Sasaki S OSAKA MED COLL, DEPT THORAC SURG, 2-7 DAIGAKU CHO, TAKATSUKI, OSAKA 569, CS JAPAN (Reprint) CYA JAPAN SO SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, (FEB 1997) Vol. 27, No. 3, pp. 202-206. Publisher: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010. ISSN: 0941-1291. DT Article; Journal FS CLIN LΑ English REC Reference Count: 9 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\* L11 ANSWER 43 OF 90 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN 1997-43118 AN DRUGU The effect of prolonged low-dose nitroglycerin infusion on left ΤI ventricular diastolic function early after myocardial infarction.
Piszczek I; Grajek S; Skorupski W; Taronska A; Grygier M; Prech M; Popiel M; Mularek Kubzdela T; Kowal J; Cieslinki A ΑU LOPoznan, Pol. Eur.Heart J. (18, Abstr.Suppl., 172, 1997) 1 Tab. CODEN: EHJODF ISSN: 0195-668X SO ΑV University School of Medical Sciences, Cardiology Department, Poznan, Poland. LΑ English DT Journal AB; LA; CT FΑ FS Literature L11 ANSWER 44 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN  $\mathbf{M}\mathbf{A}$ 97171174 EMBASE DN1997171174 TI Metabolic and hemodynamic effects of unilateral tourniquet application on lower extremities of the patients with \*\*\*coronary\*\*\* \*\*\*disease\*\*\* Erol U.; Ay B.; Dogu D. U. Erol, Dept. Anesthesiology and Reanimation, Faculty of Medicine, Marmara University, Istanbul, Turkey AU CS Marmara Medical Journal, (1997) 10/2 (91-99). SO Refs: 12 ISSN: 1019-1941 CODEN: MMJOF4

```
Journal; Article
DT
FS
      009
               Surgery
               Cardiovascular Diseases and Cardiovascular Surgery
      018
      024
               Anesthesiology
      033
               Orthopedic Surgery
LΑ
      English
      English
SL
     ANSWER 45 OF 90
                         EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
L11
      on STN
AN
      97145902
                 EMBASE
DN
      1997145902
     Perioperative risk of coronary patients undergoing major urological operations. The role of prophylactic administration of Diltiazem.
TI
      Hatziantoniou G.P.; Tasslopoulos P.A.; Fakiolas C.N.; Foussas S.G.;
AU
     Lykourinas M.G.
CS
      G.P. Hatziantoniou, Tzanio Hospital, Cardiology Department, Piraeus,
      Greece
     Hellenic Journal of Cardiology, (1997) 38/1 (28-34).
SO
      Refs: 14
      ISSN: 1011-7970 CODEN: HLKEAE
CY
      Greece
DT
      Journal; Article
FS
     018
               Cardiovascular Diseases and Cardiovascular Surgery
      028
               Urology and Nephrology
               Pharmacology
      030
      037
               Drug Literature Index
LΑ
     Greek
     Greek; English
SL
     ANSWER 46 OF 90
                         JICST-EPlus COPYRIGHT 2004 JST on STN
L11
                 JICST-EPlus
ΑN
      960687559
     Study on variation of serum enzymes during and after extracorporeal circulation. Relationship with intraoperative factors.
TI
      MATSUI YOSHIRO; ISHII KOJI; SHIIYA NORIHIKO; MURASHITA TOSHIFUMI; SASAKI
ΑU
      SHIGEYUKI; SAKÚMA MAKOTO; ÝASUDA KEISHU
CS
     Hokkaido Univ.
      Jinko Zoki, Nippon Jinko Zoki Gakkai (Japanese Journal of Artificial
SO
      Organs), (1996) vol. 25, no. 1, pp. 60-62. Journal Code: Z0557B (Fig. 4,
      Ref. 8)
      ISSN: 0300-0818
CY
      Japan
DT
      Journal; Article
LA
      Japanese
STA
     New
     ANSWER 47 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
\mathbf{AN}
      960128779
                  JICST-EPlus
ΤI
      A Case of Shower Embolism Using IABP on a Patient Undergoing Hemodialysis
     Who Had Acute Myocardial Inforction.
KISHI HISAYO; HIROOKA KEIJI; YASUDA TAKENORI; TANIGUCHI TOKUSHI; OKADA TAKEO; IKE SHINPEI; CHIN WAKATOMI; ASAO MASATO; HAYASHI TOORU
ΑU
      Osaka National Hospital
CS
      Iryo (Japanese Journal of National Medical Services), (1995) vol. 49, no.
SO
      12, pp. 1033-1035. Journal Code: F0707A (Fig. 2, Tbl. 1)
      CODEN: IRYOAV; ISSN: 0021-1699
CY
      Japan
      Journal; Short Communication
DT
LA
      Japanese
STA
     New
L11
      ANSWER 48 OF 90
                         JICST-EPlus COPYRIGHT 2004 JST on STN
                  JICST-EPlus
ΑN
      950516483
      Clinical Evaluation of Prophylactic Nitroglycerin Infusion during Coronary
TI
      Artery Bypass Grafting
      AMANO HOMĀRE; OKUDA MĀSAHIRO; FURUHASHI KAZUHISA; UTSUNOMIYA HIROFUMI;
ΑU
      NAKAI YASUSHI; MUNEYUKI MANNOSUKE
      Mie Univ., Sch. of Med.
      Masui (Japanese Journal of Anesthesiology), (1995) vol. 44, no. 4, pp. 594-596. Journal Code: F0838A (Fig. 2, Tbl. 2, Ref. 4)
SO
      CODEN: MASUAC; ISSN: 0021-4892
CY
      Japan
DT
      Journal; Article
LΑ
      Japanese
STA
      New
```

```
ANSWER 49 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
     960306626 JICST-EPlus
AN
     A Case with Cardiac Ischemia Induced by Mesenteric Traction.
TI
     SUYAMA HIDEMICHI; KAWAMOTO MASASHI; YAMANOUE TAKAO; OKADA KUNIKO; YUGE
ΑU
      OSAFUMI
     Univ. Med. Hosp. Hiroshima Univ.
Masui to Sosei (Hiroshima Journal of Anesthesia), (1995) vol. 31, no. 4,
SO
     pp. 265-266. Journal Code: S0305A (Fig. 1, Ref. 8)
      ĪŠSN: 0385-1664
CY
     Japan
DT
     Journal; Article
     Japanese
LA
STA
     New
     ANSWER 50 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
ΑN
     950199532
                  JICST-EPlus
     A Case of Acute Myocardiac Infarction Associated with Myocardial Bridge. YOSHIDA TOORU; KARASAWA NAOKO; SADA HIDEO; KAWABATA KAZUTO MURAMATSU JUN; KIKAWADA RYUICHI
TI
ΑU
CS
     Keisukai Kanazawabyoin
     Kitasato Univ., Sch. of Med.
     Kokyu to Junkan (Respiration and Circulation), (1995) vol. 43, no. 2, pp.
SO
     201-204. Journal Code: Z0660A (Fig. 3, Ref. 12)
     ISSN: 0452-3458
CY
     Japan
DT
     Journal; Short Communication
LΑ
     Japanese
STA
     New
L11
     ANSWER 51 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
                 JICST-EPlus
AN
     940955444
     The efficacy of both antegrade and retrograde cardioplegia in coronary
TI
     artery bypass surgery.
YAMAGUCHI AKIMITSU; KITAMURA NOBUO; KIMURA SHUN'ICHI; IRIE HIROSHI; KO
AU
     TOKUMITSU; SHUNTO KEISUKE
CS
     Osaka National Hospital
     Nippon Kyobu Geka Gakkai Zasshi (Journal of the Japanese Association for
SO
     Thoracic Surgery), (1994) vol. 42, no. 10, pp. 1916-1924. Journal Code: Z0767A (Fig. 6, Tbl. 3, Ref. 32)
     ISSN: 0369-4739
CY
     Japan
DT
     Journal; Article
LΑ
     Japanese
STA
    New
L11
     ANSWER 52 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
                 JICST-EPlus
AN
TI
     Serum cardiac markers in hemodialysis patients.
ΑU
     TERAKADO SETSUO; NAKAO TOSHIYUKI
     Tokyo Medical College
Nippon Toseki Igakkai Zasshi (Journal of Japanese Society for Dialysis
Therapy), (1994) vol. 27, no. 6, pp. 955-960. Journal Code: X0954A (Fig. 3, Tbl. 3, Ref. 16)
CS
SO
     ISSN: 1340-3451
CY
     Japan
DT
     Journal; Article
LA
     Japanese
STA
     New
     ANSWER 53 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN DUPLICATE 10
L11
     940331084 JICST-EPlus
AN
TI
     Coronary Artery Spasm after Mitral Valve Replacement: A Case Report.
     KANNO MĒGUMU; KURĪHARA HISAO; SATO MASATO; HAMAWAKI MASAYOSHI; HONDA
AU
CS
     Hondakinen Tohokujunkankikabyoin
SO
     Kyobu Geka (Japanese Journal of Thoracic Surgery),
                                                                 (1994) vol. 47, no. 4,
     pp. 315-318. Journal Code: Z0662A (Fig. 6, Ref. 8)
      ĪSSN: 0021-5252
CY
      Japan
DT
      Journal; Commentary
LA
      Japanese
STA
     New
L11
                        JICST-EPlus COPYRIGHT 2004 JST on STN DUPLICATE 11
     ANSWER 54 OF 90
ΑN
      940297383 JICST-EPlus
```

artery bypass surgery.
MOIZUMI YOSHIMASA; OSAKA KENSHI; AKASAKA JUN'ETSU; KONDO SHUN'ICHI;
SHIMIZU MASAYUKI; UCHIYAMA TETSUYUKI; IMAI YOSHIMICHI; KUMAGAI TOMOKO; ΑU SUZUKI ICHIRO Sendai City Medical Center Nippon Kyobu Geka Gakkai Zasshi (Journal of the Japanese Association for Thoracic Surgery), (1994) vol. 42, no. 2, pp. 198-205. Journal Code: Z0767A (Fig. 6, Tbl. 4, Ref. 25) ISSN: 0369-4739 SO CY Japan DTJournal; Article LΑ Japanese STA New ANSWER 55 OF 90 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN L11 1994-01792 DRUGU T S ANPossible Myocardial Toxicity Associated with Interleukin-4 Therapy. Trehu E G; Isner J M; Mier J W; Karp D D; Atkins M B ΤI ΑU CS LO Univ.Tufts Boston, Massachusetts, United States J.Immunother. (14, No. 4, 348-51, 1993) 2 Fig. 26 Ref. Division of Hematology-Oncology, New England Medical Center, Box 245, 750 Washington St., Boston, MA 02111, U.S.A. (M.B.A.). SO ΑV LΑ English DTJournal AB; LA; CT FA FS Literature ANSWER 56 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. L11 on STN 93338913 AN **EMBASE** DN1993338913 Is continuous normothermic blood cardioplegia really a practical way of TImyocardial preservation? Comparison with intermittent cold crystalloid cardioplegia. Demirtas M.; Dagsali S.; Tarcan S.; Sungu U. Ahmet Celebi M., Sumbulzade S., 20/3-81160 Uskudar, Istanbul, Turkey Thoracic and Cardiovascular Surgeon, (1993) 41/5 (284-289). ΑU CS SO ISSN: 0171-6425 CODEN: TVCHAF CY Germany DT Journal; Article Cardiovascular Diseases and Cardiovascular Surgery FS 018 037 Drug Literature Index LА English SLGerman; English JICST-EPlus COPYRIGHT 2004 JST on STN L11 ANSWER 57 OF 90 930378675 JICST-EPlus ΑN A clinical trial of recombinant human superoxide dismutase for myocardial TI protection. ΑU TAKEMURA TAKAHIRO Tokyo Women's Medical College, Heart Inst. of Japan Nippon Kyobu Geka Gakkai Zasshi (Journal of the Japanese Association for Thoracic Surgery), (1993) vol. 41, no. 2, pp. 247-253. Journal Code: Z0767A (Fig. 8, Tbl. 1, Ref. 22) CS SO ISSN: 0369-4739 CY Japan DT Journal; Article LA Japanese STA New ANSWER 58 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN L11 $\mathbf{A}\mathbf{N}$ 930681045 JICST-EPlus Effect of the Myocardial Protection Method in Patients with Ischemic Heart TI Disease: Relation of Duration of Aortic Cross Clamping to the Postoperative Severity of Myocardial Damage and Left Ventricular Impairment. ΑU TAMURA SUSUMU Toho Univ., School of Medicine, Ohashi Hospital Toho Igakkai Zasshi (Journal of the Medical Society of Toho University), (1993) vol. 40, no. 2, pp. 196-209. Journal Code: G0654A (Fig. 8, Tbl. 11, CS SO

CODEN: TOIZAG; ISSN: 0040-8670

CY

DT

Japan

Journal; Article

STA New L11 ANSWER 59 OF 90 PHIN COPYRIGHT 2004 PJB on STN AN 92:6000 PHIN S00308044 DN 23 Apr 1992 DED Acadesine beneficial in Coronary Artery Bypass Graft (CABG) surgery TIScrip (1992) No. 1713 p23 SO DT Newsletter FS FULL ANSWER 60 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN L11 DUPLICATE 12 1993:71410 BIOSIS ANPREV199395035910 DNCardiac isoenzymes following heart transplantation.
Ladowski, Joseph S. [Reprint author]; Sullivan, Margaret; Schatzlein,
Michael H.; Peterson, Alan C.; Underhill, David J.; Scheeringa, Ronald H.
Indiana/Ohio Heart, 7910 West Jefferson Blvd., Fort Wayne, Indiana 46804, ΤI AU CS USA Chest, (1992) Vol. 102, No. 5, pp. 1520-1521. CODEN: CHETBF. ISSN: 0012-3692. DT Article English LΑ ED Entered STN: 26 Jan 1993 Last Updated on STN: 27 Jan 1993 ANSWER 61 OF 90 L11 JICST-EPlus COPYRIGHT 2004 JST on STN 930210051 JICST-EPlus ANTI The effect of human superoxide dismutase on reperfusion injury in clinical TAKATA KOJI ΑU Okayama Univ., School of Medicine Okayama Igakkai Zasshi, (1992) vol. 104, no. 11-12, pp. 1127-1134. Journal Code: Z0158B (Fig. 5, Tbl. 3, Ref. 31) ISSN: 0030-1558 CS SO CY Japan DT Journal; Article LΑ Japanese STA New L11ANSWER 62 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN JICST-EPlus AN920133701 TI A Case of Acute Severe Myocarditis with Myocardial Infarction Like ECG Findings. The Investigation of Myocardial Interstitial Fibrosis by the Monoclonal Antibodies to Collagen Fiber Subtypes (Type I, III, IV). SUZUKI HIROYUKI; UEMURA SHIGERU; MINAMI YORIAKI; NERAI HIROYUKI; KOIKE ΑU MICHIO; MAEDA JIRO; OSHIMA AKIRÁ MIYASHIRO EIKICHI Wakayama Medical College Wakayama Rosai Hospital SO Nippon Shoni Junkanki Gakkai Zasshi (Acta Cardiologica Paediatrica Japonica), (1992) vol. 7, no. 4, pp. 560-565. Journal Code: X0809A (Fig. 5, Tbl. 2, Ref. 26) ISSN: 0911-1794 CYJapan Journal; Article DTLА Japanese STA New JICST-EPlus COPYRIGHT 2004 JST on STN L11 ANSWER 63 OF 90 JICST-EPlus AN A Case of Unstable Angina Pectoris Associated with an Active Phase of TI Polymyositis. YASŪ TAKANORI ΑU NONOGI HIROSHI; OSHIMA SHUICHI; DAIKOKU SATOSHI; HAZE KAZUO Jichiidai Omiyairyose CS National Cardiovascular Center Kokyu to Junkan (Respiration and Circulation), 491-494. Journal Code: Z0660A (Fig. 3, Ref. 9) SO (1992) vol. 40, no. 5, pp.

ISSN: 0452-3458

Journal; Article

Japan

Japanese

CY

DT

LA

```
ANSWER 64 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
      920587221 JICST-EPlus
AN
     Coronary air embolism during the mitral regurgitation tests.
TI
     IMOTO YÚTAKA; SESE AKIRA; UĚNO YASUTAKA; TŎDOROKI HARUTOMO; OE MASAHIRO;
TANAKA KEN'ICHIRO; MASAKI HIDETO
ΑU
     Kyushu Kosei Nenkin Hospital
CS
     Kosei Nenkin Byoin Nenpo (Annual Bulletin of Kosei-Nenkin Hospitals), (1992) vol. 18(1991), pp. 103-108. Journal Code: Y0366A (Fig. 2, Tbl. 1,
SO
     Ref. 6)
     ISSN: 0388-2314
CY
     Japan
     Journal; Article
DT
     Japanese
LΑ
STA
     New
     ANSWER 65 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L11
     DUPLICATE 13
      1991:428389
                    BIOSIS
AΝ
      PREV199192084554; BA92:84554
DN
     INCIDENCE OF ABNORMAL RNA STUDIES AND DYSRHYTHMIAS IN PATIENTS WITH BLUNT
TI
      CHEST TRAUMA.
     MCLEAN R F [Reprint author]; DEVITT J H; DUBBIN J; MCLELLAN B A
AU
     DEP ANESTHESIA, SUNNYBROOK HEALTH SCI CENT, 2075 BAYVIEW AVE, TORONTO,
CS
     ONTARIO M4N 3M5, CAN
     Journal of Trauma, (1991) Vol. 31, No. 7, pp. 968-970.
SO
      CODEN: JOTRA5. ISSN: 0022-5282.
DT
     Article
FS
     BA
     ENGLISH
LA
     Entered STN: 26 Sep 1991
ED
     Last Updated on STN: 26 Sep 1991
     ANSWER 66 OF 90
                         JICST-EPlus COPYRIGHT 2004 JST on STN
L11
                 JICST-EPlus
AN
      910934341
     Diagnosis of Acute Myocardial Infarction Using Dual SPECT (99mTc PYP and
TI
      201Tl Cl) Method: Diagnostic Availability and Quantitative Assessment of
      Infarct Area.
     HONDA NORIBUMI; ABE MASAHIRO; TAYA KOICHI; TAKADA YOSHIFUMI; OGAWA
ΑU
      TAKASHI; INUZUKA HIROSHI; ABE TOSHIHIRO; NAGAI YOSHIKAZU
      Tokyo Medical College
CS
     Tokyo Ika Daigaku Zasshi (Journal of Tokyo Medical College), (1991) vol. 49, no. 5, pp. 652-660. Journal Code: F0570A (Fig. 7, Tbl. 4, Ref. 20) CODEN: TIDZAH; ISSN: 0040-8905
SO
CY
      Japan
DT
      Journal; Article
LA
      Japanese
STA
     New
      ANSWER 67 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
                 JICST-EPlus
\mathbf{A}\mathbf{N}
      930153803
      Evaluation of healing process in myocardial infarction by the time course of serum myosin light chain I. The effects of early reperfusion.
TI
      ASAJI TAKAYOSHI; MURAKAMI EIJI; TAKEKOSHI NOBORU
ΑU
      Kanazawa Medical Univ.
CS
      J Cardiol, (1991) vol. 21, no. 3, pp. 579-587. Journal Code: Y0264A (Fig. 4, Tbl. 2, Ref. 20)
SO
      ISSN: 0914-5087
CY
      Japan
DT
      Journal; Article
LA
      Japanese
STA
      New
      ANSWER 68 OF 90
                          JICST-EPlus COPYRIGHT 2004 JST on STN
L11
      910363292 JICST-EPlus
AΝ
      Ischemic myocardial disorder in acute phase subarachnoid hemorrhage:
TI
      Clinical study of 52 patients.
      MATSUMURA HAJĪME; IWAĪ FUMIHARU; ICHIKIZAKI KIYOSHI
UΑ
      Second Tokyo National Hospital
CS
      Neurol Surg, (1991) vol. 19, no. 4, pp. 349-357. Journal Code: Z0684A (Fig. 9, Tbl. 10, Ref. 16)
SO
      ISSN: 0301-2603
CY
      Japan
      Journal; Article
DT
LΑ
      Japanese
```

ANSWER 69 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN L11910461437 JICST-EPlus ANClinical application of Indium-111 antimyosin antibody and Thallium-201 TI dual nuclide single photon emission computed tomography in acute myocardial infarction. YOSHIDA H; MOCHIZUKI M; KAINOUCHI M; ISHIDA T; SAKATA K; YOKOYAMA S; HOSHINO T; TAKEZAWA M; KABURAGI T Shizuoka General Hospital, Shizuoka, JPN ΑU Ann Nucl Med, (1991) vol. 5, no. 1, pp. 41-46. Journal Code: X0838A (Fig. 3, Tbl. 2, Ref. 15) SO CODEN: ANMEEX; ISSN: 0914-7187 CY Japan DT Journal; Article LA English STA New ANSWER 70 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN 900873002 JICST-EPlus L11  $\mathbf{N}\mathbf{A}$ Granulocytes cause reperfusion injury after 180 minute hypothermic TIcardioplegic arrest in dogs. ISEKI HARUKAZU; SOUMA YASUHIRO; ONOGUCHI KATSUHISA; SHIMIZU HIDEYUKI; AU INOUE TADASHI Keio Univ., School of Medicine Nippon Geka Gakkai Zasshi (Journal of Japan Surgical Society), (1990) vol. 91, no. 9, pp. 1417-1420. Journal Code: Z0009B (Fig. 4, Ref. 9) ISSN: 0301-4894 SO CY Japan DT Journal; Article LA Japanese STA New ANSWER 71 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN L11900511151 JICST-EPlus AΝ Serial changes of enzymes, CPK & LDH and their isoenzyme pattern, in anterior and posterior papillary muscle of left ventricle produced by TI ischemia HOSAKA HIDEAKI; YAMASAWA IKUHIRO; KIYOMI SADAMICHI; AOKI MAKOTO; KASAI ΑU RYUTARO; TSUMAKI NANAE; CHIYOTANDA SHIGERU; ICHIKI TAKEO; RAKUE HIROYUKI CS Tokyo Medical College Tokyo Ika Daigaku Zasshi (Journal of Tokyo Medical College), (1990) vol. SO 48, no. 2, pp. 148-157. Journal Code: F0570A (Fig. 9, Ref. 21) CODEN: TIDZAH; ISSN: 0040-8905 CY Japan DTJournal; Article LА Japanese STA New ANSWER 72 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN 900029057 JICST-EPlus L11AΝ ΤI Basic studies in relation between metabolic changes and rate pressure products on ischemic myocadium treated with ulinastatin.
YADA HIROAKI; YAMASAWA IKUHIRO; KIYOMI SADAMICHI; IKEBE NOBUHIKO; USUI MIKIO; NAKAGAWA NORIO; KASAI RYUTARO; TSUMAKI NANAE; ICHIKI TAKEO ΑU CS Tokyo Medical College Tokyo Ika Daigaku Zasshi (Journal of Tokyo Medical College), (1989) vol. SO 47, no. 5, pp. 768-778. Journal Code: F0570A (Fig. 10, Tbl. 3, Ref. 19) CODEN: TIDZAH; ISSN: 0040-8905 CY Japan DT Journal; Article LAJapanese STA New ANSWER 73 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN L11 900442718 JICST-EPlus ANEvaluation of myocardial protection with DBcAMP in crystalloid TI cardioplegic solutions. ISHIKURA YOSHIYA; ODAGIRI SHIGETO; SHIMAZU AKIRA; TOKUNAGA HIROYUKI; ΑU SHIMOKAWAJI MASATAKE; YOSHIMATSU HIROSHI Univ. of Occupational and Environmental Health Rinsho Kyobu Geka (Japanese Annals of Thoracic Surgery), (1989) vol. 9, no. 6, pp. 559-563. Journal Code: Y0501A (Fig. 4, Tbl. 3, Ref. 17) ISSN: 0389-7893 SO CY Japan

DT

Journal; Article

```
ANSWER 74 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
11د
                 JICST-EPlus
     890480721
M
     Report of a case of lung cancer with metastasis to the myocardium which
ľ
     showed electrocardiographic findings similar to acute myocardial infarction and intramyocardial mass on echocardiography.
     DAZAI YASUNOBU; KATOH ICHIJIRO; SUEDA SHOUZO; KATOH TOSHIKAZU; YOSHIDA
U
     FUJII MASAFUMI
     KAZATANI SACHIO
     Yawatahama City General Hospital
     National Shikoƙu Cancer Center Hospital
     Ehime Univ., School of Medicine
     Kokyu to Junkan (Respiration and Circulation), (1989) vol. 37, no. 4, pp.
SO
     461-465. Journal Code: Z0660A (Fig. 5, Ref. 18)
     ISSN: 0452-3458
     Japan
т
     Journal; Article
Δ
STA
     Japanese
     New
     ANSWER 75 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
11د
     DUPLICATE 14
     1989:309468
                     BIOSIS
M
     PREV198988023198; BA88:23198
CARDIAC COMPLICATIONS OF ANEURYSM REPAIR.
CAMPBELL J B [Reprint author]; BAKER J; MORRIS D M
1038 MAPLE AVE, ZANESVILLE, OH 43701, USA
Southern Medical Journal, (1989) Vol. 82, No. 4, pp. 458-461.
N
ΓI
U
CS
O
     CODEN: SMJOAV. ISSN: 0038-4348.
TC
     Article
75
     BA
     ENGLISH
ıΑ
     Entered STN: 30 Jun 1989
Last Updated on STN: 30 Jun 1989
ΞD
     ANSWER 76 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
11ء
     890429460 JICST-EPlus
M
              ***CPK***
                                ***MB***
                                              activities in meconium aspiration
ľΙ
     syndrome, neonatal transient tachypnea and neonatal transient myocardial
     ischemia.
     TAKECHI TETSUHISA; FUNAMOTO JIN'ICHI; OZAKI HITOSHI; FUJITA KEINOSUKE;
U/
     SHINO KAZUKO
     Osakashikinmuishikaishinseijijunkandotaikenkyuhan
     Osakashi Kinmu Ishikai Kenkyu Nenpo, (1989) no. 17(1987), pp. 93-96. Journal Code: Y0666A (Tbl. 6, Ref. 4)
SO
     ISSN: 0289-4521
     Japan
TC
     Journal; Article
LA
STA
     Japanese .
     New
      ANSWER 77 OF 90 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
L11
      1989-09773
AΝ
                    DRUGU
                               T S
      Myocardial Toxic Effects During Recombinant Interleukin-2 Therapy.
ΓI
      Nora R; Abrams J S; Tait N S; Hiponia D J; Silverman H J
UΡ
      Baltimore, Maryland, Rockford, Illinois, United States
J.Natl.Cancer Inst. (81, No. 1, 59-63, 1989) 4 Tab. 20 Ref.
ĹŌ
SO
      CODEN: JNCIAM
      University of Maryland Cancer Center, 22 SOuth Greene St., Baltimore, MD 21201, U.S.A. (Abrams J S).
VΑ
ĽА
      English
TC
       Journal
FΑ
      AB; LA; CT
FS
      Literature
     ANSWER 78 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
     880497628 JICST-EPlus
NA
     Sequelae mitral regurgitation and myocardial damage in a case of Kawasaki
ΤI
     disease with early regression of coronary aneurysms.
TAKECHI TETSUHISA; TANI YOSHITAKA; OZAKI MARIKO; SANO YOSHIKO; KIDERA
ΑU
      KATSUHIKO
      TADA AKIO; SHOUJU YASUO
      SAKAI YOSHIO
```

ATS

New

```
Osaka City Univ., Medical School
      Izumi Municipal Hospital
      Prog Med, (1988) vol. 8, no. 7, pp. 1743-1749. Journal Code: F0664B (Fig.
SO
      7, Ref. 10)
      ISSN: 0287-3648
CY
      Japan
DT
      Journal; Article
LΑ
      Japanese
STA
      New
L11
      ANSWER 79 OF 90
                          JICST-EPlus COPYRIGHT 2004 JST on STN
      890208376
                  JICST-EPlus
ΑN
      The efficacy of myocardial protection with prolonged aortic
ΤI
      cross-clamping.
      FUJIOKA YASUTADA; SONEDA JUN'ICHI; BAN TOSHIHIKO; OKAMOTO YOSHIFUMI;
ΑU
      MATSUDA TOSHIHIKO; HIRATA KAZUO; KIYOTA YOSHIHARU; JINNO KIMIO; OGINO
      HITOSHI
      Kyoto Univ., Faculty of Medicine, Hospital
CS
     Rinsho Kyobu Geka (Japanese Annals of Thoracic Surgery), (1988) vol. 8, no. 2, pp. 170-173. Journal Code: Y0501A (Fig. 2, Tbl. 3, Ref. 5) ISSN: 0389-7893
SO
CY
      Japan
DT
      Journal; Article
LA
      Japanese
STA
      New
L11
      ANSWER 80 OF 90
                         JICST-EPlus COPYRIGHT 2004 JST on STN
                  JICST-EPlus
AN
      880053884
      Intravenous short-term coronary thrombolysis by a high-dose urokinase in
TI
      aged patients with acute myocardial infarction.
      SĀKAI MAKOTO; UEDA KEIJI; KURAMOTO KIZUKU
ΑU
      MATSUSHITA SATORU
     Tokyo Metrop. Tama Geriatric Hospital
Nippon Ronen Igakkai Zasshi (Japanese Journal of Geriatrics), (1987) vol.
24, no. 4, pp. 354-360. Journal Code: Z0680A (Fig. 4, Tbl. 2, Ref. 13)
ISSN: 0300-9173
CS
SO
CY
      Japan
DT
      Journal; Article
_{
m LA}
      Japanese
STA
      New
      ANSWER 81 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
                  JICST-EPlus
AN
      880320268
      Assessment by total released acute myocardial infarction.
                                           ***CPK***
                                                            ***MB***
                                                                         in patients with
ΤI
      KOBAYASHI TOYOKAZU; ISHIKAWA NOBORU; KIMPARA TOSHIYUKI; KITAYAMA MASAHIKO;
ΑU
      MIURA AKIRA; INAGAKI MASAO; NISHIOKA AKINORI; WADA TAIZO; KOTOURA HAJIME
      Wakayama Red Cross Hospital
CS
SO
      Med J Wakayama Red Cross Hosp, (1987) vol. 5, pp. 92-97. Journal Code:
      G0717B (Fig. 4, Ref. 22)
      ISSN: 0289-1026
CY
      Japan
DT
      Journal; Article
LΑ
      Japanese
STA
      New
      ANSWER 82 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
L11
      870072364 JICST-EPlus
Myocardial microinfarction in a dog.
AN
ΤI
ΑU
      MACHIDA N; YAMAGA Y; YASUDA J; TOO K
      Hokkaido Univ., Sapporo, JPN
Jpn J Vet Sci, (1986) vol. 48, no. 5, pp. 1057-1062. Journal Code: F0905A
(Fig. 5, Tbl. 1, Ref. 20)
CS
SO
      CODEN: NJUZA9; ISSN: 0021-5295
CY
DT
      Journal; Short Communication
LA
      English
STA
      New
      ANSWER 83 OF 90
                          JICST-EPlus COPYRIGHT 2004 JST on STN
L11
                  JICST-EPlus
      850350256
\mathbf{AN}
                           ***CPK***
                                            ***MB***
TI
      Introduction of
                                                          (myocardial type).
      SUGISAKA SHIZUO; KAWAUCHI TERUMI; SAWADA TAEKO
ΑU
      Yachiyo Hospital
CS
```

```
pp. 11-12. Journal Code: Y0655A (Fig. 5, Tbl. 1, Ref. 1)
      ISSN: 0285-015X
CY
      Japan
DT
      Journal; Article
LΑ
      Japanese
STA
      New
L11
      ANSWER 84 OF 90 USPATFULL on STN
                   USPATFULL
        84:56652
AN
TI
        Heart attack screening method, apparatus and kit for same
IN
        Kiyasu, John Y., 94 Meadow St., Garden City, NY, United States
                                     19841009
PI
        US 4476016
        US 1982-360951
                                     19820323 (6)
AΙ
        Continuation of Ser. No. US 1980-177669, filed on 13 Aug 1980, now abandoned which is a continuation-in-part of Ser. No. US 1978-922885,
RLI
        filed on 10 Jul 1978, now abandoned which is a continuation-in-part of
        Ser. No. US 1976-730102, filed on 6 Oct 1976, now patented, Pat. No. US
        4105499
DT
        Utility
FS
        Granted
LN.CNT
        1395
        INCLM: 210/198.200
INCL
        INCLS: 422/070.000; 210/927.000
NCL
                210/198.200
                210/427.000; 422/070.000
        NCLS:
IC
         [3]
        ICM: B01N015-08
210/198.2; 210/446; 210/472; 210/DIG.24; 210/927; 055/386; 422/58;
422/59; 422/61; 422/70; 422/101; 422/104; 422/99; 435/17; 435/194;
EXF
        435/803; 435/815; 435/816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 85 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
L11
     DUPLICATE 15
AN
      1984:256373
                     BIOSIS
     PREV198477089357; BA77:89357
RELATIVE EFFICACY OF LEFT VENTRICULAR VENTING AND VENOUS DRAINAGE
DN
ΤI
      TECHNIQUES COMMONLY USED DURING CORONARY ARTERY BYPASS GRAFT SURGERY.
      ROBERTS A J [Reprint author]; FARO R S; WILLIAMS L A; COHEN J A; KNAUF D
ΑU
      K; ALEXANDER J Ā
CS
      DIV THORACIC AND CARDIOVASCULAR SURGERY, J HILLIS MILLER HEALTH CENTER,
      UNIV FLORIDA, GAINESVILLE, FL 32610, USA
SO
      Annals of Thoracic Surgery, (1983) Vol. 36, No. 4, pp. 444-452.
      ISSN: 0003-4975.
DT
      Article
FS
      BA
      ENGLISH
LΑ
L11
                             MEDLINE on STN
     ANSWER 86 OF 90
NΑ
                     MEDLINE
      84140881
DN
      PubMed ID: 6608040
     Myocardial revascularization by laser: a clinical report. Mirhoseini M; Fisher J C; Cayton M
ΤI
ΑU
      Lasers in surgery and medicine, (1983) 3 (3) 241-5.
SO
      Journal code: 8007168. ISSN: 0196-8092.
CY
      United States
DT
      (CASE REPORTS)
      Journal; Article; (JOURNAL ARTICLE)
T.A
      English
FS
      Priority Journals
EΜ
      198403
      Entered STN: 19900319
Last Updated on STN: 19900319
ED
      Entered Medline: 19840330
L11
      ANSWER 87 OF 90 USPATFULL on STN
\mathbf{A}\mathbf{N}
        82:32825 USPATFULL
ΤI
        Heart attack screening method and process
IN
        Kiyasu, John Y., 94 Meadow St., Garden City, NY, United States 11530
        US 4338396
US 1980-177662
PI
                                     19820706
        US 1980-177662 19800813 (6)
Continuation-in-part of Ser. No. US 1978-922885, filed on 10 Jul 1978, now abandoned which is a continuation-in-part of Ser. No. US
AΙ
RLI
        1976-730102, filed on 6 Oct 1976, now patented, Pat. No. US 4105499
DT
        Utility
```

```
LN.CNT 1138
INCL
         INCLM: 435/017.000
         INCLS: 210/635.000; 210/927.000; 435/194.000; 435/803.000; 435/815.000;
                  435/816.000
                  435/017.000
NCL
         NCLM:
                  210/635.000; 435/194.000; 435/803.000; 435/815.000; 435/816.000
         NCLS:
IC
         [3]
         ICM: C12Q001-50
         ICS: B01D015-08
         435/17; 435/194; 435/803; 435/816; 435/815; 023/230B; 210/198.2; 210/635; 210/656; 210/927
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 88 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
L11
      on STN
      74140012 EMBASE
AN
      1974140012
DN
TI
      Intraoperative detection of myocardial damage duruing coronary artery
      surgery by plasma creatine phosphokinase isoenzyme analysis. Oldham Jr H.N.; Roe C.R.; Young Jr W.G.; Dixon Jr S.H. Dept. Surg., Duke Univ. Med. Cent., Durham, N.C., United States
ΑU
CS
                  (1973) 74/6 (917-925).
SO
      Surgery, (197)
CODEN: SURGAZ
DT
      Journal
                 Cardiovascular Diseases and Cardiovascular Surgery
FS
      018
      029
                 Clinical Biochemistry
LA
      English
      ANSWER 89 OF 90 FEDRIP COPYRIGHT 2004 NTIS on STN
L11
      2004:204960
                       FEDRIP
AΝ
      CRISP 5M01RR00052-42
NR
                                      0753
ΤI
      OUTCOME -- EARLY DETECTION/THERAPY OF MYOCARDIAL ISCHEMIA
      Principal Investigator: MARTINEZ, ELIZABETH A; JOHNS HOPKINS MED INSTITUTIONS, 2024 E MONUMENT ST, SUITE 2-600
SF
CSP
      JOHNS HOPKINS UNIVERSITY, BALTIMORE, MARYLAND
      Supported By: NATIONAL CENTER FOR RESEARCH RESOURCES 2010 (/01/75)
CSS
DB
FYR
      2003
DE
      2011 (/30/04)
      Noncompeting Continuation (Type 5)
FU
FS
      National Institutes of Health
L11
      ANSWER 90 OF 90 FEDRIP COPYRIGHT 2004 NTIS on STN
AΝ
      2004:52483 FEDRIP
      VA 137414
0025, 544
A Rnd, Dbl-Bld, Plcb Cntl Trial of the Eff of Weekly Azithromycin on the
NR
NC
TI
      Incidence of Cor Artery Dis in Subjs w/ Evd of Exp to C. pneumoniae Principal Investigator: Hassapoyannes, Constantine A., M.D. Department of Veterans Affairs, Medical Center, Columbia, SC
SF
CSP
      Supported By: Department of Veterans Affairs. Research and Development (15), 810 Vermont Ave. N.W., Washington, D.C., 20420, United States of
CSS
      America
```

Nov 16, 2000

Department of Veterans Affairs

STN INTERNATIONAL LOGOFF AT 13:48:20 ON 13 AUG 2004

DB

FS